azacitidine profile

Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	9444
CHEMBL ID	1489
CHEBI ID	2038
SCHEMBL ID	3741
MeSH ID	M0002060

Synonym
MLS002153249
azacytidine
DIVK1C_000125
KBIO1_000125
5-aza-cr
vidaza
ladakamycin
u-18496
mylosar
ns-17
vidaza (tn)
D03021
EU-0100035
azacitidine (jan/usan/inn)
5-azacytidine, >=98% (hplc)
c8h12n4o5
SPECTRUM_001262
MOLMAP_000062
azacitidina
CHEBI:2038 ,
4-amino-1-beta-d-ribofuranosyl-s-triazin-2(1h)-one
4-amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1h)-one
azacitidinum
pyrimidine antimetabolite: inhibits nucleic acid replication
LOPAC0_000035
SPECTRUM5_001166
NCGC00178234-01
CMAP_000082
IDI1_000125
smr000857239
MLS001333122
MLS001333121
nsc-102816
5-azacytidine
nsc102816 ,
320-67-2
azacitidine
5-azac
4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,3,5-triazin-2-one
4-amino-1-beta-d-ribofuranosyl-1,3,5-triazine-2(1h)-one
NCGC00090851-01
antibiotic u 18496
s-triazin-2(1h)-one, 4-amino-1-beta-d-ribofuranosyl-
u 18496
2-(beta-d-ribofuranosyl)-4-amino-1,3,5-triazin-2-one
azacitidina [inn-spanish]
brn 0620461
ccris 60
azacitidinum [inn-latin]
nsc 102816
hsdb 6879
einecs 206-280-2
wr 183027
wr-183027
4-amino-1-beta-d-ribofuranosyl-1,3,5-traizin-2(1h)-one
5-azacytidine, hybri-max(tm), gamma-irradiated, lyophilized powder, bioxtra, suitable for hybridoma
DB00928
NCGC00090851-04
KBIO2_001742
KBIO2_002556
KBIO2_005124
KBIO2_007692
KBIOSS_001742
KBIO3_002657
KBIOSS_002565
KBIOGR_002556
KBIOGR_001444
KBIO2_004310
KBIO3_003034
KBIO2_006878
SPECTRUM4_000922
SPBIO_000892
SPECTRUM2_000786
SPECTRUM3_001509
NINDS_000125
SPECTRUM1502111
BCBCMAP01_000083
BSPBIO_003157
NCGC00090851-02
NCGC00090851-03
5azac
5-azacitidine
5 azacytidine
HMS2092D08
4-amino-1-(beta-d-ribofuranosyl)-1,3,5-triazin-2(1h)-one; ladakamycin
A 2385 ,
4-amino-1-(beta-d-ribofuranosyl)-1,3,5-triazin-2(1h)-one
NCGC00090851-08
CHEMBL1489
u-18,496
4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
HMS500G07
nmusyjaqqfhjew-kvtdhhqdsa-
inchi=1/c8h12n4o5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15h,1h2,(h2,9,11,16)/t3-,4-,5-,6-/m1/s1
4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz
HMS1921J22
NCGC00090851-06
NCGC00090851-05
NCGC00090851-07
HMS3260G11
HMS3259D19
NCGC00256541-01
tox21_302985
dtxsid9020116 ,
dtxcid10116
6-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1h-1,3,5-triazin-3-ium-2-one
A821115
nsc-758186
MLS002548894
nsc758186
pharmakon1600-01502111
tox21_111032
HMS2231F15
CCG-39046
HY-10586
CS-1287
azacitidine [usan:inn:ban]
m801h13nru ,
unii-m801h13nru
SL-000003
nsc 103-627
LP00035
azacitidine [jan]
azacitidine [who-dd]
azacitidine [iarc]
azacitidine [usan]
azacitidine [hsdb]
onureg
azacitidine [vandf]
azacitidine [ema epar]
1,3,5-triazin-2(1h)-one, 4-amino-1-.beta.-d-ribofuranosyl-
azacitidine [usp-rs]
azacitidine [mi]
azacitidine [orange book]
azacitidine [mart.]
azacitidine [inn]
S1782
AKOS015896938
gtpl6796
onureg (cc-486; oral azacitidine)
bdbm50424715
5ae ,
NC00672
AM83944
SCHEMBL3741
tox21_111032_1
NCGC00090851-10
J-700085
NCGC00260720-01
tox21_500035
NMUSYJAQQFHJEW-KVTDHHQDSA-N
4-amino-1-?-d-ribofuranosyl-1,3,5-triazin-2(1h)-one
azacitidine, pharmaceutical secondary standard; certified reference material
HB1374
4-amino-1-beta-d-ribofuranosyl-1,3,5-tr iazin-2(1h)-one
4-amino-1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1h)-one
SRI-10756_10
SRI-10756_12
4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one
sr-01000075662
SR-01000075662-1
azacitidine, united states pharmacopeia (usp) reference standard
SR-01000075662-3
SR-01000075662-7
azacitidine (vidaza) ,
1401238-97-8
AS-13697
Q416451
BRD-K03406345-001-27-8
BRD-K03406345-001-02-1
NCGC00090851-22
NCGC00090851-14
F10504
azacitidine (5-azacytidine)
azacitidine for
azacitidine (usp-rs)
azacitidina (inn-spanish)
azacitidinum (inn-latin)
5-acz
azacitidineazacitidine
azacitidine (iarc)
l01bc07
4-amino-1-beta-d-ribofuranosyl-d-triazin-2(1h)-one
azacitidine (mart.)
EN300-118700
Z1515383340

Excerpt	Reference	Relevance
" 5-AzadCyd is highly toxic in cultured cells and animals and is utilized as a potent antitumor agent for treatment of certain human cancers."	( Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Jaenisch, R; Jüttermann, R; Li, E, 1994)	0.29
" The high recombinagenic activity of these two drugs suggests that--despite their therapeutic effects against cancer--a question is raised whether these drugs should be considered for adverse effects in cancer chemotherapy."	( Somatic recombination: a major genotoxic effect of two pyrimidine antimetabolitic chemotherapeutic drugs in Drosophila melanogaster. Cunha, KS; de Andrade, HH; Graf, U; Reguly, ML, 2002)	0.31
" The reverse order of treatment produced a higher toxic effect than exposure to each prodrug alone."	( The DNA methylation inhibitor 5-azacytidine modulates 6-thioguanine toxicity in mammalian cells. Barbata, G; Caradonna, F; Sciandrello, G, 2003)	0.32
" Our goal was to see if the assessment of DNA methylation might be a useful tool, when used in conjunction with initial, basic in vitro tests, to provide a more informative preliminary appraisal of the toxic potential of chemicals to prioritize them for further evaluation."	( The value of DNA methylation analysis in basic, initial toxicity assessments. Cockerell, GL; Goodman, JI; McKim, JM; Watson, RE, 2004)	0.32
" Similar to previous studies, we show that mice that are heterozygous for a nonfunctional Dnmt1 gene are partially protected against the deleterious effects of 5-azaCdR; however, methylation levels are not restored in these mice, suggesting that adverse effects are due to another mechanism(s) in addition to DNA hypomethylation."	( Adverse effects of 5-aza-2'-deoxycytidine on spermatogenesis include reduced sperm function and selective inhibition of de novo DNA methylation. Kelly, TL; Oakes, CC; Robaire, B; Trasler, JM, 2007)	0.34
" In conclusion, the combination studied is safe and has significant clinical activity."	( Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Cortes, J; Estey, EH; Estrov, Z; Faderl, S; Garcia-Manero, G; Giles, F; Issa, JP; Kantarjian, HM; Ouzounian, S; Pierce, S; Quezada, A; Ravandi, F; Soriano, AO; Wierda, WG; Yang, H, 2007)	0.34
" The fluorescence properties of dZeb were used to quantify the amount of this analog incorporated into cellular DNA of mismatch repair-deficient cells expressing Dm-dNK and the results showed that in a mismatch correction-defective strain a high percentage of DNA bases may be replaced with the analog without long term toxic effects."	( Use of Drosophila deoxynucleoside kinase to study mechanism of toxicity and mutagenicity of deoxycytidine analogs in Escherichia coli. Betham, B; Bhagwat, AS; Marquez, VE; Shalhout, S, 2010)	0.36
" We recorded adverse reactions described in the medical history."	( [Effectiveness and safety of 5-azacitidine in three patients with myelodysplastic syndromes]. Cuevas Asencio, I; Gago Sánchez, AI; Garzás-Martín de Almagro, MC; Reyes Malia, M, )	0.13
"5-Azacitidine might be considered an effective and relatively safe drug, and may have contributed to controlling peripheral cytopenias, improving the quality of life and delaying progression to leukaemia."	( [Effectiveness and safety of 5-azacitidine in three patients with myelodysplastic syndromes]. Cuevas Asencio, I; Gago Sánchez, AI; Garzás-Martín de Almagro, MC; Reyes Malia, M, )	0.13
" We present previously unpublished data from two large phase III trials describing common adverse events (AEs) associated with azacitidine and methods to manage them."	( Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Backstrom, J; Beach, CL; Fenaux, P; Gore, SD; Hellström-Lindberg, E; List, A; Mufti, GJ; Santini, V; Seymour, JF; Silverman, LR, 2010)	0.36
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."	( Developing structure-activity relationships for the prediction of hepatotoxicity. Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)	0.36
" It appears to be well tolerated, with the most common adverse effects being myelosuppression."	( Safety and efficacy of azacitidine in myelodysplastic syndromes. Garcia-Manero, G; Martin-Santos, T; Vigil, CE, 2010)	0.36
" This requires a good control of the adverse effects of the drug, which are primarily in the first cycles of treatment."	( Adverse effects of azacitidine: onset, duration, and treatment. Martínez-Francés, A, 2011)	0.37
" Common adverse events included fatigue, injection site reactions, constipation, nausea, pruritus and febrile neutropenia."	( Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Abdel-Wahab, O; Berube, C; Bhattacharya, S; Coutre, S; Figueroa, ME; Gallegos, L; Gotlib, JR; Kohrt, HE; Levine, R; Liedtke, M; Medeiros, BC; Melnick, A; Mitchell, BS; Pollyea, DA; Zehnder, J; Zhang, B, 2012)	0.38
" Serum ferritin (SF) was measured monthly, and safety assessment included monitoring of adverse events during treatment and of liver and renal parameters."	( Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population. Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A, 2012)	0.38
" In an attempt to design an efficacious and safe prehematopoietic stem cell transplantation conditioning regimen, we investigated the cytotoxicity of the combination of busulfan (B), melphalan (M), and gemcitabine (G) in lymphoma cell lines in the absence or presence of drugs that induce epigenetic changes."	( Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Andersson, BS; Champlin, RE; Li, Y; Murray, D; Nieto, Y; Valdez, BC; Wang, G, 2012)	0.38
" Our findings suggest that 5'-aza-dC modulating DNA methylation could sensitize paraquat toxic effects on PC12 cell by oxidative stress increment and mitochondrial deficit."	( 5'-Aza-dC sensitizes paraquat toxic effects on PC12 cell. Ba, M; Kong, M; Liang, H; Ma, L; Wang, Y; Yu, Q; Yu, T, 2012)	0.38
" Azacitidine injection is associated with characteristic adverse events (AEs) that must be managed in order for patients to stay on therapy and achieve optimal therapeutic outcomes."	( Counselling and adverse event management for patients with myelodysplastic syndromes undergoing azacitidine therapy: a practice standard for Canadian nurses. Hua-Yung, C; Kurtin, S; Murray, C; Nixon, S; von Riedemann, S; Wereley, A, 2012)	0.38
" Neutropenia was the most common grade 3-4 adverse event."	( Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia. Andreu, R; Badiella, L; Bailén, A; Bargay, J; Brunet, S; Casaño, J; de Miguel, D; Falantes, JF; Figueredo, A; García-Delgado, R; González, JR; Jurado, AF; Medina, A; Ramos, F; Sanz, G; Tormo, M, 2014)	0.4
"Thrombocytopenia is an independent adverse prognostic factor in patients with Myelodysplastic syndromes (MDS)."	( A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. Cherif, H; Chowdhury, O; Garelius, H; Hellström-Lindberg, E; Jacobsen, SE; Lorenz, F; Saft, L; Svensson, T, 2014)	0.4
" Severe adverse events included infectious complications, deep vein thrombosis and transient ischaemic attack."	( A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. Cherif, H; Chowdhury, O; Garelius, H; Hellström-Lindberg, E; Jacobsen, SE; Lorenz, F; Saft, L; Svensson, T, 2014)	0.4
" Decitabine was tolerated at all doses administered, and grade 3 or 4 toxic effects included non-life-threatening hepatotoxicity and hyperglycaemia."	( Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. Benton, CB; Borthakur, G; Dara, S; Franklin, AR; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Kwari, M; O'Brien, S; Pierce, SR; Ravandi, F; Rytting, M; Thomas, DA; Yang, H, 2014)	0.4
" Treatment-emergent adverse events (TEAEs), including treatment-related TEAEs, and serious TEAEs (TESAEs) were recorded throughout the study."	( Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey. Beguin, Y; Bries, G; Deeren, D; Graux, C; Meers, S; Mineur, P; Noens, L; Potier, H; Ravoet, C; Selleslag, D; Theunissen, K; Trullemans, F; Voelter, V; Vrelust, I, 2015)	0.42
" The most common grade 3 or higher adverse events were febrile neutropenia (38 [41%] of 93 patients), pneumonia (27 [29%] of 93 patients), thrombocytopenia (23 [25%] of 93 patients), anaemia (23 [25%] of 93 patients), and sepsis (16 [17%] of 93 patients)."	( Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Azab, M; Chung, W; Daver, N; Griffiths, EA; Hao, Y; Issa, JJ; Jabbour, E; Kantarjian, H; Lowder, JN; Naim, S; O'Connell, C; Oganesian, A; Rizzieri, D; Roboz, G; Stock, W; Taverna, P; Tibes, R; Walsh, K; Yee, K, 2015)	0.42
"1 nm) for 24 hours pretreatment with or without methyltransferase inhibitor 5-aza-2'-deoxycytidine and the reactive oxygen species (ROS) scavenger α-lipoic acid to assess the possible role of methylation and ROS in the toxic effect of TNPs."	( Cross talk between poly(ADP-ribose) polymerase 1 methylation and oxidative stress involved in the toxic effect of anatase titanium dioxide nanoparticles. Bai, W; Chen, Y; Gao, A, 2015)	0.42
" The most common non-hematological adverse events were neutropenia in 21 patients and thrombocytopenia in 17 patients."	( Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes. Fujimaki, K; Kawasaki, R; Miyashita, K; Tomita, N, 2016)	0.43
"Relative risks of treatment-emergent adverse events (TEAEs) and related hospitalization is most accurate when accounting for treatment exposure."	( Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia. Beach, CL; Döhner, H; Dombret, H; Dougherty, D; Gambini, D; Minden, MD; Seymour, JF; Stone, R; Weaver, J, 2017)	0.46
" Most common grade 3-4 treatment-emergent adverse events were neutropenia (52%) and leukopenia (39%)."	( Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes. Beach, CL; Chen, TY; Chen, YC; Chou, WC; Dong, Q; Galettis, A; Hsiao, LT; Laille, E; Lin, SF; Songer, S; Yeh, SP, 2017)	0.46
" Safety was evaluated based on treatment related grades 3-4 adverse events (AEs) and early death (ED) rate."	( Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis. He, PF; Lian, XY; Lin, J; Ma, JC; Qian, J; Wen, XM; Xu, ZJ; Yao, DM; Zhang, ZH; Zhou, JD, 2017)	0.46
" Hence, NIC could exacerbate adverse effects of AZA while antioxidants such as resveratrol (RES) could prevent it."	( Nicotine Exposure Augments Renal Toxicity of 5-aza-cytidine Through p66shc: Prevention by Resveratrol. Arany, I; Dixit, M; Faisal, A; Hall, S, 2017)	0.46
"RES can protect the kidney from adverse effects of NIC in patients undergoing anticancer therapy."	( Nicotine Exposure Augments Renal Toxicity of 5-aza-cytidine Through p66shc: Prevention by Resveratrol. Arany, I; Dixit, M; Faisal, A; Hall, S, 2017)	0.46
" In addressing key issues of reducing toxic side effects and improving pharmacokinetic profiles of the therapeutic agents, we have developed a new formulation by co-packaging DAC and ATO into alendronate-conjugated bone-targeting nanoparticles (BTNPs)."	( Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity. Ferrari, M; Hu, Z; Nizzero, S; Ramirez, MR; Shen, H; Shi, C; Wu, X; Zhang, G; Zhou, J, 2017)	0.46
"Azacitidine was safe and effective in Chinese patients with HR-MDS."	( Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study. Beach, CL; Dong, Q; Du, X; Hu, Y; Jin, J; Lai, YY; Laille, E; Li, X; Liu, T; Shen, ZX; Songer, S; Sun, A; Xiao, Z; Yu, L, 2018)	0.48
" The main adverse reaction was hematological toxicity."	( [The safety of decitabine as bridging pretreatment regimen before hematopoietic stem cell transplantation in pediatric hematological malignancies]. Bian, XN; Fan, LY; Hu, SY; Kong, LJ; Li, J; Ling, J; Liu, H; Lu, J; Xiao, PF; Yao, YH, 2018)	0.48
" The anti-tumor effect and DNA demethylation effect of OR-2003 and OR-2100 were comparable to that of DAC with fewer adverse effects in vivo."	( Novel prodrugs of decitabine with greater metabolic stability and less toxicity. Hattori, N; Iida, N; Kimura, K; Kono, Y; Nakata, Y; Sako, M; Takeshima, H; Ushijima, T, 2019)	0.51
" These compounds are expected to overcome the difficulty in achieving stable pharmacokinetics in patients, leading to maximum DNA demethylation activity with minimum adverse effects."	( Novel prodrugs of decitabine with greater metabolic stability and less toxicity. Hattori, N; Iida, N; Kimura, K; Kono, Y; Nakata, Y; Sako, M; Takeshima, H; Ushijima, T, 2019)	0.51
" The therapentic efficacy and adverse reactions during treatment were compared between 2 groups."	( [Efficacy and Safety of Decitabine Combined with Half-Course Pre-excitation for the Treatment of Elderly Patients with Acute Myeloid Leukemia]. Kong, R; Liu, Q; Qiu, HC; Wang, Y; Wu, DH; Wu, PF; Zhang, XL, 2019)	0.51
" The rate of adverse reactions of digestive tract in combined therapy group was 40."	( [Efficacy and Safety of Decitabine Combined with Half-Course Pre-excitation for the Treatment of Elderly Patients with Acute Myeloid Leukemia]. Kong, R; Liu, Q; Qiu, HC; Wang, Y; Wu, DH; Wu, PF; Zhang, XL, 2019)	0.51
"Combination of disitamine and half-course prestimulation treatmentis is a safe and effective and elderly patients with AML shown a good tolerance."	( [Efficacy and Safety of Decitabine Combined with Half-Course Pre-excitation for the Treatment of Elderly Patients with Acute Myeloid Leukemia]. Kong, R; Liu, Q; Qiu, HC; Wang, Y; Wu, DH; Wu, PF; Zhang, XL, 2019)	0.51
" In hematology, the incidence of AZA-induced cutaneous adverse events (AE) has been known to be relatively high, which has not been well recognized by dermatologists."	( Cutaneous adverse events induced by azacitidine in myelodysplastic syndrome patients: Case reports and a lesson from published work review. Mizukawa, Y; Ohyama, M; Shimoda-Komatsu, Y; Takayama, N, 2020)	0.56
" The most common grade 3 or 4 adverse events were thrombocytopenia (eight [32%] of 25 patients) and hyponatraemia (five [20%])."	( Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial. Abdel-Wahab, O; Alvarez, K; Chung, SS; Gönen, M; Klimek, VM; Mi, X; Paffenholz, SV; Park, JH; Penson, AV; Rampal, RK; Sen, F; Sigler, A; Stein, EM; Tallman, MS; Taylor, J, 2020)	0.56
" Adverse events were manageable with supportive care implementation."	( Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial. Abdel-Wahab, O; Alvarez, K; Chung, SS; Gönen, M; Klimek, VM; Mi, X; Paffenholz, SV; Park, JH; Penson, AV; Rampal, RK; Sen, F; Sigler, A; Stein, EM; Tallman, MS; Taylor, J, 2020)	0.56
" Reviewed here are common adverse events (AEs) during oral azacitidine treatment in QUAZAR AML-001, and practical recommendations for AE management based on guidance from international cancer consortiums, regulatory authorities, and the authors' clinical experience treating patients in the trial."	( Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. Bailey, R; Beach, CL; Chevassut, T; Döhner, H; Dombret, H; Figuera-Alvarez, A; Hiwase, D; La Torre, I; Montesinos, P; Musso, M; Pierdomenico, F; Pocock, C; Ravandi, F; Roboz, GJ; Safah, H; Sayar, H; Selleslag, D; Skikne, B; Sohn, SK; Tse, W; Wei, AH; Zhong, J, 2021)	0.62
" Although arthralgia is common side effect associated with hypomethylating agents, arthritis has not been reported previously."	( Recurrent arthritis as an unexpected side effect associated with azacitidine in a patient with myelodysplastic syndrome. Alhan, FN; Ataş, Ü; Boduroğlu, A; Doğan, Ö; Iltar, U; Salim, O; Sözel, H; Ündar, L; Vural, E; Yücel, OK, 2022)	0.72
" The most common adverse drug reaction (ADR) was injection site reactions (ISR; 91."	( Phase 1/2 study evaluating the safety and efficacy of DSP-7888 dosing emulsion in myelodysplastic syndromes. Aakashi, K; Aotsuka, N; Fujita, J; Goto, M; Iwasaki, H; Kizaki, M; Matsumura, I; Miyazaki, Y; Nakazato, T; Naoe, T; Sekiguchi, N; Sugimoto, S; Takahara-Matsubara, M; Ueda, Y; Usuki, K, 2022)	0.72
"A pharmacovigilance analysis was performed using the FDA Adverse Event Database."	( Safety Signal between Azacitidine and Pericarditis. Aggarwal, P; Chu, B; Venkatakrishnan, A, 2023)	0.91
" The most common indications for azacitidine use in the adverse event reports were myelodysplastic syndrome (48%) and acute myelogenous leukemia (27%)."	( Safety Signal between Azacitidine and Pericarditis. Aggarwal, P; Chu, B; Venkatakrishnan, A, 2023)	0.91
" Data on adverse events were available for 67 patients (67/116, 57."	( How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies. Boyadzhieva, Z; Kötter, I; Krusche, M; Ruffer, N, 2023)	0.91
" Adverse events remain a challenge, especially an elevated risk for venous thromboembolism associated to JAKi treatment should be carefully considered."	( How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies. Boyadzhieva, Z; Kötter, I; Krusche, M; Ruffer, N, 2023)	0.91
" In clinical trials, hematologic toxicity and infection have been observed as adverse events (AEs) of this drug."	( Adverse Event Profile of Azacitidine: Analysis by Route of Administration Using Japanese Pharmacovigilance Database. Fujiwara, M; Muroi, N; Shimizu, T; Uchida, M; Uesawa, Y; Yamaoka, K, 2023)	0.91

Excerpt	Reference	Relevance
"A phase I trial and pharmacokinetic study of 5-aza-2'-deoxycytidine (5-aza-dCyd) were conducted in 21 patients with advanced solid tumors."	( Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients. Gall, HE; Leyva, A; O'Brien, AM; Pinedo, HM; van Groeningen, CJ, 1986)	0.27
" Four adult male rhesus monkeys were given single 10 mg intrathecal (n = 1) or intraventricular (n = 3) doses of AAC to determine its acute toxicity and pharmacokinetic parameters."	( Cerebrospinal fluid pharmacokinetics and toxicology of intraventricular and intrathecal arabinosyl-5-azacytosine (fazarabine, NSC 281272) in the nonhuman primate. Balis, FM; Heideman, RL; McCully, C; Poplack, DG, )	0.13
"To characterize the pharmacokinetic behavior of 5-azacitidine (5-AC), a cytidine nucleoside analog, when given with phenylbutyrate, a histone deaceytlase inhibitor."	( Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. Baker, SD; Carducci, MA; Gilbert, J; Gore, SD; Hartke, C; He, P; Rudek, MA; Zhao, M, 2005)	0.33
" Sufficient 5-AC exposure is achieved to produce pharmacodynamic effects in tumors."	( Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. Baker, SD; Carducci, MA; Gilbert, J; Gore, SD; Hartke, C; He, P; Rudek, MA; Zhao, M, 2005)	0.33
" This has greatly limited application of pharmacokinetic assays to clinical development of decitabine."	( Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Byrd, JC; Chan, KK; Grever, M; Liu, Z; Marcucci, G; Xiao, J, 2006)	0.33
"Azacitidine pharmacokinetic parameters in adolescent patients with renal compromise are not available from the medical literature."	( Azacitidine pharmacokinetics in an adolescent patient with renal compromise. Dalal, J; Gonzalez, C; Kearns, GL; Peters, C; Tsao, CF, 2007)	0.34
" The mean values for terminal phase elimination half-life (0."	( Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cashen, AF; DiPersio, J; Fisher, N; Shah, AK; Todt, L, 2008)	0.35
" Pharmacodynamic analyses included 5-methyl-2'-deoxycytidine levels, MAGE1A CpG island methylation, and fetal hemoglobin (HbF) expression."	( Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. Appleton, K; Barrett, S; Bellenger, K; Brown, R; Jadayel, D; Judson, I; Kaye, SB; Lee, C; Mackay, HJ; Mackay, L; McCormick, C; Plumb, JA; Reade, S; Schätzlein, A; Setanoians, A; Strathdee, G; Tang, A; Twelves, C, 2007)	0.34
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" The authors review the pharmacokinetic data gained from low-dose decitabine, as well as the clinical progress of decitabine in the treatment of hematologic malignancies."	( Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Bryan, J; Garcia-Manero, G; Jabbour, E; Kantarjian, H, 2011)	0.37
" Pharmacodynamic analysis showed FLT3 down-regulation on day 26 of cycle 1 (P = ."	( Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Bloomfield, CD; Blum, W; Byrd, JC; Caligiuri, MA; Chan, KK; Curfman, JP; Devine, SM; Eisfeld, AK; Garr, C; Garzon, R; Geyer, S; Grever, MR; Jacob, S; Kefauver, C; Klisovic, R; Marcucci, G; Perrotti, D; Santhanam, R; Schwind, S; Tarighat, SS; Walker, A; Wang, H; Whitman, S, 2012)	0.38
" We developed a pharmacodynamic model to characterize the interaction between CLO and DEC on an AML cell line and down-regulated p53R2 protein to understand its role."	( Synergism between clofarabine and decitabine through p53R2: a pharmacodynamic drug-drug interaction modeling. Fetterly, GJ; Ghoshal, S; Haese, JP; Karpf, AR; Thudium, KE; Wetzler, M, 2012)	0.38
" Under fed condition, Tmax was delayed ∼1."	( Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies. Boyd, TE; Dong, Q; Laille, E; Savona, MR; Scott, BL; Skikne, B, 2014)	0.4
" Terminal half-life and time to maximum plasma concentration were comparable between groups."	( A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairment. Beach, CL; Gabrail, NY; Goel, S; Kelly, K; Laille, E; Liu, L; Mita, AC; Songer, S, 2014)	0.4
" Part B was designed to evaluate the relative contribution of belinostat to the combination based on analysis of pharmacodynamic markers, and incorporated a design in which patients were randomized during cycle 1 to AZA alone, or the combination, at the maximally tolerated dose of belinostat."	( A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Bennett, M; Fulton, N; Godley, LA; Green, M; Halpern, A; Karrison, T; Koval, G; Larson, RA; Madzo, J; Malnassy, G; Mattison, RJ; Odenike, O; Ratain, MJ; Stock, W; Yee, KW, 2015)	0.42
" Reported here are the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of CC-486 extended dosing schedules in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML) from part 2 of this study."	( Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies. Cogle, CR; Garcia-Manero, G; Gore, SD; Hetzer, J; Kumar, K; Laille, E; MacBeth, KJ; Shi, T; Skikne, B, 2015)	0.42
" In the single dose pharmacokinetic study, Aza concentrations in peripheral blood and lungs were measured by LC-MS method."	( Toxicity and Pharmacokinetic Studies of Aerosolized Clinical Grade Azacitidine. Liang, Y; Perez-Soler, R; Qiu, X; Sellers, RS; Zou, Y, 2016)	0.43
"In pharmacokinetic study, aerosolized Aza was found to deposit mainly into the lung with very little drug detected in the circulation."	( Toxicity and Pharmacokinetic Studies of Aerosolized Clinical Grade Azacitidine. Liang, Y; Perez-Soler, R; Qiu, X; Sellers, RS; Zou, Y, 2016)	0.43
"Clinical and pharmacokinetic effects of azacitidine in higher-risk myelodysplastic syndromes were established in mainly Caucasian populations."	( Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes. Beach, CL; Chen, TY; Chen, YC; Chou, WC; Dong, Q; Galettis, A; Hsiao, LT; Laille, E; Lin, SF; Songer, S; Yeh, SP, 2017)	0.46
" Pharmacokinetic profiles were similar for Taiwanese (N = 12) and North American (N = 45) patients."	( Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes. Beach, CL; Chen, TY; Chen, YC; Chou, WC; Dong, Q; Galettis, A; Hsiao, LT; Laille, E; Lin, SF; Songer, S; Yeh, SP, 2017)	0.46
"Inhaled dry powder 5AZA showed superior pharmacokinetic properties in lung, liver, brain and blood compared to the injected formulation and for all tissues except lung compared to an inhaled aqueous formulation."	( 5-Azacytidine inhaled dry powder formulation profoundly improves pharmacokinetics and efficacy for lung cancer therapy through genome reprogramming. Badenoch, A; Belinsky, SA; Burke, M; Dubose, D; Dye, WW; Grimes, MJ; Kuehl, PJ; Mallis, LM; March, TH; Picchi, MA; Revelli, DA; Sniegowski, T; Tellez, CS; Tessema, M; Vodak, DT, 2020)	0.56
" We report a novel trial design to efficiently evaluate investigational therapies with a primary pharmacodynamic endpoint."	( A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint. Ahuja, N; Anders, RA; Azad, NS; Bever, KM; Christmas, B; Diaz Rivera, EA; Jaffee, EM; Judkins, C; Liu, M; Nauroth, JM; Rosner, GL; Thomas, DL; Thompson, ED; Zhang, J; Zheng, L; Zhu, Q, 2021)	0.62
" This study aimed to develop a population pharmacokinetic (PopPK) model to characterize oral-AZA concentration-time profiles in patients with AML, myelodysplastic syndrome, or chronic myelomonocytic leukemia."	( Population Pharmacokinetics of Oral Azacitidine, and Exposure-Response Analysis in Acute Myeloid Leukemia. Bailey, R; Beach, CL; Gaudy, A; Laille, E; Skikne, B; Zhou, S, 2023)	0.91

Excerpt	Reference	Relevance
" Because of the potentially large antigen load released by such a cell kill, the immune modulator pyran copolymer was also tested in combination with DAC."	( Effects of 5-aza-2'-deoxycytidine in combination with the biochemical modulator thymidine or the immune modulator pyran copolymer on L1210 leukemia-bearing mice. Covey, JM; Zaharko, DS, 1984)	0.27
"The cytotoxicity of vincristine (VCR), beta-cytosine arabinoside (Ara-C), or adriamycin (ADRIA) in combination with 5-azacytidine (Aza-CR) to L1210 leukemia in vivo was measured to determine if schedule-dependent synergistic or antagonistic drug interaction occurred."	( Chemotherapy of L1210 leukemia with 5-azacytidine in combination with vincristine, adriamycin, or beta-cytosine arabinoside. Coulter, DM; Presant, CA; Valeriote, F; Vietti, TJ, 1981)	0.26
" Since most clinical regimens for tumor therapy consist of several drugs, we investigated the antineoplastic action of Ado in combination with 5-aza-2'-deoxycytidine (5-Aza-CdR), a potent inhibitor of DNA methylation or cytosine arabinoside (Ara-C), a potent inhibitor of DNA synthesis."	( Evaluation of the antineoplastic activity of adozelesin alone and in combination with 5-aza-2'-deoxycytidine and cytosine arabinoside on DLD-1 human colon carcinoma cells. Côté, S; Momparler, RL, 1993)	0.29
"5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin has been applied in a treatment protocol for patients with a relapse of acute myeloid or lymphocytic leukemia."	( A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Archimbaud, E; Berneman, Z; Dardenne, M; Dohner, H; Jaksic, B; Jehn, U; Labar, B; Louwagie, EA; Muus, P; Stryckmans, P; Suciu, S; Tjean, M; Wijermans, P; Willemze, R; Zittoun, R, 1997)	0.3
" However, in XRS-5 cells, the drug combination caused a significant increase in the aberrations induced in those chromosomes, but with a concomitant reduction in the randomly induced-aberrations."	( Chromosomal aberrations induced by 5-azacytidine combined with VP-16 (etoposide) in CHO-K1 and XRS-5 cell lines. Cardoso, RS; Dias, FL; Guimarães, AP; Kronka, SN; Sakamoto-Hojo, ET, 2003)	0.32
" In this study, we show for the first time that VPA, in combination with RA and the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (Aza-dC), can overcome the epigenetic barriers to transcription of a prototypical silenced tumor suppressor gene, RARbeta2, in human breast cancer cells."	( Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells. Gudas, LJ; Mongan, NP, 2005)	0.33
"To characterize the pharmacokinetic behavior of 5-azacitidine (5-AC), a cytidine nucleoside analog, when given with phenylbutyrate, a histone deaceytlase inhibitor."	( Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. Baker, SD; Carducci, MA; Gilbert, J; Gore, SD; Hartke, C; He, P; Rudek, MA; Zhao, M, 2005)	0.33
" 5-AC at doses ranging from 10 to 75 mg/m2/d was administered once daily as a subcutaneous injection for 5 to 21 days in combination with phenylbutyrate administered as a continuous intravenous infusion for varying dose and duration every 28 or 35 days."	( Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. Baker, SD; Carducci, MA; Gilbert, J; Gore, SD; Hartke, C; He, P; Rudek, MA; Zhao, M, 2005)	0.33
" These findings suggest that 5-aza-CdR is a promising chemotherapeutical agent for gastric carcinomas, in combination with the anticancer drugs SN38 and GEM, in apoptosis signaling."	( Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma. Hirakawa, K; Ohira, M; Ren, J; Yashiro, M; Zhang, X, 2006)	0.33
" A Phase II study was performed on low-dose decitabine, a DNA methyltransferase inhibitor, in combination with imatinib in patients with CML in accelerated phase (AP) and myeloid blastic phase (BP)."	( Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cortes, J; Garcia-Manero, G; Gharibyan, V; Issa, JP; Jones, D; Kantarjian, HM; Morris, GM; O'brien, S; Oki, Y; Verstovsek, S, 2007)	0.34
"To determine an optimal biologic dose (OBD) of decitabine as a single agent and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute myeloid leukemia (AML)."	( Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. Blum, W; Byrd, JC; Chan, KK; Devine, H; Devine, SM; Grever, MR; Hackanson, B; Heerema, NA; Huynh, L; Kefauver, C; Klisovic, RB; Liu, S; Liu, Z; Lozanski, G; Marcucci, G; Murgo, A; Plass, C; Vukosavljevic, T, 2007)	0.34
" HL-60 and T24 cancer cell lines were treated with azacitidine or decitabine in combination with HC and DNA methylation of LRE1, MAGEA1 and CDKN2A was quantitatively measured by bisulphite-polymerase chain reaction pyrosequencing."	( Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. Byun, HM; Choi, SH; Issa, JP; Kwan, JM; Yang, AS, 2007)	0.34
" These results indicate that decitabine in combination with gemtuzumab is a regimen of promising efficacy worthy of further investigation in controlled trials."	( Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia. Chowdhury, S; Marks, PW; Seropian, S, 2009)	0.35
"This was a phase I trial to determine the minimal effective dose and optimal dose schedule for 5-azacytidine (5-AC) in combination with sodium phenylbutyrate in patients with refractory solid tumors."	( A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Ambinder, RF; Baker, SD; Carducci, MA; Donehower, RC; Gilbert, J; Gore, S; Herman, JG; Jiemjit, A; Lin, J; Rudek, MA; Zhao, M; Zwiebel, JA, 2009)	0.35
" Azacitidine in combination with histone deacetylase inhibitors might offer better efficacy by modulating the methylation and acetylation states of silenced genes."	( Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents. Silverman, LR, 2009)	0.35
" On the basis of preclinical studies indicating that hypomethylating agents can reverse platinum resistance in ovarian cancer cells, the authors conducted a phase 1 trial of low-dose decitabine combined with carboplatin in patients with recurrent, platinum-resistant ovarian cancer."	( A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Balch, C; Breen, T; Fang, F; Kulesavage, C; Li, L; Matei, DE; Nephew, KP; Schilder, J; Shen, C; Snyder, AJ; Zhang, S, 2010)	0.36
"Repetitive low-dose decitabine is tolerated when combined with carboplatin in ovarian cancer patients, and demonstrates biological (ie, DNA-hypomethylating) activity, justifying further testing for clinical efficacy."	( A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Balch, C; Breen, T; Fang, F; Kulesavage, C; Li, L; Matei, DE; Nephew, KP; Schilder, J; Shen, C; Snyder, AJ; Zhang, S, 2010)	0.36
"To investigate the impact of 5-aza-2'-deoxycytidine(5-aza-CdR) combined with imatinib on the proliferation, motility, invasion, and apoptosis of gastrointestinal stromal tumors(GIST) cells in vitro."	( [Therapeutic effect of in vitro 5-aza-2'-deoxycytidine combined with imatinib on gastrointestinal stromal tumor]. Liang, G; Liang, JF; Wu, LN; Xiao, H; Zhao, YZ; Zheng, HX, 2012)	0.38
" These results indicate that 2,4-D pulse combined with AzaC improves SE induction."	( 5-Azacytidine combined with 2,4-D improves somatic embryogenesis of Acca sellowiana (O. Berg) Burret by means of changes in global DNA methylation levels. Caprestano, CA; Fraga, HP; Guerra, MP; Micke, GA; Pescador, R; Spudeit, DA; Steinmacher, DA; Vieira, LN, 2012)	0.38
"5-Azacytidine combined with 2,4-D increases the number of Acca sellowiana somatic embryos."	( 5-Azacytidine combined with 2,4-D improves somatic embryogenesis of Acca sellowiana (O. Berg) Burret by means of changes in global DNA methylation levels. Caprestano, CA; Fraga, HP; Guerra, MP; Micke, GA; Pescador, R; Spudeit, DA; Steinmacher, DA; Vieira, LN, 2012)	0.38
" Patients were treated with escalating doses of decitabine (5-15 mg/m(2)) IV for 10 days in combination with VPA (10-20 mg/kg/day) PO on days 5-21 of a 28-day cycle."	( Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. Aimiuwu, J; Chan, KK; Chu, BF; Grever, MR; Karpenko, MJ; Liu, Z; Otterson, GA; Villalona-Calero, MA, 2013)	0.39
" We hypothesized that epigenetic modulators will reverse chemotherapy resistance, and in this article, we report studies that sought to determine the recommended phase 2 dose (RP2D), safety, and efficacy of decitabine (DAC) combined with TMZ."	( Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Beumer, JH; Buch, SC; Christner, S; Egorin, MJ; Kirkwood, JM; Lin, Y; Moschos, S; Tarhini, AA; Tawbi, HA, 2013)	0.39
"This study was aimed to evaluate the effectiveness and safety of low methylation drug decitabine combined with autologous cytokine induced killer cells (CIK) to treat the elderly patients with acute myeloid leukemia (AML)."	( [Curative effect of decitabine combined with cytokine-induced killer cells in two elderly patients with acute myeloid leukemia]. Cai, LL; Chang, C; Fan, H; Guo, B; Han, WD; Li, SX; Lin, J; Liu, Y; Lu, XC; Ran, HH; Wang, Y; Yang, B; Yang, Y; Zhai, B; Zhang, F; Zhang, L; Zhu, HL, 2013)	0.39
" We conducted a study to evaluate the safety and efficacy of decitabine (a hypomethylating agent) in combination with panitumumab (mAb against EGFR) in mCRC patients."	( A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Boucher, K; Burr, L; Davidson, C; Garrido-Laguna, I; Gilcrease, W; Jakubowski, L; Jones, D; McGregor, KA; Morrell, G; Olpin, JD; Sharma, S; Soldi, R; Wade, M; Weis, J, 2013)	0.39
" Future studies evaluating hypomethylating agents in combination with EGFR mAb in patients with mCRC are warranted."	( A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Boucher, K; Burr, L; Davidson, C; Garrido-Laguna, I; Gilcrease, W; Jakubowski, L; Jones, D; McGregor, KA; Morrell, G; Olpin, JD; Sharma, S; Soldi, R; Wade, M; Weis, J, 2013)	0.39
" Sequential treatment with azacitidine and valproic acid (VPA) in combination with carboplatin may overcome resistance to platinum-based therapy, and we conducted a phase I trial to assess safety, maximum tolerated dose (MTD), and clinical correlates."	( Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Bustinza-Linares, E; Falchook, GS; Fu, S; Hong, DS; Hu, W; Kurzrock, R; Moulder, S; Naing, A; Parkhurst, KL; Sood, AK; Wheler, JJ, 2013)	0.39
" HDACi were combined with ABT-737, which targets the intrinsic apoptosis pathway, recombinant human tumour necrosis factor-related apoptosis-inducing ligand (rhTRAIL/MD5-1), that activates the extrinsic apoptosis pathway or the DNA methyl transferase inhibitor 5-azacytidine."	( Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma. Atadja, P; Banks, KM; Bergsagel, PL; Chesi, M; Doyle, MA; Ellul, J; Faulkner, D; Johnstone, RW; Lefebure, M; Matthews, GM; Shortt, J; Vidacs, E, 2013)	0.39
"Here we investigated the effect of hydrodynamic IL-35-expressing plasmid injection in combination with a methyltransferase inhibitor (decitabine) on immune function and transplantation tolerance in mice."	( Inhibiting cardiac allograft rejection with interleukin-35 therapy combined with decitabine treatment in mice. Guo, H; He, X; Jiang, X; Wang, W; Zhao, N; Zhu, L, 2013)	0.39
" Thus, IL-35 gene therapy combined with decitabine provides a novel approach to induce transplantation tolerance."	( Inhibiting cardiac allograft rejection with interleukin-35 therapy combined with decitabine treatment in mice. Guo, H; He, X; Jiang, X; Wang, W; Zhao, N; Zhu, L, 2013)	0.39
"Decitabine (5-aza-2'-deoxycytidine; DAC) in combination with tetrahydrouridine (THU) is a potential oral therapy for sickle cell disease and β-thalassemia."	( Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice. Chan, K; Covey, JM; Engelke, K; Ling, Y; Saunthararajah, Y; Sharpnack, D; Terse, P, )	0.13
" The differences of clinical outcome and adverse events among the patients treated with decitabine combined with DAG regimen, CAG regimen or "3+7" regimen were analyzed."	( [Comparative analysis of decitabine combined with DAG regimen and other regimens in treatment of refractory/relapsed acute myeloid leukemia]. Chen, Y; Duan, Y; Gu, X; Hao, J; Li, L; Liu, J; Liu, Z; Shen, Z; Wang, L; Wang, Y; Zhao, W, 2014)	0.4
"Decitabine combined with DAG regimen is effective and well tolerated in refractory/relapsed AML patients who were unsuitable for intensive chemotherapy and hematopoietic stem cell transplantation, and the patients with low marrow blast counts are more suitable for the application of decitabine combined with DAG regimen."	( [Comparative analysis of decitabine combined with DAG regimen and other regimens in treatment of refractory/relapsed acute myeloid leukemia]. Chen, Y; Duan, Y; Gu, X; Hao, J; Li, L; Liu, J; Liu, Z; Shen, Z; Wang, L; Wang, Y; Zhao, W, 2014)	0.4
" The present article describes our experience with ultra-low-dose decitabine combined with infusion of autologous cytokine-induced killer (CIK) cells for 2 elderly patients with myelodysplastic syndrome-transformed AML."	( Ultra-low-dose decitabine combined with autologous cytokine-induced killer cells for elderly patients with acute myeloid leukemia transformed from myelodysplastic syndrome. Cai, L; Chi, X; Li, S; Lu, X; Tuo, S; Wang, H; Wang, X; Wu, X; Yang, B; Yang, Y; Yu, R; Zhang, F; Zhu, H, 2014)	0.4
"2 mg/kg three times weekly for 2 weeks (starting on day 1), in combination with oral panobinostat 10, 20, or 30 mg every 96 h (starting on day 8), and oral temozolomide 150 mg/m(2)/day on days 9 through 13."	( Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). Deutsch, J; Frees, M; Laux, D; Leon-Ferre, R; Milhem, M; Smith, BJ; Xia, C, 2014)	0.4
"This triple agent of dual epigenetic therapy in combination with traditional chemotherapy was generally well tolerated by the cohort and appeared safe to be continued in a Phase II trial."	( Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). Deutsch, J; Frees, M; Laux, D; Leon-Ferre, R; Milhem, M; Smith, BJ; Xia, C, 2014)	0.4
"This study was aimed to investigate the clinical characteristics of relapsed-refractory acute myeloid leukemia (AML) with AML1-ETO⁺, and its therapeutic efficacy and side effects when decitabine combined with modified CAG regimen was used."	( [Clinical efficacy of decitabine combined with modified CAG regimen for relapsed-refractory acute myeloid leukemia with AML1-ETO⁺]. Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY, 2014)	0.4
"This study was aimed to investigate the effects of bortezomib combined with 5-azacytidine on the apoptosis of K562 cells and expressiom of SHIP mRNA."	( [Effects of bortezomib combined with 5-azacytidine on the apoptosis of K562 cells and expression of SHIP mRNA]. Jia, ZQ; Rong, HQ; Su, W; Tao, J; Wei, YL; Wei, YT; Yu, CX, 2014)	0.4
"This study was purposed to compare the clinical efficacy and adverse reactions of low-dose decitabine combined with CAG regimen (aclarubicin, Ara-C, and G-CSF) and CAG regimen alone in intermediate to high-risk myelodysplastic syndromes (MDS), and evaluate the validity and efficacy of the former regimen as new treatment method of intermediate to high-risk myelodysplastic syndromes."	( [Comparison of clinical efficacy between decitabine combined with CAG regimen and CAG regimen alone in patients with intermediate to high-risk myelodysplastic syndromes]. Cui, GX; Wu, WZ; Zhang, YP, 2014)	0.4
" The aim of the study presented here was to analyze the effects of a pharmacological inhibition of EZH2 alone and in combination with other anticancer drugs on RTs cells in vitro."	( Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines. Borchardt, C; Clemens, D; Dirksen, U; Frühwald, MC; Kool, M; Unland, R, 2015)	0.42
"Treating MDS/AML with decitabine alone, in combination with half or one course CAG regimen produced high efficacy."	( [The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen]. Chen, S; Fu, Z; Gao, S; Han, Y; Jin, Z; Ma, X; Qiu, H; Sun, A; Tang, X; Wu, D, 2014)	0.4
"In this Phase 1b study, the safety and tolerability of maintenance therapy, comprising lenalidomide (0-25 mg, days 5-25) in combination with azacitidine (50-75 mg/m(2) , days 1-5) every 28 d, was explored in 40 patients with acute myeloid leukaemia (AML) in complete remission after chemotherapy."	( Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia. Avery, S; Fleming, S; Govindaraj, C; McManus, J; Patil, S; Perruzza, S; Plebanski, M; Spencer, A; Stevenson, W; Tan, P; Wei, A, 2015)	0.42
"This study was to investigate the therapeutic effectiveness and side effect of decitabine combined with modified CAG regimen for relapse or refractory patients with acute myeloid leukemia."	( [Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia]. Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY, 2015)	0.42
"After treatment by using decitabine combined with modified CAG regimen, 7 patients achived complete remission, 1 patient achived partial remission, 2 patient did not achieve remission, the overall remission rate was 80% (8/10), the median time of white blood cell count recovery was 18."	( [Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia]. Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY, 2015)	0.42
"The treatment of decitabine combined with modified CAG regimen for relapsed and refractory AML shows high response rate, low side effects, so it worthy to further clinical study."	( [Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia]. Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY, 2015)	0.42
"All patients in this study were treated with decitabine of 15 mg/m2 for 5 days and G-CSF for priming, in combination with cytarabine of 10-mg/m2 q12h for 7 days and aclarubicin of 10 mg/day for 4 days (D-CAG)."	( Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Chen, Y; Ding, J; Duan, L; Gu, J; Hong, M; Li, J; Li, Y; Liu, P; Lu, H; Pan, L; Qian, S; Qiu, H; Shi, J; Wang, J; Wu, H; Xu, J; Xu, Y; Yu, K; Zhang, R; Zhang, S; Zhou, J; Zhou, S; Zhu, H; Zhu, Y, 2015)	0.42
" In this open-label, phase I/II clinical study, we analyzed the toxicity and efficacy of low dose decitabine combined with taxol and platinum chemotherapy in treatment of refractory and recurrent ovarian cancer."	( Low Dose Decitabine Combined with Taxol and Platinum Chemotherapy to Treat Refractory/Recurrent Ovarian Cancer: An Open-Label, Single-Arm, Phase I/II Study. Chen, M; Fu, X; Han, W; Meng, Y; Nie, J; Wang, X; Wang, Y; Zhang, Y, 2015)	0.42
"Low dose decitabine combined with taxol and platinum was well-tolerated and suitable for treating refractory/refractory ovarian cancer."	( Low Dose Decitabine Combined with Taxol and Platinum Chemotherapy to Treat Refractory/Recurrent Ovarian Cancer: An Open-Label, Single-Arm, Phase I/II Study. Chen, M; Fu, X; Han, W; Meng, Y; Nie, J; Wang, X; Wang, Y; Zhang, Y, 2015)	0.42
" Patients are randomized to one of the four treatment groups: DAC alone or in combination with VPA or ATRA or with both add-on drugs."	( DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute mye Cieslik, C; Döhner, K; Grishina, O; Hackanson, B; Lübbert, M; Lubrich, B; May, AM; Müller, MJ; Schmoor, C, 2015)	0.42
"To investigate the therapeutic efficacy and side effects of treating patients with myelodysplastic syndrome-RAEB (MDS-RAEB) and with refractory acute myeloid leukemia (AML) by using decitabine combined with CAG regimen."	( [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia]. Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL, 2015)	0.42
" All the patients received decitabine combined with CAG regimen consisting of decitabine 20 mg/(m(2) · d), d 1-5; aclarubicin 10 mg/d, d 6-13; cytarabine 20 mg/d, d 6-19; G-CSF 300 µg/d, d 6-19."	( [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia]. Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL, 2015)	0.42
"Decitabine combined with CAG regimen is effective and safe for treatment of MDS-RAEB and refractory AML patients, which can prolong lives of patiens with refractory hematological diseases."	( [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia]. Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL, 2015)	0.42
"We conducted a study exploring the clinical safety and efficacy of decitabine in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), combined with a complex karyotype."	( Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively. Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y, 2015)	0.42
"From April 2009 to September 2013, a total of 35 patients with AML/MDS combined with a complex karyotype diagnosed in the First Affiliated Hospital of Soochow University were included for retrospective analysis."	( Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively. Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y, 2015)	0.42
"Decitabine alone or combination with AAG can improve outcome of AML/MDS with a complex karyotype, there being no significant difference decitabine in inducing remission rates in patients with different karyotype."	( Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively. Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y, 2015)	0.42
"In this study we retrospectively analyzed 53 refractory or relapsed CN- AML patients receiving the therapy including decitabine combined with CAG and CAG- like regimen in our center from April 2011 to October 2014."	( [Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen]. Chen, S; Qiu, H; Shen, H; Sun, A; Sun, Y; Wu, D; Xu, Y; Yang, Z, 2015)	0.42
"Decitabine combined with CAG or CAG-like regimen was an effective and safe treatment for refractory or relapsed CN- AML patients."	( [Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen]. Chen, S; Qiu, H; Shen, H; Sun, A; Sun, Y; Wu, D; Xu, Y; Yang, Z, 2015)	0.42
" We conclude that targeting MC2 Ag, combined with epigenetic drug-enhanced antigenicity, allows for significant and tumor-selective T cell responses."	( MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses. Coulie, PG; da Silva, M; Debets, R; Kunert, A; Lamers, C; Sleijfer, S; van Brakel, M; van Steenbergen-Langeveld, S, 2016)	0.43
" We conducted a prospective study of 23 elderly patients (median age, 68 years; range, 60 to 87 years) with newly diagnosed AML to evaluate the efficacy and toxicity of decitabine plus granulocyte colony-stimulating factor priming, low-dose aclarubicin, and cytarabine (DCAG) chemotherapy combined with HLA-mismatched stem cell microtransplantation (SC-MST) without graft-versus-host disease (GVHD) prophylaxis."	( Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen-Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. Chen, Y; Huang, J; Li, J; Li, Y; Lian, Y; Qian, S; Wu, Y; Xie, Y; Zhang, X; Zhao, H; Zhu, Y, 2017)	0.46
" As an extension, 10 additional patients with myelodysplastic syndrome were enrolled to assess the safety and efficacy of pracinostat in combination with azacitidine."	( Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Abaza, YM; Alfonso, A; Borthakur, G; Chang, JE; Chong, TH; Chuah, C; Dong, XQ; Durkes, DE; Estrov, Z; Ferrajoli, A; Foudray, MC; Garcia-Manero, G; Goh, BC; Jabbour, EJ; Kadia, TM; Kantarjian, HM; Koh, LP; Konopleva, MY; Wierda, WG, 2017)	0.46
"To investigate the clinical efficacy of decitabine combined with low-dose IA for treating patients with myelodysplastic syndrome-EB."	( [Clinical Observation of Therapeutic Regimen Consisted of Decitabine Combined with Low-Dose IA Regimen for Myelodysplastic Syndrome-EB]. Hao, JX; Li, J; Wu, D; Zhang, M, 2017)	0.46
"To investigate the clinical efficacy of low-dose decitabine combined with CAG regimen in patients with myelodysplastic syndrome-refractory anemia with excess blasts (MDS-RAEB) through retrospective analysis."	( [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)]. Guo, R; Han, HH; Jiang, ZX; Liu, YF; Sun, H; Wang, M, 2017)	0.46
"Thirty-six patients with MDS-RAEB who ever received low-dose decitabine combined with CAG regimen were enrolled into decitabine + CAG group and 40 patients with MDS-RAEB treated by decitabine alone in our center were enolled into the control group."	( [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)]. Guo, R; Han, HH; Jiang, ZX; Liu, YF; Sun, H; Wang, M, 2017)	0.46
"Low-dose decitabine combined with CAG regimen has better clinical efficacy for patients with MDS-RAEB than that of decitabine alone."	( [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)]. Guo, R; Han, HH; Jiang, ZX; Liu, YF; Sun, H; Wang, M, 2017)	0.46
"To investigate the curative effect and safety of decitabine combined with IAG regimen for treating senile MDS-transformed AML patients."	( [Curative Effect of Decitabine Combined with IAG Regimen for Senile Patients with Myelodysplastic Syndrome (MDS) Transformed Acute Myeloid Leukemia]. Guo, XZ; Huang, YQ; Pan, JX; Wu, SX; Zhang, XY, 2017)	0.46
"Decitabine combined with IAG regimen is an effective for treating senile MDS-transformed AML patients."	( [Curative Effect of Decitabine Combined with IAG Regimen for Senile Patients with Myelodysplastic Syndrome (MDS) Transformed Acute Myeloid Leukemia]. Guo, XZ; Huang, YQ; Pan, JX; Wu, SX; Zhang, XY, 2017)	0.46
"To investigate the therapeutic effectiveness and side effects of decitabine combined with or without cytarabine-based low dose regimen for acute myeloid leukemia in geratic patients."	( [Clinical Efficacy of Decitabine Combined with or without Cytarabine-based Low Dose Regimen for Senile patients with Acute Myeloid Leukemia]. DU, Y; Jing, Y; Li, PF; Liu, M; Peng, CJ; Sun, JZ; Wang, ZH; Yao, YB; Zhou, HW; Zhou, MH, 2018)	0.48
"Decitabine combined with or without cytarabine-based low dose regimen is promising for the treatment of geriatric acute myeloid leukemia, thus improving the overall response rate, and prolonging overall survival time."	( [Clinical Efficacy of Decitabine Combined with or without Cytarabine-based Low Dose Regimen for Senile patients with Acute Myeloid Leukemia]. DU, Y; Jing, Y; Li, PF; Liu, M; Peng, CJ; Sun, JZ; Wang, ZH; Yao, YB; Zhou, HW; Zhou, MH, 2018)	0.48
"To develop new rehabilitation therapies for chronic stroke, this study examined the effectiveness of task-specific training (TST) and TST combined with DNA methyltransferase inhibitor in chronic stroke recovery."	( Effect of Inhibition of DNA Methylation Combined with Task-Specific Training on Chronic Stroke Recovery. Choi, DH; Choi, IA; Kim, HY; Lee, CS; Lee, J, 2018)	0.48
" To evaluate antitumor activity in vivo, 5-aza was administered alone and in combination with temozolomide (TMZ) in a PDX glioma model harboring IDH1 R132H mutation."	( Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. Borodovsky, A; Chan, T; da Costa Rosa, M; Festuccia, WT; Riggins, GJ; Yamashita, AS, 2019)	0.51
"5-Aza provided a survival benefit as a single agent but worked best in combination with TMZ in 2 different IDH1 R132H mutant glioma models."	( Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. Borodovsky, A; Chan, T; da Costa Rosa, M; Festuccia, WT; Riggins, GJ; Yamashita, AS, 2019)	0.51
"In preclinical studies, oral azacitidine (CC-486), a hypomethylating agent, has been shown to have a direct anti-MM effect and in vitro anti-MM synergism when combined with lenalidomide (LEN)."	( Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study). Bergin, K; Bowen, KM; Couto, S; Guzman, R; Kalff, A; Khong, T; Mithraprabhu, S; Ren, Y; Reynolds, J; Spencer, A; Thakurta, A; Wang, M, 2019)	0.51
"Ibrutinib alone or in combination with cytarabine or azacitidine demonstrated an acceptable safety profile."	( Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia. Cortes, JE; Graef, T; Jonas, BA; Luan, Y; Stein, AS, 2019)	0.51
"The objective of this research was to characterize the venetoclax exposure-efficacy and exposure-safety relationships and determine its optimal dose in elderly patients with newly diagnosed acute myeloid leukemia (AML) receiving venetoclax in combination with low intensity therapies (hypomethylating agent [HMA; azacitidine or decitabine] or low-dose cytarabine [LDAC])."	( Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis. Agarwal, S; Friedel, A; Gopalakrishnan, S; Hayslip, J; Kirschbrown, W; Menon, R; Mensing, S; Potluri, J; Salem, AH, 2019)	0.51
"To investigate the efficacy and safety of decitabine combined with half-course pre-excitation for the treatment of elderly patients with acute myeloid leukemia (AML)."	( [Efficacy and Safety of Decitabine Combined with Half-Course Pre-excitation for the Treatment of Elderly Patients with Acute Myeloid Leukemia]. Kong, R; Liu, Q; Qiu, HC; Wang, Y; Wu, DH; Wu, PF; Zhang, XL, 2019)	0.51
"We recommend the "venetoclax + HMAs combined with dose-adjusted CAH/HAG" regimen as an effective treatment for adult R/RAML."	( Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports. Bai, J; Lian, X; Pei, Z; Song, Q; Wang, H; Wang, J; Zhang, B, 2020)	0.56
"To evaluate the efficacy of decitabine combined with low-dose CEG regimen (DCEG) and decitabine combined with low-dose CAG regimen (DCAG) in the treatment of elderly patients with MDS and MDS-transformed acute myeloid leukemia (AML)."	( [Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen]. He, HS; Hua, JS; Li, F; Ma, IX; Wang, XH; Wang, XQ; Wu, M; Xie, YH; Yang, RY; Ye, XJ, 2020)	0.56
" The treament results of decitabine combined with CEG and decitabine combined with CAG were compared."	( [Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen]. He, HS; Hua, JS; Li, F; Ma, IX; Wang, XH; Wang, XQ; Wu, M; Xie, YH; Yang, RY; Ye, XJ, 2020)	0.56
"Decitabine combined with CEG regimen could improve the survival of patients with high-risk MDS and MDS-transformed AML."	( [Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen]. He, HS; Hua, JS; Li, F; Ma, IX; Wang, XH; Wang, XQ; Wu, M; Xie, YH; Yang, RY; Ye, XJ, 2020)	0.56
" Importantly, the drug combination reduced significantly the growth rate of subcutaneous tumors, but in an orthotopic mouse model, the combination did not improve survival and 5-Aza alone provided the best survival benefit."	( Evaluation of a DNA demethylating agent in combination with all-trans retinoic acid for IDH1-mutant gliomas. da Costa Rosa, M; Riggins, GJ; Yamashita, AS, 2022)	0.72
"Use of DNA demethylating agent in combination with retinoids shows promise, but further optimization and preclinical studies are required for treatment of intracranial IDH-mutant gliomas."	( Evaluation of a DNA demethylating agent in combination with all-trans retinoic acid for IDH1-mutant gliomas. da Costa Rosa, M; Riggins, GJ; Yamashita, AS, 2022)	0.72
"Venetoclax (Ven) in combination with azacitidine or decitabine (hypomethylating agent; HMA) is the standard-of-care treatment for older (≥75 years) or intensive chemotherapy ineligible adults with newly diagnosed acute myeloid leukemia (AML)."	( Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia. Arora, S; Bachiashvili, K; Bathini, S; Bhatia, R; Di Stasi, A; Diamond, B; Godby, K; Gupta, U; Jamy, O; Oliver, JD; Rangaraju, S; Salzman, D; Vachhani, P; Worth, S; Zainaldin, C, 2022)	0.72
"The purpose of this study was to identify the incidence, sites and main pathogens, and risk factors for infectious complications occurring in patients with adult acute myeloid leukemia (AML) during the first course of venetoclax combined with decitabine or azacitidine."	( A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia. Chen, RR; Jin, J; Li, L; Mai, WY; Meng, HT; Qian, JJ; Sun, JN; Tong, HY; Wang, LL; Xie, WZ; Ye, XJ; Yu, WJ; Zhang, Y; Zhu, HH; Zhu, LX, 2022)	0.72
"A retrospective cohort analysis was performed of 81 patients with AML older than 14 years who received the first cycle of venetoclax combined with a hypomethylating agent (HMA) between March 2018 and March 2021 at our institution."	( A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia. Chen, RR; Jin, J; Li, L; Mai, WY; Meng, HT; Qian, JJ; Sun, JN; Tong, HY; Wang, LL; Xie, WZ; Ye, XJ; Yu, WJ; Zhang, Y; Zhu, HH; Zhu, LX, 2022)	0.72
"Compared with conventional chemotherapy, the incidence of infectious complications of venetoclax combined with decitabine or azacitidine significantly decreased."	( A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia. Chen, RR; Jin, J; Li, L; Mai, WY; Meng, HT; Qian, JJ; Sun, JN; Tong, HY; Wang, LL; Xie, WZ; Ye, XJ; Yu, WJ; Zhang, Y; Zhu, HH; Zhu, LX, 2022)	0.72
"Using individual patient-level data from the phase 3 VIALE-A trial, this study assessed the cost-effectiveness of venetoclax in combination with azacitidine compared with azacitidine monotherapy for patients newly diagnosed with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy, from a United States (US) third-party payer perspective."	( Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective. Chai, X; Downs, L; Iantuono, E; Ma, E; Montez, M; Nie, X; Pratz, KW; Xie, J; Yin, L, 2022)	0.72
" Low-dose chemotherapy in combination with decitabine or azacitidine showed a similar response rate and prognosis."	( Hypomethylating agents combined with low-dose chemotherapy for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: a real-world clinical experience. Cao, J; Chen, Y; Hu, J; Luo, L; Yang, T; Yang, X; Ye, Y; Zheng, J; Zheng, X; Zheng, Z, 2023)	0.91
" The purpose of this study was to evaluate, from a Canadian perspective, the economic impact of venetoclax in combination with azacitidine (Ven+Aza) for the treatment of patients with newly diagnosed AML who are 75 years or older or who have comorbidities that preclude using IC."	( Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis. Au, Y; Bui, CN; Chai, X; Guinan, K; Lachaine, J; Mathurin, K; Schuh, AC, 2022)	0.72
" Venetoclax is a selective BCL-2 inhibitor, which combined with hypomethylating agents (HMAs), increased responses and prolonged survival in unfit and previously untreated acute myeloid leukemia."	( 15-days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high-risk myelodysplastic syndromes: A retrospective single-center study. Jiang, L; Jin, J; Lang, W; Lu, C; Luo, Y; Ma, L; Mei, C; Ren, Y; Tong, H; Xu, G; Xu, W; Yang, H; Ye, L; Zhou, X; Zhu, H, 2023)	0.91
" In phase I dose escalation, cusatuzumab was then administered on days 3 and 17, in combination with azacitidine (75 mg/m2) on days 1-7, every 28 days."	( Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy. Adès, L; Bacher, U; Bargetzi, M; Fung, S; Gaidano, G; Gandini, D; Hultberg, A; Johnson, A; Ma, X; Müller, R; Nottage, K; Ochsenbein, AF; Pabst, T; Papayannidis, C; Recher, C; Riether, C; Shah, P; Tryon, J; Vey, N; Xiu, L, 2023)	0.91
"Azacitidine (AZA) is a DNA methyltransferase inhibitor and epigenetic modulator that can be an effective agent in combination with chemotherapy for patients with high-risk acute myeloid leukemia (AML)."	( Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy. Cahill, K; Chen, C; Fulton, N; Han, D; He, C; Liang, G; Odenike, O; Stock, W; Wang, L; You, Q; Zhang, W, 2023)	0.91
" We propose venetoclax combined with azacytidine as a useful treatment approach in elderly patients, although clinicians should be mindful that therapeutic modifications may be essential to minimize and/or avoid adverse events."	( Venetoclax Combined with Azacytidine Can Be a First-line Treatment Option for Elderly Blastic Plasmacytoid Dendritic Cell Neoplasm. Fujita, J; Hirose, Y; Kamimura, R; Kiyohara, E; Nagate, Y; Nakaya, A; Nojima, S; Shibayama, H, 2023)	0.91

Excerpt	Reference	Relevance
"The primary objectives of this study were to characterize the absolute bioavailability of azacitidine after subcutaneous (SC) administration and to compare the single-dose pharmacokinetics of azacitidine following SC and intravenous (IV) administration."	( Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. Beach, CL; Eller, M; Lintz, L; Marcucci, G; Silverman, L, 2005)	0.33
" A highly potent and orally bioavailable compound (compound 9) was identified and selected for development."	( Tricyclic HIV integrase inhibitors: potent and orally bioavailable C5-aza analogs. Cai, R; Chen, X; Jabri, S; Jin, H; Kim, CU; Lansdown, R; Metobo, S; Mish, M; Pastor, R; Pyun, P; Tsiang, M; Wright, M, 2008)	0.35
" Despite recent advances in the clinical development of azacytidine, the use of the drug is limited by its low bioavailability and dependency on variably expressed nucleoside transporters for cellular uptake."	( Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy. Brueckner, B; Fichtner, I; Hals, PA; Lyko, F; Markelova, MR; Rius, M; Sandvold, ML, 2010)	0.36
" The bioavailability of azacitidine following subcutaneous administration was 91."	( Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes. Akiyama, H; Ando, K; Hata, T; Hotta, T; Ishikawa, T; Kobayashi, Y; Nakao, S; Ogawa, Y; Ogura, M; Ohashi, H; Ohnishi, K; Ohyashiki, K; Okamoto, S; Ozawa, K; Taniwaki, M; Tobinai, K; Tomita, A; Uchida, T; Usui, N, 2011)	0.37
" However, it exhibits a low oral bioavailability (only 9% in mice), because of low permeability across the intestine membrane and rapid metabolism to inactive metabolite."	( A carrier-mediated prodrug approach to improve the oral absorption of antileukemic drug decitabine. Fan, R; Gao, Y; He, Z; Jin, L; Lian, H; Liu, J; Sun, J; Sun, Y; Xu, Y; Zhang, T; Zhang, Y, 2013)	0.39
"As an initial step towards the clinical translation of these drugs for the treatment of HIV-1 infection, we synthesized decitabine and gemcitabine prodrugs in order to increase drug permeability, which has generally been shown to correlate with increased bioavailability in vivo."	( Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs. Bonnac, L; Clouser, CL; Mansky, LM; Patterson, SE, 2014)	0.4
" The subcutaneous dosing route for consecutive days and reduced bioavailability of 5-azacytidine because of inactivation by cytidine deaminase may limit the expansion of epigenetic therapy into Phase III trials."	( Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model. Belinsky, SA; Cheng, YS; Grimes, MJ; Kuehl, PJ; March, TH; Picchi, MA; Reed, MD; Tellez, CS; Tessema, M, 2013)	0.39
" Tetrahydrouridine, a competitive inhibitor of cytidine deaminase, was used in the combination to improve oral bioavailability of DAC."	( Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice. Chan, K; Covey, JM; Engelke, K; Ling, Y; Saunthararajah, Y; Sharpnack, D; Terse, P, )	0.13
" Appropriate delivery systems able to enrich Decitabine at the site of action and improve its bioavailability would reduce the incidence of toxicity on healthy tissues."	( Novel epigenetic target therapy for prostate cancer: a preclinical study. Cinti, C; Gherardini, L; Grimaldi, S; Naldi, I; Pani, L; Pelosi, G; Taranta, M; Viglione, F, 2014)	0.4
" The review will provide a complete insight to the readers about the mechanisms of action, efficacy to demethylate and re-express various cancer-related genes, anti-tumor activity, cytotoxicity profile, stability, and bioavailability of these drugs."	( Nucleosidic DNA demethylating epigenetic drugs - A comprehensive review from discovery to clinic. Agrawal, K; Das, V; Hajdúch, M; Vyas, P, 2018)	0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"To determine if an oral dosing strategy might be feasible in the clinic with AZA, we attempted to increase the bioavailability of oral AZA through the use of CDZ, in a murine model."	( Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model. Arrate, M; Azab, M; Boyd, K; Fuller, L; Gorska, AE; Keer, H; Oganesian, A; Ramsey, HE; Savona, MR, 2020)	0.56
" We report here the discovery of a novel class of orally bioavailable DNMT1-selective inhibitors as exemplified by GSK3482364."	( Atkins, C; Benowitz, AB; Butlin, R; Cockerill, M; Ennulat, D; Gilmartin, AG; Gore, ER; Groy, A; Halsey, W; Jordan, A; Kruger, RG; Long, ER; Luengo, J; McCabe, MT; McNulty, DE; Montoute, MN; Ogilvie, D; Pappalardi, M; Raoof, A; Rueda, L; Stowell, A; Waddell, I; Wu, Z, 2021)	0.62
" The development of oral HMAs has been an area of active interest; however, oral bioavailability has been quite poor due to rapid metabolism by cytidine deaminase (CDA)."	( Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies. Cahill, K; Odenike, O; Patel, AA; Saygin, C, 2021)	0.62
" Focusing on AML and MDS, this report reviews the rationale for the use of orally bioavailable AZA and its potential use in all-oral combination therapy regimens; the unique pharmacokinetic and pharmacodynamic profile of Oral-AZA compared with injectable AZA; the clinical safety and efficacy of Oral-AZA maintenance therapy in patients with AML in first remission and for treatment of patients with active MDS; and ongoing Oral-AZA clinical trials."	( Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. Beach, CL; Döhner, H; Garcia-Manero, G; La Torre, I; Santini, V; Skikne, B; Wei, AH, 2022)	0.72
"This study aims to prepare gold nanoparticles as a new nano-formula of 5-azacitidine that can improve its bioavailability and decrease its side effects."	( Multifunctional Eldin, SSE; Hassan, AH; Rashed, HM; Sakr, TM; Salem, HF, 2023)	0.91
" Venetoclax is an orally bioavailable small molecule BCL-2 inhibitor that is synergistic with hypomethylating agents."	( Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Alvarado, Y; Andreeff, M; Bazinet, A; Chien, K; Colla, S; Darbaniyan, F; Ganan-Gomez, I; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Masarova, L; McCue, D; Mirabella, B; Montalban-Bravo, G; Ohanian, M; Qiao, W; Ravandi, F; Short, N; Takahashi, K; Yilmaz, M, 2022)	0.72
" Previously, we showed the promising oral bioavailability and antileukemia effects of a new HMA, OR2100 (OR21)."	( Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia. Fukuda-Kurahashi, Y; Hoshiko, T; Kamachi, K; Kawasoe, K; Kimura, S; Kurahashi, Y; Ureshino, H; Watanabe, T; Yamamoto, Y; Yoshida-Sakai, N, 2023)	0.91

Excerpt	Relevance	Reference
" Eighteen patients were treated with 5-azacytidine at a dosage of 200-250 mg/m2/day X 5 intravenously (i."	( A comparative clinical trial of 5-azacytidine and guanazole in previously treated adults with acute nonlymphocytic leukemia. Levi, JA; Wiernik, PH, 1976)	0.26
" 5-Azacytidine was administered subcutaneously at a dosage of 100 mg/m2/day for 10 days."	( Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma. Bellet, RE; Berd, D; Catalano, RB; Mastrangelo, MJ, 1978)	0.26
" Rather stable intravenous dosage forms can be formulated."	( 5-Azacytidine hydrolysis kinetics measured by high-pressure liquid chromatography and 13C-NMR spectroscopy. Chan, KK; Giannini, DD; Sadee, W; Staroscik, JA, 1979)	0.26
" The potential utility of the bisulfite-I addition product as a I prodrug in parenteral and possible oral dosage forms is discussed."	( Stabilization of 5-azacytidine by nucleophilic addition of bisulfite ion. Chatterji, DC; Gallelli, JF, 1979)	0.26
" Mutational dose-response studies with X-rays, ethyl methanesulfonate (EMS), and ICR-191 were conducted in 4 of these revertant cell lines."	( Heritable alterations at the adenine phosphoribosyltransferase (APRT) locus in human lymphoblastoid cell lines. Amundson, SA; Fortunato, JE; Liber, HL, 1992)	0.28
" Both methods can be used to assess the sensitivity of blasts to chemotherapeutic drugs, but different dose-response curves are obtained with each."	( A comparison of the lethal effects in culture of cytosine arabinoside and arabinofuranosyl-5-azacytosine acting on the blast cells fo acute myeloblastic leukemia. McCulloch, EA; Yang, GS, 1992)	0.28
" There is a clear-cut inverse dose-response relationship in leukemia induction, as the higher dose principally shows a lower degree of effectiveness."	( Diaplacental carcinogenic effects of 5-azacytidine in NMRI-mice. Geber, E; Lehmacher, W; Schmahl, W, 1985)	0.27
" A single dose of AZA-C (65 mg/kg, ip) produced increases in hepatic MT concentrations 8 hr after dosing that were still elevated at 48 hr."	( Induction of hepatic metallothionein following 5-azacytidine administration. Poirier, LA; Waalkes, MP, 1985)	0.27
" This enhancement is particularly striking at decreased effector:target ratios (as low as one effector per five targets) and is also demonstrated by a shift to lower concentrations of the phorbol diester dose-response curve."	( Enhancement of phorbol diester-induced HL-60-mediated cytotoxicity by retinoic acid, dimethyl sulfoxide, and 5-azacytidine. Hall, RE; Leftwich, JA, 1986)	0.27
" The induction frequency per viable cell appears to be dose dependent for these four types of radiation, and the dose-response curves are approximately linear."	( Induction of proline prototrophs in CHO-K1 cells by heavy ions. Craise, LM; Mei, MT; Yang, TC, 1986)	0.27
" Dose-response studies (250-3000 rad, 72 hr) indicated that similar dose-response relationships for the appearance of MT in the liver and kidney were observed."	( Increased metallothionein content in rat liver and kidney following X-irradiation. Aono, K; Hashimoto, K; Hayashi, H; Kondoh, S; Shiraishi, N; Takeda, Y; Yamamoto, H, 1986)	0.27
"Sensitivities to drugs acting on cells in culture can be measured as dose-response curves, provided a quantitative assay is available for a relevant cell function."	( Response to 5-azacytidine of leukemic blast cells in suspension: a biological parameter associated with response to chemotherapy. Curtis, JE; McCulloch, EA; Senn, JS; Tritchler, DL; Wang, C, 1987)	0.27
"In mammals, X-chromosome dosage compensation is achieved by inactivating one X chromosome in female cells."	( Effect of ageing on reactivation of the human X-linked HPRT locus. Axelman, J; Beggs, AH; Migeon, BR, 1988)	0.27
" For aza-dC a dose-response relationship was demonstrated for doses up to 50 mg kg-1 (3 times q 12 h); a higher dose resulted in only a slight increase in median survival time (MST)."	( Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia. Colly, LP; Lurvink, E; Richel, DJ; Willemze, R, 1988)	0.27
" We were unable to demonstrate a consistent dosage effect of methionine on fragile X expression."	( The effect of methionine and 5-azacytidine on fragile X expression. Abruzzo, MA; Jacobs, PA; Mayer, M, 1985)	0.27
" Infectious virus and nucleocapsid production were decreased or stopped, depending on the anesthetic dosage used."	( Anesthetic action and virus replication: inhibition of measles virus replication in cells exposed to halothane. Bedows, E; Knight, PR; Nahrwold, ML, 1980)	0.26
"Eight patients with osteogenic sarcoma and seven patients with Ewing's sarcoma, all with advanced metastatic disease refractory to conventional therapy, were treated with 5-azacytidine (NSC-102816) intravenously at a dosage of 150 mg/m2 in three divided doses daily X 5 days."	( Phase II study of 5-azacytidine in sarcomas of bone. Glaubiger, DL; LeVine, AS; Poplack, DG; Reaman, GH; Srinivasan, U, 1982)	0.26
" In dose-response studies 5-azacytidine given daily at 3-4 mg/kg produced maximal Hb F increases."	( 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. DeSimone, J; Hall, L; Heller, P; Zwiers, D, 1982)	0.26
" push in a dosage of 150 mg/m2 for 5 days."	( 4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia. Brodsky, I; Bulova, S; Conroy, JF; Kahn, SB; Lebedda, J; Sklaroff, R, 1983)	0.27
" The frequency of TGr mutations increased linearly with the number of EMS treatments whereas the yield of BrdUrdr mutations showed a curvilinear dose-response curve."	( Mutations resistant to bromodeoxyuridine in mouse lymphoma cells selected by repeated exposure to EMS. Characteristics of phenotypic instability and reversion to HAT resistance by 5-azacytidine. Nakamura, N; Okada, S, 1983)	0.27
" Dose-response curves indicated that the induction of cytokeratin was the result of an interaction of the drug with few targets."	( 5-Azacytidine is able to induce the conversion of teratocarcinoma-derived mesenchymal cells into epithelia cells. Darmon, M; Lamblin, D; Nicolas, JF, 1984)	0.27
" The plasma concentration time data for the first 12 h after dosing was computer fitted to a two compartment open model."	( Pharmacokinetics of 5,6-dihydro-5-azacytidine (NSC-264880) in the foxhound. Cheng, H; Malspeis, L; Staubus, AE, 1983)	0.27
" The establishment of general teratological data revealed clear-cut dose-response relationships after administration of this agent on either day 12 or day 14 of gestation."	( Embryotoxicity of 5-azacytidine in mice. Phase- and dose-specificity studies. Kriegel, H; Schmahl, W; Török, P, 1984)	0.27
" PDGF dose-response curves obtained with the variant cells were shifted approximately an order of magnitude toward higher PDGF concentrations relative to PDGF dose-response curves obtained with the parental 100A cells."	( Growth control variant cell line having increased serum requirement and decreased response to platelet-derived growth factor: reversion by 5-azacytidine. Coppock, DL; Straus, DS, 1984)	0.27
" On replating in graded NaCl, a family of dose-response curves is obtained, rising in level of resistance according to the degree of hypertonicity used to isolate the variants initially."	( Osmotic stress variants in Chinese hamster cells. Harris, M, 1993)	0.29
" The initial dosage was 30 mg/M2/day, 80% of the maximum tolerated dosage in adults, with subsequent 30% dosage escalations."	( A phase I trial of fazarabine in refractory pediatric solid tumors. A Pediatric Oncology Group study. Bernstein, ML; Devine, S; Dubowy, R; Grier, H; Kung, F; Land, V; Murphy, S; Whitehead, VM, 1993)	0.29
" Postimplantation dosing produced an increase in resorptions and a decrease in fetal survival and fetal weight, with no gross external malformations evident."	( Effect of 5-azacytidine administration during very early pregnancy. Cummings, AM, 1994)	0.29
" Twenty-three patients with histologically proven recurrent cervical cancer with measurable disease received FZB at a dosage of 30 mg/m2 per day for 5 days; cycles repeated every 28 days."	( A phase II study of fazarabine (NSC 281272) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. Blessing, JA; Manetta, A; Mann, WJ; Smith, DM, 1995)	0.29
" Both dosages of 5-azacytidine resulted in significant increases in preimplantation loss, and the high dosage of 5-azacytidine caused a decrease in fertility."	( Developmental exposure of male germ cells to 5-azacytidine results in abnormal preimplantation development in rats. Doerksen, T; Trasler, JM, 1996)	0.29
" album female somatic cells, which indicate their distinct transcriptional activities as a possible consequence of the negative dosage compensation of X-linked genes."	( DNA methylation patterns of Melandrium album chromosomes. Castiglione, MR; Siroky, J; Vyskot, B, 1998)	0.3
" The present study was designed to determine the effect of repeated decitabine dosing on HbF levels and hematologic toxicity over a 9-month treatment period."	( Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Bressler, L; DeSimone, J; Dorn, L; Koshy, M; Lavelle, D; Molokie, R; Talischy, N, 2002)	0.31
" Responders were treated at all three decitabine dose levels, and no dose-response correlation was observed."	( Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Andersson, B; Champlin, R; Couriel, D; de Lima, M; Donato, M; Gajewski, J; Giralt, S; Kantarjian, H; Khouri, I; Ravandi, F; Shahjahan, M; van Besien, K, 2003)	0.32
" There was no evidence of a dose-response effect."	( Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Andreeff, M; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, FJ; Issa, JP; Kantarjian, HM; Keating, M; O'Brien, S; Rios, MB; Shan, J; Talpaz, M, 2003)	0.32
" Chronic dosing and sustained increases in hemoglobin F and total hemoglobin levels may be possible."	( Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Bressler, L; Chen, YH; DeSimone, J; Dorn, L; Gavazova, S; Hillery, CA; Hoffman, R; Lavelle, D; Molokie, R; Saunthararajah, Y, 2003)	0.32
" This information sparked further clinical trials using a lower dosing schedule since the original studies using higher doses were associated with significant myelosuppression and induction toxicity."	( Decitabine dosing schedules. Issa, JP; Kantarjian, HM, 2005)	0.33
" Decitabine appears to be a promising new therapy for the treatment of MDS; however, defining the optimal dosing schedule and exploring the possible use in combination with other agents such as the histone deacetylase inhibitors need further evaluation."	( Decitabine in myelodysplastic syndromes. Saba, HI; Wijermans, PW, 2005)	0.33
" Dose-response correlations and the duration of response to aza-deoxycytidine (ADC) and trichostatin A (TSA) were characterized."	( Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. Dowdy, SC; Eberhardt, NL; Gonzalez Bosquet, J; Jiang, SW; Podratz, KC; Xiong, Y; Zhao, Y, 2005)	0.33
"The pharmacology, pharmacokinetics, clinical efficacy, dosage and administration, and safety of azacitidine are reviewed."	( Azacitidine: a novel agent for myelodysplastic syndromes. Hahn, K; Kolesar, JM; Sullivan, M, 2005)	0.33
" The recommended dosage of azacitidine for the first treatment cycle is 75 mg/m(2) daily for seven days."	( Azacitidine: a novel agent for myelodysplastic syndromes. Hahn, K; Kolesar, JM; Sullivan, M, 2005)	0.33
" To ensure proper treatment with azacitidine, nurses should have an understanding of dosage and administration guidelines, commonly observed adverse events, monitoring and care of adverse events, and monitoring of laboratory tests."	( Advances in myelodysplastic syndrome: nursing implications of azacitidine. Demakos, EP; Linebaugh, JA, 2005)	0.33
" One example of epigenetic gene regulation is dosage compensation of the X chromosome in mammalian females."	( X-inactivation status varies in human embryonic stem cell lines. Baetge, EE; Batten, JL; Carpenter, MK; Hall, L; Hoffman, LM; Lawrence, J; Pardasani, D; Young, H, )	0.13
"Since appropriate dosing schedules of decitabine are being investigated, comparison of the clinical effectiveness of 5-AzaC and decitabine would be premature at this time."	( 5-azacytidine and decitabine monotherapies of myelodysplastic disorders. Kuykendall, JR, 2005)	0.33
" The present subcutaneous dosing schedule, 75 mg/m(2) for 7/28 days, is based on early clinical studies and may constitute a practical problem for patients."	( A pharmacodynamic study of 5-azacytidine in the P39 cell line. Aggerholm, A; Hassan, M; Hellström-Lindberg, E; Hokland, P; Khan, R, 2006)	0.33
" The model provides information about the relation between azacytidine dose intensity and exposure time on malignant myeloid cells, which could serve as a rationale for further clinical development of practical, safe, and cost-effective dosing schedules."	( A pharmacodynamic study of 5-azacytidine in the P39 cell line. Aggerholm, A; Hassan, M; Hellström-Lindberg, E; Hokland, P; Khan, R, 2006)	0.33
" Major responses associated with cytogenetic complete response developed in patients receiving prolonged dosing schedules of aza-CR."	( Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Baylin, S; Carducci, M; Carraway, H; Dauses, T; Dover, G; Galm, O; Gore, SD; Grever, M; Herman, JG; Jiemjit, A; Karp, JE; Manning, J; Mays, A; Miller, CB; Murgo, A; Rudek, MA; Smith, BD; Sugar, E; Weng, LJ; Zhao, M; Zwiebel, J, 2006)	0.33
"MTT method and flow cytometry were used to detect the growth and apoptosis of Daudi cells after treated with different dosage of 5-Aza-CdIR."	( [SHP-1 gene's methylation status of Daudi lymphoma cell and the demethylation effect of 5-aza-2'-deoxycytidine]. Fang, JC; Feng, ZY; He, D; He, XL; Li, L; Qiu, G; Su, ZL; Zhu, MF, 2006)	0.33
"The PK of this dosing regimen was evaluated in sixteen patients with MDS or AML."	( Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cashen, AF; DiPersio, J; Fisher, N; Shah, AK; Todt, L, 2008)	0.35
"0 ng/ml, and the mean area under the plasma concentration-time curve (AUC0-infinity), 152-163 ng h/ml, were unchanged during dosing of decitabine for 3 days."	( Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cashen, AF; DiPersio, J; Fisher, N; Shah, AK; Todt, L, 2008)	0.35
"Decitabine dosed at 15 mg/m2 iv every 8 h for 3 days resulted in a predictable and manageable toxicity profile in patients with MDS/AML."	( Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cashen, AF; DiPersio, J; Fisher, N; Shah, AK; Todt, L, 2008)	0.35
" Patients with >24% methylation may benefit from alternative dosing or combination strategies."	( CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Chronis, C; Ho, A; John, A; Khan, S; Mufti, GJ; Pomplun, S; Raj, K; Samuel, J; Thomas, NS, 2007)	0.34
" Ongoing studies are evaluating alternative dosing schedules for these drugs and the activity and safety of this class of agent in combination with histone deacetylase inhibitors."	( Use of hypomethylating agents in myelodysplastic syndromes. Atallah, E; Garcia-Manero, G, 2007)	0.34
" Since these low-dose regimens are well-tolerated with minimal toxicity, they are suitable for chronic dosing to maintain promoter hypomethylation and expression of target genes."	( Oral decitabine reactivates expression of the methylated gamma-globin gene in Papio anubis. Chin, J; Desimone, J; Hankewych, M; Lavelle, D; Phiasivongsa, P; Redkar, S; Roxas, B; Saunthararajah, Y; Singh, M; Tang, C; Vaitkus, K; Will, R, 2007)	0.34
" Our data show that, in addition to gene dosage changes arising from LOI and hypermethylation-induced gene silencing, gene activation resulting from hypomethylation is also prevalent in WTs."	( Hypomethylation and aberrant expression of the glioma pathogenesis-related 1 gene in Wilms tumors. Baker, JA; Brown, KW; Chilukamarri, L; Dallosso, AR; Greenhough, A; Hancock, AL; Huang, TH; Malik, K; Malik, S; Royer-Pokora, B; Zabkiewicz, J, 2007)	0.34
" Recent clinical trials investigate new dosing schedules, routes of administration, and combination regimens."	( Current status of epigenetic treatment in myelodysplastic syndromes. Kuendgen, A; Lübbert, M, 2008)	0.35
" Optimizing dosing schedules of decitabine to maximize hypomethylation (low dose, high dose intensity, and multiple cycles) have further improved results, suggesting that decitabine is an active therapy that alters the natural course of MDS."	( Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, H, 2008)	0.35
" Further research is needed to determine the appropriate patient selection and dosing schedules."	( Review: recent clinical trials in epigenetic therapy. Issa, JP; Oki, Y, 2006)	0.33
" Meanwhile, adoption of a co-solvent mixture as the reaction medium could also greatly lower the enzyme dosage and the molar ratio of acyl donor to 5-azacytidine."	( Efficiently enhancing regioselective acylation of 5-azacytidine catalysed by Candida antarctica lipase B with co-solvent mixtures as the reaction media. Chen, X; Wu, H; Zong, M, 2009)	0.35
"Azacitidine (AZA) is effective treatment for myelodysplastic syndromes (MDS) at a dosing schedule of 75 mg/m(2)/d subcutaneously for 7 days every 4 weeks."	( Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. Backstrom, JT; Beach, CL; Cohn, AL; Cosgriff, TM; Fernando, IJ; Gersh, RH; Hainsworth, JD; Lyons, RM; McIntyre, HJ; Modi, SS, 2009)	0.35
"All three alternative dosing regimens produced HI, RBC transfusion independence, and safety responses consistent with the currently approved AZA regimen."	( Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. Backstrom, JT; Beach, CL; Cohn, AL; Cosgriff, TM; Fernando, IJ; Gersh, RH; Hainsworth, JD; Lyons, RM; McIntyre, HJ; Modi, SS, 2009)	0.35
" This study assessed the efficacy and safety of an alternative dosing regimen administered on an outpatient basis in academic and community-based practices."	( Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. Albitar, M; Arora, S; Baer, MR; Buckstein, R; Cullen, MT; Garcia-Manero, G; Godley, LA; Kantarjian, H; Larsen, JS; Slack, JL; Steensma, DP, 2009)	0.35
"Three dosing regimens were studied in 27 patients with advanced solid tumors, and toxicity was recorded."	( A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Ambinder, RF; Baker, SD; Carducci, MA; Donehower, RC; Gilbert, J; Gore, S; Herman, JG; Jiemjit, A; Lin, J; Rudek, MA; Zhao, M; Zwiebel, JA, 2009)	0.35
" Recent clinical trials have been investigating new dosing schedules, routes of administration, and combination of decitabine with other agents, including histone deacetylase (HDAC) inhibitors."	( Decitabine. Blagitko-Dorfs, N; Daskalakis, M; Hackanson, B, 2010)	0.36
" Hematologic AEs, most frequently observed during early treatment cycles, decreased during subsequent cycles and were usually managed with dosing delays (23-29%)."	( Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Backstrom, J; Beach, CL; Fenaux, P; Gore, SD; Hellström-Lindberg, E; List, A; Mufti, GJ; Santini, V; Seymour, JF; Silverman, LR, 2010)	0.36
" The present results show the applicability of our novel statistical methodology for quantitatively assessing drug synergy across a wide range of doses of agents with complex dose-response profiles, a methodology with great potential for advancing the development of chemopreventive combinations."	( Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention. Fujimoto, J; Hong, WK; Kong, M; Lee, JJ; Lotan, R, 2010)	0.36
"This study aims to determine the optimal dosing and administration route for azacitidine to reduce global DNA methylation levels in the peripheral blood of patients with hematologic malignancies."	( A phase I biological study of azacitidine (Vidaza™) to determine the optimal dose to inhibit DNA methylation. Bernstein, I; Byun, HM; Douer, D; Gorospe, G; Groshen, S; Hergesheimer, J; Mohrbacher, A; O'Connell, C; Yang, AS, )	0.13
" The hydralazine dose was given according with the acetylator phenotype, and valproate was dosed at 30 mg/kg/day."	( Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. Arias-Bofill, D; Candelaria, M; Cervera, E; de la Cruz-Hernández, E; Dueñas-Gonzalez, A; González-Fierro, A; Herrera, A; Labardini, J; Pérez-Cárdenas, E; Taja-Chayeb, L; Trejo-Becerril, C; Vidal, S, 2011)	0.37
" Hence, the study on the systems reported herein could provide a good basis for designing aza nucleoside prodrug systems that are less hydrophilic than their parental drugs and can be used, in different dosage forms, to release the parent drug in a controlled manner."	( Prodrugs of aza nucleosides based on proton transfer reaction. Karaman, R, 2010)	0.36
" The recommended dosage of azacitidine is 75 mg/m(2) daily for 7 days, with different treatment schedules validated."	( Safety and efficacy of azacitidine in myelodysplastic syndromes. Garcia-Manero, G; Martin-Santos, T; Vigil, CE, 2010)	0.36
" However, the sequential schedule of decitabine 10 mg/m(2)/day on days 1 to 5 and vorinostat 200 mg twice a day on days 6 to 12 was more deliverable than both MTDs with fewer delays on repeated dosing and it represents the recommended phase II (RP2D) dose of this combination."	( Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Chen, EX; Egorin, MJ; Espinoza-Delgado, I; Hirte, HW; Holleran, JL; Hotte, SJ; Laughlin, A; McGill, S; Moretto, P; Oza, AM; Siu, LL; Stathis, A; Stayner, LA; Wang, L; Webster, S; Zhang, WJ, 2011)	0.37
" The US Food and Drug Administration has approved a 5-day outpatient decitabine dosing regimen, which might reduce administration costs compared with the standard 3-day inpatient regimen."	( Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective. Fleurence, R; Kim, E; Knopf, K; Linnehan, JE; Pan, F; Peng, S, 2010)	0.36
"The aim of this study was to assess the cost-effectiveness of 5-day dosing of decitabine versus BSC in US patients with intermediate- and high-risk MDS from a US payer perspective."	( Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective. Fleurence, R; Kim, E; Knopf, K; Linnehan, JE; Pan, F; Peng, S, 2010)	0.36
"In this study, decitabine administered on a 5-day dosing schedule was likely a cost-effective treatment option in patients with intermediate- and high-risk MDS from a US payer perspective."	( Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective. Fleurence, R; Kim, E; Knopf, K; Linnehan, JE; Pan, F; Peng, S, 2010)	0.36
" Most importantly, the elevated gene dosage of DNMT3B is associated with increased resistance to the growth-inhibitory effect mediated by DNA demethylating agents."	( DNMT3B gene amplification predicts resistance to DNA demethylating drugs. Esteller, M; Melo, SA; Simó-Riudalbas, L, 2011)	0.37
" Erlotinib was dosed at 150 mg daily, and 5-azacytidine was escalated by increasing the number of daily doses of 75 mg/m(2) per cycle."	( A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies. Bauman, J; Belinsky, S; Fekrazad, M; Jones, D; Lee, SJ; Muller, C; Ravindranathan, M; Rutledge, T; Verschraegen, C, 2012)	0.38
" The present study assessed an effective treatment dosage based on the cell viability, cytotoxicity, apoptosis and methylation assays for the investigated cell lines."	( Integrated epigenetics of human breast cancer: synoptic investigation of targeted genes, microRNAs and proteins upon demethylation treatment. Barekati, Z; Bitzer, J; Grussenmeyer, T; Hartmann, N; Jenoe, P; Kohler, C; Lefkovits, I; Letzkus, M; Moes, S; Radpour, R; Schumacher, MM; Staedtler, F; Zhong, XY, 2011)	0.37
" No grade 3 or 4 nonhematological toxicity was observed during either dosing schedule."	( Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development. Balch, C; Bonney, PL; Dhawan, D; Fang, F; Guo, Z; Hahn, NM; Hartman-Frey, C; Jones, DR; Knapp, DW; Kwon, EM; Nephew, KP; Ostrander, EA; Parker, HG, 2012)	0.38
" Migration was affected weakly by combined high dosage irradiation/5‑Aza treatment."	( Pharmacological genome demethylation increases radiosensitivity of head and neck squamous carcinoma cells. Brieger, J; Fruth, K; Koutsimpelas, D; Mann, SA; Mann, WJ; Pongsapich, W, 2012)	0.38
" A great deal remains to be learned about the optimal dosing and scheduling of the DNMT inhibitors, alone and in combination."	( New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome. Gore, SD, 2011)	0.37
" Over the years, the dosing of decitabine has been refined, such that for acute myeloid leukemia, a 5-day schedule of 20 mg/m(2) is now commonly utilized."	( Decitabine for acute myeloid leukemia. Marks, PW, 2012)	0.38
" Treatment with valproic acid (VPA), a histone deacetylase inhibitor, at 3 dosing regimens (300mg/kg at D2-9PP; 100mg/kg at D2-4PP, 200mg/kg at D5-7PP, 300mg/kg at D8-9PP; 100mg/kg at D2-5PP, 200mg/kg at D6-9PP) prior to daily separation reversed such a decrease in fear-potentiated startle."	( Neonatal isolation decreases cued fear conditioning and frontal cortical histone 3 lysine 9 methylation in adult female rats. Chen, LH; Cheng, LY; Cherng, CG; Kao, GS; Su, CC; Tzeng, WY; Wang, CY; Yu, L, 2012)	0.38
" This novel dosing schedule has yet to be evaluated in a Phase 3 trial."	( The role of decitabine for the treatment of acute myeloid leukemia. Ganetsky, A, 2012)	0.38
"Differential progression of global DNA hypomethylation was studied by comparatively dosing zebularine (ZEB) and 5-azacytidine (AZA)."	( 3-D DNA methylation phenotypes correlate with cytotoxicity levels in prostate and liver cancer cell models. Gertych, A; Oh, JH; Tajbakhsh, J; Wawrowsky, KA; Weisenberger, DJ, 2013)	0.39
" The subcutaneous dosing route for consecutive days and reduced bioavailability of 5-azacytidine because of inactivation by cytidine deaminase may limit the expansion of epigenetic therapy into Phase III trials."	( Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model. Belinsky, SA; Cheng, YS; Grimes, MJ; Kuehl, PJ; March, TH; Picchi, MA; Reed, MD; Tellez, CS; Tessema, M, 2013)	0.39
"5-AZn-2' deoxycytidylic acid had significant inhibition effect on proliferation of A549 cells in vitro, and the inhibition was notably dependent on time and dosage during 48-72 h; SOD level was significantly lower than those of control group (P<0."	( Effect of 5- AZn-2 '-deoxycytidine on proliferation of human lung adenocarcinoma cell line A549 in vitro. Cui, W; Huang, HQ; Li, N; Zhang, GS, 2013)	0.39
" An oral azacitidine formulation would allow extended dosing schedules, potentially improving safety and/or efficacy."	( Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies. Boyd, TE; Dong, Q; Laille, E; Savona, MR; Scott, BL; Skikne, B, 2014)	0.4
" However, the prolonged administration of AZA by itself seems to increase HN rate compared with standard dosing and warrants additional investigation."	( Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. Czader, M; Erba, HP; Figueroa, ME; Gabrilove, J; Gore, SD; Greenberg, PL; Herman, J; Juckett, M; Ketterling, R; Litzow, M; Malick, L; Melnick, A; Paietta, E; Prebet, T; Smith, MR; Sun, Z; Tallman, MS, 2014)	0.4
" A total of 79 patients received reduced dosage decitabine treatment (15 mg/M2/day intravenously for five consecutive days every four weeks)."	( Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis. Chang, C; Chen, Y; Hou, M; Li, X; Song, L; Song, Q; Su, J; Wu, D; Wu, L; Xu, F; Zhang, X; Zhang, Z; Zhou, L, 2014)	0.4
" Recent and ongoing clinical trials investigate new dosing schedules, routes of administration, and combination of decitabine with other agents, including histone deacetylase inhibitors."	( Decitabine. Daskalakis, M; Hackanson, B, 2014)	0.4
" Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days including a 2-day break (AZA 5-2-2); or 7 days (AZA 7); all 28-day cycles."	( Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia. Andreu, R; Badiella, L; Bailén, A; Bargay, J; Brunet, S; Casaño, J; de Miguel, D; Falantes, JF; Figueredo, A; García-Delgado, R; González, JR; Jurado, AF; Medina, A; Ramos, F; Sanz, G; Tormo, M, 2014)	0.4
" First, we defined conditions for which clinically relevant dosing could induce sustained induction of RNA and protein."	( A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene. Baylin, SB; Beaty, R; Bunz, F; Cui, Y; Hausheer, F; Issa, JP; Zahnow, C, 2014)	0.4
" The 75 mg/m2 dosing group received 4 additional days of SC azacitidine."	( A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairment. Beach, CL; Gabrail, NY; Goel, S; Kelly, K; Laille, E; Liu, L; Mita, AC; Songer, S, 2014)	0.4
"Azacitidine is dose proportional over the 25-100 mg/m2 dosing range."	( A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairment. Beach, CL; Gabrail, NY; Goel, S; Kelly, K; Laille, E; Liu, L; Mita, AC; Songer, S, 2014)	0.4
" HI and red blood cell TI rates were similar regardless of administration route or dosing schedule."	( Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA registry. Grinblatt, DL; Komrokji, RS; Narang, M; Sekeres, MA; Sullivan, KA; Swern, AS, 2015)	0.42
" We summarize the results of recent preclinical studies and clinical trials for decitabine and discuss the connections among its hypomethylating effect, immune-activated mechanisms and clinical activity in solid tumors, keeping in mind the goal of optimizing dosing schedules."	( Decitabine: a promising epi-immunotherapeutic agent in solid tumors. Fu, X; Han, W; Li, X; Mei, Q; Nie, J, 2015)	0.42
" To reveal the effect of AZA dosage on infection risk we limited our analysis to the infection rate after the first AZA dose alone."	( Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome. Akria, L; Arad, A; Aviv, A; Braester, A; Dally, N; Filanovsky, K; Gafter-Gvili, A; Gatt, ME; Hellmann, I; Herishanu, Y; Herzog-Tzarfati, K; Leiba, R; Merkel, D; Mittelman, M; Nagler, A; Nemets, A; Ofran, Y; Ronson, A; Rouvio, O; Silbershatz, I; Tadmor, T; Vidal, L; Yeganeh, S, 2015)	0.42
" All patients were treated with AZA at the standard dosage of 75 mg/m(2)."	( Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. Alimena, G; Andriani, A; Andrizzi, C; Ciccone, F; De Gregoris, C; Di Veroli, A; Latagliata, R; Maurillo, L; Montanaro, M; Villivà, N; Voso, MT, 2015)	0.42
"1% and 30-month overall survival rate after decitabine dosing 61."	( [Therapeutic efficacies of decitabine application prior to hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia]. Fu, C; Han, Y; Jin, Z; Liu, H; Ma, L; Miao, M; Qiu, H; Tang, X; Wang, J; Wang, P; Wu, D; Yan, S; Zheng, H; Zhou, J, 2015)	0.42
" In part 1 of this two-part study, a 7-day CC-486 dosing schedule showed clinical activity, was generally well tolerated, and reduced DNA methylation."	( Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies. Cogle, CR; Garcia-Manero, G; Gore, SD; Hetzer, J; Kumar, K; Laille, E; MacBeth, KJ; Shi, T; Skikne, B, 2015)	0.42
" Median number of CC-486 treatment cycles was 7 (range 2-24) for the 14-day dosing schedule and 6 (1-24) for the 21-day schedule."	( Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Cogle, CR; Edenfield, WJ; Garcia-Manero, G; Gore, SD; Hetzer, J; Kambhampati, S; Kumar, K; Laille, E; MacBeth, KJ; Scott, B; Shi, T; Skikne, B; Tefferi, A, 2016)	0.43
" Oral administration of azacitidine may enhance patient convenience, eliminate injection-site reactions, allow for alternative dosing and scheduling, and enable long-term treatment."	( Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Boyd, T; Cogle, CR; Garcia-Manero, G; Scott, BL, 2015)	0.42
" In vitro experiments suggested that concurrent dosing showed stronger synergy than sequential dosing."	( The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia. Al-Kali, A; Bhagavatula, K; Bogenberger, JM; Delman, DH; Foran, JM; Hansen, N; Mesa, RA; Mohan, J; Oliver, GR; Rakhshan, F; Tibes, R; Wood, T, 2015)	0.42
" The 5-AZA-CdR was selected as a representative demethylation agent to validate the principle of the TDQ method on three levels: significant dose-response relationships between the concentration of 5-AZA-CdR and the methylation level of promoters, mRNA expression level of the EGFP gene, and the fluorescence intensity of EGFP proteins."	( A novel quantification method for the total demethylation potential of aquatic sample extracts from Bohai Bay using the EGFP reporter gene. Guo, C; Han, M; Jiang, Y; Liang, B; Lv, Z; Nie, J; Qian, Y; Wang, X; Wei, Y; Wu, J; Yang, Y; Zhang, J, 2015)	0.42
"Our results provide an alternative approach for predicting what combinations, dosing and scheduling of drug delivery should be used to better individualize therapy of AML."	( Synergisitic and Antagonistic AML Cell Type-specific Responses to 5-Aza-2-deoxycitidine and 1-h-D-Arabinofuranoside. Arceci, RJ; Elmoneim, AA; Heuston, E; Triche, T; Wai, DH, 2016)	0.43
"Patients received a median of five cycles of Aza (range, 2-9) and sorafenib with a median daily dosage of 750 mg (range 400-800) for 129 d (range, 61-221)."	( Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT. Dienst, A; Germing, U; Haas, R; Heyn, C; Kobbe, G; Kondakci, M; Nachtkamp, K; Rautenberg, C; Schmidt, PV; Schroeder, T, 2017)	0.46
" Higher rates of treatment discontinuation may partially explain these results, suggesting alternative dosing and schedules to improve tolerability may be required to determine the potential of the combination."	( Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. Abaza, Y; Anz, B; Babu, S; Berdeja, JG; Boccia, R; DeZern, AE; Essell, J; Garcia-Manero, G; Ghalie, R; Heller, B; Jabbour, E; Kantarjian, HM; Komrokji, RS; Kuriakose, P; Lyons, RM; Maris, M; Montalban-Bravo, G; Ravandi, F; Reeves, J; Roboz, GJ; Sekeres, MA; Wright, D, 2017)	0.46
"X-chromosome inactivation is a mechanism of dosage compensation in which one of the two X chromosomes in female mammals is transcriptionally silenced."	( A high-throughput small molecule screen identifies synergism between DNA methylation and Aurora kinase pathways for X reactivation. Bartolomei, MS; Bedalov, A; Carrette, LL; Dial, TO; Hasaka, T; Jadhav, A; Kesner, B; Lee, JT; Lessing, D; Maloney, DJ; Payer, B; Simeonov, A; Szanto, A; Theriault, J; Wei, C, 2016)	0.43
" The levels of phospho-nuclear factor-kappa B (pNF-ĸB)(Thr) decreased with increasing dosage of Dox in different groups, while down-regulation of heat shock protein 70 (HSP70) was observed only in the AzaC+Dox group of cells."	( Azacytidine-induced Chemosensitivity to Doxorubicin in Human Breast Cancer MCF7 Cells. Khan, GN; Kim, EJ; Lee, SH; Shin, TS, 2017)	0.46
" To aid clinicians in their daily clinical practice, we also comment on some practical aspects such as dosing and schedule, the choice of HMA and the use of complementary cellular therapies."	( Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. Germing, U; Haas, R; Kobbe, G; Rautenberg, C; Schroeder, T, 2018)	0.48
" Several dose-response experiments were carried out during two periods, including not only the very first days of development (0-6 days post-fertilization, dpf), as done in previous studies, but also, and as a novelty, the period of gonadal development (10-30 dpf)."	( Treatment with a DNA methyltransferase inhibitor feminizes zebrafish and induces long-term expression changes in the gonads. Imués, MA; Piferrer, F; Ribas, L; Vanezis, K, 2017)	0.46
" By dosing schedule, 24·7% received AZA for seven consecutive days, 12·4% for six consecutive days and 62·9% by 5-2-2."	( Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada. Buckstein, R; Cheung, MC; Fallahpour, S; Gill, T; Lau, O; Maloul, A; Mozessohn, L; Zhang, L, 2018)	0.48
" Oral CC-486 allows extended dosing to prolong azacitidine activity."	( CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. Champlin, RE; Craddock, C; de Lima, M; Giralt, SA; Hetzer, J; Hubbell, B; Laille, E; Oran, B; Papadopoulos, EB; Scott, BL; Skikne, BS; William, BM, 2018)	0.48
" This study of extended CC-486 dosing included patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML)."	( Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies. Becerra, C; Conkling, P; Dong, Q; Kellerman, A; Kingsley, EC; Kolibaba, K; Laille, E; Morris, JC; Rifkin, RM; Savona, MR; Skikne, BS; Ukrainskyj, SM, 2018)	0.48
" Future studies with higher doses and/or increased dosing frequency are warranted."	( Infusion of 5-Azacytidine (5-AZA) into the fourth ventricle or resection cavity in children with recurrent posterior Fossa Ependymoma: a pilot clinical trial. Fletcher, S; Hagan, J; Miesner, E; Patel, R; Sabin, J; Sandberg, DI; Shah, MN; Sirianni, RW; Smith, S; Taylor, MD; Yu, B, 2019)	0.51
" These results highlight that stable epigenetic changes are possible following a single dose of RT and may have significant clinical implications for cancer treatment involving recurrent or fractionated dosing regimens."	( DNA methylation changes following DNA damage in prostate cancer cells. Ambrose, M; Berry, R; Brettingham-Moore, KH; Holloway, AF; Jeffreys, SA; Joo, JE; Phillips, JL; Skala, M; Sutton, LP; Taberlay, PC; Young, A, 2019)	0.51
"Multiple cycles of azacitidine and midostaurin were not well-tolerated, but persistent inhibition of FLT3 wild-type phosphorylation suggest intermittent dosing of midostaurin should be considered in future low-intensity regimens for FLT3-mutant AML."	( A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia. Cooper, BW; Craig, MD; Gallogly, MM; Kane, DM; Lazarus, HM; Levis, MJ; Metheny, L; Tomlinson, BK; William, BM, 2020)	0.56
"To determine if an oral dosing strategy might be feasible in the clinic with AZA, we attempted to increase the bioavailability of oral AZA through the use of CDZ, in a murine model."	( Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model. Arrate, M; Azab, M; Boyd, K; Fuller, L; Gorska, AE; Keer, H; Oganesian, A; Ramsey, HE; Savona, MR, 2020)	0.56
"Following pharmacokinetic and pharmacodynamic assessment of oral AZA dosed with CDZ in murine and monkey models, we tested this regimen in vivo with a human cell line-derived xenograft transplantation experiment (CDX)."	( Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model. Arrate, M; Azab, M; Boyd, K; Fuller, L; Gorska, AE; Keer, H; Oganesian, A; Ramsey, HE; Savona, MR, 2020)	0.56
" Although extensive data exist for adult myeloid malignancies, there are limited preclinical data on the efficacy and/or dosing of venetoclax for pediatric myelodysplastic syndrome (MDS) or AML and thus little information to guide use of this regimen in pediatric patients."	( Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia. Franklin, AK; Gore, L; Maloney, KW; Treece, AL; Winters, AC, 2020)	0.56
" However, as the efficacy and safety of rational dosing regimens are lacking, we evaluated the effectiveness and safety of reduced-dose azacitidine (AZA) vs."	( Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study. Du, X; Hu, N; Pan, L; Qin, T; Qu, S; Wang, B; Wang, X; Xiao, Z; Xu, Z, 2021)	0.62
" Both HMAs led to objective hematologic or non-hematologic AEs (27%-43%), while dosage modification/delay were more frequent in patients treated with azacitidine (81% vs."	( Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review. Deng, C; Du, X; Geng, S; Huang, X; Li, M; Weng, J; Wu, P; Xu, R, 2021)	0.62
" Careful patient selection and alternative dosing schedule is needed in future clinical trials to evaluate clinical outcome."	( Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes? Atallah, E; Badar, T, 2021)	0.62
" Avelumab was dosed at 3 mg/kg for the first 7 patients and at 10 mg/kg for the subsequent 12 patients."	( A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Alexander, L; Andreeff, M; Borthakur, G; Bueso-Ramos, C; Cheung, CM; Daver, N; DiNardo, CD; Garcia-Manero, G; Herbrich, SM; Jabbour, E; Kadia, TM; Konopleva, MY; Kornblau, S; Loghavi, S; Pemmaraju, N; Pierce, SA; Ravandi, F; Saxena, K; Tang, G; Wang, SA, 2021)	0.62
" AEs infrequently required permanent discontinuation of oral azacitidine (13%), suggesting they were effectively managed with use of concomitant medications and oral azacitidine dosing modifications."	( Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. Bailey, R; Beach, CL; Chevassut, T; Döhner, H; Dombret, H; Figuera-Alvarez, A; Hiwase, D; La Torre, I; Montesinos, P; Musso, M; Pierdomenico, F; Pocock, C; Ravandi, F; Roboz, GJ; Safah, H; Sayar, H; Selleslag, D; Skikne, B; Sohn, SK; Tse, W; Wei, AH; Zhong, J, 2021)	0.62
" Although extended dosing may provide the optimal scheduling, the reliance of injectable formulation of the drug limits it to intermittent treatment."	( Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes. Lane, SW; Straube, J; Vu, T, 2021)	0.62
" Oral-AZA allows convenient extended AZA dosing for 14 days per 28-day treatment cycle, which is not feasible with injectable AZA."	( Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. Beach, CL; Döhner, H; Garcia-Manero, G; La Torre, I; Santini, V; Skikne, B; Wei, AH, 2022)	0.72
" This phase 1/2 open-label study evaluated the safety and efficacy of DSP-7888 dosing emulsion in patients with myelodysplastic syndromes (MDS)."	( Phase 1/2 study evaluating the safety and efficacy of DSP-7888 dosing emulsion in myelodysplastic syndromes. Aakashi, K; Aotsuka, N; Fujita, J; Goto, M; Iwasaki, H; Kizaki, M; Matsumura, I; Miyazaki, Y; Nakazato, T; Naoe, T; Sekiguchi, N; Sugimoto, S; Takahara-Matsubara, M; Ueda, Y; Usuki, K, 2022)	0.72
" Additional studies are needed to establish safe dosing for patients with hepatic impairment."	( FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy. de Claro, RA; Gehrke, BJ; Jen, EY; Lee, SL; Leong, R; Li, H; Li, M; Ma, L; McLamore, S; Ni, N; Przepiorka, D; Theoret, MR; Vallejo, J; Wang, X, 2022)	0.72
" In this review, we discuss the path to regulatory approval of azacitidine and decitabine, highlighting the substantial efforts that have been made to optimize the dosing schedule and administration of these drugs, including the development of new, oral formulations of both agents."	( Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions. Kantarjian, H; Short, NJ, 2022)	0.72
"Low-dose azacitidine (AZA) regimens, primarily 5-day AZA, have been used in lower risk myelodysplastic syndrome (LrMDS) but they have yet to be directly compared to the standard 7-day, uninterrupted dosing schedule."	( Five-day versus 7-day treatment regimen with azacitidine in lower risk myelodysplastic syndrome: A phase 2, multicenter, randomized trial. Choi, EJ; Hong, J; Kim, YJ; Lee, JH; Lee, KH; Park, S; Park, SY; Shin, DY; Yoon, SS, 2022)	0.72
" However, the dosage of venetoclax is fixed, irrespective of body surface area (BSA) or weight."	( Utility of therapeutic drug monitoring of venetoclax in acute myeloid leukemia. Kobayashi, M; Kosugi, N; Suzaki, K; Yasu, T, 2022)	0.72
" Given the role of TET2 as a regulator of genomic methylation, we hypothesized that mutant TET2 allele dosage affects response to 5'-Aza."	( Biallelic TET2 mutations confer sensitivity to 5'-azacitidine in acute myeloid leukemia. Alharbi, A; Allan, JM; Allsop, D; Altmann, H; Altschuler, SJ; Ariceta, B; Bell, HL; Blair, H; Bornhäuser, M; Bowes, E; Bziuk, Z; Diaz, RA; Dill, C; Elstob, C; Fadly, M; Fitzgibbon, J; Fordham, SE; Haferlach, T; Heidenreich, O; Jackson, GH; Jones, GL; Kunadt, D; Lin, WY; Marr, HJ; Martinez-Lopez, J; Meggendorfer, M; Menne, T; Mohr, B; Montesinos, P; Nandana, D; Onel, K; Park, C; Piddock, R; Prosper, F; Rahman, T; Robinson, A; Röllig, C; Ruhnke, L; Soura, EN; Stölzel, F; Villar, S; Wagenführ, L; Wobus, M; Wu, LF, 2023)	0.91
" Dosage adjustments for drug interactions and safety varied between centers."	( Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy. Belhabri, A; Bertoli, S; Billotey, NC; Bulabois, C; Cartet, E; Dumas, PY; Fornecker, L; Giltat, A; Guepin, GR; Guerineau, E; Houyou, D; Hunault, M; Kaphan, E; Lachenal, F; Laloi, L; Laribi, K; Michallet, AS; Michallet, M; Michel, C; Morisset, S; Paul, F; Pigneux, A; Puisset, F; Récher, C; Rocher, C; Santagostino, A; Simand, C; Simonet, MB; Tabrizi, R; Villate, A, 2023)	0.91
"To observe the efficacy and safety of different induction regimens of same total dosage of azacitidine (Aza), including standard dose (standard dose group) and low-dose long-term (adjusted dose group), in the treatment of elderly acute myeloid leukemia (AML)."	( [Multicenter Prospective Study of Different Induction Regimens of Azacytidine in Treatment of Elderly Patients with Acute Myeloid Leukemia]. Chu, XX; Deng, XZ; Liu, XD; Ran, XH; Wang, CZ; Wang, L; Wang, LQ; Yang, EQ; Yu, HY; Zhao, CT, 2023)	0.91

Role	Description
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
N-glycosyl-1,3,5-triazine
nucleoside analogue	An analogue of a nucleoside, being an N-glycosyl compound in which the nitrogen-containing moiety is a modified nucleotide base. They are commonly used as antiviral products to prevent viral replication in infected cells.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	0.5623	0.0032	45.4673	12,589.2998	AID2517
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	39.8107	0.0447	17.8581	100.0000	AID485294
interleukin 8	Homo sapiens (human)	Potency	0.9439	0.0473	49.4806	74.9780	AID651758
glp-1 receptor, partial	Homo sapiens (human)	Potency	2.5119	0.0184	6.8060	14.1254	AID624417
pregnane X receptor	Rattus norvegicus (Norway rat)	Potency	28.6288	0.0251	27.9203	501.1870	AID651751
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	2.0298	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
ATAD5 protein, partial	Homo sapiens (human)	Potency	7.6285	0.0041	10.8903	31.5287	AID493106; AID493107; AID504466; AID504467; AID624248; AID624249; AID624251; AID624252
Fumarate hydratase	Homo sapiens (human)	Potency	28.9342	0.0030	8.7949	48.0869	AID1347053
NFKB1 protein, partial	Homo sapiens (human)	Potency	2.2387	0.0282	7.0559	15.8489	AID895; AID928
PPM1D protein	Homo sapiens (human)	Potency	13.1373	0.0052	9.4661	32.9993	AID1347411
TDP1 protein	Homo sapiens (human)	Potency	5.8941	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	17.3491	0.0007	14.5928	83.7951	AID1259369; AID1259392
Thrombopoietin	Homo sapiens (human)	Potency	3.1623	0.0251	7.3048	31.6228	AID917; AID918
AR protein	Homo sapiens (human)	Potency	3.4863	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID588515; AID588516; AID743035; AID743042; AID743054; AID743063
Smad3	Homo sapiens (human)	Potency	14.5015	0.0052	7.8098	29.0929	AID588855
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	22.3872	0.0112	12.4002	100.0000	AID1030
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	5.3080	0.0006	57.9133	22,387.1992	AID1259378
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	28.9314	0.0010	22.6508	76.6163	AID1224838; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	3.8599	0.0004	17.9460	75.1148	AID1346784; AID1347036
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	9.2494	0.0123	7.9835	43.2770	AID1346984; AID1645841
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	4.5787	0.0002	14.3764	60.0339	AID588533; AID720692
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	37.0293	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	1.9880	0.0008	17.5051	59.3239	AID1159527; AID1159531; AID588544
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	2.6708	0.0015	30.6073	15,848.9004	AID1224819; AID1224820; AID1224821; AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	1.0964	0.3758	27.4851	61.6524	AID743220
pregnane X nuclear receptor	Homo sapiens (human)	Potency	7.4593	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	11.5270	0.0002	29.3054	16,493.5996	AID588513; AID588514; AID743069; AID743075; AID743078
polyprotein	Zika virus	Potency	28.9342	0.0030	8.7949	48.0869	AID1347053
67.9K protein	Vaccinia virus	Potency	3.7970	0.0001	8.4406	100.0000	AID720579; AID720580
Parkin	Homo sapiens (human)	Potency	6.5131	0.8199	14.8306	44.6684	AID720572
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	29.6906	0.0010	24.5048	61.6448	AID588535; AID743215
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	0.8913	0.0010	19.4141	70.9645	AID588536
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	31.6228	0.0237	23.2282	63.5986	AID588541
arylsulfatase A	Homo sapiens (human)	Potency	3.7933	1.0691	13.9551	37.9330	AID720538
IDH1	Homo sapiens (human)	Potency	1.6360	0.0052	10.8652	35.4813	AID686970
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	0.0224	0.0355	20.9770	89.1251	AID504332
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	11.8832	0.0007	23.0674	1,258.9301	AID743085
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	10.9841	0.0017	23.8393	78.1014	AID743083
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	0.1188	0.0016	28.0151	77.1139	AID1259385
activating transcription factor 6	Homo sapiens (human)	Potency	22.8756	0.1434	27.6121	59.8106	AID1159516; AID1159519
Bloom syndrome protein isoform 1	Homo sapiens (human)	Potency	0.0016	0.5406	17.6392	96.1227	AID2364; AID2528
peripheral myelin protein 22 isoform 1	Homo sapiens (human)	Potency	30.1313	23.9341	23.9341	23.9341	AID1967
hemoglobin subunit beta	Homo sapiens (human)	Potency	1.2589	0.3162	9.0861	31.6228	AID931
cellular tumor antigen p53 isoform a	Homo sapiens (human)	Potency	3.1623	0.3162	12.4435	31.6228	AID924
chromobox protein homolog 1	Homo sapiens (human)	Potency	100.0000	0.0060	26.1688	89.1251	AID540317
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	11.0772	0.0003	23.4451	159.6830	AID743065; AID743067
huntingtin isoform 2	Homo sapiens (human)	Potency	12.5893	0.0006	18.4198	1,122.0200	AID1688
ras-related protein Rab-9A	Homo sapiens (human)	Potency	100.0000	0.0002	2.6215	31.4954	AID485297
serine/threonine-protein kinase mTOR isoform 1	Homo sapiens (human)	Potency	5.1807	0.0037	8.6189	23.2809	AID2660; AID2667; AID2668
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	2.0768	0.0006	27.2152	1,122.0200	AID651741; AID743202; AID743219
urokinase-type plasminogen activator precursor	Mus musculus (house mouse)	Potency	0.7943	0.1585	5.2879	12.5893	AID540303
plasminogen precursor	Mus musculus (house mouse)	Potency	0.7943	0.1585	5.2879	12.5893	AID540303
urokinase plasminogen activator surface receptor precursor	Mus musculus (house mouse)	Potency	0.7943	0.1585	5.2879	12.5893	AID540303
geminin	Homo sapiens (human)	Potency	2.2968	0.0046	11.3741	33.4983	AID463097; AID504364; AID624296; AID624297
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	0.0161	0.0056	12.3677	36.1254	AID624032
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	31.6228	0.2512	15.8432	39.8107	AID504327
muscarinic acetylcholine receptor M1	Rattus norvegicus (Norway rat)	Potency	1.1220	0.0010	6.0009	35.4813	AID943
lamin isoform A-delta10	Homo sapiens (human)	Potency	3.4569	0.8913	12.0676	28.1838	AID1459; AID1487
Interferon beta	Homo sapiens (human)	Potency	13.1373	0.0033	9.1582	39.8107	AID1347411
Cellular tumor antigen p53	Homo sapiens (human)	Potency	3.7363	0.0023	19.5956	74.0614	AID651631; AID651743; AID720552
Integrin beta-3	Homo sapiens (human)	Potency	3.1623	0.3162	11.4157	31.6228	AID924
Integrin alpha-IIb	Homo sapiens (human)	Potency	3.1623	0.3162	11.4157	31.6228	AID924
D(1A) dopamine receptor	Sus scrofa (pig)	Potency	0.7362	0.0037	8.1081	23.2809	AID2667
Nuclear receptor ROR-gamma	Homo sapiens (human)	Potency	3.3491	0.0266	22.4482	66.8242	AID651802
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	28.1838	0.0096	10.5250	35.4813	AID1479145
ATPase family AAA domain-containing protein 5	Homo sapiens (human)	Potency	3.9478	0.0119	17.9420	71.5630	AID651632; AID720516
Ataxin-2	Homo sapiens (human)	Potency	7.9781	0.0119	12.2221	68.7989	AID588378; AID651632
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	0.3815	0.0601	10.7453	37.9330	AID485367; AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Adenosine receptor A3	Homo sapiens (human)	Ki	2.8450	0.0000	0.9306	10.0000	AID1802102
DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)	IC50 (µMol)	0.3000	0.0186	1.6488	6.0000	AID1505769
Adenosine receptor A2a	Homo sapiens (human)	Ki	2.8450	0.0000	1.0609	9.7920	AID1802102
Adenosine receptor A1	Homo sapiens (human)	Ki	2.8450	0.0002	0.9316	10.0000	AID1802102
Multidrug and toxin extrusion protein 1	Homo sapiens (human)	IC50 (µMol)	500.0000	0.0100	2.7656	10.0000	AID721754
Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0025	1.1480	9.2000	AID1505768
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activity	Integrin beta-3	Homo sapiens (human)
positive regulation of protein phosphorylation	Integrin beta-3	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Integrin beta-3	Homo sapiens (human)
positive regulation of cell-matrix adhesion	Integrin beta-3	Homo sapiens (human)
cell-substrate junction assembly	Integrin beta-3	Homo sapiens (human)
cell adhesion	Integrin beta-3	Homo sapiens (human)
cell-matrix adhesion	Integrin beta-3	Homo sapiens (human)
integrin-mediated signaling pathway	Integrin beta-3	Homo sapiens (human)
embryo implantation	Integrin beta-3	Homo sapiens (human)
blood coagulation	Integrin beta-3	Homo sapiens (human)
positive regulation of endothelial cell migration	Integrin beta-3	Homo sapiens (human)
positive regulation of gene expression	Integrin beta-3	Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiation	Integrin beta-3	Homo sapiens (human)
positive regulation of fibroblast migration	Integrin beta-3	Homo sapiens (human)
negative regulation of lipid storage	Integrin beta-3	Homo sapiens (human)
response to activity	Integrin beta-3	Homo sapiens (human)
smooth muscle cell migration	Integrin beta-3	Homo sapiens (human)
positive regulation of smooth muscle cell migration	Integrin beta-3	Homo sapiens (human)
platelet activation	Integrin beta-3	Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathway	Integrin beta-3	Homo sapiens (human)
cell-substrate adhesion	Integrin beta-3	Homo sapiens (human)
activation of protein kinase activity	Integrin beta-3	Homo sapiens (human)
negative regulation of lipid transport	Integrin beta-3	Homo sapiens (human)
regulation of protein localization	Integrin beta-3	Homo sapiens (human)
regulation of actin cytoskeleton organization	Integrin beta-3	Homo sapiens (human)
cell adhesion mediated by integrin	Integrin beta-3	Homo sapiens (human)
positive regulation of cell adhesion mediated by integrin	Integrin beta-3	Homo sapiens (human)
positive regulation of osteoblast proliferation	Integrin beta-3	Homo sapiens (human)
heterotypic cell-cell adhesion	Integrin beta-3	Homo sapiens (human)
substrate adhesion-dependent cell spreading	Integrin beta-3	Homo sapiens (human)
tube development	Integrin beta-3	Homo sapiens (human)
wound healing, spreading of epidermal cells	Integrin beta-3	Homo sapiens (human)
cellular response to platelet-derived growth factor stimulus	Integrin beta-3	Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathway	Integrin beta-3	Homo sapiens (human)
wound healing	Integrin beta-3	Homo sapiens (human)
apoptotic cell clearance	Integrin beta-3	Homo sapiens (human)
regulation of bone resorption	Integrin beta-3	Homo sapiens (human)
positive regulation of angiogenesis	Integrin beta-3	Homo sapiens (human)
positive regulation of bone resorption	Integrin beta-3	Homo sapiens (human)
symbiont entry into host cell	Integrin beta-3	Homo sapiens (human)
platelet-derived growth factor receptor signaling pathway	Integrin beta-3	Homo sapiens (human)
positive regulation of fibroblast proliferation	Integrin beta-3	Homo sapiens (human)
mesodermal cell differentiation	Integrin beta-3	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Integrin beta-3	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Integrin beta-3	Homo sapiens (human)
negative regulation of lipoprotein metabolic process	Integrin beta-3	Homo sapiens (human)
negative chemotaxis	Integrin beta-3	Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosol	Integrin beta-3	Homo sapiens (human)
regulation of serotonin uptake	Integrin beta-3	Homo sapiens (human)
angiogenesis involved in wound healing	Integrin beta-3	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Integrin beta-3	Homo sapiens (human)
platelet aggregation	Integrin beta-3	Homo sapiens (human)
cellular response to mechanical stimulus	Integrin beta-3	Homo sapiens (human)
cellular response to xenobiotic stimulus	Integrin beta-3	Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferation	Integrin beta-3	Homo sapiens (human)
blood coagulation, fibrin clot formation	Integrin beta-3	Homo sapiens (human)
maintenance of postsynaptic specialization structure	Integrin beta-3	Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalization	Integrin beta-3	Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trapping	Integrin beta-3	Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreading	Integrin beta-3	Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathway	Integrin beta-3	Homo sapiens (human)
regulation of trophoblast cell migration	Integrin beta-3	Homo sapiens (human)
regulation of extracellular matrix organization	Integrin beta-3	Homo sapiens (human)
cellular response to insulin-like growth factor stimulus	Integrin beta-3	Homo sapiens (human)
negative regulation of endothelial cell apoptotic process	Integrin beta-3	Homo sapiens (human)
positive regulation of T cell migration	Integrin beta-3	Homo sapiens (human)
cell migration	Integrin beta-3	Homo sapiens (human)
positive regulation of leukocyte migration	Integrin alpha-IIb	Homo sapiens (human)
cell-matrix adhesion	Integrin alpha-IIb	Homo sapiens (human)
integrin-mediated signaling pathway	Integrin alpha-IIb	Homo sapiens (human)
angiogenesis	Integrin alpha-IIb	Homo sapiens (human)
cell-cell adhesion	Integrin alpha-IIb	Homo sapiens (human)
cell adhesion mediated by integrin	Integrin alpha-IIb	Homo sapiens (human)
inflammatory response	Adenosine receptor A3	Homo sapiens (human)
signal transduction	Adenosine receptor A3	Homo sapiens (human)
activation of adenylate cyclase activity	Adenosine receptor A3	Homo sapiens (human)
regulation of heart contraction	Adenosine receptor A3	Homo sapiens (human)
negative regulation of cell population proliferation	Adenosine receptor A3	Homo sapiens (human)
response to wounding	Adenosine receptor A3	Homo sapiens (human)
regulation of norepinephrine secretion	Adenosine receptor A3	Homo sapiens (human)
negative regulation of cell migration	Adenosine receptor A3	Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activity	Adenosine receptor A3	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Adenosine receptor A3	Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathway	Adenosine receptor A3	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
DNA methylation-dependent heterochromatin formation	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
DNA-templated transcription	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
positive regulation of gene expression	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
negative regulation of gene expression	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
methylation	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
epigenetic programming of gene expression	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylation	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
cellular response to amino acid stimulus	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
chromosomal DNA methylation maintenance following DNA replication	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
cellular response to bisphenol A	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell apoptotic process	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell differentiation involved in phenotypic switching	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
synaptic transmission, dopaminergic	Adenosine receptor A2a	Homo sapiens (human)
response to amphetamine	Adenosine receptor A2a	Homo sapiens (human)
regulation of DNA-templated transcription	Adenosine receptor A2a	Homo sapiens (human)
phagocytosis	Adenosine receptor A2a	Homo sapiens (human)
apoptotic process	Adenosine receptor A2a	Homo sapiens (human)
inflammatory response	Adenosine receptor A2a	Homo sapiens (human)
cellular defense response	Adenosine receptor A2a	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
cell-cell signaling	Adenosine receptor A2a	Homo sapiens (human)
synaptic transmission, cholinergic	Adenosine receptor A2a	Homo sapiens (human)
central nervous system development	Adenosine receptor A2a	Homo sapiens (human)
blood coagulation	Adenosine receptor A2a	Homo sapiens (human)
sensory perception	Adenosine receptor A2a	Homo sapiens (human)
locomotory behavior	Adenosine receptor A2a	Homo sapiens (human)
blood circulation	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of cell population proliferation	Adenosine receptor A2a	Homo sapiens (human)
response to xenobiotic stimulus	Adenosine receptor A2a	Homo sapiens (human)
response to inorganic substance	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of glutamate secretion	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmission	Adenosine receptor A2a	Homo sapiens (human)
regulation of norepinephrine secretion	Adenosine receptor A2a	Homo sapiens (human)
response to purine-containing compound	Adenosine receptor A2a	Homo sapiens (human)
response to caffeine	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Adenosine receptor A2a	Homo sapiens (human)
synaptic transmission, glutamatergic	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of urine volume	Adenosine receptor A2a	Homo sapiens (human)
vasodilation	Adenosine receptor A2a	Homo sapiens (human)
eating behavior	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of vascular permeability	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of neuron apoptotic process	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleep	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of alpha-beta T cell activation	Adenosine receptor A2a	Homo sapiens (human)
astrocyte activation	Adenosine receptor A2a	Homo sapiens (human)
neuron projection morphogenesis	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of protein secretion	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of inflammatory response	Adenosine receptor A2a	Homo sapiens (human)
regulation of mitochondrial membrane potential	Adenosine receptor A2a	Homo sapiens (human)
membrane depolarization	Adenosine receptor A2a	Homo sapiens (human)
regulation of calcium ion transport	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Adenosine receptor A2a	Homo sapiens (human)
excitatory postsynaptic potential	Adenosine receptor A2a	Homo sapiens (human)
inhibitory postsynaptic potential	Adenosine receptor A2a	Homo sapiens (human)
prepulse inhibition	Adenosine receptor A2a	Homo sapiens (human)
apoptotic signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of long-term synaptic potentiation	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
temperature homeostasis	Adenosine receptor A1	Homo sapiens (human)
response to hypoxia	Adenosine receptor A1	Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathway	Adenosine receptor A1	Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system process	Adenosine receptor A1	Homo sapiens (human)
negative regulation of acute inflammatory response	Adenosine receptor A1	Homo sapiens (human)
negative regulation of leukocyte migration	Adenosine receptor A1	Homo sapiens (human)
positive regulation of peptide secretion	Adenosine receptor A1	Homo sapiens (human)
positive regulation of systemic arterial blood pressure	Adenosine receptor A1	Homo sapiens (human)
negative regulation of systemic arterial blood pressure	Adenosine receptor A1	Homo sapiens (human)
regulation of glomerular filtration	Adenosine receptor A1	Homo sapiens (human)
protein targeting to membrane	Adenosine receptor A1	Homo sapiens (human)
phagocytosis	Adenosine receptor A1	Homo sapiens (human)
inflammatory response	Adenosine receptor A1	Homo sapiens (human)
signal transduction	Adenosine receptor A1	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Adenosine receptor A1	Homo sapiens (human)
cell-cell signaling	Adenosine receptor A1	Homo sapiens (human)
nervous system development	Adenosine receptor A1	Homo sapiens (human)
negative regulation of cell population proliferation	Adenosine receptor A1	Homo sapiens (human)
response to inorganic substance	Adenosine receptor A1	Homo sapiens (human)
negative regulation of glutamate secretion	Adenosine receptor A1	Homo sapiens (human)
response to purine-containing compound	Adenosine receptor A1	Homo sapiens (human)
lipid catabolic process	Adenosine receptor A1	Homo sapiens (human)
negative regulation of synaptic transmission, GABAergic	Adenosine receptor A1	Homo sapiens (human)
positive regulation of nucleoside transport	Adenosine receptor A1	Homo sapiens (human)
negative regulation of neurotrophin production	Adenosine receptor A1	Homo sapiens (human)
positive regulation of protein dephosphorylation	Adenosine receptor A1	Homo sapiens (human)
vasodilation	Adenosine receptor A1	Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, non-REM sleep	Adenosine receptor A1	Homo sapiens (human)
negative regulation of apoptotic process	Adenosine receptor A1	Homo sapiens (human)
positive regulation of potassium ion transport	Adenosine receptor A1	Homo sapiens (human)
positive regulation of MAPK cascade	Adenosine receptor A1	Homo sapiens (human)
negative regulation of hormone secretion	Adenosine receptor A1	Homo sapiens (human)
cognition	Adenosine receptor A1	Homo sapiens (human)
leukocyte migration	Adenosine receptor A1	Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain	Adenosine receptor A1	Homo sapiens (human)
negative regulation of lipid catabolic process	Adenosine receptor A1	Homo sapiens (human)
positive regulation of lipid catabolic process	Adenosine receptor A1	Homo sapiens (human)
regulation of sensory perception of pain	Adenosine receptor A1	Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergic	Adenosine receptor A1	Homo sapiens (human)
fatty acid homeostasis	Adenosine receptor A1	Homo sapiens (human)
excitatory postsynaptic potential	Adenosine receptor A1	Homo sapiens (human)
long-term synaptic depression	Adenosine receptor A1	Homo sapiens (human)
mucus secretion	Adenosine receptor A1	Homo sapiens (human)
negative regulation of mucus secretion	Adenosine receptor A1	Homo sapiens (human)
triglyceride homeostasis	Adenosine receptor A1	Homo sapiens (human)
regulation of cardiac muscle cell contraction	Adenosine receptor A1	Homo sapiens (human)
apoptotic signaling pathway	Adenosine receptor A1	Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentration	Adenosine receptor A1	Homo sapiens (human)
negative regulation of long-term synaptic potentiation	Adenosine receptor A1	Homo sapiens (human)
negative regulation of long-term synaptic depression	Adenosine receptor A1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Adenosine receptor A1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Nuclear receptor ROR-gamma	Homo sapiens (human)
xenobiotic metabolic process	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of glucose metabolic process	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of steroid metabolic process	Nuclear receptor ROR-gamma	Homo sapiens (human)
intracellular receptor signaling pathway	Nuclear receptor ROR-gamma	Homo sapiens (human)
circadian regulation of gene expression	Nuclear receptor ROR-gamma	Homo sapiens (human)
cellular response to sterol	Nuclear receptor ROR-gamma	Homo sapiens (human)
positive regulation of circadian rhythm	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of fat cell differentiation	Nuclear receptor ROR-gamma	Homo sapiens (human)
positive regulation of DNA-templated transcription	Nuclear receptor ROR-gamma	Homo sapiens (human)
adipose tissue development	Nuclear receptor ROR-gamma	Homo sapiens (human)
T-helper 17 cell differentiation	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Nuclear receptor ROR-gamma	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
organic cation transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
putrescine transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
thiamine transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
amino acid import across plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine import across plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-alpha-amino acid transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
proton transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
cellular response to starvation	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
regulation of DNA replication	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
DNA methylation-dependent heterochromatin formation	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
synaptonemal complex assembly	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
spermatid development	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
long-term memory	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
fertilization	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
peptidyl-lysine dimethylation	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
regulation of protein modification process	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
organ growth	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
phenotypic switching	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylation	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
response to ethanol	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
behavioral response to cocaine	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
oocyte development	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
neuron fate specification	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
response to fungicide	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
cellular response to cocaine	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
negative regulation of autophagosome assembly	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
cell population proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of B cell proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nuclear DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
signal transduction in response to DNA damage	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
isotype switching	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of isotype switching to IgG isotypes	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloading	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
regulation of mitotic cell cycle phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of cell cycle G2/M phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast growth factor binding	Integrin beta-3	Homo sapiens (human)
C-X3-C chemokine binding	Integrin beta-3	Homo sapiens (human)
insulin-like growth factor I binding	Integrin beta-3	Homo sapiens (human)
neuregulin binding	Integrin beta-3	Homo sapiens (human)
virus receptor activity	Integrin beta-3	Homo sapiens (human)
fibronectin binding	Integrin beta-3	Homo sapiens (human)
protease binding	Integrin beta-3	Homo sapiens (human)
protein disulfide isomerase activity	Integrin beta-3	Homo sapiens (human)
protein kinase C binding	Integrin beta-3	Homo sapiens (human)
platelet-derived growth factor receptor binding	Integrin beta-3	Homo sapiens (human)
integrin binding	Integrin beta-3	Homo sapiens (human)
protein binding	Integrin beta-3	Homo sapiens (human)
coreceptor activity	Integrin beta-3	Homo sapiens (human)
enzyme binding	Integrin beta-3	Homo sapiens (human)
identical protein binding	Integrin beta-3	Homo sapiens (human)
vascular endothelial growth factor receptor 2 binding	Integrin beta-3	Homo sapiens (human)
metal ion binding	Integrin beta-3	Homo sapiens (human)
cell adhesion molecule binding	Integrin beta-3	Homo sapiens (human)
extracellular matrix binding	Integrin beta-3	Homo sapiens (human)
fibrinogen binding	Integrin beta-3	Homo sapiens (human)
protein binding	Integrin alpha-IIb	Homo sapiens (human)
identical protein binding	Integrin alpha-IIb	Homo sapiens (human)
metal ion binding	Integrin alpha-IIb	Homo sapiens (human)
extracellular matrix binding	Integrin alpha-IIb	Homo sapiens (human)
molecular adaptor activity	Integrin alpha-IIb	Homo sapiens (human)
fibrinogen binding	Integrin alpha-IIb	Homo sapiens (human)
integrin binding	Integrin alpha-IIb	Homo sapiens (human)
G protein-coupled adenosine receptor activity	Adenosine receptor A3	Homo sapiens (human)
DNA binding	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
RNA binding	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
DNA (cytosine-5-)-methyltransferase activity	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
protein binding	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
zinc ion binding	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
methyl-CpG binding	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
DNA-methyltransferase activity	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
promoter-specific chromatin binding	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
G protein-coupled adenosine receptor activity	Adenosine receptor A2a	Homo sapiens (human)
protein binding	Adenosine receptor A2a	Homo sapiens (human)
calmodulin binding	Adenosine receptor A2a	Homo sapiens (human)
lipid binding	Adenosine receptor A2a	Homo sapiens (human)
enzyme binding	Adenosine receptor A2a	Homo sapiens (human)
type 5 metabotropic glutamate receptor binding	Adenosine receptor A2a	Homo sapiens (human)
identical protein binding	Adenosine receptor A2a	Homo sapiens (human)
protein-containing complex binding	Adenosine receptor A2a	Homo sapiens (human)
alpha-actinin binding	Adenosine receptor A2a	Homo sapiens (human)
G protein-coupled receptor binding	Adenosine receptor A1	Homo sapiens (human)
purine nucleoside binding	Adenosine receptor A1	Homo sapiens (human)
protein binding	Adenosine receptor A1	Homo sapiens (human)
heat shock protein binding	Adenosine receptor A1	Homo sapiens (human)
G-protein beta/gamma-subunit complex binding	Adenosine receptor A1	Homo sapiens (human)
heterotrimeric G-protein binding	Adenosine receptor A1	Homo sapiens (human)
protein heterodimerization activity	Adenosine receptor A1	Homo sapiens (human)
G protein-coupled adenosine receptor activity	Adenosine receptor A1	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription factor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
protein binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
oxysterol binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
zinc ion binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
ligand-activated transcription factor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
nuclear receptor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
protein binding	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-amino acid transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
polyspecific organic cation:proton antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
transcription corepressor binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
p53 binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
protein binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
zinc ion binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
protein-lysine N-methyltransferase activity	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
enzyme binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
histone H3K9 methyltransferase activity	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
histone H3K27 methyltransferase activity	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
C2H2 zinc finger domain binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
histone H3K56 methyltransferase activity	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
histone H3K9me2 methyltransferase activity	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
promoter-specific chromatin binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
protein binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP hydrolysis activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloader activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
glutamatergic synapse	Integrin beta-3	Homo sapiens (human)
nucleus	Integrin beta-3	Homo sapiens (human)
nucleoplasm	Integrin beta-3	Homo sapiens (human)
plasma membrane	Integrin beta-3	Homo sapiens (human)
cell-cell junction	Integrin beta-3	Homo sapiens (human)
focal adhesion	Integrin beta-3	Homo sapiens (human)
external side of plasma membrane	Integrin beta-3	Homo sapiens (human)
cell surface	Integrin beta-3	Homo sapiens (human)
apical plasma membrane	Integrin beta-3	Homo sapiens (human)
platelet alpha granule membrane	Integrin beta-3	Homo sapiens (human)
lamellipodium membrane	Integrin beta-3	Homo sapiens (human)
filopodium membrane	Integrin beta-3	Homo sapiens (human)
microvillus membrane	Integrin beta-3	Homo sapiens (human)
ruffle membrane	Integrin beta-3	Homo sapiens (human)
integrin alphav-beta3 complex	Integrin beta-3	Homo sapiens (human)
melanosome	Integrin beta-3	Homo sapiens (human)
synapse	Integrin beta-3	Homo sapiens (human)
postsynaptic membrane	Integrin beta-3	Homo sapiens (human)
extracellular exosome	Integrin beta-3	Homo sapiens (human)
integrin alphaIIb-beta3 complex	Integrin beta-3	Homo sapiens (human)
glycinergic synapse	Integrin beta-3	Homo sapiens (human)
integrin complex	Integrin beta-3	Homo sapiens (human)
protein-containing complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complex	Integrin beta-3	Homo sapiens (human)
receptor complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-vitronectin complex	Integrin beta-3	Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complex	Integrin beta-3	Homo sapiens (human)
focal adhesion	Integrin beta-3	Homo sapiens (human)
cell surface	Integrin beta-3	Homo sapiens (human)
synapse	Integrin beta-3	Homo sapiens (human)
plasma membrane	Integrin alpha-IIb	Homo sapiens (human)
focal adhesion	Integrin alpha-IIb	Homo sapiens (human)
cell surface	Integrin alpha-IIb	Homo sapiens (human)
platelet alpha granule membrane	Integrin alpha-IIb	Homo sapiens (human)
extracellular exosome	Integrin alpha-IIb	Homo sapiens (human)
integrin alphaIIb-beta3 complex	Integrin alpha-IIb	Homo sapiens (human)
blood microparticle	Integrin alpha-IIb	Homo sapiens (human)
integrin complex	Integrin alpha-IIb	Homo sapiens (human)
external side of plasma membrane	Integrin alpha-IIb	Homo sapiens (human)
plasma membrane	Adenosine receptor A3	Homo sapiens (human)
presynaptic membrane	Adenosine receptor A3	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Adenosine receptor A3	Homo sapiens (human)
dendrite	Adenosine receptor A3	Homo sapiens (human)
plasma membrane	Adenosine receptor A3	Homo sapiens (human)
synapse	Adenosine receptor A3	Homo sapiens (human)
female germ cell nucleus	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
nucleus	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
nucleoplasm	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
replication fork	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
pericentric heterochromatin	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
nucleus	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
plasma membrane	Adenosine receptor A2a	Homo sapiens (human)
intermediate filament	Adenosine receptor A2a	Homo sapiens (human)
plasma membrane	Adenosine receptor A2a	Homo sapiens (human)
membrane	Adenosine receptor A2a	Homo sapiens (human)
dendrite	Adenosine receptor A2a	Homo sapiens (human)
axolemma	Adenosine receptor A2a	Homo sapiens (human)
asymmetric synapse	Adenosine receptor A2a	Homo sapiens (human)
presynaptic membrane	Adenosine receptor A2a	Homo sapiens (human)
neuronal cell body	Adenosine receptor A2a	Homo sapiens (human)
postsynaptic membrane	Adenosine receptor A2a	Homo sapiens (human)
presynaptic active zone	Adenosine receptor A2a	Homo sapiens (human)
glutamatergic synapse	Adenosine receptor A2a	Homo sapiens (human)
plasma membrane	Adenosine receptor A1	Homo sapiens (human)
plasma membrane	Adenosine receptor A1	Homo sapiens (human)
basolateral plasma membrane	Adenosine receptor A1	Homo sapiens (human)
axolemma	Adenosine receptor A1	Homo sapiens (human)
asymmetric synapse	Adenosine receptor A1	Homo sapiens (human)
presynaptic membrane	Adenosine receptor A1	Homo sapiens (human)
neuronal cell body	Adenosine receptor A1	Homo sapiens (human)
terminal bouton	Adenosine receptor A1	Homo sapiens (human)
dendritic spine	Adenosine receptor A1	Homo sapiens (human)
calyx of Held	Adenosine receptor A1	Homo sapiens (human)
postsynaptic membrane	Adenosine receptor A1	Homo sapiens (human)
presynaptic active zone	Adenosine receptor A1	Homo sapiens (human)
synapse	Adenosine receptor A1	Homo sapiens (human)
dendrite	Adenosine receptor A1	Homo sapiens (human)
nucleus	Nuclear receptor ROR-gamma	Homo sapiens (human)
nucleoplasm	Nuclear receptor ROR-gamma	Homo sapiens (human)
nuclear body	Nuclear receptor ROR-gamma	Homo sapiens (human)
chromatin	Nuclear receptor ROR-gamma	Homo sapiens (human)
nucleus	Nuclear receptor ROR-gamma	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
apical plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
nucleus	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
nucleoplasm	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
nuclear speck	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
chromatin	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
nucleus	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
Elg1 RFC-like complex	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nucleus	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1505768	Inhibition of human G9a using biotinylated-H3K9 peptide as substrate after 1 hr in presence of SAM by TR-FRET assay	2018	Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15	Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.
AID1148522	Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as dose required for maximal activity administered qd from day 1 to day 9 post tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1465530	Toxicity in NOD.SCID mouse assessed as maximum mean body weight loss at 8 mg/kg, iv qd for every 7 days (Rvb = 9%)	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.
AID1133459	Toxicity in mouse L1210 cells allografted CDF1 mouse assessed as change in body weight between day 1 and day 9 at 2.5 mg/kg, ip dosed on days 1, 5 and 9	1978	Journal of medicinal chemistry, Feb, Volume: 21, Issue:2	Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine.
AID409950	Inhibition of human brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID409952	Inhibition of human brain MAOB	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID355582	Antiproliferative activity against human HT-29 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method
AID1148519	Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as dose required for maximal activity administered qd from day 1 to day 9 post tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1437967	Antiproliferative activity against human SKM1-R cells after 48 hrs by XTT assay	2017	Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4	In Vitro and in Vivo Evaluation of Fully Substituted (5-(3-Ethoxy-3-oxopropynyl)-4-(ethoxycarbonyl)-1,2,3-triazolyl-glycosides as Original Nucleoside Analogues to Circumvent Resistance in Myeloid Malignancies.
AID1133448	Antitumor activity against mouse L1210 cells allografted in CDF1 mouse assessed as increase in life span at 2.5 mg/kg, ip relative to control	1978	Journal of medicinal chemistry, Feb, Volume: 21, Issue:2	Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine.
AID1148506	Antitumor activity against mouse B16 cells allografted in ip dosed mouse assessed as dose required for minimal activity administered qd from day 1 to day 9 post tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID355586	Antiproliferative activity against mouse P388 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method
AID99173	Cross resistance profile versus L1210/R71 cells.	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1148482	Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as change in body weight at optimal dose administered qd from day 1 to day 9 post tumor implantation measured on day 5 relative to control	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1419794	Growth inhibition of human KB cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Natural Products with Heteroatom-Rich Ring Systems.
AID1148501	Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as dose required for minimal activity administered every 6 hrs on day 1, 5 and 9 post tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1298411	Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in gag level at 25 to 400 uM after 2 to 72 hrs by qPCR method	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID1437985	Antiproliferative activity against human SKM1-S cells after 48 hrs by DAPI-staining-based flow cytometric method	2017	Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4	In Vitro and in Vivo Evaluation of Fully Substituted (5-(3-Ethoxy-3-oxopropynyl)-4-(ethoxycarbonyl)-1,2,3-triazolyl-glycosides as Original Nucleoside Analogues to Circumvent Resistance in Myeloid Malignancies.
AID1288538	Inhibition of UHRF1 in human MCF7 cells assessed as decrease in methylation at RAR beta exon at 15 uM after 72 hrs by methylation specific-PCR method	2016	European journal of medicinal chemistry, May-23, Volume: 114	Tandem virtual screening targeting the SRA domain of UHRF1 identifies a novel chemical tool modulating DNA methylation.
AID1148514	Toxicity in ip dosed mouse allografted with mouse P388 cells assessed as dose required for optimal activity administered qd from day 1 to day 9 post tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1148532	Cytotoxicity against mouse L1210 cells assessed as cessation of growth in presence of cytidine	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1148490	Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as increase in life span at optimal dose administered qd on day 1 post tumor implantation relative to control	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1148494	Antitumor activity against 5-azacytidine-resistant mouse L1210 cells allografted in ip dosed mouse assessed as increase in life span at optimal dose administered qd from day 1 to day 9 post tumor implantation relative to control	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1465526	Toxicity in iv dosed NOD.SCID mouse xenografted with gamma-irradiated human Kasumi-1 cells administered as qd for every 7 days	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.
AID1148478	Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as change in body weight at optimal dose administered qd from day 1 to day 9 post tumor implantation measured on day 5 relative to control	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1298422	Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as Env mutation at 260 uM incubated for 2 hrs prior to infection measured at 72 hrs post infection by illumina sequencing method (Rvb = 21.4%)	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID1134737	Toxicity in CDF1 mouse assessed as change in body weight at 12.5 mg/kg, ip measured on day 5 relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID1419773	Antibacterial activity against Escherichia coli	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Natural Products with Heteroatom-Rich Ring Systems.
AID1148483	Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as change in body weight at optimal dose administered qd from day 1 to day 9 post intracerebral tumor implantation measured on day 5 relative to control	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1298419	Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as Gag mutation at 260 uM incubated for 2 hrs prior to infection measured at 72 hrs post infection by illumina sequencing method (Rvb = 18.4%)	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1148500	Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as dose required for minimal activity administered qd on day 1, 5 and 9 post tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1298414	Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in U5-gag level at 25 to 400 uM after 2 to 72 hrs by qPCR method	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID355578	Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
AID1505769	Inhibition of human DNMT1 using polydeoxyinosine polydeoxycytosine DNA as substrate after 15 mins in presence of SAM by TR-FRET assay	2018	Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15	Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.
AID1134742	Toxicity in CDF1 mouse assessed as change in body weight at 1.56 mg/kg, ip measured on day 5 relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID355583	Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
AID1148499	Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as dose required for minimal activity administered qd on day 1 post tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1148513	Toxicity in ip dosed mouse allografted with mouse L1210 cells assessed as dose required for optimal activity administered qd from day 1 to day 9 post intracerebral tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1148495	Antitumor activity against mouse L1210 cells allografted in po dosed mouse assessed as increase in life span at optimal dose administered qd from day 1 to day 9 post tumor implantation relative to control	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1134729	Antitumor activity in mouse L1210 cells allografted in CDF1 mouse assessed as increase in life span at 0.78 mg/kg, ip administered as qd for 9 days relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1148486	Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as change in body weight at optimal dose administered every 6 hrs on day 1, 5 and 9 post tumor implantation measured on day 5 relative to control	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1323835	Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by Cheng-Prusoff analysis	2016	Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21	Identification of small molecules that bind to the mitochondrial protein mitoNEET.
AID1134727	Antitumor activity in mouse L1210 cells allografted in CDF1 mouse assessed as increase in life span at 3.12 mg/kg, ip administered as qd for 9 days relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1298347	Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as C to G transversion at 260 uM incubated for 2 hrs prior to infection measured at 72 hrs post infection by illumina sequencing method relative to control	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID1298421	Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as Vif mutation at 260 uM incubated for 2 hrs prior to infection measured at 72 hrs post infection by illumina sequencing method (Rvb = 19.2%)	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID1148529	Therapeutic index, ratio of toxicity in ip dosed mouse allografted with mouse L1210 cells assessed as optimal dose required for maximum increase in life span to antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as lowest	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1148497	Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as increase in life span at optimal dose administered qd from day 1 to day 9 post tumor implantation relative to control	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1134744	Drug degradation in water solution at 25 degC after 5.5 hrs by reverse phase liquid chromatography	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1148530	Therapeutic index, ratio of toxicity in ip dosed mouse allografted with mouse L1210 cells assessed as highest dose required for 40% increase in life span to antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as lowest dose	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID23271	Partition coefficient (logD7.4)	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID1133455	Toxicity in mouse L1210 cells allografted CDF1 mouse assessed as change in body weight between day 1 and day 9 at 40 mg/kg, ip dosed on days 1, 5 and 9	1978	Journal of medicinal chemistry, Feb, Volume: 21, Issue:2	Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1437984	Antiproliferative activity against human SKM1-S cells after 48 hrs by XTT assay	2017	Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4	In Vitro and in Vivo Evaluation of Fully Substituted (5-(3-Ethoxy-3-oxopropynyl)-4-(ethoxycarbonyl)-1,2,3-triazolyl-glycosides as Original Nucleoside Analogues to Circumvent Resistance in Myeloid Malignancies.
AID1148498	Antitumor activity against mouse B16 cells allografted in ip dosed mouse assessed as increase in life span at optimal dose administered qd from day 1 to day 9 post tumor implantation relative to control	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1134739	Toxicity in CDF1 mouse assessed as change in body weight at 6.25 mg/kg, ip measured on day 5 relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID408557	Antiproliferative activity against human 5637 cells after 96 hrs by crystal violet assay	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Synthesis of indirubin-N'-glycosides and their anti-proliferative activity against human cancer cell lines.
AID1133450	Toxicity in mouse L1210 cells allografted CDF1 mouse assessed as change in body weight between day 1 and day 5 at 40 mg/kg, ip dosed on days 1 and 5	1978	Journal of medicinal chemistry, Feb, Volume: 21, Issue:2	Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine.
AID1298420	Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as Pol mutation at 260 uM incubated for 2 hrs prior to infection measured at 72 hrs post infection by illumina sequencing method (Rvb = 18.5%)	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID1148520	Antitumor activity against mouse L1210 cells allografted in po dosed mouse assessed as dose required for maximal activity administered qd from day 1 to day 9 post tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1148484	Antitumor activity against mouse L1210 cells allografted in po dosed mouse assessed as change in body weight at optimal dose administered qd from day 1 to day 9 post tumor implantation measured on day 5 relative to control	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID721753	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1148517	Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as dose required for maximal activity administered qd on day 1, 5 and 9 post tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1148516	Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as dose required for maximal activity administered qd on day 1 post tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID408560	Antiproliferative activity against human MCF7 cells after 96 hrs by crystal violet assay	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Synthesis of indirubin-N'-glycosides and their anti-proliferative activity against human cancer cell lines.
AID1148515	Toxicity in ip dosed mouse allografted with mouse B16 cells assessed as dose required for optimal activity administered qd from day 1 to day 9 post tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID625295	Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1298423	Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as Nef mutation at 260 uM incubated for 2 hrs prior to infection measured at 72 hrs post infection by illumina sequencing method (Rvb = 22.6%)	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID1133454	Toxicity in mouse L1210 cells allografted CDF1 mouse assessed as change in body weight between day 1 and day 5 at 2.5 mg/kg, ip dosed on days 1 and 5	1978	Journal of medicinal chemistry, Feb, Volume: 21, Issue:2	Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine.
AID408559	Antiproliferative activity against human KYSE70 cells after 96 hrs by crystal violet assay	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Synthesis of indirubin-N'-glycosides and their anti-proliferative activity against human cancer cell lines.
AID1148487	Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as change in body weight at optimal dose administered qd on day 1, 5 and 9 post tumor implantation measured on day 5 relative to control	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1134743	Toxicity in CDF1 mouse assessed as change in body weight at 0.78 mg/kg, ip measured on day 5 relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID721754	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1298294	Reduction in dCTP level in human U373-MAGI cells at EC75 after 4 hrs by LC-MS/MS analysis relative to control	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID1148503	Antitumor activity against mouse L1210 cells allografted in po dosed mouse assessed as dose required for minimal activity administered qd from day 1 to day 9 post tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1133445	Antitumor activity against mouse L1210 cells allografted in CDF1 mouse assessed as increase in life span at 20 mg/kg, ip relative to control	1978	Journal of medicinal chemistry, Feb, Volume: 21, Issue:2	Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine.
AID521220	Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	2007	Nature chemical biology, May, Volume: 3, Issue:5	Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1298345	Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as increase in mutation frequency at 260 uM incubated for 2 hrs prior to infection measured at 72 hrs post infection by illumina sequencing method	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID1148507	Toxicity in ip dosed mouse allografted with mouse L1210 cells assessed as dose required for optimal activity administered qd on day 1 post tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID355580	Antiproliferative activity against human HT-29 cells at 1 ug after 48 hrs by two-layer agar-diffusion method
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1148518	Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as dose required for maximal activity administered every 6 hrs on day 1, 5 and 9 post tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1134725	Antitumor activity in mouse L1210 cells allografted in CDF1 mouse assessed as increase in life span at 6.25 mg/kg, ip administered as qd for 9 days relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1054215	Antiviral activity against HIV1 assessed as viral infection	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors.
AID1148533	Cytotoxicity against mouse L1210 cells assessed as cessation of growth in presence of uridine	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1148488	Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as change in body weight at optimal dose administered qd on day 1 post tumor implantation measured on day 5 relative to control	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1134741	Toxicity in CDF1 mouse assessed as change in body weight at 3.12 mg/kg, ip measured on day 5 relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID1288539	Inhibition of UHRF1 in human MCF7 cells assessed as DNA global demethylation by measuring 5-methylcytosine level at 15 uM after 72 hrs by HPLC-MS/MS analysis (Rvb = 1.7 +/- 0.36%)	2016	European journal of medicinal chemistry, May-23, Volume: 114	Tandem virtual screening targeting the SRA domain of UHRF1 identifies a novel chemical tool modulating DNA methylation.
AID1133458	Toxicity in mouse L1210 cells allografted CDF1 mouse assessed as change in body weight between day 1 and day 9 at 5 mg/kg, ip dosed on days 1, 5 and 9	1978	Journal of medicinal chemistry, Feb, Volume: 21, Issue:2	Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine.
AID1133447	Antitumor activity against mouse L1210 cells allografted in CDF1 mouse assessed as increase in life span at 5 mg/kg, ip relative to control	1978	Journal of medicinal chemistry, Feb, Volume: 21, Issue:2	Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine.
AID1148523	Drug degradation in 1 N ammonium hydroxide solution assessed as l-beta-D-Ribofuranosyl-3-guanylurea level	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1148493	Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as increase in life span at optimal dose administered qd from day 1 to day 9 post tumor implantation relative to control	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1133452	Toxicity in mouse L1210 cells allografted CDF1 mouse assessed as change in body weight between day 1 and day 5 at 10 mg/kg, ip dosed on days 1 and 5	1978	Journal of medicinal chemistry, Feb, Volume: 21, Issue:2	Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID355585	Antiproliferative activity against mouse P388 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1323834	Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by scintillation proximity assay	2016	Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21	Identification of small molecules that bind to the mitochondrial protein mitoNEET.
AID1133444	Antitumor activity against mouse L1210 cells allografted in CDF1 mouse assessed as increase in life span at 40 mg/kg, ip relative to control	1978	Journal of medicinal chemistry, Feb, Volume: 21, Issue:2	Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine.
AID355581	Antiproliferative activity against human HT-29 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method
AID1148512	Toxicity in po dosed mouse allografted with mouse L1210 cells assessed as dose required for optimal activity administered qd from day 1 to day 9 post tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1148508	Toxicity in ip dosed mouse allografted with mouse L1210 cells assessed as dose required for optimal activity administered qd on day 1, 5 and 9 post tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1148491	Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as increase in life span at optimal dose administered qd on day 1, 5 and 9 post tumor implantation relative to control	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1133471	Toxicity in mouse L1210 cells allografted CDF1 mouse assessed as mortality at 2.5 to 40 mg/kg, ip	1978	Journal of medicinal chemistry, Feb, Volume: 21, Issue:2	Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID1148504	Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as dose required for minimal activity administered qd from day 1 to day 9 post intracerebral tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1133457	Toxicity in mouse L1210 cells allografted CDF1 mouse assessed as change in body weight between day 1 and day 9 at 10 mg/kg, ip dosed on days 1, 5 and 9	1978	Journal of medicinal chemistry, Feb, Volume: 21, Issue:2	Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine.
AID1133456	Toxicity in mouse L1210 cells allografted CDF1 mouse assessed as change in body weight between day 1 and day 9 at 20 mg/kg, ip dosed on days 1, 5 and 9	1978	Journal of medicinal chemistry, Feb, Volume: 21, Issue:2	Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine.
AID1148489	Drug degradation in lactated Ringer's solution at 25 degC after 4.7 hrs	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1148521	Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as dose required for maximal activity administered qd from day 1 to day 9 post intracerebral tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1437988	Induction of apoptosis in human SKM1-S cells assessed as caspase 3 cleavage at 1 uM by Western blot method	2017	Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4	In Vitro and in Vivo Evaluation of Fully Substituted (5-(3-Ethoxy-3-oxopropynyl)-4-(ethoxycarbonyl)-1,2,3-triazolyl-glycosides as Original Nucleoside Analogues to Circumvent Resistance in Myeloid Malignancies.
AID1437989	Induction of apoptosis in human SKM1-R cells assessed as caspase 3 cleavage at 10 uM by Western blot method	2017	Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4	In Vitro and in Vivo Evaluation of Fully Substituted (5-(3-Ethoxy-3-oxopropynyl)-4-(ethoxycarbonyl)-1,2,3-triazolyl-glycosides as Original Nucleoside Analogues to Circumvent Resistance in Myeloid Malignancies.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1148496	Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as increase in life span at optimal dose administered qd from day 1 to day 9 post intracerebral tumor implantation relative to control	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1133451	Toxicity in mouse L1210 cells allografted CDF1 mouse assessed as change in body weight between day 1 and day 5 at 20 mg/kg, ip dosed on days 1 and 5	1978	Journal of medicinal chemistry, Feb, Volume: 21, Issue:2	Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine.
AID1148481	Antitumor activity against mouse B16 cells allografted in ip dosed mouse assessed as change in body weight at optimal dose administered qd from day 1 to day 9 post tumor implantation measured on day 5 relative to control	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1298404	Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as increase in frequency of G to C transversion at 260 uM incubated for 2 hrs prior to infection measured at 72 hrs post infection by illumina sequencing m	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID1298405	Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as increase in frequency of C to G transversion at 260 uM incubated for 2 hrs prior to infection measured at 72 hrs post infection by illumina sequencing m	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID98149	Compound was tested for its inhibitory activity against L1210 lymphoid leukemia	1987	Journal of medicinal chemistry, Feb, Volume: 30, Issue:2	Synthesis and antitumor activity of fluorine-substituted 4-amino-2(1H)-pyridinones and their nucleosides. 3-Deazacytosines.
AID1148502	Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as dose required for minimal activity administered qd from day 1 to day 9 post tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1148531	Cytotoxicity against mouse L1210 cells assessed as cessation of growth	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1133453	Toxicity in mouse L1210 cells allografted CDF1 mouse assessed as change in body weight between day 1 and day 5 at 5 mg/kg, ip dosed on days 1 and 5	1978	Journal of medicinal chemistry, Feb, Volume: 21, Issue:2	Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine.
AID1148492	Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as increase in life span at optimal dose administered every 6 hrs on day 1, 5 and 9 post tumor implantation relative to control	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1199273	Half life in sc dosed patient with myelodysplastic syndrome	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Targeting DNA methylation with small molecules: what's next?
AID1133473	Half life in rat	1978	Journal of medicinal chemistry, Feb, Volume: 21, Issue:2	Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine.
AID1288542	Inhibition of UHRF1 in human MCF7 cells assessed as reduction in global 5-methylcytosine level at 15 uM after 72 hrs by HPLC-MS/MS analysis relative to control	2016	European journal of medicinal chemistry, May-23, Volume: 114	Tandem virtual screening targeting the SRA domain of UHRF1 identifies a novel chemical tool modulating DNA methylation.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1298346	Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as G to C transversion at 260 uM incubated for 2 hrs prior to infection measured at 72 hrs post infection by illumina sequencing method relative to control	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID1437998	Antiproliferative activity against human SKM1-R cells after 48 hrs by DAPI-staining-based flow cytometric method	2017	Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4	In Vitro and in Vivo Evaluation of Fully Substituted (5-(3-Ethoxy-3-oxopropynyl)-4-(ethoxycarbonyl)-1,2,3-triazolyl-glycosides as Original Nucleoside Analogues to Circumvent Resistance in Myeloid Malignancies.
AID355584	Antiproliferative activity against mouse P388 cells at 1 ug after 48 hrs by two-layer agar-diffusion method
AID1148505	Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as dose required for minimal activity administered qd from day 1 to day 9 post tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1134728	Antitumor activity in mouse L1210 cells allografted in CDF1 mouse assessed as increase in life span at 1.56 mg/kg, ip administered as qd for 9 days relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1464041	Partition coefficient, log P of the compound	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1148509	Toxicity in ip dosed mouse allografted with mouse L1210 cells assessed as dose required for optimal activity administered every 6 hrs on day 1, 5 and 9 post tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1464040	Solubility in water	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis.
AID1845917	Inhibition of HIV-1 latency infected in human ACH-2 cells assessed as fold increase in HIV production by measuring p24 level incubated for 48 hrs in presence of BIX01294 by ELISA	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	HIV latency reversal agents: A potential path for functional cure?
AID408558	Antiproliferative activity against human A427 cells after 96 hrs by crystal violet assay	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Synthesis of indirubin-N'-glycosides and their anti-proliferative activity against human cancer cell lines.
AID1148510	Toxicity in ip dosed mouse allografted with mouse L1210 cells assessed as dose required for optimal activity administered qd from day 1 to day 9 post tumor implantation	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1133446	Antitumor activity against mouse L1210 cells allografted in CDF1 mouse assessed as increase in life span at 10 mg/kg, ip relative to control	1978	Journal of medicinal chemistry, Feb, Volume: 21, Issue:2	Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine.
AID311935	Partition coefficient, log P of the compound	2008	Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2	Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1148479	Half life of the compound at 25 degC at pH 7 by HPLC analysis	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745847	CMV-Luciferase Counterscreen for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745846	Firefly Luciferase Counterscreen for Inhibitors of ATXN expression
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745849	Viability Counterscreen for CMV-Luciferase Assay of Inhibitors of ATXN expression
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1745848	Confirmatory qHTS for Inhibitors of ATXN expression
AID1745850	Viability Counterscreen for Confirmatory qHTS for Inhibitors of ATXN expression
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID686947	qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1802102	Radioligand Binding Assay from Article 10.1021/acschembio.6b00357: \\Structure-Based Screening of Uncharted Chemical Space for Atypical Adenosine Receptor Agonists\\	2016	ACS chemical biology, 10-21, Volume: 11, Issue:10	Structure-Based Screening of Uncharted Chemical Space for Atypical Adenosine Receptor Agonists.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	877 (12.05)	18.7374
1990's	589 (8.09)	18.2507
2000's	1730 (23.76)	29.6817
2010's	3296 (45.27)	24.3611
2020's	789 (10.84)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	479 (6.41%)	5.53%
Reviews	549 (7.35%)	6.00%
Case Studies	358 (4.79%)	4.05%
Observational	18 (0.24%)	0.25%
Other	6,070 (81.21%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (635)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase I-II Study to Assess Venetoclax + Azacitidine and Donor Lymphocyte Infusion in Patients With MDS or AML (Blasts < 30%) in Relapse After Allohematopoietic Stem Cell Transplantation [NCT05226455]	Phase 1/Phase 2	48 participants (Anticipated)	Interventional	2022-11-23	Recruiting
Phase II Study of Venetoclax With Alternative Hypomethylating Agent for Patients With Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure: A University of California Hematologic Malignancies Consortium Protocol [NCT04905810]	Phase 2	20 participants (Anticipated)	Interventional	2022-02-09	Recruiting
Targeting TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia (AML) With Azacitidine and Ascorbic Acid [NCT03397173]	Phase 2	12 participants (Actual)	Interventional	2018-03-16	Completed
A Single Arm, Phase 2 Study Evaluating Safety and Efficacy of Maintenance Therapy With Hypomethylating Agent and Venetoclax After Allogeneic Stem Cell Transplantation in Patients With f High-risk Myeloid Malignancies. [NCT05841771]	Phase 2	78 participants (Anticipated)	Interventional	2023-01-01	Recruiting
Azacitidine in Combination With or Without All-trans Retinoic Acid in Newly Diagnosed Unfit Acute Myeloid Leukemia or Intermediate,High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria [NCT05175508]	Phase 2/Phase 3	180 participants (Anticipated)	Interventional	2021-05-01	Recruiting
Randomized Phase-II Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine [NCT01180322]	Phase 2	277 participants (Actual)	Interventional	2010-11-30	Completed
Blinded Cross-over Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia [NCT01290302]	Phase 1	36 participants (Actual)	Interventional	2010-10-31	Completed
A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients ≥18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy [NCT03151408]	Phase 3	406 participants (Actual)	Interventional	2017-06-23	Terminated(stopped due to The IDMC recommended to stop the study prematurely due to a lack of efficacy.)
Pacritinib in Combination With Azacitidine in Patients With Chronic Myelomonocytic Leukemia [NCT06159491]	Phase 1/Phase 2	26 participants (Anticipated)	Interventional	2024-01-02	Not yet recruiting
A Phase 1 Study of Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) [NCT06158100]	Phase 1	25 participants (Anticipated)	Interventional	2024-02-28	Not yet recruiting
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Inductio [NCT05520567]	Phase 1/Phase 2	70 participants (Anticipated)	Interventional	2023-01-27	Recruiting
A Phase 1b Study of JNJ-75276617 in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations [NCT05453903]	Phase 1	150 participants (Anticipated)	Interventional	2022-10-04	Recruiting
A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma [NCT04340843]	Phase 2	32 participants (Anticipated)	Interventional	2020-09-08	Suspended(stopped due to Other - Completed stage 1 accrual)
Phase I Study of APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies [NCT04214860]	Phase 1	51 participants (Actual)	Interventional	2019-12-13	Completed
An Open-Label Phase II Study of Relatlimab (BMS-986016) With Nivolumab (BMS-936558) in Combination With 5-Azacytidine for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older Acute Myeloid Leukemia Patients [NCT04913922]	Phase 2	30 participants (Anticipated)	Interventional	2021-05-05	Recruiting
An Open Label, Single Arm, Single-Center Exploratory Study to Evaluate the Efficacy and Safety of Selinexor and HAAG +/- HMA in Relapsed/Refractory Acute Leukemia (AML) Patients [NCT05805072]		20 participants (Anticipated)	Interventional	2023-05-01	Not yet recruiting
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer [NCT04891068]	Phase 2	40 participants (Anticipated)	Interventional	2022-01-10	Recruiting
A Phase I Study of Azacitidine Combined With Mitoxantrone and Etoposide (A-NOVE) Chemotherapy for Patients' Age ≥ 60 With Poor Prognosis Acute Myeloid Leukemia (AML) [NCT01260714]	Phase 1	13 participants (Actual)	Interventional	2010-12-31	Terminated(stopped due to Inadequate accrual rate)
Efficacy and Safety of PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation [NCT05772273]		43 participants (Anticipated)	Interventional	2023-03-15	Recruiting
Phase II Multicentric Trial Maintenance Therapy With 6 Monthly Revlimid® Cycles Alternated With 6 Monthly Vidaza® Cycles in First CR After Induction LIA Chemotherapy for Elderly Fit Patients With Poor Prognosis Acute Myeloid Leukemia. [NCT01301820]	Phase 2	120 participants (Actual)	Interventional	2011-01-31	Completed
A Multicenter, Randomized, Open-label, Parallel-group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS) [NCT00071799]	Phase 3	358 participants (Actual)	Interventional	2003-11-01	Completed
A Multicentric Phase 2 Study of Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-MUTATED Acute Myeloid Leukemia [NCT04867928]	Phase 2	35 participants (Anticipated)	Interventional	2022-03-01	Recruiting
PHASE 1B/PHASE 3 MULTICENTER STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION REGIMENS THAT INCLUDE AN IMMUNE AGONIST, EPIGENETIC MODULATOR, CD20 ANTAGONIST AND/OR CONVENTIONAL CHEMOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHO [NCT02951156]	Phase 3	29 participants (Actual)	Interventional	2016-12-16	Terminated(stopped due to Study was terminated due to closure of study arms following futility analysis and difficulty in enrolling participants due to evolving treatment landscape)
A Phase 2, Multicenter, Randomized, Open-label, Parallel-group Study of a Lenalidomide (Revlimid®) Regimen or a Sequential Azacitidine (Vidaza®) Plus Lenalidomide (Revlimid®) Regimen Versus an Azacitidine (Vidaza®) Regimen for Therapy of Older Subjects Wi [NCT01358734]	Phase 2	88 participants (Actual)	Interventional	2012-04-27	Completed
OPEN LABEL PHASE 2 STUDY ON THE EFFICACY AND TOLERANCE OF A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS - PONAZA TRIAL [NCT03895671]	Phase 2	40 participants (Anticipated)	Interventional	2019-06-19	Recruiting
A Phase I and Expansion Cohort Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia [NCT03194932]	Phase 1	62 participants (Actual)	Interventional	2017-07-11	Completed
Plasma Dosage of Venetoclax in the Follow-up of Acute Myeloid Leukemias Ineligible for Intensive Chemotherapy in the First Line of Treatment and Treated With Azacitidine + Venetoclax. Pilot Study VENETACIBLE [NCT06030089]		20 participants (Anticipated)	Interventional	2023-10-15	Not yet recruiting
An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of DCLL9718S in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Patients With Previously Untreated AML U [NCT03298516]	Phase 1	19 participants (Actual)	Interventional	2017-11-15	Completed
Pilot Open-label Trial of Nivolumab Combined With Chemotherapy in Refractory Myelodysplastic Syndromes. [NCT03259516]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2017-05-25	Terminated(stopped due to Slow recruitment rate)
Treatment of Relapsed Acute Leukemia After Allogeneic Stem Cell Transplantation: Disease Stabilization Through Chemotherapy, Immunomodulatory Treatment and Immunotherapy [NCT01369368]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2013-08-31	Recruiting
A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML [NCT05183035]	Phase 3	98 participants (Anticipated)	Interventional	2022-10-01	Recruiting
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocyt [NCT04266301]	Phase 3	530 participants (Actual)	Interventional	2020-06-08	Active, not recruiting
A PHASE II STUDY OF Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS) [NCT02038816]	Phase 2	1 participants (Actual)	Interventional	2014-03-31	Terminated(stopped due to accrual too slow, insufficient patients)
Azacytidine Combined With Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma: a Multicenter Single Arm Phase II Study [NCT05179213]	Phase 2	20 participants (Anticipated)	Interventional	2022-01-01	Not yet recruiting
A Phase I/II Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) [NCT03699384]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2018-10-03	Withdrawn(stopped due to Study sponsor discontinued support)
Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cel [NCT03113643]	Phase 1	72 participants (Anticipated)	Interventional	2017-06-26	Recruiting
A Phase II Trial of the DNA Methyl Transferase Inhibitor, SGI-110 (Guadecitabine), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer [NCT03165721]	Phase 2	9 participants (Actual)	Interventional	2017-08-16	Terminated(stopped due to Study closed to enrollment due to low accrual.)
Multicentre, Open-label, Randomized Phase II Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 International Prognostic Scoring System(IPSS )) Without the 5q Deletion and Tran [NCT01338337]	Phase 2	40 participants (Actual)	Interventional	2010-11-30	Completed
Concomitant Omacetaxine Mepesuccinate and Azacitidine for Patients With Previously Untreated High Grade Myelodysplastic Syndromes [NCT03564873]	Phase 1/Phase 2	51 participants (Anticipated)	Interventional	2018-09-17	Recruiting
A Phase I-II Study of the Efficacy and Safety of Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes [NCT01305135]	Phase 1/Phase 2	41 participants (Actual)	Interventional	2010-12-30	Completed
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant [NCT03850418]	Phase 2	43 participants (Anticipated)	Interventional	2019-07-01	Recruiting
A Phase Ib/II Study of APG-115 Alone or in Combination With Azacitidine in Patients With Relapse/Refractory AML, CMML or MDS [NCT04358393]	Phase 1/Phase 2	69 participants (Anticipated)	Interventional	2020-12-04	Recruiting
A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome [NCT03813147]	Phase 1	12 participants (Actual)	Interventional	2019-05-17	Active, not recruiting
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leuke [NCT01522976]	Phase 2	282 participants (Actual)	Interventional	2012-03-01	Active, not recruiting
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT02785900]	Phase 3	240 participants (Actual)	Interventional	2016-05-31	Terminated(stopped due to Due to safety; specifically a higher rate of deaths, including fatal infections, in the SGN33A arm versus the control arm)
Clinical Study on the Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Combined Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma [NCT05182957]	Phase 2	40 participants (Anticipated)	Interventional	2022-12-14	Recruiting
A Phase II Study of Tosedostat in Combination With Either Cytarabine or Decitabine in Newly Diagnosed AML or High-Risk MDS [NCT01567059]	Phase 2	34 participants (Actual)	Interventional	2012-05-31	Completed
A Multicenter, Single-Arm, Phase I/II Dose Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Minimally-Pretreated Follicular Lymphoma [NCT04722601]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2021-09-01	Completed
Phase II Trial of APR-246 in Combination With Azacitidine as Maintenance Therapy for TP53 Mutated AML or MDS Following Allogeneic Stem Cell Transplant [NCT03931291]	Phase 2	33 participants (Actual)	Interventional	2019-09-16	Completed
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of Mutation TP53 (TP53) Mutant Myeloid Neoplasms [NCT03588078]	Phase 1/Phase 2	53 participants (Actual)	Interventional	2018-09-15	Active, not recruiting
Chidamide Plus Azacitidine Epigenetic Repression for the Treatment of Previously Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma [NCT05958719]	Phase 2	37 participants (Anticipated)	Interventional	2023-03-02	Recruiting
Phase I / II, Open Label, Dose Escalation Part (Phase I) Followed by Non-comparative Expansion Part (Phase II), Multi-centre Study, Evaluating Safety, Pharmacokinetics and Efficacy of S65487, a Bcl2 Inhibitor Combined With Azacitidine in Adult Patients Wi [NCT04742101]	Phase 1/Phase 2	89 participants (Anticipated)	Interventional	2021-03-10	Recruiting
Phase I/II, International, Multicentre, Open-label, Non-randomised, Non-comparative, Study Evaluating the Safety, Tolerability and Clinical Activity of Intravenously Administered S64315, a Selective Mcl-1 Inhibitor, in Combination With Azacitidine in Pati [NCT04629443]	Phase 1/Phase 2	17 participants (Actual)	Interventional	2021-02-17	Active, not recruiting
A Multi-Center Relative Bioavailability Study of Azacitidine 75 mg/m2 Subcutaneous Injection In Myelodysplastic Syndrome Patients Under Fasting Conditions [NCT01152346]	Phase 1	19 participants (Actual)	Interventional	2011-04-30	Completed
A Phase I Study of Epigenetic Immunomodulation Through the Use of Azacitidine, Lenalidomide, and Grifola Frondosa in Patients With Advanced Malignancy [NCT01200004]	Phase 1	1 participants (Actual)	Interventional	2012-04-30	Terminated(stopped due to Slow Accrual.)
A Phase II Study of Pevonedistat (MLN4924, TAK924) and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission Acute Myelogenous Leukemia [NCT03709576]	Phase 2	3 participants (Actual)	Interventional	2018-07-18	Terminated(stopped due to Funding pulled)
A Multicenter, Phase 2 Study of Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia in Complete Remission After Induction Chemotherapy [NCT00387647]	Phase 2	24 participants (Actual)	Interventional	2006-08-31	Completed
Phase II Study for the Use of Vidaza™ to Restore Responsiveness of Patients' Prostate Cancers to Hormonal Therapy [NCT00384839]	Phase 2	36 participants (Actual)	Interventional	2006-04-30	Completed
Therapy of Myelodysplastic Syndrome (MDS) With Azacitidine Given in Combination With Etanercept: A Phase I/II Study. [NCT00118287]	Phase 1/Phase 2	32 participants (Actual)	Interventional	2005-04-30	Completed
A Phase II Study of the Efficacy and Safety of Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q [NCT01088373]	Phase 2	50 participants (Actual)	Interventional	2010-03-25	Completed
HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukemia: a Multicenter, Open-label, Randomized Phase 3 Trial [NCT05586074]	Phase 3	324 participants (Anticipated)	Interventional	2023-03-03	Recruiting
Phase II Open-Label, Single-Center Study Evaluating Safety and Efficacy of Pembrolizumab Following Induction With the Hypomethylating Agent Azacitidine in Patients With Advanced Pancreatic Cancer After Failure of First-Line Therapy [NCT03264404]	Phase 2	36 participants (Actual)	Interventional	2017-10-01	Active, not recruiting
A Phase II Study With a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) - AMLSG 24-15 [NCT03338348]	Phase 2	9 participants (Actual)	Interventional	2018-04-19	Completed
A Phase Ib/II Open Label Dose Confirmation, Proof of Concept Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Unfit Adult AML Participants Who Responded Sub-optimally to First-line Venetoclax Plus Azacitidine Treatment and in Partici [NCT05155709]	Phase 1/Phase 2	56 participants (Anticipated)	Interventional	2022-05-17	Recruiting
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects With Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second [NCT04229979]	Phase 3	140 participants (Anticipated)	Interventional	2021-02-08	Recruiting
A Multicenter Clinical Study of Microtransplantation Combined With Azacytidine to Improve the Efficacy of Elderly Acute Myeloid Leukemia [NCT05262465]		300 participants (Anticipated)	Interventional	2020-07-01	Recruiting
A Phase I Study of Safety, Pharmacokinetics and Efficacy of HMPL-523 With Azacitidine in Elderly Patients With Previously Untreated Acute Myeloid Leukemia [NCT03483948]	Phase 1	7 participants (Actual)	Interventional	2018-10-09	Terminated(stopped due to Slow Enrollment)
A Phase II Trial of Azacitidine (NSC-102816) Plus Gemtuzumab Ozogamicin (NSC-720568) as Induction and Post-Remission Therapy in Patients of Age 60 and Older With Previously Untreated Non-M3 Acute Myeloid Leukemia [NCT00658814]	Phase 2	133 participants (Actual)	Interventional	2008-12-01	Active, not recruiting
Retrospective, Observational, Monocentric Study to Assess Efficacy and Safety of the Combination of an Hypomethylating Agent in Combination With Venetoclax for Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy [NCT04454580]		15 participants (Anticipated)	Observational	2020-08-01	Recruiting
A Phase 2, Multicenter, Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Azacitidine and to Compare Azacitidine to Historical Controls in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome [NCT02447666]	Phase 2	28 participants (Actual)	Interventional	2015-09-15	Completed
The Efficacy and Safety of Azacytidine Combined With HAG Regimen Versus Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy: a Prospective, Randomized Controlled Trial [NCT03873311]	Phase 4	114 participants (Anticipated)	Interventional	2019-09-01	Recruiting
A Phase IB/II Study of Epacadostat (INCB024360) in Combination With Pembrolizumab (MK-3475) and Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer [NCT03182894]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2018-09-30	Withdrawn(stopped due to Study will not be conducted due to changes related to the investigational agent.)
A Phase 1b Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination With Azacitidine in Subjects With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS) [NCT02942290]	Phase 1	129 participants (Anticipated)	Interventional	2017-01-12	Active, not recruiting
Randomized, Multicenter, Phase 3 Study of Azacytidine (AZA) + Venetoclax as Maintenance Therapy in Patients With AML in Remissionin Younger Adults With Favorable-risk AML in First Remission After Conventional Chemotherapy [NCT05404906]	Phase 2/Phase 3	124 participants (Anticipated)	Interventional	2022-06-25	Recruiting
To Evaluate Safety and Efficiency of AZA Combined With Chidamide as Maintenance Therapy in High-risk Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation：A Multicenter, Single-arm Study [NCT05270200]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2022-02-01	Recruiting
Prospective, Single-center, Single-arm, Open-label Study of Obinutuzumab, Zanubrutinib and Lenalidomide Sequential CD19/CD22 CAR-T in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [NCT05797948]		20 participants (Anticipated)	Interventional	2022-07-01	Enrolling by invitation
A Study to Evaluate the Efficacy and Safety of Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in the Refractory or Relapsed PTCL: A Phase 2, Single-center, Single-arm, Open Label Trial [NCT04052659]	Phase 2	30 participants (Anticipated)	Interventional	2021-04-15	Not yet recruiting
A Phase I/II Study of Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation [NCT02750254]	Phase 1	5 participants (Actual)	Interventional	2016-06-27	Terminated(stopped due to Toxicity. Only enrolled patients in phase I portion of trial.)
An Open-label, Phase I Study to Assess the Safety of NKR-2 Treatment Administered Concurrently With 5-azacytidine in Treatment-naïve Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients Not Candidates for Intensive Therapy [NCT03612739]	Phase 1	0 participants (Actual)	Interventional	2018-12-31	Withdrawn(stopped due to Sponsor decision)
A Phase 1, Open-label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With High Risk (IPI 3 or More) Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3B Follicular Lymphoma. [NCT02343536]	Phase 1	59 participants (Actual)	Interventional	2015-04-29	Completed
Risk Stratified Treatment for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia: A Phase I/II Non-randomized Study of Trametinib and Azacitidine With or Without Chemotherapy (IND #164058) [NCT05849662]	Phase 1/Phase 2	58 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
A Multicentric Phase I/II Study of Jaktinib Hydrochloride Tablets in Combination With Azacitidine for Injection in Patients With Myelodysplastic Syndromes(MDS) With Myelofibrosis(MF) or MDS/Myeloproliferative Neoplasms With MF [NCT04866056]	Phase 1/Phase 2	1 participants (Actual)	Interventional	2021-09-30	Terminated(stopped due to Corporate policy adjustments)
A Window Trial of 5-Azacytidine or Nivolumab or Combination Nivolumab Plus 5-Azacytidine in Resectable HPV-Associated Head and Neck Squamous Cell Cancer [NCT05317000]	Early Phase 1	50 participants (Anticipated)	Interventional	2023-03-23	Recruiting
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies [NCT04771130]	Phase 1/Phase 2	260 participants (Anticipated)	Interventional	2021-05-24	Recruiting
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination With Azacitidine in Patients With Recurrent, Resectable Osteosarcoma [NCT03628209]	Phase 1/Phase 2	51 participants (Anticipated)	Interventional	2019-10-03	Recruiting
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms [NCT03072043]	Phase 1/Phase 2	55 participants (Actual)	Interventional	2017-05-18	Completed
Maintenance Therapy With Azacitidine and Valproic Acid After Allogeneic Stem Cell Transplant in Patients With High-Risk Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)(Version 1_06 Jan 2012) [NCT02124174]	Phase 2	50 participants (Anticipated)	Interventional	2012-01-31	Recruiting
A Phase I/II Trial of AK117 (Anti-CD47) in Patients With Higher-risk Myelodysplastic Syndrome [NCT04900350]	Phase 1/Phase 2	190 participants (Anticipated)	Interventional	2021-06-18	Recruiting
Phase-II Trial to Assess the Efficacy and Toxicity of 5-Azacitidine in Addition to Standard DLI for the Treatment of Patients With AML or MDS Relapsing After Allogeneic Stem Cell Transplantation [NCT00795548]	Phase 2	30 participants (Actual)	Interventional	2008-11-30	Completed
A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV [NCT02959437]	Phase 1/Phase 2	70 participants (Actual)	Interventional	2017-02-27	Terminated(stopped due to Study terminated by Sponsor)
Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs (Chidamide and Azacitidine) in ENKTL-HLH: A Single-arm, Multi-center, Phase II, Exploratory Clinical Study [NCT05008666]	Phase 2	37 participants (Anticipated)	Interventional	2021-12-01	Not yet recruiting
Open-label, Phase 2 Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia [NCT06022003]	Phase 2	33 participants (Anticipated)	Interventional	2023-12-15	Not yet recruiting
A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine After Allogeneic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia (AML) (VIALE-T) [NCT04161885]	Phase 3	424 participants (Anticipated)	Interventional	2020-02-26	Recruiting
Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome [NCT03383575]	Phase 2	63 participants (Anticipated)	Interventional	2018-01-17	Recruiting
A Phase Ib/II Study of Guadecitabine (SGI-110) Plus Nivolumab in Refractory CIMP+ Metastatic Colorectal Cancer [NCT03576963]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2020-01-30	Withdrawn(stopped due to No funding)
A Phase I/II, Open-label, 2 Arm Study to Investigate the Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of GSK2879552 Administered Alone or in Combination With Azacitidine, in Adult Subjects With IPSS-R High and Very High Risk Myelodyspl [NCT02929498]	Phase 1/Phase 2	7 participants (Actual)	Interventional	2017-07-31	Terminated(stopped due to The risk benefit in the study population does not favor continuation of the study)
Phase II Study of Daratumumab in Combination With Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated With Daratumumab [NCT04407442]	Phase 2	5 participants (Actual)	Interventional	2020-11-30	Terminated(stopped due to Slow enrollment and change in sponsor direction)
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies [NCT02587598]	Phase 1/Phase 2	97 participants (Actual)	Interventional	2015-12-29	Terminated
Phase I Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia: MDS, MDS/MPNs, and Myelofibrosis [NCT03326310]	Phase 1	18 participants (Anticipated)	Interventional	2018-09-04	Recruiting
Phase I/II Evaluation of Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies [NCT04648826]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2021-12-14	Withdrawn(stopped due to Due to notification from EMD Serono, for Bintrafusp alfa (M7824) regarding an observed increase in the frequently of early progression and death.)
A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies [NCT04447027]	Phase 1	30 participants (Anticipated)	Interventional	2020-12-17	Recruiting
Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer [NCT01167816]	Phase 1	9 participants (Actual)	Interventional	2010-07-31	Terminated(stopped due to The study was terminated as the Prinicipal Investigator left the site- all previous subjects enrolled are deceased)
A Randomized Phase II Trial of MLN4924 (Pevonedistat) With Azacitidine Versus Azacitidine in Adult Relapsed or Refractory Acute Myeloid Leukemia [NCT03745352]	Phase 2	0 participants (Actual)	Interventional	2019-05-20	Withdrawn(stopped due to Inadequate accrual rate)
A Phase 2, Open-label Trial to Evaluate the Efficacy and Safety of MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma, and to Evaluate the Pharmacokinetics of Different F [NCT00543582]	Phase 2	23 participants (Actual)	Interventional	2007-10-31	Terminated(stopped due to Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All Celgene-sponsored trials with MGCD0103 will be closed.)
Phase I Study of Decitabine (Dacogen) and Selinexor (KPT-330) in Acute Myeloid Leukemia [NCT02093403]	Phase 1	25 participants (Actual)	Interventional	2014-03-31	Completed
Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk Myelodysplastic Syndromes∕Myeloproliferative Neoplasms [NCT05817955]	Phase 2	50 participants (Anticipated)	Interventional	2022-11-01	Recruiting
A Phase 2, Randomized, Open-label Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hem [NCT04264806]	Phase 2	0 participants (Actual)	Interventional	2021-05-06	Withdrawn(stopped due to The cusatuzumab MDS strategy is under revision)
VIDAZA® Drug Use Examination [NCT02137629]		511 participants (Actual)	Observational	2010-12-27	Completed
A Phase Ib/II Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia [NCT04980885]	Phase 1/Phase 2	160 participants (Anticipated)	Interventional	2021-08-13	Recruiting
Prospective Randomized Study on the Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-myelodysplastic Syndromes, Performed Upfront or Preceded by Azacitidine or Conventional Chemotherapy According to the BM-blast Proportion [NCT04184505]	Phase 3	274 participants (Anticipated)	Interventional	2020-11-27	Recruiting
A Multicenter, Randomized, Open-Label Study Comparing Three Alternative Dosing Regimens of Subcutaneous Azacitidine Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes [NCT00102687]	Phase 2	151 participants (Actual)	Interventional	2005-01-01	Completed
Phase I Dose-Escalation Study of Azacitidine (Vidaza) and Bortezomib (Velcade) in T-Cell Lymphoma [NCT01129180]	Phase 1	8 participants (Actual)	Interventional	2010-05-31	Completed
Phase II Study of 5-azacytidine Maintenance After Allogeneic Hematopoietic Cell Transplantation for High-risk Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) [NCT02204020]	Phase 2	0 participants (Actual)	Interventional	2015-04-30	Withdrawn(stopped due to Lack of interest with investigators - no subjects enrolled)
A Phase 1, Open-label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects [NCT02223052]	Phase 1	89 participants (Actual)	Interventional	2014-10-27	Completed
A Phase 1-2, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) [NCT01261312]	Phase 1/Phase 2	401 participants (Actual)	Interventional	2010-12-31	Completed
Single-arm, Open Label, Phase II Study of MBG453 (Sabatolimab) Added to FDA Approved Hypomethylating Agents of Investigator's Choice (IV/SC/Oral) for Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria [NCT04878432]	Phase 2	90 participants (Anticipated)	Interventional	2022-03-17	Recruiting
A Two-Stage, Open-Label Phase 2 Study of Pracinostat and Azacitidine in Patients With IPSS-R High and Very High Risk Myelodysplastic Syndromes Previously Untreated With Hypomethylating Agents [NCT03151304]	Phase 2	64 participants (Actual)	Interventional	2017-06-01	Terminated(stopped due to Sponsor's decision as at the completion of the primary analysis, the data were considered mature)
Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine in Patients With AML, MDS or CMML [NCT04730258]	Phase 1/Phase 2	72 participants (Anticipated)	Interventional	2021-04-16	Recruiting
A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination With a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients With High Risk AML, MDS, and MDS/MPN Overlap S [NCT03613532]	Phase 1	78 participants (Anticipated)	Interventional	2018-10-24	Recruiting
Randomized Phase 3 Study Evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patient With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma [NCT03593018]	Phase 3	86 participants (Actual)	Interventional	2018-11-09	Active, not recruiting
An Open-Label Phase 1a/1b Dose Escalation and Expansion Cohort Study of SL-172154 (SIRPα-Fc-CD40L) in Combination With Azacitidine or With Azacitidine and Venetoclax for the Treatment of Subjects With Higher-Risk Myelodysplastic Syndrome (MDS) or Acute My [NCT05275439]	Phase 1	107 participants (Anticipated)	Interventional	2022-03-17	Recruiting
A Phase II Trial of Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors [NCT03238248]	Phase 2	71 participants (Actual)	Interventional	2017-08-07	Active, not recruiting
A Phase 1/1b Dose Escalation, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 as a Single Agent and in Combination With Azacitidine in Patients With Relapsed or Refractory Hematologic Malignancies [NCT02543879]	Phase 1	94 participants (Actual)	Interventional	2015-09-30	Completed
A Phase Ib/II Study Assessing the BET-bromodomain (BRD) Inhibitor OTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT) [NCT02303782]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2015-01-31	Withdrawn
Phase I Study of Decitabine and Haplo-identical Natural Killer Cells in Acute Myeloid Leukemia (AML) [NCT02316964]	Phase 1	8 participants (Actual)	Interventional	2015-04-21	Completed
an Single Center，Single Arm, Phase 3 Study to Evaluate Efficacy and Safety of PD-1 Inhibitor Combined With Azacytidine and HAG Regimen for Patients With Relapsed or Refractory Acute Myeloid Leukemia. [NCT04722952]	Phase 3	30 participants (Anticipated)	Interventional	2021-05-01	Recruiting
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy and in Combination With Azacitidine in Subjects With Advanced Hematologic Malignancies [NCT01110473]	Phase 1	52 participants (Actual)	Interventional	2010-04-30	Completed
A Clinical Study to Evaluate the Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Acute Myelocytic Leukemia [NCT06105658]	Phase 2	20 participants (Anticipated)	Interventional	2023-10-31	Recruiting
A Phase I Study of Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy [NCT05065866]	Phase 1	30 participants (Anticipated)	Interventional	2021-11-18	Recruiting
Phase I/II Study of Azacitidine in Combination With Quizartinib for Patients With Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms With FLT3 or CBL Mutations [NCT04493138]	Phase 1/Phase 2	58 participants (Anticipated)	Interventional	2020-07-21	Recruiting
A Multi-center, Phase II, Single-arm Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults [NCT05282719]	Phase 2	33 participants (Anticipated)	Interventional	2022-04-30	Enrolling by invitation
A Phase 2 Study of Azacitidine in Chronic Myelomonocytic Leukemia (CMML) [NCT01235117]	Phase 2	30 participants (Anticipated)	Interventional	2010-01-31	Completed
A Phase I/II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (Vidaza®) in Intermediate-2 and High Risk MDS Patients [NCT01305460]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2011-07-05	Completed
A PHASE 1 DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVENOUS PF-06747143, ADMINISTERED AS SINGLE AGENT OR IN COMBINATION WITH STANDARD CHEMOTHERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA [NCT02954653]	Phase 1	8 participants (Actual)	Interventional	2016-11-28	Terminated(stopped due to The study was terminated due to a change in sponsor prioritization.)
A Phase II Study of Epigenetic Priming Using Azacitidine Followed by Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma [NCT03719989]	Phase 2	27 participants (Anticipated)	Interventional	2018-12-01	Not yet recruiting
A Phase I/II Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents in Participants With Myelodysplastic Syndrome and Acute Myeloid Leukaemia [NCT03614728]	Phase 1/Phase 2	30 participants (Actual)	Interventional	2018-10-16	Terminated(stopped due to Trial terminated due to internal review of clinical data in context of indication under investigation)
Randomized Phase II Trial Seeking the Most Promising Drug Association With Azacitidine- in Higher Risk Myelodysplastic Syndromes [NCT01342692]	Phase 2	320 participants (Anticipated)	Interventional	2011-06-30	Active, not recruiting
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies [NCT03248479]	Phase 1	258 participants (Actual)	Interventional	2017-09-08	Terminated(stopped due to This study has been discontinued due to futility based on the results of a planned analysis of the ENHANCE trial.)
A Randomized, Open-label, Parallel-Group Study Comparing the Efficacy and Safety of DACOGEN (Decitabine) for Injection and VIDAZA (Azacitidine) for Injection In Subjects With Intermediate or High Risk Myelodysplastic Syndromes (MDS) [NCT01011283]	Phase 4	26 participants (Actual)	Interventional	2009-11-30	Terminated(stopped due to The study was stopped due to insufficient enrollment.)
A Phase I Study of Uproleselan Combined With Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients With Treatment Naive Acute Myeloid Leukemia [NCT04964505]	Phase 1	25 participants (Anticipated)	Interventional	2021-07-02	Recruiting
Phase II Study of 5-azacytidine and Lintuzumab in Myelodysplastic Syndromes (MDS) [NCT00997243]	Phase 2	7 participants (Actual)	Interventional	2009-11-30	Terminated(stopped due to Drug no longer being supplied by sponsor)
A Combination of PKC412 and 5-Azacytidine for the Treatment of Patients With Refractory or Relapsed Acute Leukemia and Myelodysplastic Syndrome (MDS) [NCT01202877]	Phase 1/Phase 2	54 participants (Actual)	Interventional	2011-03-31	Completed
Phase I/II Study of Azacitidine and CAPOX (Capecitabine + Oxaliplatin) in Metastatic Colorectal Cancer Patients Enriched for Hypermethylation of CpG Promoter Islands [NCT01193517]	Phase 1/Phase 2	26 participants (Actual)	Interventional	2010-08-31	Completed
Phase I/II Study of the Combination of 5-azacitidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) [NCT01038635]	Phase 1/Phase 2	94 participants (Actual)	Interventional	2009-12-31	Completed
A Phase 2, Monocentric, Pilot Study to Evaluate Safety and Efficacy of CC 486 (Oral Azacitidine) Plus Best Supportive Care as Maintenance of Response to sc Azacitidine in IPSS Higher Risk Elderly MDS Patients [NCT04806906]	Phase 2	10 participants (Anticipated)	Interventional	2021-03-24	Recruiting
Venetoclax Based Regimen for the Treatment of Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia [NCT05149378]	Phase 2	25 participants (Anticipated)	Interventional	2021-11-01	Recruiting
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial) [NCT03013998]	Phase 1/Phase 2	2,000 participants (Anticipated)	Interventional	2016-11-30	Recruiting
Phase I/II, Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) [NCT02829840]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2016-09-30	Withdrawn
Single Arm,Open Label,Phase I Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia [NCT05659992]	Phase 1	30 participants (Anticipated)	Interventional	2022-01-10	Recruiting
Azacitidine and Venetoclax (ABT-199) as Induction Therapy With Venetoclax Maintenance in Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML) [NCT03466294]	Phase 2	42 participants (Actual)	Interventional	2018-05-15	Active, not recruiting
An Open-label, Multicenter, Phase 1a/1b Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed, Refractory, or Newly Diagnosed Cancers [NCT04553692]	Phase 1	430 participants (Anticipated)	Interventional	2020-09-23	Recruiting
A Phase 1 Study of SEA-CD70 in Myeloid Malignancies [NCT04227847]	Phase 1	140 participants (Anticipated)	Interventional	2020-08-07	Recruiting
A Phase 2, Open-Label, Single-Arm Rollover Study to Evaluate Long-Term Safety in Subjects Who Participated in Other Celgene Sponsored CC-486 (Oral Azacitidine) Clinical Trials in Hematological Disorders [NCT02494258]	Phase 2	4 participants (Actual)	Interventional	2015-10-22	Active, not recruiting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia [NCT02147873]	Phase 2	118 participants (Actual)	Interventional	2014-06-30	Terminated(stopped due to Study terminated due to lack of efficacy)
A Phase Ib Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of APG-115 as a Single Agent or in Combination With Azacitidine or Cytarabine in Patients With Relapse/Refractory AML and Relapsed/Progressed High/Very High Risk MDS [NCT04275518]	Phase 1	102 participants (Anticipated)	Interventional	2020-07-06	Recruiting
A Randomized, run-in, Multi-center, Phase II Study of Nivolumab Combined With Ipilimumab and Guadecitabine or Nivolumab Combined With Ipilimumab in Melanoma and NSCLC Patients Resistant to Anti-PD-1/PD-L1 (NIBIT-ML1) [NCT04250246]	Phase 2	184 participants (Anticipated)	Interventional	2020-03-31	Not yet recruiting
A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination With Azacitidine in Subjects With Relapsed/Refractory Myelodysplastic Syndromes [NCT02966782]	Phase 1	70 participants (Actual)	Interventional	2017-03-07	Completed
A Randomized Phase II Trial to Simultaneously Evaluate Two Schedules of the Histone Deacetylase Inhibitor Entinostat in Combination With 5-Azacytidine (5AC, NSC 102816) in Elderly Patients With Acute Myeloid Leukemia (AML) [NCT01305499]	Phase 2	52 participants (Actual)	Interventional	2011-07-01	Active, not recruiting
A Phase II Study of 5-Azacitidine (5AC) in Combination With Sargramostim (GM-CSF) as Maintenance Treatment, After Definitive Therapy With Either Stem Cell Transplant (SCT) or Cytarabine-based Chemotherapy, in Patients With Poor-risk Acute Myeloid Leukemia [NCT01700673]	Phase 2	25 participants (Actual)	Interventional	2013-06-30	Completed
A Phase 1b/2 Study of TP-0903 in Patients With Acute Myeloid Leukemia and FLT3 Mutations [NCT04518345]	Early Phase 1	3 participants (Actual)	Interventional	2020-11-05	Completed
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 [NCT03493646]	Phase 2	60 participants (Anticipated)	Interventional	2018-06-18	Active, not recruiting
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Relapsed and/or Treatment-Refractory Leukemia [NCT02071927]	Phase 1	43 participants (Actual)	Interventional	2014-03-31	Completed
A Pilot Clinical Trial to Evaluate the Biological Activity of 5-azacitidine on ER and PR Expression in Triple Negative Invasive Breast Cancer [NCT01292083]		0 participants (Actual)	Interventional	2011-01-31	Withdrawn(stopped due to No accrual last 2 years)
Phase II Study of 5-Azacytidine (AZA) + Venetoclax as Maintenance Therapy in Patients With AML in Remission [NCT04062266]	Phase 2	50 participants (Anticipated)	Interventional	2019-09-13	Recruiting
"A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial" [NCT03092674]	Phase 2/Phase 3	78 participants (Actual)	Interventional	2018-02-02	Active, not recruiting
Precision Therapy Versus Standard Therapy in Acute Myeloid Leukaemia and Myelodysplastic Syndrome in Elderly [NCT05025098]	Phase 2	36 participants (Anticipated)	Interventional	2021-06-22	Recruiting
Phase I/Ib Study of Azacitidine or Decitabine With Hedgehog Pathway Inhibition in Myeloid Malignancies [NCT02129101]	Phase 1	63 participants (Actual)	Interventional	2014-05-31	Completed
A Randomized, Multicenter, Open-label, Phase 2 Study, With a Safety Run-in Part to Evaluate Safety, Pharmacodynamics and Efficacy of Azacitidine Compared to No Anticancer Treatment in Children and Young Adults With Acute Myeloid Leukemia in Molecular Rela [NCT02450877]	Phase 2	7 participants (Actual)	Interventional	2015-08-12	Completed
A Multicenter, Phase 3 Study of Venetoclax and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy for Patients With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M) [NCT04102020]	Phase 3	112 participants (Actual)	Interventional	2020-03-26	Active, not recruiting
A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 as Monotherapy or in Combination With Tremelimumab With or Without Azacitidine in Subjects With Myelodysplastic Syndrome After Treatment With Hypomethylating Agents [NCT02117219]	Phase 1	67 participants (Actual)	Interventional	2014-05-20	Completed
Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial [NCT05554419]	Phase 2	184 participants (Anticipated)	Interventional	2024-08-16	Not yet recruiting
A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Patients Wit [NCT04778397]	Phase 3	346 participants (Anticipated)	Interventional	2021-07-01	Active, not recruiting
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia [NCT02675452]	Phase 1	142 participants (Actual)	Interventional	2016-06-13	Active, not recruiting
A Clinical Study to Evaluate the Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk Myelodysplastic Syndromes [NCT06109064]	Phase 2	14 participants (Anticipated)	Interventional	2023-10-27	Recruiting
A Collaboration Phase 2 Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia [NCT05955261]	Phase 2	70 participants (Anticipated)	Interventional	2023-07-25	Recruiting
A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination With Azacitidine in Patients With 11q23-Rearranged Acute Myeloid Leukemia [NCT03701295]	Phase 1/Phase 2	1 participants (Actual)	Interventional	2020-03-06	Completed
Proof-Of-Concept Study of Metabolically Optimized, Non-Cytotoxic 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies [NCT04187703]	Early Phase 1	20 participants (Anticipated)	Interventional	2020-11-16	Recruiting
A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies [NCT05476770]	Phase 1	54 participants (Anticipated)	Interventional	2022-11-11	Recruiting
A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination With Azacitidine or Cytarabine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation [NCT02719574]	Phase 1/Phase 2	336 participants (Actual)	Interventional	2016-04-30	Active, not recruiting
Phase 2 Study of SGI-110 in Patients With Higher Risk MDS [NCT02131597]	Phase 2	71 participants (Actual)	Interventional	2014-11-10	Active, not recruiting
A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytope [NCT01566695]	Phase 3	216 participants (Actual)	Interventional	2013-04-26	Active, not recruiting
Phase II Randomized Trial With A Modified Dose & Schedule of Subcutaneously Administered Azacitidine & Erythropoietin v Azacitidine Alone in Patients With Low-Risk Myelodysplastic Syndromes (Less Than 11% Marrow & Peripheral Blood Blasts) [NCT00379912]	Phase 2	15 participants (Actual)	Interventional	2006-09-30	Terminated(stopped due to Insufficient response rate)
Phase I Study of Azacitidine in Combination With Cisplatin Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck [NCT00443261]	Phase 1	1 participants (Actual)	Interventional	2007-02-28	Terminated(stopped due to Accrual problems)
A Phase I Study of Vosaroxin Plus Azacitidine for Patients With Myelodysplastic Syndrome [NCT01913951]	Phase 1	35 participants (Actual)	Interventional	2013-11-22	Active, not recruiting
A Phase I/II Clinical Trial of Omacetaxine, Azacitidine, and G-CSF for Relapsed and/or Refractory Myelodysplastic Syndromes [NCT02835794]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2016-08-31	Withdrawn(stopped due to Lack of funding to support clinical trial)
Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma: A Phase I Trial [NCT00901069]	Phase 1	12 participants (Actual)	Interventional	2009-05-31	Completed
Phase I Study of Azacitidine in Combination With Cisplatin in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck [NCT00901537]	Phase 1	8 participants (Actual)	Interventional	2009-02-28	Terminated(stopped due to Sponsor terminated due to no enrollments within last 4 months.)
A Prospective Single-center Study on the Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RS [NCT06004765]	Phase 4	138 participants (Anticipated)	Interventional	2023-08-31	Not yet recruiting
A Phase I Dose-Finding Clinical Trial With Expansion Cohort Evaluating CC-486 in Patients With Relapsed/Refractory T-Cell Large Granular Lymphocytic Leukemia (T-LGLL) [NCT05141682]	Phase 1/Phase 2	21 participants (Anticipated)	Interventional	2022-05-01	Recruiting
A Phase II Study to Evaluate the Safety and Efficacy of Venetoclax in Combination With Azacitidine and CAG(VA-CAG) as Induction Therapy in Newly Diagnosed Patients With Acute Myeloid Leukemia(AML) [NCT05662956]	Phase 1/Phase 2	62 participants (Anticipated)	Interventional	2022-12-01	Recruiting
A Phase 1/2, Open-label, 2-arm Study Evaluating BLU-263 as Monotherapy and in Combination With Azacitidine, in Patients With KIT Altered Hematologic Malignancies [NCT05609942]	Phase 1/Phase 2	67 participants (Anticipated)	Interventional	2023-09-25	Recruiting
A Phase 1 Study of AMG 176 as Monotherapy and in Combination With Azacitidine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia [NCT05209152]	Phase 1	120 participants (Anticipated)	Interventional	2022-11-14	Recruiting
A Phase Ib Study Evaluating the Safety and Efficacy of IBI188 in Combination With Demethylating Agents in Subjects With Acute Myeloid Leukemia [NCT04485052]	Phase 1/Phase 2	222 participants (Anticipated)	Interventional	2020-09-25	Suspended(stopped due to Pause for changes in development strategies)
An Open-label, Phase II Basket Study of a hypoMEThylating Agent Oral Azacitidine and DURvalumab (MEDI4736) (Anti-PDL1) in Advanced Solid Tumors (METADUR) [NCT02811497]	Phase 2	28 participants (Actual)	Interventional	2016-09-30	Completed
The Feasibility of a Bridging Treatment With Low-dose Azacitidine (AZA) in Combination With Short Term CAG Derived Regimen Prior to Allogeneic Stem Cell Transplantation (Allo-HSCT) in Patients With Advanced Myelodysplastic Syndromes (MDS) [NCT04216355]	Phase 2/Phase 3	20 participants (Anticipated)	Interventional	2020-01-31	Recruiting
Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial [NCT05628623]	Phase 2	184 participants (Anticipated)	Interventional	2023-10-23	Not yet recruiting
A Single Arm Phase II Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine (sc) in Adult Patients With Newly Diagnosed Acute Myeloid Leukaemia (AML) Who Are Not Considered Candidates for Intensive Treatment Regimens [NCT06014489]	Phase 2	142 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Comparing the Efficacy and Safety of Venetoclax Combined With Decitabine/Azacitidine and Aclarubicin Versus Venetoclax Combined With Decitabine/Azacitidine in Treatment-Naive Elderly Patients With Acute Myeloid Leukemia [NCT05264883]	Phase 3	170 participants (Anticipated)	Interventional	2021-03-01	Recruiting
A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell L [NCT04799275]	Phase 2/Phase 3	422 participants (Anticipated)	Interventional	2021-05-20	Recruiting
A Phase I/II Study of Venetoclax in Combination With Azacitidine in Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) [NCT04550442]	Phase 1/Phase 2	58 participants (Anticipated)	Interventional	2020-09-04	Recruiting
A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients With Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma [NCT03530683]	Phase 1	177 participants (Actual)	Interventional	2018-06-07	Active, not recruiting
Phase Ib, Open Label, Combination Study of Nintedanib With 5-Azacitidine in Acute Myeloid Leukemia Characterized by HOX Gene Overexpression, That Are Not Candidates of Intensive Chemotherapy [NCT03513484]	Phase 1	44 participants (Anticipated)	Interventional	2018-11-14	Active, not recruiting
A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation [NCT02421939]	Phase 3	371 participants (Actual)	Interventional	2015-10-20	Active, not recruiting
Phase I/II Study of Sorafenib and 5-Azacitidine for the Treatment of Patients With Refractory or Relapsed Acute Leukemia and Myelodysplastic Syndrome (MDS) - (VZ-MDS-PI-0227) [NCT01254890]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2011-01-31	Completed
A Multisite Phase Ib Study of Pevonedistat, Azacitidine (or Decitabine), and Venetoclax (PAVE) for the Treatment of Patients With Acute Myelogenous Leukemia (AML) [NCT04172844]	Phase 1	24 participants (Anticipated)	Interventional	2020-01-13	Active, not recruiting
A Phase I and Phase II Study of the Efficacy and Safety of Maintenance Treatment With Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes Who Achieved Hematological Response to Azacitidine [NCT01324960]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2011-03-31	Withdrawn
A Phase II Study of Azacitidine (Vidaza®) Combined to Epoetin Beta (NeoRecormon®) in IPSS Low-risk and Intermediate-1 MDS Patients, Resistant to ESA [NCT01015352]	Phase 2	98 participants (Actual)	Interventional	2009-02-28	Completed
A Phase I/II Study of Azacitidine (Vidaza), Docetaxel and Prednisone for Patients With Hormone Refractory Metastatic Prostate Cancer Previously Treated With a Taxotere Containing Regimen. [NCT00503984]	Phase 1/Phase 2	22 participants (Actual)	Interventional	2007-05-31	Terminated(stopped due to Withdrawal of Funding)
A Phase 1 Study of CTEP 5-Azacytidine in Combination With Oxaliplatin in Patients With Advanced Cancers Relapsed or Refractory or Refractory to Any Platinum Therapy [NCT01039155]	Phase 1	41 participants (Actual)	Interventional	2009-12-31	Completed
A Phase I/II Study of Entinostat in Combination With 5-Azacytidine in Patients With Recurrent Advanced Non-Small Cell Lung Cancer [NCT00387465]	Phase 1/Phase 2	94 participants (Actual)	Interventional	2006-08-31	Completed
An Randomized Controlled Study of Azacitidine Combined With Homoharringtonine Compared With Azacitidine for Patients With Int/High -Risk MDS and AML-MRC [NCT03978364]	Phase 3	100 participants (Anticipated)	Interventional	2019-06-01	Recruiting
Phase II Study of Azacitidine in Myelofibrosis [NCT00381693]	Phase 2	10 participants (Actual)	Interventional	2006-08-31	Terminated(stopped due to Due to lack of accrual and trial has demonstrated too little clinical benefit)
A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 as Monotherapy and in Combination With Azacitidine in Subjects With Relapsed or Refractory My [NCT04139434]	Phase 1	36 participants (Anticipated)	Interventional	2020-07-06	Recruiting
Expanded Access for CC-486 [NCT03723135]		0 participants	Expanded Access		Approved for marketing
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation [NCT03173248]	Phase 3	146 participants (Actual)	Interventional	2017-06-26	Active, not recruiting
Evaluation of Ruxolitinib and Azacytidine Combination as a Therapy for Patients With Myelofibrosis and Myelodysplastic Syndrome/ Myeloproliferative Neoplasm [NCT01787487]	Phase 2	125 participants (Anticipated)	Interventional	2013-03-13	Recruiting
Inhibition of DNA Methylation by 1-Hr Infusion of 5-aza-2'-Deoxycitidine (Decitabine) x 10 Days (M-F) With Escalating Doses of Sub-Q Pegylated (PEG) Interferon-alpha 2B (PEG-Intron): A Phase I Study With Molecular Correlates [NCT00701298]	Phase 1	30 participants (Actual)	Interventional	2009-04-30	Terminated
A Single-arm, Open-label, Phase II Study of Sabatolimab in Combination With Azacitidine and Venetoclax in Adult Participants With High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria [NCT04812548]	Phase 2	20 participants (Actual)	Interventional	2021-05-31	Completed
A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute [NCT02677922]	Phase 1/Phase 2	130 participants (Actual)	Interventional	2016-06-03	Active, not recruiting
A Phase I, Dose-Ranging Study to Evaluate the Pharmacokinetics and Safety of Azacitidine Administered Subcutaneously (SC) and as Different Oral Formulations in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute My [NCT00761722]	Phase 1	31 participants (Actual)	Interventional	2008-08-12	Completed
A Phase IIA Study of Subcutaneous 5-aza-2'- Deoxycytidine (Decitabine) in Patients With Thalassemia Intermedia [NCT00661726]	Phase 2	6 participants (Actual)	Interventional	2008-01-31	Completed
A Pilot Study Of Pre-Transplant 5-Azacitidine (Vidaza) In Patients With High-Risk Myelodysplastic Syndrome (MDS) Who Are Candidates For Allogeneic Hematopoietic Cell Transplantation [NCT00660400]		25 participants (Actual)	Interventional	2008-03-31	Completed
A Phase II Study of Azacitidine, Venetoclax and Trametinib for Patients With Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome [NCT04487106]	Phase 2	21 participants (Actual)	Interventional	2020-07-21	Completed
A Randomized, Multi-center Phase II Trial to Assess the Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML [NCT00915252]	Phase 2	214 participants (Actual)	Interventional	2009-07-31	Completed
Pilot Study of 5 Azacytidine in the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukaemia With High-risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities [NCT00915785]	Phase 2	40 participants (Actual)	Interventional	2005-11-30	Completed
A Phase I Study of a Combination of 5-azacitidine Followed by Lenalidomide in High-risk MDS or Relapsed/Refractory AML Patients With Cytogenetic Abnormalities Including -5 or Del(5q) [NCT00923234]	Phase 1	0 participants	Interventional	2009-06-30	Terminated(stopped due to The primary objective has already been answered with the number of recruited patients.)
A Phase 4, Open-Label, Single-Arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes. [NCT01201811]	Phase 4	44 participants (Actual)	Interventional	2010-10-01	Completed
Phase I Study of Vidaza and Velcade (Bortezomib) in Acute Myeloid Leukemia [NCT00624936]	Phase 1	23 participants (Actual)	Interventional	2008-04-30	Completed
Venetoclax and Azacitidine Combination Therapy for Patients With Accelerated or Blast Phase BCR-ABL Negative Myeloproliferative Neoplasm (VAAMP) [NCT05074355]	Phase 2	40 participants (Anticipated)	Interventional	2023-09-16	Not yet recruiting
A Phase 1/1b Study of Pevonedistat in Combination With Select Standard of Care Agents in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myelogenous Leukemia, or Advanced Solid Tumors With Severe Renal Impairmen [NCT03814005]	Phase 1	17 participants (Actual)	Interventional	2019-07-10	Completed
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocy [NCT04256317]	Phase 2/Phase 3	317 participants (Anticipated)	Interventional	2020-05-21	Recruiting
A Phase II Study of the Impact of Clinicogenetic Risk-Stratified Management on Outcomes of Acute Myeloid Leukemia in Older Patients [NCT03226418]	Phase 2	75 participants (Actual)	Interventional	2017-07-07	Active, not recruiting
Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome [NCT03066648]	Phase 1	241 participants (Actual)	Interventional	2017-07-06	Completed
A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies [NCT03465540]	Phase 1	24 participants (Actual)	Interventional	2018-08-17	Terminated(stopped due to Strategic decisions)
5-Azacytidine to Treat Acute Myeloid Leukemia in Elderly or Frail Patients Not Suitable for Intensive Chemotherapy. A Multicenter Phase II Trial. [NCT00739388]	Phase 2	47 participants (Actual)	Interventional	2008-07-31	Completed
A Phase 1, Multicenter, Open-label Study to Evaluate the Pharmacokinetics of CC-486 (Onureg®) in Subjects With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Adult Subjects With Myeloid Malignancies [NCT05209295]	Phase 1	32 participants (Anticipated)	Interventional	2023-11-30	Recruiting
Phase Ib/II Investigator Initiated Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies [NCT03471260]	Phase 1/Phase 2	96 participants (Anticipated)	Interventional	2018-03-19	Recruiting
Phase II Study of Azacitidine and Entinostat (SNDX-275) in Patients With Advanced Breast Cancer [NCT01349959]	Phase 2	58 participants (Actual)	Interventional	2011-04-21	Active, not recruiting
A Phase I Dose Escalation Study of Oral SB939 When Administered Thrice Weekly (Every Other Day) for 3 Weeks in a 4-week Cycle in Patients With Advanced Malignancies [NCT00741234]	Phase 1	85 participants (Actual)	Interventional	2007-04-30	Completed
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat (LBH589) Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). [NCT00946647]	Phase 1/Phase 2	113 participants (Actual)	Interventional	2009-12-02	Completed
Randomized Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) [NCT00887068]	Phase 3	187 participants (Actual)	Interventional	2009-04-21	Completed
Clinical and Biological Effects of 5-Azacitidine Five Days/Monthly Schedule in Symptomatic Low-risk Myelodysplastic Syndromes (MDSs) [NCT00897130]	Phase 2	28 participants (Actual)	Interventional	2008-08-31	Completed
A Phase Ⅱ, Open Label, Single Arm, Single-Center Study to Evaluate the Efficacy and Safety of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients [NCT05433532]	Phase 2	20 participants (Anticipated)	Interventional	2022-05-01	Recruiting
A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA [NCT03416179]	Phase 3	730 participants (Actual)	Interventional	2018-04-20	Completed
A Proof of Concept Study of Non-DNA Damaging DNMT1 Depletion Therapy for Myelodysplastic Syndrome [NCT01165996]	Phase 1/Phase 2	25 participants (Actual)	Interventional	2010-07-31	Completed
Phase I/IIa Study of the Oral 5-Azacitidine in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies [NCT01998035]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2013-11-30	Terminated(stopped due to PI left institution)
A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast A [NCT03268954]	Phase 3	454 participants (Actual)	Interventional	2017-11-28	Active, not recruiting
A Phase Ib Study of the Safety, Pharmacokinetic of APG-2575 Single Agent and in Combination With Homoharringtonine or Azacitidine in Patients With Relapsed/Refractory AML [NCT04501120]	Phase 1/Phase 2	284 participants (Anticipated)	Interventional	2020-09-28	Recruiting
Phase I Study of Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy in Patients With Resectable Esophageal Cancer [NCT01386346]	Phase 1	12 participants (Actual)	Interventional	2011-06-30	Completed
A Phase I Study of the Safety and Feasibility of Azacitidine After Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Stem Cell Transplantation [NCT01390311]	Phase 1	14 participants (Actual)	Interventional	2012-04-30	Completed
A Study of Chidamide With AZA in MRD Positive AML After Transplant [NCT06066905]		60 participants (Anticipated)	Interventional	2023-10-26	Recruiting
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML) [NCT05834244]	Phase 1	32 participants (Anticipated)	Interventional	2023-10-26	Recruiting
"Phase I/II of Venetoclax in Combination With Azacitidine in Treatment Naïve and Relapse Refractory High Risk MDS Individuals" [NCT04160052]	Phase 1/Phase 2	116 participants (Anticipated)	Interventional	2019-10-01	Recruiting
Comparison Between 5-azacytidine Treatment and 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability [NCT01404741]	Phase 2	191 participants (Actual)	Interventional	2011-07-31	Completed
A Phase I/II Study of Venetoclax and Azacitidine and Lintuzumab-Ac225 in Patients With Refractory or Relapsed AML [NCT03932318]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2023-03-31	Withdrawn(stopped due to study postponed)
A Phase I/II Study Evaluating The Efficacy OF 5-Azacitidine And Bevacizumab In Advanced Renal Cell Carcinoma [NCT00934440]	Phase 1/Phase 2	11 participants (Actual)	Interventional	2009-06-30	Terminated
A Phase 2, Randomized, Double-Blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Subjects With Acute Myeloid Leukemia in Complete Remi [NCT05197426]	Phase 2	15 participants (Anticipated)	Interventional	2022-01-17	Recruiting
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes Wi [NCT05365035]	Phase 2	60 participants (Anticipated)	Interventional	2022-09-23	Recruiting
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function [NCT00652626]	Phase 1	31 participants (Actual)	Interventional	2008-11-01	Completed
A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Azacitidine in Patients Newly Diagnosed With Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) [NCT04401748]	Phase 3	531 participants (Actual)	Interventional	2020-09-10	Active, not recruiting
Azacitidine Maintenance Therapy After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia (CML) [NCT00813124]	Phase 2	24 participants (Actual)	Interventional	2008-12-31	Completed
Phase I/II Trial of Azacitidine Plus Lenalidomide in the Treatment of Acute Myeloid Leukemia [NCT01016600]	Phase 1/Phase 2	31 participants (Actual)	Interventional	2010-04-30	Completed
Phase IA/B Combination Study of ADI-PEG 20, Venetoclax and Azacitidine in Patients With Acute Myeloid Leukemia (AML) [NCT05001828]	Phase 1	60 participants (Anticipated)	Interventional	2022-04-05	Recruiting
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma [NCT05355051]	Phase 2	24 participants (Anticipated)	Interventional	2022-10-05	Recruiting
A Pilot Study of 5-Azacytidine and Oral Sodium Phenylbutyrate in Severe Thalassemia [NCT00005934]	Phase 2	24 participants	Interventional	2000-06-30	Completed
Randomized Phase 3 Study Evaluation the Efficacy and Safety of Oral Azacitidine(CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma [NCT03703375]	Phase 3	22 participants (Actual)	Interventional	2018-11-06	Active, not recruiting
A Phase I/II Clinical Trial of the Hypomethylating Agent Azacitidine (Vidaza) With the Nanoparticle Albumin Bound Paclitaxel (Abraxane) in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer [NCT00748553]	Phase 1/Phase 2	30 participants (Actual)	Interventional	2008-09-30	Completed
A Phase II Open-Label, Single-arm, Two-Stage, Multicenter Trial of Pracinostat in Combination With Azacitidine in Elderly (Age 65 Years or Older) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT01912274]	Phase 2	50 participants (Actual)	Interventional	2013-12-24	Completed
A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies [NCT00996515]	Phase 1	30 participants (Actual)	Interventional	2008-06-30	Completed
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LP-108, a BCL-2 Inhibitor, Combined With Azacitidine In Subjects With AML, MDS, CMML [NCT05641259]	Phase 1	198 participants (Anticipated)	Interventional	2023-02-14	Recruiting
A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim (AMG 531) Treatment of Subjects With Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Hypomethylating Agents [NCT00321711]	Phase 2	69 participants (Actual)	Interventional	2006-10-01	Completed
A Phase I Trial Evaluating the Effects of Plerixafor (AMD3100) and G-CSF in Combination With Azacitidine (Vidaza) for the Treatment of MDS [NCT01065129]	Phase 1	28 participants (Actual)	Interventional	2010-09-02	Completed
Clinical and Biological Evaluation of Azacitidine in Transfusion-dependent Patients With Low and Intermediate-1 Risk MDS, and Low-risk CMML, Who Are Either Refractory to or Not Eligible for Treatment With Erythropoietin +/- G-CSF [NCT01048034]	Phase 2	30 participants (Actual)	Interventional	2010-01-31	Completed
A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes [NCT00384956]	Phase 2	25 participants (Actual)	Interventional	2006-08-31	Completed
A PHASE 2, SINGLE ARM STUDY TO DETERMINE THE SAFETY AND EFFICACY OF AZACITIDINE, AND LENALIDOMIDE IN HIGHER RISK MYELODYSPLASTIC SYNDROME [NCT01053806]	Phase 2	6 participants (Anticipated)	Interventional	2011-08-31	Recruiting
A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid (ATRA) in Combination With Induction Chemotherapy, or Azacitidine and Idarubicin as Salvage Therapy and Idarubicin With Cytarabine or Azacitidine as Maintenance Thera [NCT01067274]	Phase 3	0 participants (Actual)	Interventional	2010-04-30	Withdrawn(stopped due to Study abandoned)
A Randomized Phase II Trial of Azacitidine With or Without the Histone Deacetylase Inhibitor Entinostat for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type), and Acute Myeloid Leukemia With Multilineage Dysplasi [NCT00313586]	Phase 2	197 participants (Actual)	Interventional	2006-08-31	Completed
Genome-Wide Methylation and Gene Re-expression Analysis of Resectable Lung Tumor Tissue Pairs Obtained Pre- and Post-Treatment With 5-Azacytidine and Entinostat [NCT01886573]	Phase 1	40 participants (Anticipated)	Interventional	2013-06-30	Terminated
A Phase 1, Multicenter, Open-label, Dose-escalation Study of Oral Azacitidine (CC-486) in Japanese Subjects With Hematological Neoplasms [NCT01908387]	Phase 1	2 participants (Actual)	Interventional	2013-07-31	Terminated(stopped due to Due to Slow Accrual study was terminated.)
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia [NCT04086264]	Phase 1/Phase 2	292 participants (Anticipated)	Interventional	2019-11-06	Recruiting
A Phase I/II Study of Azacitidine, Venetoclax and Pevonedistat in Adults With Newly Diagnosed Secondary or Therapy-Related AML [NCT03862157]	Phase 1/Phase 2	51 participants (Actual)	Interventional	2019-02-27	Active, not recruiting
A Phase II Trial to Assess the Efficacy and Toxicity of SGI-110 With DLI for the Treatment of AML or MDS Relapsing After Allogeneic Stem Cell Transplantation [NCT02684162]	Phase 2	55 participants (Actual)	Interventional	2016-06-22	Active, not recruiting
A Phase I Multicenter Study of Arsenic Trioxide and Azacitidine in Patients With Myelodysplastic Syndromes [NCT00234000]	Phase 1	1 participants (Actual)	Interventional	2007-02-28	Terminated(stopped due to The study was closed due to poor enrollment)
Phase II Randomized Study of Pembrolizumab With or Without Epigenetic Modulation With CC-486 in Patients With Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer [NCT02900560]	Phase 2	34 participants (Actual)	Interventional	2016-12-20	Terminated
A Phase 1b Dose Escalation Study of Lemzoparlimab in Combination With Venetoclax and/or Azacitidine in Subjects With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) [NCT04912063]	Phase 1	40 participants (Actual)	Interventional	2021-06-25	Completed
A Prospective, Single-Arm, 2-Stage, Open-label, Phase II Trial of Azacitidine in Relapsed and Refractory Multiple Myeloma. [NCT00412919]	Phase 2	7 participants (Actual)	Interventional	2006-12-31	Terminated(stopped due to Lack of efficacy)
Expanded Access Program: Pevonedistat (in Combination With Azacitidine) for the First-line Treatment of Higher Risk Myelodysplastic Syndromes [NCT04484363]		0 participants	Expanded Access		No longer available
A Phase 1b Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of BC3402 in Combination With Azacitidine in Subjects With Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) [NCT05970822]	Phase 1	32 participants (Anticipated)	Interventional	2023-06-18	Recruiting
A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy [NCT02993523]	Phase 3	443 participants (Actual)	Interventional	2017-02-02	Active, not recruiting
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Dia [NCT02085408]	Phase 3	727 participants (Actual)	Interventional	2011-02-04	Active, not recruiting
Safety and Efficacy of Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients (Aged 18-59) With Acute Myeloid Leukemia [NCT03573024]	Phase 2	36 participants (Anticipated)	Interventional	2018-11-28	Recruiting
Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia [NCT04296214]		0 participants (Actual)	Observational	2020-01-01	Withdrawn(stopped due to Poor recruitment)
Phase I Study of Inhaled Vidaza® in Patients With Advanced NSCLC [NCT02009436]	Phase 1	8 participants (Actual)	Interventional	2015-02-09	Completed
Sequential Administration of 5-azacytidine (AZA) and Donor Lymphocyte Infusion (DLI) for Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) in Relapse After Allogeneic Stem Cell Transplantation. [NCT02017457]	Phase 2	50 participants (Actual)	Interventional	2013-12-31	Completed
Pilot Study of Sodium Phenylbutyrate Plus Azacytidine [NCT00006019]	Phase 2	0 participants	Interventional	2000-05-31	Completed
A Phase I/II Trial Of Very Low to Low-Doses of Continuous Azacitidine in Combination With Standard Doses of Lenalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [NCT01155583]	Phase 1/Phase 2	45 participants (Actual)	Interventional	2010-06-30	Completed
Treatment of High Risk Myelodysplastic Syndromes (MDS) Not Candidates for Allogeneic Transplantation of Hematopoietic Progenitors (ALO-HSCT) [NCT04602273]		150 participants (Anticipated)	Observational	2016-12-12	Recruiting
A Phase II, Single Arm Study of Tislelizumab Combined With DNA Demethylation Agent +/- CAG Regimen in the Treatment of Patients With High-risk AML or AML Patients Older Than 60 Years of Age Who Are Unfit for Intensive Chemotherapy [NCT04541277]	Phase 2	55 participants (Anticipated)	Interventional	2020-09-01	Recruiting
A Phase 2 Trial Investigating Decitabine in Combination With a JAK-Inhibitor as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Patients With Accelerated/Blast Phase Myeloproliferative Neoplasms [NCT04282187]	Phase 2	25 participants (Anticipated)	Interventional	2020-03-24	Recruiting
Dexamethasone Plus Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Patients With First Relapsed or Refractory Acute Myeloid Leukemia: a Randomized, Controlled, Open-label, Multicenter, Phase III Study [NCT03765541]	Phase 3	142 participants (Anticipated)	Interventional	2020-01-13	Recruiting
A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT03164057]	Phase 2	206 participants (Actual)	Interventional	2017-06-15	Active, not recruiting
An Open-Label Phase II Study of Nivolumab (BMS-936558) in Combination With 5-Azacytidine (Vidaza) or Nivolumab With Ipilimumab in Combination With 5-Azacytidine for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia and Newly Diagn [NCT02397720]	Phase 2	149 participants (Actual)	Interventional	2015-04-07	Completed
Combination of Nivolumab and Ipilimumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) [NCT02530463]	Phase 2	99 participants (Actual)	Interventional	2015-09-08	Active, not recruiting
A Phase II Study of the Use of 5-Azacytidine as Pre-Transplant Cytoreduction Prior to Allogeneic Stem Cell Transplantation for High Risk Myelodysplastic Syndromes [NCT00721214]	Phase 2	16 participants (Actual)	Interventional	2008-07-31	Completed
Tagraxofusp-Based Therapy to Eradicate Measurable Residual Disease of Acute Myelogenous Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation [NCT05720988]	Phase 1	29 participants (Anticipated)	Interventional	2024-08-03	Not yet recruiting
A Phase II Trial With Azacitidine Single Agent in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Who Are Ineligible for Standard Induction Therapy: A Department of Veterans Affairs Multi-Site Study [NCT00728520]	Phase 2	40 participants (Anticipated)	Interventional	2008-07-31	Recruiting
A Prospective, Single Arm, Multicenter Clinical Study to Evaluate the Efficacy of Venetoclax Combined With Azacytidine or DA Regimen in Prevention the Relapse of Consecutive MRD Positive AML Patients [NCT05361057]	Phase 2	40 participants (Anticipated)	Interventional	2022-05-01	Recruiting
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia [NCT00911066]	Phase 1	72 participants (Actual)	Interventional	2009-06-30	Completed
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia [NCT05042531]		30 participants (Anticipated)	Interventional	2021-11-13	Recruiting
Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma [NCT02701673]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2016-06-30	Withdrawn
A Phase II Multicenter Single-armed Study Using Subject-specific Minimal Residual Disease Markers to Adopt Treatment After Allogeneic Stem Cell Transplantation for Subjects With Myelodysplastic Syndrome [NCT05788679]	Phase 2	200 participants (Anticipated)	Interventional	2022-11-22	Recruiting
A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies [NCT05292664]	Phase 1	92 participants (Anticipated)	Interventional	2023-03-29	Recruiting
A Phase 2 Study Evaluating the Efficacy of Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma [NCT01121757]	Phase 2	11 participants (Actual)	Interventional	2010-04-30	Terminated(stopped due to The study closed temporarily in February 2012 pending analysis of samples collected. In October, 2012, Celgene requested closure of the study.)
Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours Using the Quadratic Phenotypic Optimization Platform (QPOP) and an Artificial Intelligence-based Platform (CURATE.AI) [NCT05381038]	Phase 1/Phase 2	10 participants (Anticipated)	Interventional	2022-06-30	Not yet recruiting
Peptide Vaccination in Combination With Azacitidine for Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia - A Phase I Study [NCT02750995]	Phase 1	5 participants (Actual)	Interventional	2016-04-30	Completed
A Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide In Patients With Unresectable Or Metastatic Soft Tissue Sarcoma or Malignant Mesothelioma [NCT00629343]	Phase 1	28 participants (Actual)	Interventional	2007-10-31	Active, not recruiting
Phase II Study of Azacitadine and Entinostat in Patients With Metastatic Colorectal Cancer [NCT01105377]	Phase 2	47 participants (Actual)	Interventional	2010-04-30	Completed
A Multi-center Phase II Study of CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma [NCT03542266]	Phase 2	21 participants (Actual)	Interventional	2018-06-01	Completed
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients With MDS [NCT03094637]	Phase 2	40 participants (Actual)	Interventional	2017-11-06	Active, not recruiting
A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia [NCT01074047]	Phase 3	488 participants (Actual)	Interventional	2010-06-01	Completed
A Phase 1-2 Study of Azacitidine in Combination With Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia [NCT00890929]	Phase 1/Phase 2	45 participants (Actual)	Interventional	2009-04-30	Completed
A Phase 2 Trial of Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Who Are Ineligible for Other Leukemia Protocols [NCT00948064]	Phase 2	110 participants (Actual)	Interventional	2009-09-08	Completed
A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia [NCT05211570]	Phase 1/Phase 2	78 participants (Anticipated)	Interventional	2022-06-01	Recruiting
A Phase 2 Study of Chidamide, Azacitidine Combined With GM Regimen for Patients With Relapsed and Refractory DLBCL [NCT05823701]	Phase 2	23 participants (Anticipated)	Interventional	2022-09-30	Recruiting
A Phase 2 Randomized Double-Blind Placebo-Controlled Study of Pracinostat in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate Risk-2 or High-Risk Myelodysplastic Syndrome (MDS) [NCT01873703]	Phase 2	102 participants (Actual)	Interventional	2013-06-30	Completed
Phase II Trial of Venetoclax in Combination With Azacitidine and CAG as Induction Therapy in Patients With Refractory/Relapse Acute Myeloid Leukemia [NCT05807347]	Phase 2	42 participants (Anticipated)	Interventional	2023-02-01	Recruiting
Phase I Study of Prolonged Low Dose Decitabine (5-Aza-Deoxycytidine, NSC #127716) in Patients With Biopsiable Advanced Cancers Refractory to Standard Therapy [NCT00089089]	Phase 1	42 participants (Actual)	Interventional	2004-09-30	Terminated
Neoadjuvant Azacitidine With Carboplatin and Paclitaxel for Suboptimal Newly Diagnosed Ovarian Cancer [NCT00842582]	Phase 1	0 participants (Actual)	Interventional	2009-02-28	Withdrawn(stopped due to No enrollment. Unable to recruit due to lack of eligible patients.)
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS) [NCT02018926]	Phase 1/Phase 2	18 participants (Actual)	Interventional	2013-12-31	Completed
Clinical Efficacy and Safety of Adaptive Treatment of Acute Myeloid Leukemia (AML) Based on D14 MRD results-a Multicenter, Single-arm, Prospective Clinical Study [NCT05736978]	Phase 2	58 participants (Anticipated)	Interventional	2023-03-31	Recruiting
Phase I Study of Decitabine (Dacogen) and Bortezomib (Velcade) in Acute Myeloid Leukemia [NCT00703300]	Phase 1	19 participants (Actual)	Interventional	2008-06-30	Completed
The Efficacy and Safety of Azacitidine in Combination With Chidamide in the Treatment of Newly Diagnosed Peripheral T-Cell Lymphoma Unfit for Conventional Chemotherapy [NCT04480125]	Phase 2	28 participants (Anticipated)	Interventional	2020-06-20	Recruiting
Efficacy and Safety of Azacitidine Combined With Interferon in the Treatment of Recurrence of Allogeneic Hematopoietic Stem Cell Transplantation in Myeloid Tumors of the Blood System [NCT04078399]		30 participants (Anticipated)	Interventional	2019-08-28	Recruiting
A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With IPSS-R L [NCT05469737]	Phase 2/Phase 3	230 participants (Anticipated)	Interventional	2022-12-14	Recruiting
A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy [NCT04150029]	Phase 2	90 participants (Actual)	Interventional	2020-09-01	Active, not recruiting
Multi Centers, Open-trial Phase II Study Evaluating 5-azacytidine (Vidaza®) + Valproic Acid (Depakine ®) Before Administration of Retinoic Acid (Vesanoid®) in Patients With Acute Myelogenous Leukemia and High Risk Myelodysplasia. [NCT00339196]	Phase 2	25 participants (Actual)	Interventional	2006-07-31	Completed
A Phase 1 Study of 5-azacitidine in Combination With Interferon-Alfa 2B in Unresectable or Metastatic Melanoma and Renal Cell Carcinoma [NCT00217542]	Phase 1	42 participants (Actual)	Interventional	2005-07-31	Completed
Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia [NCT06085638]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2023-09-14	Withdrawn(stopped due to Zero participants accrued)
A Phase 1/1b, Open-label Study of Pevonedistat (MLN4924, TAK-924) as Single Agent and in Combination With Azacitidine in Adult East Asian Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) [NCT02782468]	Phase 1	23 participants (Actual)	Interventional	2016-05-16	Completed
A Phase I/IIa, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent and in Combination With Venetoclax and Azacitidine in Patients With Relapsed/Refractory Hematologic Malignancies [NCT04588922]	Phase 1/Phase 2	135 participants (Anticipated)	Interventional	2021-05-10	Recruiting
Multicenter,Open Label,Phase 2 Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia [NCT06068621]	Phase 2	200 participants (Anticipated)	Interventional	2023-08-01	Recruiting
A Phase II Study of Maintenance With Azacitidine in MDS Patients Achieving Complete or Partial Remission (CR or PR) After Intensive Chemotherapy [NCT00446303]	Phase 2	39 participants (Actual)	Interventional	2006-07-31	Terminated
Phase II Study of Decitabine in Acute Myeloid Leukemia [NCT00492401]	Phase 2	55 participants (Actual)	Interventional	2007-05-31	Completed
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine ± Venetoclax in Acute Myeloid Leukemia (AML) Patients Wi [NCT04372433]	Phase 1	106 participants (Anticipated)	Interventional	2020-09-14	Recruiting
A Phase 1, Open Label, Multicentre Clinical Trial of SyB C-1101 in Combination With Azacytidine in Patients With Myelodysplastic Syndrome [NCT02783547]	Phase 1	0 participants (Actual)	Interventional	2015-12-31	Withdrawn(stopped due to The trial was withdrawn due to problems with the manufacture of the investigational drug.)
A Phase II Study of Venetoclax in Combination With Azacitidine in the Post-Transplant Setting for AML, T Cell Leukemia, and Mixed Phenotype Acute Leukemia [NCT04128501]	Phase 2	125 participants (Anticipated)	Interventional	2020-05-05	Recruiting
Four-Arm Randomized Phase II Study of SGI-110: 5 Days, Versus 10 Days, Versus 5 Days + Idarubicin, Versus 5 Days + Cladribine, in Previously Untreated Patients >/= 70 Years With Acute Myeloid Leukemia [NCT02096055]	Phase 2	44 participants (Actual)	Interventional	2014-04-04	Completed
A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndrome / Acute Myeloid Leukaemia, With Eltrombopag Support for Thrombocytopenia. [NCT01488565]	Phase 2	25 participants (Actual)	Interventional	2010-12-31	Completed
A Phase II Trial of 5-Azacytidine (NSC #102816) and Ethyol (Amifostine) in the Treatment of Adults With Myelodysplastic Syndromes [NCT00005598]	Phase 2	0 participants	Interventional	2000-10-31	Completed
Phase I Investigation of the Feasibility of Combining 5-azacytidine With Highdose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy in a Sequential Manner for Remission Induction in High-risk Acute Myelogenous Leukemia (AML) [NCT01839240]	Phase 1	50 participants (Actual)	Interventional	2012-06-06	Completed
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors [NCT01478685]	Phase 1	169 participants (Actual)	Interventional	2011-11-29	Completed
A Single Arm Study to Evaluate the Safety and Efficiency of Azacitidine (AZA) Combination With Venetoclax and ATRA in Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT05654194]	Phase 3	30 participants (Anticipated)	Interventional	2022-10-31	Recruiting
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement [NCT02828358]	Phase 2	78 participants (Actual)	Interventional	2017-04-01	Active, not recruiting
A Phase 1 Study of Azacitidine in Combination With MEC (Mitoxantrone, Etoposide, Cytarabine) in Relapsed and Refractory Acute Myeloid Leukemia [NCT01249430]	Phase 1	24 participants (Actual)	Interventional	2011-01-20	Completed
A Phase II, Single Arm Study Examining the Combination of Revlimid (Lenalidomide) and Vidaza (Azacitidine) (RA-CLL) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) [NCT01241786]	Phase 2	5 participants (Actual)	Interventional	2010-07-31	Terminated(stopped due to The study was closed early due to poor accrual)
A Phase 1b Study Evaluating the Safety and Efficacy of IBI188 in Combination With Azacitidine in Subjects With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (MDS) [NCT04511975]	Phase 1	32 participants (Anticipated)	Interventional	2020-08-24	Suspended(stopped due to pause for further assessment and study adjustment)
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML). [NCT00528983]	Phase 1	133 participants (Actual)	Interventional	2007-09-11	Completed
Phase I Trial of Sequential Azacitidine and Valproic Acid Plus Carboplatin in the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer [NCT00529022]	Phase 1	36 participants (Actual)	Interventional	2007-08-31	Completed
Phase Ib Clinical Trial of TQB2928 Injection Combination Therapy in Patients With Hematological Malignancies [NCT06008405]	Phase 1	48 participants (Anticipated)	Interventional	2023-09-30	Recruiting
An Open-Label Phase Ib/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 mAb, Smoothened Inhibitor, Anti-CD33 mAb, Bcl-2 Inhibitor and Azacitidine as Single-Agents and/or Combinations for the Treatment of Patients With Acute Myeloid [NCT03390296]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2017-12-27	Completed
Pilot Phase II Study of 5-Azacytidine in Previously Treated Patients With Advanced NSCLC [NCT01281124]	Phase 2	1 participants (Actual)	Interventional	2011-01-12	Completed
A Double-Blind, Phase III, Randomised Study to Compare the Efficacy and Safety of Oral Azacitidine (CC-486) Versus Placebo in Subjects With Acute Myeloid Leukaemia or Myelodysplastic Syndromes as Maintenance After Allogeneic Haematopoietic Stem Cell Trans [NCT04173533]	Phase 3	324 participants (Anticipated)	Interventional	2019-06-14	Recruiting
A Prospective, Multi-Center Study to Evaluate the Efficacy and Safety of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-cell Acute Lymphoblastic Leukemia Patients [NCT05376111]	Phase 2	28 participants (Anticipated)	Interventional	2022-04-01	Recruiting
Phase I Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes [NCT05426798]	Phase 1	73 participants (Anticipated)	Interventional	2022-04-29	Recruiting
Pilot Study Targeting Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer As Part of Adjuvant Therapy and Preventive Strategy [NCT01209520]		6 participants (Actual)	Interventional	2009-07-31	Completed
Phase 1 Study to Evaluate Safety and Efficacy of APR-548 in Combination With Azacitidine for the Treatment of TP53-Mutant Myelodysplastic Syndromes [NCT04638309]	Phase 1	4 participants (Actual)	Interventional	2021-09-20	Terminated(stopped due to Sponsor decision)
Clinical Trial for the Safety and Efficacy of Induction Chemotherapy With Azacitidine+Venetoclax (VA) and Bridging CD19CD22 CAR-T Therapy in Adult Patients With Newly Diagnosed High-Risk and Ph-negative (Ph-) B-ALL [NCT06078306]	Phase 2	20 participants (Anticipated)	Interventional	2023-10-10	Not yet recruiting
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine (CC-486) Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Chinese Patients With Acute Myeloid Leukemia in Compl [NCT05413018]	Phase 2	78 participants (Anticipated)	Interventional	2022-08-19	Recruiting
An Open Pilot Study to Assess the Pharmacokinetics, Tolerability, and Safety of NEX-18a Given as a Subcutaneous Injection for the Treatment of Intermediate 2 or Higher-risk MDS, CMML or AML [NCT05048498]	Phase 1	2 participants (Actual)	Interventional	2021-04-27	Completed
A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations [NCT04603001]	Phase 1	260 participants (Anticipated)	Interventional	2020-12-01	Active, not recruiting
AZA PH GL 2003 CL 001 - Extension A Multicenter, Randomized, Open-label, Parallel-group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic S [NCT01186939]	Phase 3	40 participants (Actual)	Interventional	2007-04-01	Completed
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone [NCT01993641]	Phase 2	45 participants (Actual)	Interventional	2013-12-31	Completed
Primary Comparison of Liposomal Anthracycline Based Treatment Versus Conventional Care Strategies Before Allogeneic Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML [NCT04061239]	Phase 2	150 participants (Anticipated)	Interventional	2019-08-19	Recruiting
Oral Azacitidine (CC-486) Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma [NCT03450343]	Phase 1	9 participants (Actual)	Interventional	2019-04-04	Active, not recruiting
A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Induction Chemotherapy for Newly Diagnosed Fit Adults With Acute Myeloid Leukemia [NCT04801797]	Phase 2	172 participants (Anticipated)	Interventional	2021-05-20	Recruiting
Phase I/II Trial of Azacytidine + R-CHOP in Diffuse Large B-Cell Lymphoma [NCT01004991]	Phase 1/Phase 2	14 participants (Actual)	Interventional	2010-01-31	Completed
Restoration of Radioiodine Uptake in Thyroid Carcinoma: A Clinical Trial [NCT00004062]	Phase 1	0 participants	Interventional	1999-07-31	Completed
A Phase I Trial of SAHA (NSC 701852) and Decitabine (IND 50733, NSC 127716) in Patients With Relapsed, Refractory or Poor Prognosis Leukemia [NCT00357708]	Phase 1	50 participants (Actual)	Interventional	2006-06-30	Completed
A Phase I/II Study of Weekly Schedule Of Brentuximab Vedotin Alone and In Combination With 5-Azacytidine In Cluster of Differentiation Antigen (CD30)-Positive Relapsed/Refractory Acute Myeloid Leukemia [NCT02096042]	Phase 1/Phase 2	1 participants (Actual)	Interventional	2014-04-30	Terminated(stopped due to Slow accrual.)
A Phase I Study of Decitabine in Combination With Valproic Acid in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma [NCT00109824]	Phase 1	42 participants (Actual)	Interventional	2006-03-31	Completed
A Phase 1 Study of Vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in Combination With Decitabine in Patients With Advanced Solid Tumors, Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myel [NCT00275080]	Phase 1	80 participants (Actual)	Interventional	2006-02-28	Completed
Treatment of MDS/AML Patients With an Impending Hematological Relapse With Azacitidine Alone or in Combination With PEvonedistat - a Randomized Phase 2 Trial [NCT04712942]	Phase 2	14 participants (Actual)	Interventional	2021-01-01	Completed
Phase II Study of the Targeted Mutant IDH2 Inhibitor Enasidenib in Combination With Azacitidine for Relapsed/Refractory AML [NCT03683433]	Phase 2	50 participants (Anticipated)	Interventional	2018-09-18	Recruiting
Clinical Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring In Elderly or Unfit Patients With Acute Myeloid Leukemia [NCT04490707]	Phase 3	60 participants (Anticipated)	Interventional	2020-09-01	Recruiting
Venetoclax Combined With Azacitidine Plus Homoharringtonine Versus Venetoclax Combined With Azacitidine for Relapsed/Refractory Acute Myeloid Leukemia：an Open-label, Multicentre, Randomised Phase 3 Trial [NCT05457361]	Phase 3	162 participants (Anticipated)	Interventional	2022-03-01	Recruiting
Lenalidomide and Azacitidine for Adaptive Immunotherapy in Multiple Myeloma: Pilot Study of Autologous Lymphocyte Mobilization Following Immuno-modulatory Therapy [NCT01050790]		17 participants (Actual)	Interventional	2010-01-31	Completed
A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome [NCT00454480]	Phase 2/Phase 3	2,000 participants (Anticipated)	Interventional	2006-08-31	Completed
Azacitidine Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for AML and MDS [NCT00350818]	Phase 1	90 participants (Actual)	Interventional	2005-10-31	Completed
A Phase II Study of Arsenic Trioxide in Combination With 5-Azacitidine in Myelodysplastic Syndromes [NCT00118196]	Phase 2	1 participants (Actual)	Interventional	2005-04-30	Terminated(stopped due to Due to limited resources available to conduct study)
AVIDA The Vidaza® (Azacitidine) Patient Registry [NCT00481273]		479 participants (Actual)	Observational	2006-10-31	Completed
A Multicenter, Non-Randomized, Open-Label Study to Evaluate Efficacy and Safety of Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome Red Cell Transfusion Dependent With Low or Intermediate -1 Risk. [NCT00495547]	Phase 2	16 participants (Actual)	Interventional	2009-02-28	Terminated
Phase I Study of Low-Dose Hypomethylating Agent Azacitidine Combined With the Histone Deacetylase Inhibitor Valproic Acid in Patients With Advanced Cancers [NCT00496444]	Phase 1	69 participants (Actual)	Interventional	2005-05-31	Completed
Phase 2 Study of 5 Days Azacytidine Priming Prior to Fludarabine, Cytarabine and Granulocyte-Colony Stimulating Factor (G-CSF) Combination for Patients With Relapsed or Refractory AML [NCT02275663]	Phase 2	37 participants (Anticipated)	Interventional	2014-12-31	Recruiting
A Pilot Study of Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance in Adult AML Patients Eligible for Reduced Intensity Allogeneic Stem Cell Transplant [NCT06180863]	Phase 2	0 participants (Actual)	Interventional	2023-11-30	Withdrawn(stopped due to Lack of funding.)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients With Acute Myeloid Leukemia Who [NCT05079230]	Phase 3	432 participants (Anticipated)	Interventional	2022-07-07	Active, not recruiting
A Randomized Phase II Study of the Combination of 5-Azacytidine With Valproic Acid (VPA) Versus Low-Dose Ara-C in Patients With AML/MDS Not Eligible for Other Studies [NCT00382590]	Phase 2	11 participants (Actual)	Interventional	2005-08-31	Completed
Phase II Study of 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia [NCT00413478]	Phase 2	9 participants (Actual)	Interventional	2006-09-30	Terminated(stopped due to Slow accrual.)
A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL) [NCT04747236]	Phase 2	50 participants (Anticipated)	Interventional	2021-02-19	Recruiting
"Randomized Phase I/II Study of 5-Azacytidine in Combination With Cytosine Arabinoside in Patients With Relapsed/Refractory Acute Myelogenous Leukemia or High Risk Myelodysplastic Syndrome - SPORE" [NCT00569010]	Phase 1/Phase 2	36 participants (Actual)	Interventional	2005-12-31	Completed
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML [NCT01168219]	Phase 2	68 participants (Actual)	Interventional	2010-07-15	Completed
An Open-label Phase Ib Study of DSP107 for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) [NCT04937166]	Phase 1	36 participants (Anticipated)	Interventional	2022-01-13	Recruiting
A Phase 2, International, Multicenter, Randomized, Open-label, Parallel Group to Evaluate the Efficacy and Safety of Cc-486 (Oral Azacitidine) Alone in Combination With Durvalumab (MEDI4736) in Subjects With Myelodysplastic Syndromes Who Fail to Achieve a [NCT02281084]	Phase 2	65 participants (Actual)	Interventional	2015-07-06	Active, not recruiting
A Phase I/II Trial of the Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed AML [NCT00766116]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2005-07-31	Completed
Phase 1/Phase 2 Study of IMM01 Combined With Azacitidine in Patients With AML and MDS [NCT05140811]	Phase 1/Phase 2	126 participants (Anticipated)	Interventional	2022-01-05	Recruiting
Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy [NCT04905407]	Phase 2	95 participants (Anticipated)	Interventional	2021-08-26	Recruiting
Phase II Study of Azacytidine Followed by GM-CSF in Patients With Low- or Intermediate-1- Risk Myelodysplastic Syndrome (MDS) [NCT01542684]	Phase 2	8 participants (Actual)	Interventional	2012-03-31	Terminated(stopped due to Slow Accrual)
Randomized Phase II Trial With Safety run-in Phase Evaluating Low-dose AZA, ATRA and Pioglitazone Versus Standard Dose Azacitidine in Patients >=60 Years With AML Who Are Refractory to Standard Induction Chemotherapy [NCT02942758]	Phase 2	10 participants (Actual)	Interventional	2017-04-10	Terminated(stopped due to Due to financial reasons.)
A Phase 1 Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia [NCT06177067]	Phase 1	24 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Study of the Efficacy and Safety of Venetoclax Plus Azacytidine Versus Daunorubicin Plus Cytarabine in Adult Acute Myeloid Leukemia (AML) Patients With Adverse Risk Features [NCT05939180]	Phase 2/Phase 3	108 participants (Anticipated)	Interventional	2023-07-01	Recruiting
Adoptive Therapy With TCR Gene-engineered T Cells to Treat Patients With MAGE-C2-positive Melanoma and Head and Neck Cancer [NCT04729543]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2020-10-20	Recruiting
Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle or Resection Cavity in Children With Recurrent Posterior Fossa Ependymoma: A Pilot Study [NCT02940483]	Early Phase 1	6 participants (Actual)	Interventional	2017-02-01	Completed
A PHASE 1, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS AND EFFECT OF FOOD OF A NEW TABLET FORMULATION OF ORAL AZACITIDINE, AND TO EVALUATE THE SAFETY AND EFFICACY OF ORAL AZACITIDINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES, CHRONIC M [NCT01519011]	Phase 1	34 participants (Actual)	Interventional	2012-02-07	Completed
ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-naïve Patients With Higher Risk Myelodysplastic Syndrome [NCT04313881]	Phase 3	539 participants (Actual)	Interventional	2020-09-09	Terminated(stopped due to Study discontinued due to futility based on a planned analysis)
Phase I/II Study of the Combination of Quizartinib (AC220) With 5-Azacytidine or Low-Dose Cytarabine for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) [NCT01892371]	Phase 1/Phase 2	200 participants (Anticipated)	Interventional	2013-11-12	Completed
A Phase 2 Study of Decitabine in Combination With Midostaurin (PKC412) for Elderly Patients With Newly Diagnosed FLT3-ITD/TKD Positive Acute Myeloid Leukemia [NCT01846624]	Phase 2	13 participants (Actual)	Interventional	2013-06-30	Terminated(stopped due to Accrual factor)
Phase I Trial of Oral 5-azacitidine With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma [NCT01537744]	Phase 1	18 participants (Actual)	Interventional	2012-02-29	Completed
A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF THE MTOR KINASE INHIBITOR CC-223 IN COMBINATION WITH ERLOTINIB OR ORAL AZACITIDINE IN ADVANCED NON-SMALL CELL LUNG CANCER [NCT01545947]	Phase 1	76 participants (Actual)	Interventional	2012-05-01	Completed
A Multicentre Open Randomized Phase II Study of the Efficacy and Safety of Azacitidine Alone or in Combination With Lenalidomide in High-risk Myeloid Disease (High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia) With a Karyotype Including Del(5q [NCT01556477]	Phase 2	72 participants (Anticipated)	Interventional	2012-03-31	Recruiting
A Dose-Finding Trial of the Histone Deacetylase Inhibitor MS-275 (NSC 706995) in Combination With 5-Azacitidine (5AC, NSC 102816) in Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMMoL) and Acute Myeloid Leukemia (AML) [NCT00101179]	Phase 1	63 participants (Actual)	Interventional	2004-11-03	Completed
A Phase I/II Study to Evaluate the Safety Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Standard AZACITIDINE+ VENETOCLAX in Patients With Refractory Acute Myeloid Leukemia [NCT06150040]	Phase 1/Phase 2	35 participants (Anticipated)	Interventional	2023-12-04	Recruiting
A Phase I Study Of Decitabine (DAC) (IND # 50733) In Children With Relapsed Or Refractory Acute Leukemia [NCT00042796]	Phase 1	21 participants (Actual)	Interventional	2002-12-31	Terminated(stopped due to Administratively complete.)
Phase I Study of 5-Aza-2'-Deoxycytidine (Decitabine) as a Biologic Modifier of Retinoid Responsive Genes in Patients With High-Risk Myelodysplastic Syndromes and Acute Myelogenous Leukemia (De-novo, Relapsed or Secondary) [NCT00049582]	Phase 1	36 participants (Actual)	Interventional	2002-09-30	Terminated
Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome [NCT01541280]	Phase 2	30 participants (Actual)	Interventional	2011-11-30	Completed
A Phase I Study of Decitabine (NSC# 127716, IND# 50733) in Combination With Doxorubicin and Cyclophosphamide in the Treatment of Relapsed or Refractory Solid Tumors [NCT00075634]	Phase 1	21 participants (Actual)	Interventional	2003-12-31	Completed
A Phase I Study of Decitabine in Combination With Valproic Acid in Patients With Selected Hematologic Malignancies [NCT00079378]	Phase 1	84 participants (Actual)	Interventional	2004-02-29	Completed
A Phase I Study Of The Toxicities, Biologic And Clinical Effects Of Daily 5 Aza 2'Deoxycytidine (DAC), NSC 127716 (IND 50733) For Four Weeks In Patients With Advanced Malignancies [NCT00030615]	Phase 1	24 participants (Actual)	Interventional	2001-12-31	Completed
Clinical Efficacy and Safety of Selinexol Combined With Azacitidine and Venetoclax (SAV Regimen) in the Treatment of Acute Myeloid Leukemia (AML)-a Multi-center, Single-arm, Prospective Clinical Study [NCT05736965]	Phase 2	58 participants (Anticipated)	Interventional	2023-02-20	Recruiting
A Multicenter, Single-arm, Open Clinical Efficacy Observational Study of Cidapenem Combined With Azacitidine and Mitoxantrone Liposome (CAM) Regimen for Relapsed/Refractory Intra-nodal Follicular Adjuvant T-cell Lymphoma (nTFHL) [NCT05772728]		23 participants (Anticipated)	Interventional	2023-04-30	Not yet recruiting
A Phase 2, Open-Label, Multi-Center Study to Assess Safety and Efficacy of Second/Third-Line Treatment With NAB®-Paclitaxel (ABI-007) In Combination With Epigenetic Modifying Therapy Of CC-486, Or Immunotherapy of Durvalumab (MEDI4736), Or As Monotherapy [NCT02250326]	Phase 2	240 participants (Actual)	Interventional	2015-01-07	Completed
Phase II Study of Imatinib Mesylate (Gleevec, STI-571) (NSC#716051) and Decitabine (5-AZA-2'-Deoxycitidine) (NSC#127716), in Chronic Myelogenous Leukemia in Accelerated and Blastic Phases [NCT00054431]	Phase 2	80 participants (Actual)	Interventional	2003-01-31	Completed
A Phase I Study of 5-azacytidine (Vidaza) With Interferon α2b in Metastatic Melanoma Patients [NCT00398450]	Phase 1	12 participants (Anticipated)	Interventional	2006-02-28	Completed
A Phase II Study of the Efficacy, Safety and Determinants of Response to 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia (CMML) [NCT01350947]	Phase 2	11 participants (Actual)	Interventional	2011-04-30	Completed
A Phase I Study of Decitabine in Combination With Valproic Acid in Patients With Non-Small Cell Lung Cancer [NCT00084981]	Phase 1	25 participants (Actual)	Interventional	2004-04-30	Completed
Azacitidine Compared to Conventional Chemotherapy in Consolidation of Elderly Patients (65 Years or Older) With AML in First Complete Remission [NCT01794169]	Phase 2	130 participants (Anticipated)	Interventional	2013-03-31	Terminated(stopped due to Poor recruitment)
A Phase I/II Study of Revlimid (Lenalidomide) in Combination With Vidaza (Azacitidine) in Patients With Advanced Myelodysplastic Syndrome (MDS) [NCT00352001]	Phase 1/Phase 2	37 participants (Actual)	Interventional	2006-05-31	Completed
A Randomized Study to Evaluate the Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients [NCT05188326]	Phase 3	54 participants (Actual)	Interventional	2010-11-28	Completed
MRD-guided Treatment With Pembrolizumab and Azacitidine in NPM1mut AML Patients With an Imminent Hematological Relapse [NCT03769532]	Phase 2	28 participants (Anticipated)	Interventional	2019-08-21	Recruiting
A Open Label, Phase II, Non Randomized, Clinical Trial of Chemotherapy Treatment With 5-Azacytidine Plus Valproic Acid and Eventually Atra for Patients Diagnosed With Intermediate II and High Risk Myelodysplastic Syndrome (MDS). EudraCT Number 2005-004811 [NCT00439673]	Phase 2	62 participants (Actual)	Interventional	2007-05-31	Completed
An Exploratory Phase 1b Open-label Multi-arm Trial to Evaluate the Safety and Efficacy of CC-90009 in Combination With Anti-Leukemia Agents in Subjects With Acute Myeloid Leukemia [NCT04336982]	Phase 1/Phase 2	76 participants (Anticipated)	Interventional	2020-08-05	Active, not recruiting
A Randomized, Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly ( [NCT02775903]	Phase 2	213 participants (Actual)	Interventional	2016-06-03	Completed
A Pilot Study of CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia [NCT02995655]	Phase 1	20 participants (Actual)	Interventional	2017-04-07	Completed
A Multicenter Open-Label Phase 2a Study of Ibrutinib Monotherapy or in Combination With Either Cytarabine or Azacitidine in Subjects With Acute Myeloid Leukemia [NCT02351037]	Phase 2	36 participants (Actual)	Interventional	2015-02-28	Terminated(stopped due to Study data do not support development in AML.)
An Open-Label Phase IB/II Study of Magrolimab in Combination With Azacitidine and Venetoclax for the Treatment of Patients With Acute Myeloid Leukemia (AML) [NCT04435691]	Phase 1/Phase 2	110 participants (Actual)	Interventional	2020-07-28	Active, not recruiting
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML [NCT01861002]	Phase 1	15 participants (Actual)	Interventional	2013-05-22	Completed
A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer [NCT02260440]	Phase 2	31 participants (Actual)	Interventional	2015-01-31	Completed
A Phase III Multicenter, Randomized, Open Label Study of APR-246 in Combination With Azacitidine Versus Azacitidine Alone for the Treatment of (Tumor Protein) TP53 Mutant Myelodysplastic Syndromes [NCT03745716]	Phase 3	154 participants (Actual)	Interventional	2019-01-11	Completed
A Prospective,Randomized,and Comparative Study on the Efficacy of Venetoclax Combined With CACAG Regimen and BAT Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia [NCT06084819]	Phase 2	200 participants (Anticipated)	Interventional	2023-08-01	Recruiting
A Single Arm, Open-label Phase 3b Study to Describe the Safety and Tolerability of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy [NCT05907057]	Phase 3	245 participants (Anticipated)	Interventional	2023-06-14	Recruiting
Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination With Ziftomenib or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib for the Treatment of Patients With Acute Myeloid Leukemia [NCT05735184]	Phase 1	212 participants (Anticipated)	Interventional	2023-07-18	Recruiting
A Phase 1b/2 Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation [NCT03684811]	Phase 1/Phase 2	93 participants (Actual)	Interventional	2018-11-01	Completed
An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies. [NCT04068597]	Phase 1/Phase 2	250 participants (Anticipated)	Interventional	2019-08-09	Recruiting
A Single-arm Clinical Study of Azacitidine in Combination With R-CHOP (ARCHOP) for the Treatment of TP53-mutated Previously Untreated Diffuse Large B-cell Lymphoma [NCT06158399]	Phase 2	52 participants (Anticipated)	Interventional	2023-11-22	Recruiting
A Multi-center, Prospective, Single-arm Study of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia (R/R AML) [NCT05305859]	Phase 2	30 participants (Anticipated)	Interventional	2022-04-01	Recruiting
Phase I/II Study of Cytarabine or 5-Azacitidine Combined With Tosedostat to Evaluate the Safety and Tolerability in Older Patients With Acute Myeloid Leukemia (AML) or High Risk MDS [NCT01636609]	Phase 1	18 participants (Actual)	Interventional	2012-11-20	Terminated(stopped due to In 2013 the FDA put a temporary hold on the trial and the Phase II portion of this study was cancelled.)
Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML. [NCT01607645]	Phase 2	7 participants (Actual)	Interventional	2012-07-31	Terminated(stopped due to The study was terminated early because there were other competing protocols.)
A Phase I Dose Escalation to Maximally Tolerated Dose Trial of 5-Azacytidine (5 AC, NSC 102816) in Combination With Sodium Phenylbutyrate (PB, NSC 657802) in Patients With Refractory Solid Tumors [NCT00005639]	Phase 1	34 participants (Actual)	Interventional	2000-03-31	Completed
A Randomized, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of 5-day Azacitidine for Patients With Lower-risk Myelodysplastic Syndrome [NCT01652781]	Phase 2	92 participants (Anticipated)	Interventional	2012-03-31	Recruiting
A Multicenter, Phase I/II Study of Sequential Epigenetic and Immune Targeting in Combination With Nab-Paclitaxel/Gemcitabine in Patients With Advanced Pancreatic Ductal Adenocarcinoma. [NCT04257448]	Phase 1/Phase 2	75 participants (Anticipated)	Interventional	2020-05-25	Active, not recruiting
Phase II Study of Azacitidine in Myelofibrosis [NCT00569660]	Phase 2	34 participants (Actual)	Interventional	2005-06-30	Completed
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy [NCT02203773]	Phase 1	212 participants (Actual)	Interventional	2014-10-06	Terminated(stopped due to Strategic considerations)
A Study of Using Epigenetic Modulators to Enhance Response to MK-3475 in Microsatellite Stable Advanced Colorectal Cancer [NCT02512172]	Phase 1	27 participants (Actual)	Interventional	2016-02-19	Completed
An Open Label, Phase I Trial of Intravenous Administration of Volasertib as Monotherapy and in Combination With Azacitidine in Patients With Myelodysplastic Syndrome After Hypomethylating Agents Treatment Failure [NCT02721875]	Phase 1	1 participants (Actual)	Interventional	2016-04-28	Terminated
An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. [NCT05201066]	Phase 2	70 participants (Anticipated)	Interventional	2023-02-13	Recruiting
Phase I-II Study of Association of Deferasirox, Vitamin D and Azacytidine as Treatment of High Risk MDS (IPSS Int-2 and High) [NCT01718366]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2013-02-28	Active, not recruiting
Therapeutic Effect of Chemotherapy Azacytidine Plus CAOLD Regimen on Patients With Relapsed/Refractory Angioimmunoblastic T-cell Lymphoma [NCT06176027]	Phase 1/Phase 2	52 participants (Anticipated)	Interventional	2023-12-30	Recruiting
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection as Monotherapy or in Combination With Azacitidine or Venetoclax in Patients With Relapsed/Refractory Myeloid or B-cell Malignancies [NCT05107856]	Phase 1	132 participants (Anticipated)	Interventional	2022-03-22	Active, not recruiting
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1) [NCT04797780]	Phase 3	550 participants (Anticipated)	Interventional	2021-02-08	Recruiting
An Open-label, Multicenter, Phase 1b Study of OV-1001 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia [NCT04150887]	Phase 1	61 participants (Actual)	Interventional	2019-12-23	Active, not recruiting
Phase I Study of AR-42 and Decitabine in Acute Myeloid Leukemia [NCT01798901]	Phase 1	13 participants (Actual)	Interventional	2013-09-17	Completed
A Phase 1b, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia Who Are 60 Years or Older [NCT01814826]	Phase 1	64 participants (Actual)	Interventional	2013-04-10	Completed
A Phase Ib/II Study Evaluating Navitoclax After Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome [NCT05564650]	Phase 1/Phase 2	37 participants (Anticipated)	Interventional	2023-01-12	Recruiting
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy [NCT01828346]	Phase 1/Phase 2	21 participants (Actual)	Interventional	2013-06-30	Completed
Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients With Active or Relapsed Hodgkin or Non-Hodgkin Lymphoma [NCT01333046]	Phase 1	36 participants (Actual)	Interventional	2012-01-31	Active, not recruiting
A Phase 3b, Randomized, Open-Label, Double Crossover Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Adult Patients With IPSS R Intermediate Myelodysplastic Syndrome, Low Blast Acute Myeloid Leukemia, IPSS Inte [NCT05883956]	Phase 3	42 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
Study of the Effect of Demethylating Agent Azacitidine on Prevention of Acute Kidney Injury-chronic Kidney Disease Continuum [NCT05325099]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2022-06-30	Not yet recruiting
Addition of Suberoylanilide Hydroxamic Acid (Vorinostat) to Azacitidine in Patients With Higher Risk Myelodysplastic Syndromes (MDS): a Phase II add-on Study in Patients With Azacitidine Failure. [NCT01748240]	Phase 2	21 participants (Actual)	Interventional	2013-03-31	Terminated(stopped due to inefficiency)
BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First L [NCT04284787]	Phase 2	76 participants (Anticipated)	Interventional	2021-02-16	Active, not recruiting
A Phase 1/2 Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination With Azacitidine in Patients With the Myelodysplastic Syndrome (MDS) [NCT00392353]	Phase 1/Phase 2	135 participants (Anticipated)	Interventional	2006-11-22	Active, not recruiting
A MULTI-CENTER CONTINUATION STUDY EVALUATING AZACITIDINE WITH OR WITHOUT GLASDEGIB (PF-04449913) IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA, MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIA [NCT04842604]	Phase 3	14 participants (Actual)	Interventional	2021-05-17	Completed
Phase II Study of Venetoclax Added to Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed by Consolidation With Cladribine Plus LDAC Alternating With 5-Azacitidine With Venetoclax in Patients With Untreated AML [NCT03586609]	Phase 2	145 participants (Anticipated)	Interventional	2018-10-25	Recruiting
A Randomized, Controlled, Open-label, Multicenter Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) [NCT05709093]	Phase 3	552 participants (Anticipated)	Interventional	2023-03-30	Recruiting
A Phase Ib/II, Open Label, Proof-of-concept Study of Sabatolimab and Magrolimab-based Therapy for Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome [NCT05367401]	Phase 1/Phase 2	63 participants (Anticipated)	Interventional	2024-12-20	Not yet recruiting
A Phase I/IB Pilot Study of CC-486 Combined With Lenalidomide and Obinutuzumab for Relapsed/Refractory Indolent B-Cell Lymphoma [NCT04578600]	Phase 1	8 participants (Actual)	Interventional	2020-10-23	Active, not recruiting
Phase 1b/2a Safety and Immunogenicity of the DNMT Inhibitor Azacitidine During Anti-Tuberculosis Therapy [NCT03941496]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2022-10-31	Withdrawn(stopped due to The study was halted prematurely due to Bristol-Myers Squibb's (BMS) decision to withdraw support for this study.)
Initial Cytoreductive Therapy for Myelodysplastic Syndrome Prior to Allogeneic Hematopoietic Cell Transplantation (the ICT-HCT Study) [NCT01812252]	Phase 2	46 participants (Actual)	Interventional	2013-04-02	Completed
A Phase 1 Study of CC-486 Plus Nivolumab in Patients With Hodgkin Lymphoma Refractory to PD-1 Therapy [NCT05162976]	Phase 1	33 participants (Anticipated)	Interventional	2022-01-03	Recruiting
Phase II Study of Clinical Efficacy of Venetoclax in Combination With Azacitidine in Patients With Therapy Related Myelodysplastic Syndrome (t-MDS) [NCT05379166]	Phase 2	53 participants (Anticipated)	Interventional	2022-06-23	Recruiting
A Phase Ib/II, Open Label Study of Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation [NCT04623216]	Phase 1/Phase 2	59 participants (Anticipated)	Interventional	2021-09-14	Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission [NCT01757535]	Phase 3	472 participants (Actual)	Interventional	2013-04-24	Active, not recruiting
Phase I-II Study of Low-Dose Azacitidine (Vidaza) in Patients With Chronic Myeloid Leukemia Who Have Minimal Residual Disease While Receiving Therapy With Tyrosine Kinase Inhibitors (VZ-CML-PI-0236) [NCT01460498]	Phase 1	3 participants (Actual)	Interventional	2012-08-08	Completed
Onureg® (Oral Azacitidine) Post-Marketing Surveillance in Korean Patients With Acute Myeloid Leukemia [NCT06073769]		154 participants (Anticipated)	Observational	2023-09-30	Not yet recruiting
Department of Hematology, The Second Affiliated Hospital of Kunming Medical University. [NCT06073730]	Phase 3	154 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
To Evaluate Safety and Efficacy of Azacitidine Combination With Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients：A Multicenter, Single-arm Study [NCT05471700]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2022-09-01	Recruiting
Phase I Trial of Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia Big Ten Cancer Research Consortium BTCRC-AML18-342 [NCT04128020]	Phase 1	0 participants (Actual)	Interventional	2019-10-10	Withdrawn(stopped due to Funder withdrew funding after not accruing any subjects after 1 year.)
A Umbrella Study in Relapsed/Refractory Peripheral T-cell Lymphoma Guided by Molecular Subtypes [NCT05559008]	Phase 1/Phase 2	116 participants (Anticipated)	Interventional	2022-09-30	Recruiting
Clinical Study of Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated Acute Myeloid Leukemia [NCT05053425]		30 participants (Anticipated)	Interventional	2021-10-20	Recruiting
A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma [NCT05495100]	Phase 2	45 participants (Anticipated)	Interventional	2022-08-11	Recruiting
Randomized Phase II Trial of Adjuvant Combined Epigenetic Therapy With 5-Azacitidine and Entinostat in Resected Stage I Non-small Cell Lung Cancer Versus Standard Care [NCT01207726]	Phase 2	13 participants (Actual)	Interventional	2010-09-30	Terminated(stopped due to Slow Accrual due to patients not wanting daily clinic administration of 5AZA and/or 6 months of treatment after surgery.)
A Phase 1/2, Open-label, Multicenter Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia (AML) and Treatment-naïve [NCT04748848]	Phase 1	1 participants (Actual)	Interventional	2021-10-14	Terminated(stopped due to Business objectives have changed.)
A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy [NCT03941964]	Phase 3	60 participants (Actual)	Interventional	2019-08-15	Completed
A Pilot Study of the Combination of 5-azacitidine (5-AZA) and All-trans Retinoic Acid (ATRA) for Prostate Cancer (PCa) With PSA-only Recurrence After Definitive Local Treatment [NCT03572387]	Phase 2	14 participants (Actual)	Interventional	2018-08-20	Completed
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia [NCT01926587]	Phase 1/Phase 2	45 participants (Actual)	Interventional	2013-08-31	Completed
A Phase I/II Study of Nivolumab in Combination With 5-azacytidine in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (BMS Reference CA209-9JY) [NCT03825367]	Phase 1/Phase 2	13 participants (Actual)	Interventional	2019-11-29	Active, not recruiting
Salsalate + Venetoclax/Decitabine for Patients With Acute Myelogenous Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease [NCT04146038]	Phase 2	5 participants (Actual)	Interventional	2020-10-26	Completed
Randomized, Sequential, Open-Label Study to Evaluate the Efficacy of IDH Targeted/Non- Targeted Versus Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DAT [NCT05401097]	Phase 2	125 participants (Anticipated)	Interventional	2022-09-13	Recruiting
Phase Ib/II Study of the Glutaminase Inhibitor CB-839 in Combination With Azacitidine in Patients With Advanced Myelodysplastic Syndrome [NCT03047993]	Phase 1/Phase 2	29 participants (Actual)	Interventional	2017-11-15	Completed
A Phase 1B, Open-label, Global, Multicenter, Dose Determination Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of CC-486 (ONUREG®) in Combination Therapy in Subjects With Acute Myeloid Leukemia (AML) [NCT04887857]	Phase 1	66 participants (Anticipated)	Interventional	2021-12-01	Active, not recruiting
Study Evaluating the Safety and Efficacy of the Dexamethasone, Azacytidine, Pegaspargase, Tislelizumab With NK/T Cell Lymphoma [NCT04899414]	Phase 2	50 participants (Anticipated)	Interventional	2021-05-18	Not yet recruiting
A Phase I/II Study of Midostaurin (PKC412) and 5-Azacitidine for Elderly Patients With Acute Myelogenous Leukemia. [NCT01093573]	Phase 1/Phase 2	34 participants (Actual)	Interventional	2009-07-31	Completed
Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20 mg/m2 IV Daily for 3 Days Every Month) Versus Azacitidine (AZA; 75 mg/m2 SC/IV Daily for 3 Days Every Month) in Myelodysplastic Syndrome (MDS) Patients With Low and Intermediate-1 Risk Diseas [NCT01720225]	Phase 2	113 participants (Actual)	Interventional	2012-11-06	Completed
A Randomized Phase III, Multicentre, Open Label Clinical Trial Comparing Azacitidine Plus Pevonedistat Versus Azacitidine in Older/Unfit Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Chemotherapy [NCT04090736]	Phase 3	302 participants (Actual)	Interventional	2019-09-24	Active, not recruiting
Phase I Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors [NCT02429466]	Phase 1	14 participants (Actual)	Interventional	2015-04-27	Completed
A Phase 1 Study of Doxorubicin, CC-486 (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma [NCT04639843]	Phase 1	0 participants (Actual)	Interventional	2022-11-03	Withdrawn(stopped due to Safety issues with PI3 kinase inhibitors)
Azacitidine Plus Lenalidomide Combination in Elderly Patients With Previously Treated Acute Myeloid Leukemia (AML) & High-Risk Myelodysplastic Syndromes (MDS) (VIREL2 Trial) [NCT01442714]	Phase 2	33 participants (Actual)	Interventional	2011-08-31	Terminated(stopped due to Lack of efficacy - Inability to meet the primary response endpoint)
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double Blind Study to Assess the Safety and Efficacy of CC-486 (Oral Azacitidine) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo in Subjects With Previously Treated Loca [NCT02546986]	Phase 2	100 participants (Actual)	Interventional	2015-10-09	Active, not recruiting
The Second Affiliated Hospital of Kunming Medical University [NCT05949762]	Phase 1/Phase 2	45 participants (Anticipated)	Interventional	2023-04-01	Recruiting
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Azacitidine and Chidamide Combined With CHOP (AC-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma With T-follicular Helper Phenotype (PTCL-TFH) [NCT05678933]	Phase 3	200 participants (Anticipated)	Interventional	2023-01-01	Enrolling by invitation
An Open Label, Single Arm, Phase I/II in the Combination of Azacytidine, Bendamustine and Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's [NCT04897477]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2021-04-22	Recruiting
Efficacy and Safety of Ambulatory Low-dose Venetoclax and Azacitidne as First Line Therapy in Newly Diagnosed AML: a Pilot Study [NCT05048615]	Phase 2	15 participants (Actual)	Interventional	2021-07-26	Completed
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML) [NCT02343939]	Phase 1/Phase 2	148 participants (Actual)	Interventional	2015-07-01	Terminated
Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of Secondary Acute Myeloid Leukemia [NCT05513131]	Phase 2	30 participants (Anticipated)	Interventional	2021-09-30	Recruiting
Phase 1b Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes in Previously Treated Patients or in Untreated Patients Unfit for or Who Refuse Intense Therapy [NCT02553941]	Phase 1	21 participants (Actual)	Interventional	2016-05-17	Completed
A Phase 1, Multicenter, Open-label Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Subjects With Myelodysplastic Syndromes [NCT01571648]	Phase 1	5 participants (Actual)	Interventional	2012-04-01	Completed
Phase II Randomised Trial of 5-azacitidine Versus 5-azacitidine in Combination With Vorinostat in Patients With Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndromes Ineligible for Intensive Chemotherapy [NCT01617226]	Phase 2	260 participants (Actual)	Interventional	2012-09-30	Completed
A Phase II Trial of Revlimid® (Lenalidomide) and Low Dose Vidaza® (Azacitidine) in Patients With Low - Intermediate-1 Risk Myelodysplastic Syndromes [NCT01379274]	Phase 2	2 participants (Actual)	Interventional	2011-01-31	Terminated(stopped due to Loss of funding.)
A Phase 3 Multicenter, Open-label, Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FLT3 Mutation in Patients Not Eligible for Intensi [NCT02752035]	Phase 3	183 participants (Actual)	Interventional	2016-08-01	Active, not recruiting
A Phase I Study of PXD101 in Combination With Azacitidine (5-Aza) for Advanced Hematologic Malignancies [NCT00351975]	Phase 1	56 participants (Actual)	Interventional	2006-06-30	Completed
An Open-label Phase 1b Study of PF-04449913 (Glasdegib) in Combination With Azacitidine in Patients With Previously Untreated Higher-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia [NCT02367456]	Phase 1	73 participants (Actual)	Interventional	2015-04-28	Completed
A Phase II Study Examining the Use of Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed Acute Myelogenous Leukemia (AML) in Elderly Patients [NCT02341495]	Phase 2	4 participants (Actual)	Interventional	2013-02-28	Terminated(stopped due to Study was terminated early due to low patient accrual.)
A Phase I Study of PLX51107 (A Novel Bromodomain Inhibitor) in Combination With Azacytidine for Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia (AML) [NCT04022785]	Phase 1	43 participants (Actual)	Interventional	2019-09-09	Completed
Phase II Study of Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes [NCT02469415]	Phase 2	3 participants (Actual)	Interventional	2015-09-30	Terminated(stopped due to FDA Clinical Hold)
A Phase 2, Randomized, Open-label, Two-arm Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal Women With ER+, HER2- Metastatic Breast Cancer Who Have P [NCT02374099]	Phase 2	97 participants (Actual)	Interventional	2015-03-13	Terminated
A Phase I Study of SGI-110 Combined With Irinotecan Followed by a Randomized Phase II Study of SGI-110 Combined With Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer Patients [NCT01896856]	Phase 1/Phase 2	118 participants (Actual)	Interventional	2013-10-23	Completed
An Open Label Phase I Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics and Efficacy of Intravenous Volasertib in Combination With Subcutaneous Azacitidine in Patients With Previously Untreated High-risk Myelodyspla [NCT01957644]	Phase 1	16 participants (Actual)	Interventional	2013-11-06	Terminated
Sequential Treatment With Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia [NCT01743859]	Phase 2	37 participants (Actual)	Interventional	2012-12-06	Completed
A Phase II Study of Risk-adapted Donor Lymphocyte Infusion and Azacitidine for the Prevention of Hematologic Malignancy Relapse Following Allogeneic Stem Cell Transplantation [NCT02458235]	Phase 2	17 participants (Actual)	Interventional	2015-06-02	Completed
An Open Label Phase I Trial of Intravenous Volasertib in Combination With Subcutaneous Azacitidine in Japanese Patients With Higher-risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia [NCT02201329]	Phase 1	5 participants (Actual)	Interventional	2014-08-31	Completed
Phase II Combination of Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) [NCT02599649]	Phase 2	10 participants (Actual)	Interventional	2016-03-21	Terminated(stopped due to Enrollment was stopped after the sponsor's decision not to pursue the development of lirilumab for myeloid malignancies.)
A Phase Ib Study Evaluating the Safety and Efficacy of IBI188 in Combination With Azacitidine in Subjects With Newly Diagnosed Higher Risk Myelodysplastic Syndrome [NCT04485065]	Phase 1	120 participants (Anticipated)	Interventional	2020-09-30	Suspended(stopped due to Suspended for changes in development strategy)
An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer [NCT02901899]	Phase 2	45 participants (Actual)	Interventional	2016-11-30	Active, not recruiting
A Phase I/II Multicenter Study Combining Guadecitabine, a DNA Methyltransferase Inhibitor, With Atezolizumab, an Immune Checkpoint Inhibitor, in Patients With Intermediate or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia [NCT02935361]	Phase 1/Phase 2	33 participants (Actual)	Interventional	2016-11-02	Active, not recruiting
Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20 mg/m2 IV Daily for 3 Days Every Month) Versus Azacitidine (AZA; 75 mg/m2 SC/IV Daily for 3 Days Every Month) Versus Azacitidine (AZA; 75 mg/m2 SC/IV Daily for 5 Days Every Month) in MDS Patie [NCT02269280]	Phase 2	268 participants (Actual)	Interventional	2014-10-13	Active, not recruiting
An Open-Label Phase II Study of Lirilumab (BMS-986015) in Combination With 5-Azacytidine (Vidaza) for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia [NCT02399917]	Phase 2	36 participants (Actual)	Interventional	2015-04-20	Terminated(stopped due to This study was terminated early due to response rates not meeting the anticipated minimum of 30%.)
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies [NCT02265510]	Phase 1/Phase 2	83 participants (Actual)	Interventional	2014-09-10	Terminated
A Phase 4 Study of Venetoclax in Combination With Azacitidine in Newly Diagnosed Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy in China [NCT05144243]	Phase 4	44 participants (Actual)	Interventional	2022-01-06	Active, not recruiting
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, [NCT03926624]	Phase 3	450 participants (Anticipated)	Interventional	2019-11-22	Recruiting
A Single Arm Phase II Trial of Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse [NCT01995578]	Phase 2	32 participants (Actual)	Interventional	2013-12-31	Completed
An Open-Label Phase Ib/II Study of Avelumab in Combination With 5-Azacytidine (Vidaza) for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia [NCT02953561]	Phase 1/Phase 2	19 participants (Actual)	Interventional	2017-02-20	Terminated(stopped due to PDOL request)
A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) [NCT02807558]	Phase 2	155 participants (Actual)	Interventional	2016-08-31	Active, not recruiting
A 2-year, Multi-center, Phase II, Open-label, Fixed-dose, Randomized Comparative Trial of Azacitidine, With or Without Deferasirox in Patients With Higher Risk Myelodysplastic Syndromes [NCT02159040]	Phase 2	1 participants (Actual)	Interventional	2014-09-11	Terminated
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies [NCT02711137]	Phase 1/Phase 2	137 participants (Actual)	Interventional	2016-05-18	Terminated(stopped due to Study terminated due to safety issues.)
A Randomized, Double-blind, Placebo-controlled, Phase III, Multi-centre Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With IPSS Intermediate-1, Intermediate 2 and High-risk Myelodysplastic Syndromes (MDS) SUPPORT: A StUdy of [NCT02158936]	Phase 3	356 participants (Actual)	Interventional	2014-06-10	Terminated
A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast [NCT02610777]	Phase 2	120 participants (Actual)	Interventional	2016-04-14	Completed
Phase I/Ib Trial of COmbined 5'aZacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain and Solid Tumors [NCT03206021]	Phase 1	31 participants (Actual)	Interventional	2017-08-01	Active, not recruiting
Epigenetic Modification for Relapse Prevention: a Dose-finding Study of Vorinostat Used in Combination With Low-dose Azacitidine in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies [NCT03843528]	Phase 1	15 participants (Anticipated)	Interventional	2019-05-01	Recruiting
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS) [NCT02706899]	Phase 1/Phase 2	19 participants (Actual)	Interventional	2016-02-29	Terminated(stopped due to Sponsor decision based on portfolio prioritization)
Phase I-II Study of Crenolanib Combined With Standard Salvage Chemotherapy, and Crenolanib Combined With 5-Azacitidine in Acute Myeloid Leukemia Patients With FLT3 Activating Mutations [NCT02400281]	Phase 1/Phase 2	28 participants (Actual)	Interventional	2015-09-30	Completed
T-cell Lymphoma Series：A Genotype-guided Therapy in Newly Diagnosed Patients With Peripheral T-cell Lymphoma （THEORY Study） [NCT05675813]	Phase 1/Phase 2	264 participants (Anticipated)	Interventional	2023-01-15	Not yet recruiting
Azacitidine in Combination With Venetoclax Treatment for Prevention of Relapse in MRD Positive Post Allogeneic Hematopoietic Stem Cell Transplantation Acute Myelogenous Leukemia/ Myelodysplastic Syndrome Patients [NCT04809181]	Phase 2	95 participants (Anticipated)	Interventional	2021-03-19	Recruiting
Efficacy and Safety of Tislelizumab Combined Treatment in Refractory Natural Killer/T-cell Lymphoma [NCT05058755]		62 participants (Anticipated)	Interventional	2021-09-17	Recruiting
A Phase 1/2 Study of Evorpacept (ALX148) in Combination With Venetoclax and Azacitidine in Patients With Acute Myeloid Leukemia (AML) (ASPEN-05) [NCT04755244]	Phase 1/Phase 2	97 participants (Anticipated)	Interventional	2021-05-05	Active, not recruiting
A Phase 1/2 Study of Evorpacept (ALX148) in Combination With Azacitidine in Patients With Higher Risk Myelodysplastic Syndrome (MDS) (ASPEN-02) [NCT04417517]	Phase 1/Phase 2	65 participants (Actual)	Interventional	2020-10-02	Active, not recruiting
Phase I/II Open-Label Study to Assess Safety, Tolerability and Preliminary Efficacy of the CLEVER-1 Antibody Bexmarilimab in Combination With Azacitidine or Azacitidine/Venetoclax in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemi [NCT05428969]	Phase 1/Phase 2	181 participants (Anticipated)	Interventional	2022-06-02	Recruiting
Combination Intraventricular Chemotherapy Pilot Study: 5-Azacytidine (5-AZA) and Trastuzumab Infusions Into the Fourth Ventricle or Resection Cavity in Children and Adults With Recurrent or Residual Posterior Fossa Ependymoma [NCT04958486]	Early Phase 1	10 participants (Anticipated)	Interventional	2021-07-08	Recruiting
Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle or Resection Cavity in Children and Adults With Recurrent Posterior Fossa Ependymoma: A Phase I Study [NCT03572530]	Phase 1	9 participants (Anticipated)	Interventional	2019-02-08	Recruiting
A Phase 1 Study of Milademetan (DS 3032b), an Oral MDM2 Inhibitor, In Dose Escalation as a Single Agent and In Dose Escalation/Expansion In Combination With 5 Azacitidine In Subjects With Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndr [NCT02319369]	Phase 1	74 participants (Actual)	Interventional	2014-11-25	Terminated(stopped due to This study was terminated based on a business decision by the Sponsor.)
A Single-center, Single-arm Clinical Study of the Clinical Efficacy and Safety of CD47 Monoclonal Antibody Combined With Azacitidine in the Treatment of Recurrent AML After Transplantation [NCT05266274]		69 participants (Anticipated)	Interventional	2021-12-14	Recruiting
A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination With Gemtuzumab Ozogamicin (Mylotarg®) and Azacitidine (Vidaza®) in Patients 50 Years of Age and Older With Relapsed/Refractory Non-APL Acute Myeloid Leukemia (AML) [NCT00895934]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2009-05-31	Completed
A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia Patients Not Eligible for I [NCT03217838]	Phase 1	50 participants (Actual)	Interventional	2017-07-31	Terminated(stopped due to strategic decision)
Epigenetic Priming With 5-Azacytidine Prior to in Vivo T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With High Risk Myeloid Malignancies in Morphologic Remission [NCT02497404]	Phase 2	40 participants (Actual)	Interventional	2015-02-13	Completed
Characteristics, Treatment Patterns, and Clinical Outcomes in Non-intensive Chemotherapy Acute Myeloid Leukemia (AML) Patients - a US Real-World Study Using Electronic Medical Record Data [NCT04230564]		0 participants (Actual)	Observational	2020-10-31	Withdrawn(stopped due to Study was cancelled prior to any enrollment)
A Phase II Study of Epigenetic Therapy With Azacitidine and Entinostat With Concurrent Nivolumab in Subjects With Metastatic Non-Small Cell Lung Cancer. [NCT01928576]	Phase 2	101 participants (Actual)	Interventional	2013-11-06	Completed
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy [NCT01869114]	Phase 2	57 participants (Actual)	Interventional	2013-07-08	Active, not recruiting
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation [NCT03666559]	Phase 2	8 participants (Actual)	Interventional	2020-09-22	Active, not recruiting
An Open-Label Phase 1/2 Multi-Arm Study of DS-1594b as a Single-Agent and in Combination With Azacitidine and Venetoclax or Mini-HCVD for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) [NCT04752163]	Phase 1/Phase 2	17 participants (Actual)	Interventional	2021-03-25	Completed
A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation [NCT02577406]	Phase 3	319 participants (Actual)	Interventional	2015-12-30	Active, not recruiting
Phase II Study of the Combination of 5-azacytidine With Valproic Acid and All-trans Retinoic Acid in Patients With High Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia [NCT00326170]	Phase 2	34 participants (Actual)	Interventional	2005-07-31	Completed
Efficacy of Concomitant Use of Azacitidine and Homoharringtonine in Children With Juvenile Myelomonocytic Leukemia [NCT04505995]		30 participants (Anticipated)	Interventional	2020-01-01	Recruiting
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy [NCT04266795]	Phase 2	164 participants (Actual)	Interventional	2020-10-13	Active, not recruiting
Phase II Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma [NCT02816021]	Phase 2	24 participants (Actual)	Interventional	2017-02-14	Active, not recruiting
A Phase II Trial to Improve Outcomes in Patients With Resected Pancreatic Adenocarcinoma at High Risk for Recurrence Using Epigenetic Therapy [NCT01845805]	Phase 2	49 participants (Actual)	Interventional	2014-01-10	Completed
A Study of Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy in Patients With Acute Myeloid Leukemia Who Had Relapsed/Refractory Disease or Positive Minimal Residual Disease [NCT05362942]	Phase 2	52 participants (Anticipated)	Interventional	2022-05-01	Not yet recruiting
A Randomized Phase II Trial of Cytotoxic Chemotherapy With or Without Epigenetic Priming in Patients With Advanced Non-Small Cell Lung Cancer [NCT01935947]	Phase 2	17 participants (Actual)	Interventional	2013-05-31	Terminated
Phase I/II Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory DLBCL [NCT01120834]	Phase 1/Phase 2	17 participants (Actual)	Interventional	2010-09-30	Completed
Treatment of Post-Transplant Relapse and Persistent Disease in Patients With MDS, CMML and AML With Azacitidine [NCT01083706]	Phase 2	43 participants (Actual)	Interventional	2010-04-30	Completed
A Multicenter, Randomized, Controlled Clinical Trial of Venetoclax, Azacytidine Combined With Chidamide for the Treatment of Newly Diagnosed Acute Monocytic Leukemia Patients That Are Ineligible for Intensive Chemotherapy [NCT05566054]	Phase 2	92 participants (Anticipated)	Interventional	2022-03-01	Recruiting
A Phase 1, Open-label, Dose Finding Study of CC-95251 Alone and in Combination With Antineoplastic Agents in Subjects With Acute Myeloid Leukemia and Myelodysplastic Syndromes [NCT05168202]	Phase 1	218 participants (Anticipated)	Interventional	2022-01-19	Recruiting
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS [NCT03593915]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2018-08-29	Terminated(stopped due to The sponsor decided not to continue the study based on the overall company strategy in AML.)
Venetoclax Combining Chidamide and Azacitidine (VCA) Regimen Followed by Dicitabine Combined With Liposome Mitoxantrone, Cytarabine, and G-CSF (D-MAG) Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) : A Multi [NCT05603884]	Phase 2	66 participants (Anticipated)	Interventional	2022-12-01	Recruiting
Phase II Study of Tagraxofusp in Newly Diagnosed Secondary AML After Previous Exposure to Hypomethylating Agents [NCT05442216]	Phase 2	53 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Myeloid Malignancies [NCT04778410]	Phase 2	59 participants (Anticipated)	Interventional	2021-06-28	Active, not recruiting
Phase I, Dose De-Escalation to Minimal Effective Pharmacologic Dose Trial of Sodium Phenylbutyrate (PB, NSC 657802) in Combination With 5-Azacytidine (5-AZA, NSC 102816) in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) [NCT00004871]	Phase 1	0 participants	Interventional	2000-05-31	Completed
Phase II Study of Sorafenib Plus 5-Azacitidine for the Initial Therapy of Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome With FLT3-ITD Mutation [NCT02196857]	Phase 2	16 participants (Actual)	Interventional	2015-02-06	Completed
A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID) [NCT02985190]	Phase 2	30 participants (Actual)	Interventional	2017-01-26	Completed
A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes [NCT02508870]	Phase 1	46 participants (Actual)	Interventional	2015-09-30	Completed
A Phase 2 Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome [NCT03486353]	Phase 2	0 participants (Actual)	Interventional	2019-10-31	Withdrawn(stopped due to Program terminated)
A Phase I Clinical Trial of NY-ESO-1 Protein Immunization in Combination With 5-AZA-2'-Deoxycytidine (Decitabine) in Patients Receiving Liposomal Doxorubicin for Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma [NCT01673217]	Phase 1	18 participants (Actual)	Interventional	2009-04-30	Completed
A Prospective, Multicenter, Phase III, Non-randomized Study of Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma [NCT05075460]	Phase 3	107 participants (Anticipated)	Interventional	2021-10-01	Not yet recruiting
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas [NCT04803201]	Phase 2	170 participants (Anticipated)	Interventional	2021-07-30	Recruiting
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger With High-Risk (Adverse) Acute Myeloid L [NCT05554406]	Phase 2	268 participants (Anticipated)	Interventional	2024-02-01	Not yet recruiting
Treatment of Patients With MDS or AML With an Impending Hematological Relapse With Azacitidine (Vidaza) [NCT01462578]	Phase 2	93 participants (Actual)	Interventional	2011-09-30	Completed
Phase I- II Study of in Vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus With or Without Vidaza (Azacitidine) for the Treatment of Steroid-refractory Acute Graft-versus-host Disease [NCT01453140]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2011-08-31	Terminated(stopped due to Dose Limiting Toxicities)
A Pilot/Safety Study of sEphB4-HSA in Combination With a Hypomethylating Agent (HMA) for Patients With Relapsed or Refractory Myelodysplastic Syndrome (MDS) and AML Previously Treated With a Hypomethylating Agent [NCT03146871]	Phase 2	7 participants (Actual)	Interventional	2017-04-20	Terminated(stopped due to Lack of funding)
A Phase 2, Randomized, Open-Label Study of Azacitidine (Vidaza) vs MGCD0103 vs Azacitidine in Combination With MGCD0103 for the Treatment of Elderly Subjects With Newly Diagnosed AML or Intermediate-2 or High-Risk MDS [NCT00666497]	Phase 2	6 participants (Actual)	Interventional	2008-06-30	Terminated(stopped due to Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All Celgene-sponsored trials with MGCD0103 with be closed.)
Venetoclax Plus Azacitidine Versus Standard Intensive Chemotherapy for Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and NPM1 Mutations Eligible for Intensive Treatment [NCT05904106]	Phase 2	146 participants (Anticipated)	Interventional	2023-08-31	Not yet recruiting
A Phase 1 Study of Cusatuzumab Plus Azacitidine in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment [NCT04241549]	Phase 1	6 participants (Actual)	Interventional	2020-03-25	Completed
A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy [NCT04023526]	Phase 2	103 participants (Actual)	Interventional	2019-07-29	Active, not recruiting
A Single-arm Dose Finding Phase Ib Multicenter Study of the Oral Smoothened Antagonist LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients [NCT02323139]	Phase 1	23 participants (Actual)	Interventional	2015-02-10	Completed
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies [NCT02712905]	Phase 1/Phase 2	116 participants (Actual)	Interventional	2016-05-05	Terminated(stopped due to Strategic Business Decision)
Phase 1/2a Study of Anti-PD-L1 Monoclonal Antibody Durvalumab in Combination With Pralatrexate and Romidepsin, Oral 5-Aza and Romidepsin, Romidepsin Alone, or Oral 5-Azacitidine for Treatment of Patients With Relapsed and Refractory PTCL [NCT03161223]	Phase 1/Phase 2	148 participants (Anticipated)	Interventional	2018-05-30	Recruiting
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials [NCT05564390]	Phase 2	750 participants (Anticipated)	Interventional	2024-02-01	Not yet recruiting
A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial [NCT05554393]	Phase 2	153 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer [NCT03206047]	Phase 1/Phase 2	75 participants (Anticipated)	Interventional	2017-11-08	Active, not recruiting
A Phase I Trial of 5Azacitidine and Suberoylanilide Hydroxamic Acid in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma and Nasal NK-T Cell Lymphoma [NCT00336063]	Phase 1	18 participants (Actual)	Interventional	2006-03-03	Active, not recruiting
A Phase 3, Open-Label, Multicenter, Randomized Study of SKLB1028 Versus Salvage Chemotherapy in Patients With FLT3-mutated Acute Myeloid Leukemia Refractory to or Relapsed After First-line Treatment（ALIVE） [NCT04716114]	Phase 3	315 participants (Anticipated)	Interventional	2021-03-24	Recruiting
Azacitidine (AZA) Combined With N-Acetyl-L-cysteine (NAC) for Prolonged Isolated Thrombocytopenia (PIT) After Hematopoietic Stem Cell Transplantation (HSCT) [NCT05126004]	Phase 2	100 participants (Anticipated)	Interventional	2021-12-01	Not yet recruiting
Phase I Trial of OPB-111077 in Combination With Decitabine and Venetoclax for the Treatment of AML Refractory to or Ineligible for Intensive Chemotherapy [NCT03063944]	Phase 1	37 participants (Actual)	Interventional	2017-03-17	Active, not recruiting
OAG and Decitabine for Newly Diagnosed Acute Myeloid Leukemia Patients Greater Than or Equal to 65 Years of Age [NCT02029417]	Phase 2	2 participants (Actual)	Interventional	2014-07-31	Terminated(stopped due to Major revisions needed in study)
Phase I/II Study of SP-2577 (Seclidemstat) in Combination With Azacitidine for Patients With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia [NCT04734990]	Phase 1/Phase 2	44 participants (Anticipated)	Interventional	2021-07-07	Recruiting
A Phase I/II Study of Azacitidine, Venetoclax, and Gilteritinib for Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome With an Activating FLT3 Mutation [NCT04140487]	Phase 1/Phase 2	42 participants (Anticipated)	Interventional	2019-12-17	Recruiting
Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplasic Syndrom or an Acute Myeloid Leukemia and Treated by Azacytidine [NCT02489929]		35 participants (Anticipated)	Interventional	2015-08-31	Not yet recruiting
A Single-arm, Multi-Center, Phase Ib/Ⅱ Clinical Trial of Max-40279-01 in Combination With Azacitidine (AZA) in Adult Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) [NCT05061147]	Phase 1/Phase 2	100 participants (Anticipated)	Interventional	2021-09-16	Recruiting
Phase-II Trial to Assess the Efficacy and Safety of Lenalidomide in Addition to 5-Azacitidine and Donor Lymphocyte Infusions (DLI) for the Treatment of Patients With MDS, CMML or AML Who Relapse After Allogeneic Stem Cell Transplantation [NCT02472691]	Phase 2	50 participants (Actual)	Interventional	2015-05-31	Completed
A PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF-04449913 (GLASDEGIB), AN ORAL HEDGEHOG INHIBITOR, ADMINISTERED AS A SINGLE AGENT IN JAPANESE PATIENTS WITH SELECT HEMATOLOGIC MALIGNANCIES AND IN [NCT02038777]	Phase 1	48 participants (Actual)	Interventional	2014-03-25	Active, not recruiting
Action of the Vidaza on the Atrial Fibrillation [NCT03298321]		14 participants (Anticipated)	Observational	2018-12-20	Recruiting
Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition at Toulouse and Bordeaux University Hospital [NCT03284593]		199 participants (Actual)	Observational	2014-12-31	Active, not recruiting
Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation [NCT01747499]	Phase 1/Phase 2	54 participants (Actual)	Interventional	2013-04-15	Terminated(stopped due to Enrolling 8 more patients would be statistically unlikely that the primary endpoint would be reached (reduce day 180 grade II-IV GVHD rates to 20% or less))
Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine [NCT00085293]	Phase 2	12 participants (Actual)	Interventional	2004-05-31	Completed
A Multi-Center, Phase 1 Trial of Combining Anti-CD47 Antibody (Magrolimab) With Azacitidine as Post-Transplant Maintenance Therapy in Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation for Treatment of High-Risk AML or MDS [NCT05823480]	Phase 1	44 participants (Anticipated)	Interventional	2023-12-09	Not yet recruiting
Clinical Study of Azacitidine Combined With Homoharringtonie Based Regimens in Acute Myeloid Leukemia [NCT04248595]	Phase 2	100 participants (Anticipated)	Interventional	2019-12-01	Recruiting
A Phase I-II, Multicentre, Open Label Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine, Plus Venetoclax and Quizartinib in Newly Diagnosed Acute Myeloid Leukemia Patients Aged Equal or More Than [NCT04687761]	Phase 1/Phase 2	84 participants (Anticipated)	Interventional	2020-11-04	Recruiting
Azacitidine/Vorinostat/GemBuMel With Autologous Stem-Cell Transplant (SCT) in Patients With Refractory Lymphomas [NCT01983969]	Phase 1/Phase 2	61 participants (Actual)	Interventional	2013-11-07	Completed
Decitabine Followed by Bone Marrow Transplant and High-Dose Cyclophosphamide for the Treatment of Relapsed and Refractory Acute Myeloid Neoplasms [NCT01707004]	Phase 2	20 participants (Actual)	Interventional	2013-05-16	Completed
A Phase 2, Multicenter, International, Single Arm Study To Assess The Safety And Efficacy Of Single Agent Cc-486 (Oral Azacitidine) In Previously Treated Subjects With Locally Advanced Or Metastatic Nasopharyngeal Carcinoma [NCT02269943]	Phase 2	36 participants (Actual)	Interventional	2015-02-13	Completed
A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Azacitidine in Adult Chinese Subjects With Higher-Risk Myelodysplastic Syndromes [NCT01599325]	Phase 2	72 participants (Actual)	Interventional	2012-07-24	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00071799 (16) [back to overview]	Kaplan-Meier Estimate for Median Time to Transformation to Acute Myeloid Leukemia (AML) or Death From Any Cause, Whichever Occurred First
NCT00071799 (16) [back to overview]	Kaplan-Meier Estimates for Median Time to Transformation to Acute Myeloid Leukemia (AML)
NCT00071799 (16) [back to overview]	Kaplan-Meier Estimates for Median Time to Transformation to Acute Myeloid Leukemia (AML) Based on the Last Bone Marrow Assessment
NCT00071799 (16) [back to overview]	Number of Infections Per Treatment Year Requiring Intravenous Antibiotics, Antifungals or Antivirals
NCT00071799 (16) [back to overview]	Number of Participants Who Died
NCT00071799 (16) [back to overview]	Time to Disease Progression, Relapse After Complete or Partial Remission, or Death From Any Cause
NCT00071799 (16) [back to overview]	Number of Participants Considered Hematologic Responders by Investigator Determinations Using International Working Group (IWG 2000) Criteria for Myelodysplastic Syndrome (MDS)
NCT00071799 (16) [back to overview]	Number of Participants in Different Categories of Adverse Experiences During Core Study Period
NCT00071799 (16) [back to overview]	Number of Participants Showing Hematologic Improvement Using International Working Group (IWG 2000) Criteria for Myelodysplastic Syndrome (MDS) Assessed by Independent Review Committee
NCT00071799 (16) [back to overview]	Summary of Participants' Platelet Transfusion Status for Participants Who Were Transfusion Dependent at Baseline
NCT00071799 (16) [back to overview]	Summary of Participants' Platelet Transfusion Status for Participants Who Were Transfusion Independent at Baseline
NCT00071799 (16) [back to overview]	Summary of Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Dependent at Baseline
NCT00071799 (16) [back to overview]	Summary of Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Independent at Baseline
NCT00071799 (16) [back to overview]	Duration of Any Hematologic Improvement
NCT00071799 (16) [back to overview]	Summary of Subgroup Analyses for Kaplan-Meier Estimates for Time to Death From Any Cause
NCT00071799 (16) [back to overview]	Kaplan-Meier Estimates for Median Time to Death From Any Cause
NCT00085293 (2) [back to overview]	Frequency of Adverse Events According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
NCT00085293 (2) [back to overview]	Restoration of Radioiodine Uptake in Metastatic Lesions as Demonstrated by Diagnostic Whole-body Scanning After Decitabine Administration
NCT00102687 (19) [back to overview]	Red Blood Cell (RBC) Transfusion Status at Baseline and End of Maintenance Study Period (24 Months)
NCT00102687 (19) [back to overview]	Red Blood Cell (RBC) Transfusion Status at Baseline and End of Initial Study Period (6 Months)
NCT00102687 (19) [back to overview]	Platelet Transfusion Status at Baseline and End of Maintenance Study Period (24 Months)
NCT00102687 (19) [back to overview]	Platelet Transfusion Status at Baseline and End of Initial Study Period (6 Months)
NCT00102687 (19) [back to overview]	Number of Participants With Best Hematological Improvement Derived Using International Working Group 2000 (IWG 2000) Criteria for MDS During the Initial Study Period.
NCT00102687 (19) [back to overview]	Number of Participants Who Improved or Maintained The Hematologic Response From the Initial Study Period (Based on IWG 2000 Criteria For MDS) During the Maintenance Period
NCT00102687 (19) [back to overview]	Number of Participants In Best Hematological Response Categories as Determined by the Investigator Using International Working Group 2000 (IWG 2000) Criteria For Myelodysplastic Syndromes (MDS) During the Initial Study Period.
NCT00102687 (19) [back to overview]	Number of Participants With Overall Best Hematologic Response and Hematologic Improvement Based on IWG 2000 Criteria For MDS During the Initial Study Period
NCT00102687 (19) [back to overview]	Change From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Maintenance Study Period
NCT00102687 (19) [back to overview]	Change From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Initial Study Period
NCT00102687 (19) [back to overview]	Baseline Platelet Values
NCT00102687 (19) [back to overview]	Baseline Absolute Neutrophil Count (ANC) Values
NCT00102687 (19) [back to overview]	Change From Baseline in Platelets at the End of Initial Study Period (6 Months)
NCT00102687 (19) [back to overview]	Change From Baseline in Platelets at the End of the Maintenance Study Period (Month 24)
NCT00102687 (19) [back to overview]	Change From Baseline in Hemoglobin at the End of the Maintenance Study Period
NCT00102687 (19) [back to overview]	Change From Baseline in Hemoglobin at End of Initial Study Period (6 Months)
NCT00102687 (19) [back to overview]	Baseline Hemoglobin Values
NCT00102687 (19) [back to overview]	Change From Baseline in Absolute Neutrophil Count (ANC) at the End of the Maintenance Study Period (Month 24)
NCT00102687 (19) [back to overview]	Change From Baseline in Absolute Neutrophil Count (ANC) at the End of Initial Study Period (6 Months)
NCT00313586 (1) [back to overview]	Proportion of Patients With Clinical Response
NCT00321711 (4) [back to overview]	Platelet Transfusion
NCT00321711 (4) [back to overview]	Occurrence of a Clinically Significant Thrombocytopenic Event
NCT00321711 (4) [back to overview]	Hypomethylating Agent Dose Reduction and Delay Due to Thrombocytopenia
NCT00321711 (4) [back to overview]	Achieving an Overall Response (Complete or Partial Response, CR or PR) at the End of the Treatment Period
NCT00326170 (1) [back to overview]	Number of Participants With Response
NCT00352001 (8) [back to overview]	PHASE II: Determine the Number of Patients With Responses for Efficacy(Measured as Response Rate)
NCT00352001 (8) [back to overview]	Number of Patients That Experience Grade 3 or 4 Treatment Related Non-hematologic Adverse Events
NCT00352001 (8) [back to overview]	Overall Survival Among Patients With Complete Response
NCT00352001 (8) [back to overview]	PHASE I: Maximum Tolerated Dose of Azacitidine
NCT00352001 (8) [back to overview]	PHASE I: Maximum Tolerated Dose of Lenalidomide
NCT00352001 (8) [back to overview]	PHASE II: Determine the Number of Patients With Responses for Efficacy(Measured as Response Rate)
NCT00352001 (8) [back to overview]	Time to Relapse After Achieving Complete Response
NCT00352001 (8) [back to overview]	Time to Transformation to Acute Myeloid Leukemia or Death
NCT00379912 (6) [back to overview]	Analysis of CD34, CD71, CD36 Cells in Aspirated Bone Marrow for Both Responders and Non-responders at Baseline and After Three and Six Cycles
NCT00379912 (6) [back to overview]	Overall Response After Cycle 3
NCT00379912 (6) [back to overview]	Overall Response Rate After Six Cycles
NCT00379912 (6) [back to overview]	Safety Profile of the Modified Dose/Schedule of Azacitidine and Erythropoietin or a Modified Dose of Azacitidine Alone
NCT00379912 (6) [back to overview]	BclXL Expression
NCT00379912 (6) [back to overview]	Percent Apoptosis in 34+36+71+ Cells at Baseline, Three Cycles and Six Cycles
NCT00381693 (3) [back to overview]	Number of Participants With Treatment Related Adverse Events
NCT00381693 (3) [back to overview]	Overall Survival (OS)
NCT00381693 (3) [back to overview]	Patients With Confirmed Response (Complete Remission or Partial Remission on 2 Consecutive Evaluation at Least 4 Weeks Apart) During the First 4 Months of Treatment
NCT00382590 (1) [back to overview]	Number of Participants With Response
NCT00384839 (6) [back to overview]	Objective Response Rate by Recist (ORR)
NCT00384839 (6) [back to overview]	Percentage of Patients With PSA Doubling Time >=3 Months.
NCT00384839 (6) [back to overview]	Changes in Fetal Hemoglobin (HbF) With Time.
NCT00384839 (6) [back to overview]	1-year Overall Survival (OS)
NCT00384839 (6) [back to overview]	PSA Response Rate
NCT00384839 (6) [back to overview]	Progression-free Survival
NCT00384956 (7) [back to overview]	Rate of Overall Survival
NCT00384956 (7) [back to overview]	Time to Best Response
NCT00384956 (7) [back to overview]	Rate of Complete Remission (CR) and Partial Remission (PR)
NCT00384956 (7) [back to overview]	Rate of Transfusion Independence
NCT00384956 (7) [back to overview]	Duration of Response (DOR)
NCT00384956 (7) [back to overview]	Progression-free Survival (PFS)
NCT00384956 (7) [back to overview]	Rate of Hematologic Improvement
NCT00387465 (9) [back to overview]	(Phase I) Maximum Tolerated Dose (MTD) of Azacitidine When Given Together With Entinostat as Determined by Number of Participants Experiencing Dose-limiting Toxicity (DLT)
NCT00387465 (9) [back to overview]	Effect of Entinostat and Azacitidine on DNA Methylation and Response
NCT00387465 (9) [back to overview]	Overall Survival
NCT00387465 (9) [back to overview]	Pharmacokinetic Profile of Azacitidine as Measured by AUC (ng*hr/mL)
NCT00387465 (9) [back to overview]	Pharmacokinetic Profile of Azacytidine as Measured by Tmax
NCT00387465 (9) [back to overview]	Pharmacokinetic Profile of Azacitidine as Measured by Cmax
NCT00387465 (9) [back to overview]	Average Steady State Trough Concentration (ng/mL) of Entinostat
NCT00387465 (9) [back to overview]	Progression-free Survival
NCT00387465 (9) [back to overview]	Pharmacokinetic Profile of Azacitidine as Measured by Half-life
NCT00387647 (3) [back to overview]	Number of Participants With Adverse Events
NCT00387647 (3) [back to overview]	Overall Survival (OS)
NCT00387647 (3) [back to overview]	Rate of Disease Free Survival at One Year
NCT00413478 (1) [back to overview]	Tumor Response Rate (Complete, Partial) of Azacytidine
NCT00439673 (2) [back to overview]	The Primary Objective of the Trial is to Assess the Efficacy of the Combined Use of Valproic Acid (VPA) in Combination With 5-Azacytidine (5-Aza C) in the Treatment of MDS.
NCT00439673 (2) [back to overview]	Time to Transformation to AML
NCT00443261 (1) [back to overview]	Evaluate the Safety and Toxicity of Azacitidine (5-azacytidine, Vidaza®) and Cisplatin Combination
NCT00492401 (2) [back to overview]	Measurement of DNMT Protein in Peripheral Blood or Bone Marrow Cells
NCT00492401 (2) [back to overview]	Rate of Complete Remission
NCT00503984 (8) [back to overview]	Phase I - Recommended Phase Two Dose (RPTD) of Azacitidine and Docetaxel in Combination With Prednisone. (Prednisone)
NCT00503984 (8) [back to overview]	Phase I - Recommended Phase Two Dose (RPTD) of Azacitidine and Docetaxel in Combination With Prednisone. (Azacitidine and Docetaxel)
NCT00503984 (8) [back to overview]	Number of Participants Achieving Complete Response (CR) or Partial Response (CR) to Protocol Therapy.
NCT00503984 (8) [back to overview]	Duration of Response
NCT00503984 (8) [back to overview]	Progression-Free Survival (PFS)
NCT00503984 (8) [back to overview]	Overall Survival (OS)
NCT00503984 (8) [back to overview]	Number of Participants Experiencing Adverse Events After Beginning Protocol Therapy.
NCT00503984 (8) [back to overview]	Number of Participants Achieving Prostate-specific Antigen (PSA) Response.
NCT00569010 (1) [back to overview]	Number of Participants With Complete Remission
NCT00569660 (1) [back to overview]	Number of Participants With Objective Clinical Response
NCT00652626 (17) [back to overview]	Apparent Total Clearance of Azacitidine (CL/F)
NCT00652626 (17) [back to overview]	Apparent Volume of Distribution of Azacitidine (Vz/F)
NCT00652626 (17) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point
NCT00652626 (17) [back to overview]	Maximum Plasma Concentration of Azacitidine (Cmax)
NCT00652626 (17) [back to overview]	Terminal Phase Half-life of Azacitidine (t½)
NCT00652626 (17) [back to overview]	Time to Maximum Plasma Concentration of Azacitidine (Tmax)
NCT00652626 (17) [back to overview]	Area Under the Plasma Concentration-time Curve From Time 0 to Infinity After Single and Multiple Doses of Azacitidine
NCT00652626 (17) [back to overview]	Maximum Plasma Concentration of Azacitidine (Cmax) After Single and Multiple Doses of Azacitidine
NCT00652626 (17) [back to overview]	Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose After Single and Multiple Doses of Azacitidine
NCT00652626 (17) [back to overview]	Apparent Volume of Distribution of Azacitidine (Vz/F) After Single and Multiple Doses of Azacitidine
NCT00652626 (17) [back to overview]	Area Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Time Point After Single and Multiple Doses of Azacitidine
NCT00652626 (17) [back to overview]	Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose
NCT00652626 (17) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to Infinity
NCT00652626 (17) [back to overview]	Terminal Phase Half-life of Azacitidine (t½) After Single and Multiple Doses of Azacitidine
NCT00652626 (17) [back to overview]	Time to Maximum Plasma Concentration of Azacitidine (Tmax) After Single and Multiple Doses of Azacitidine
NCT00652626 (17) [back to overview]	Apparent Total Clearance of Azacitidine (CL/F) After Single and Multiple Doses of Azacitidine
NCT00652626 (17) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT00658814 (4) [back to overview]	Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug
NCT00658814 (4) [back to overview]	30-Day Survival
NCT00658814 (4) [back to overview]	Complete Response
NCT00658814 (4) [back to overview]	Relapse-free Survival
NCT00660400 (4) [back to overview]	Percentage of Participants With Overall Survival (OS)
NCT00660400 (4) [back to overview]	Overall Response Rate (ORR)
NCT00660400 (4) [back to overview]	Percentage of Participants Who Proceed to Hematopoietic Cell Transplantation (HCT)
NCT00660400 (4) [back to overview]	Percentage of Participants With Relapse-free Survival (RFS)
NCT00661726 (12) [back to overview]	Change in Platelet Count From Baseline to Peak (the Follow-up Time Point With the Highest Value)
NCT00661726 (12) [back to overview]	Change in Erythropoietin Levels From Baseline to Nadir (the Follow-up Time Point With the Lowest Value)
NCT00661726 (12) [back to overview]	Change in Absolute Reticulocyte Count From Baseline to Nadir (the Follow-up Time Point With the Lowest Value)
NCT00661726 (12) [back to overview]	Change in Absolute Fetal Hemoglobin (HbF) From Baseline to Peak (the Follow-up Time Point With the Highest Value)
NCT00661726 (12) [back to overview]	Change in Indirect Bilirubin From Baseline to Nadir (the Follow-up Time Point With the Lowest Value)
NCT00661726 (12) [back to overview]	Change in Neutrophil Counts From Baseline to Nadir (the Follow-up Time Point With the Lowest Value)
NCT00661726 (12) [back to overview]	Change in Percentage of Annexin-positive Cells From Baseline to Nadir (the Follow-up Time Point With the Lowest Value)
NCT00661726 (12) [back to overview]	Change in Total Hemoglobin (Hb) From Baseline to Peak (the Follow-up Time Point With the Highest Value)
NCT00661726 (12) [back to overview]	Change in Percentage of Red Blood Cell (RBC) Hb Concentration From Baseline to Peak (the Follow-up Time Point With the Highest Value)
NCT00661726 (12) [back to overview]	Change in Serum Lactate Dehydrogenase (LDH) From Baseline to Nadir (the Follow-up Time Point With the Lowest Value)
NCT00661726 (12) [back to overview]	Change in Red Blood Cell (RBC) Deformability From Baseline to Peak (the Follow-up Time Point With the Highest Value)
NCT00661726 (12) [back to overview]	Number of Evaluable Patients With an Increase From Baseline in Hemoglobin (Hb) of ≥1.5 g/dL
NCT00721214 (8) [back to overview]	Two-year Event-free Survival From Time of Treatment Initiation With 5-Azacytidine for All Study Cohorts
NCT00721214 (8) [back to overview]	One Year Event Free Survival (EFS) for Allogeneic Transplant Recipients After Transplantation
NCT00721214 (8) [back to overview]	One-year Event-free Survival From Time of Treatment Initiation With 5-Azacytidine for All Study Cohorts
NCT00721214 (8) [back to overview]	One-year Overall Survival From Time of Treatment Initiation With 5-Azacytidine for All Study Cohorts
NCT00721214 (8) [back to overview]	One Year Overall Survival of Allogeneic Transplant Recipients After Transplantation
NCT00721214 (8) [back to overview]	Two Year Overall Survival of Allogeneic Transplant Recipients After Transplantation
NCT00721214 (8) [back to overview]	Two Year Event Free Survival (EFS) for Allogeneic Transplant Recipients After Transplantation
NCT00721214 (8) [back to overview]	Two-year Overall Survival From Time of Treatment Initiation With 5-Azacytidine for All Study Cohorts.
NCT00748553 (3) [back to overview]	Phase I: Percentage of Participants Responding to Treatment
NCT00748553 (3) [back to overview]	Phase II: Percentage of Participants With Objective Response Rate (ORR) Measured Using RECIST 1.0 Criteria
NCT00748553 (3) [back to overview]	Number of Participants With ER+ Status
NCT00766116 (2) [back to overview]	Number of Participants With Response to the Combination Treatment of Mylotarg With 5-azacitidine
NCT00766116 (2) [back to overview]	Number of Participants With Dose Limiting Toxicities
NCT00813124 (1) [back to overview]	Number of Participants With Molecular Response
NCT00887068 (2) [back to overview]	Overall Survival (OS)
NCT00887068 (2) [back to overview]	Relapse-free Survival (RFS)
NCT00890929 (9) [back to overview]	Remission Duration
NCT00890929 (9) [back to overview]	Time to PR
NCT00890929 (9) [back to overview]	Overall Survival (OS)
NCT00890929 (9) [back to overview]	4-week Survival Rate
NCT00890929 (9) [back to overview]	Overall Response Rate (ORR)
NCT00890929 (9) [back to overview]	OS of Responders
NCT00890929 (9) [back to overview]	Time to CR
NCT00890929 (9) [back to overview]	Maximum Tolerated Dose (MTD) of Lenalidomide
NCT00890929 (9) [back to overview]	Compete Remission (CR) Rate
NCT00895934 (4) [back to overview]	Number of Participants With Complete Remission
NCT00895934 (4) [back to overview]	Number of Participants With Dose-limiting Toxicity (Phase I)
NCT00895934 (4) [back to overview]	Disease Relapse
NCT00895934 (4) [back to overview]	Number of Participants With Dose-limiting Toxicity After the Vorinostat Dose
NCT00934440 (2) [back to overview]	Time to Progression
NCT00934440 (2) [back to overview]	Toxicities by Dose Level
NCT00946647 (10) [back to overview]	Clinical Response Other Than Composite Clinical Response for Myeloid Dysplastic Syndromes(MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Per Investigator (Phase Llb)
NCT00946647 (10) [back to overview]	Number of Participants With Dose Limiting Toxicity (DLT) (Phase lb)
NCT00946647 (10) [back to overview]	Time to Progression (TTP) (Phase Llb)
NCT00946647 (10) [back to overview]	Clinical Response Other Than Composite Clinical Response for Acute Myelogenous Leukemia (AML) Patients Per Investigator (Phase Llb)
NCT00946647 (10) [back to overview]	Hematologic Improvement (HI) for Myeloid Dysplastic Syndromes(MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Per Investigator (Phase Llb)
NCT00946647 (10) [back to overview]	1-year Survival Rate (Phase Llb)
NCT00946647 (10) [back to overview]	Overall Response Rate (ORR) Assessed by Best Overall Response: Participants With AML Per Investigator (Phase Llb)
NCT00946647 (10) [back to overview]	Overall Response Rate (ORR) Assessed by Best Overall Response: Participants With MDS/CMML Per Investigator (Phase Llb)
NCT00946647 (10) [back to overview]	Number of Dose Limiting Toxicity (DLT) (Phase lb)
NCT00946647 (10) [back to overview]	Composite Complete Response (Phase Llb)
NCT00948064 (3) [back to overview]	Response Rate
NCT00948064 (3) [back to overview]	Survival at Day 60
NCT00948064 (3) [back to overview]	Survival at Day 60
NCT00997243 (3) [back to overview]	Complete Response Rate
NCT00997243 (3) [back to overview]	Overall Response Rate
NCT00997243 (3) [back to overview]	Toxicities of the Combination
NCT01004991 (1) [back to overview]	Complete Response
NCT01011283 (2) [back to overview]	Overall Response Rate (ORR), Defined as Proportion of Patients Having Complete Response (CR) and Marrow Complete Response (mCR) After Completion of 3 Cycles of Study Drug.
NCT01011283 (2) [back to overview]	Overall Response Rate (ORR), Defined as Proportion of Patients Having Complete Response (CR) and Marrow Complete Response (mCR) After Completion of 6 Cycles of Study Drug.
NCT01016600 (15) [back to overview]	Partial Remission Rate (PR)
NCT01016600 (15) [back to overview]	Toxicity Profile (Grade 3/4 Toxicities)
NCT01016600 (15) [back to overview]	Duration of CR for Complete Responders
NCT01016600 (15) [back to overview]	Overall Survival
NCT01016600 (15) [back to overview]	Morphologic Leukemia-free State
NCT01016600 (15) [back to overview]	Morphologic Complete Remission Rate (CRm)
NCT01016600 (15) [back to overview]	Event Free Survival
NCT01016600 (15) [back to overview]	Cytogenetic CR (CRc) Rate
NCT01016600 (15) [back to overview]	CR With Incomplete Blood Counts Rate
NCT01016600 (15) [back to overview]	Response Rate (CRm + CRc + CRi + PR)
NCT01016600 (15) [back to overview]	Time to Progression (TTP)
NCT01016600 (15) [back to overview]	Relapse Free Survival (RFS)
NCT01016600 (15) [back to overview]	Phase II Only - Complete Remission Rate (CRm + CRi) in Participants With Untreated AML ≥60 Years of Age
NCT01016600 (15) [back to overview]	Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs)
NCT01016600 (15) [back to overview]	Phase I Only - Maximum Tolerated Dose (MTD)
NCT01038635 (3) [back to overview]	Overall Response Rate (ORR) of Lenalidomide in Combination With 5-azacytidine (5-AZA) in Participants With Leukemia
NCT01038635 (3) [back to overview]	Number of Dose Limiting Toxicities for Determining Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With 5-azacytidine (5-AZA)
NCT01038635 (3) [back to overview]	Overall Response: Number of Participants With CR or CRi Response
NCT01050790 (6) [back to overview]	Toxicity as Assessed by NCI CTCAE v3.0
NCT01050790 (6) [back to overview]	Progression-free and Overall Survival
NCT01050790 (6) [back to overview]	Feasibility to Mobilize and Infuse Autologous Lymphocytes (ALI) After Immunomodulatory Therapy and After Stem Cell Transplant Engraftment
NCT01050790 (6) [back to overview]	Time to Progression Post Transplant
NCT01050790 (6) [back to overview]	Complete Response Rate at 6 Months
NCT01050790 (6) [back to overview]	CTA Expression Before and After Azacitidine Therapy
NCT01074047 (33) [back to overview]	Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain
NCT01074047 (33) [back to overview]	Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain
NCT01074047 (33) [back to overview]	Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain
NCT01074047 (33) [back to overview]	Healthcare Resource Utilization (HRU): Number of Inpatient Hospitalizations
NCT01074047 (33) [back to overview]	Healthcare Resource Utilization (HRU): Rate of Inpatient Hospitalizations Per Year
NCT01074047 (33) [back to overview]	HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea
NCT01074047 (33) [back to overview]	HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea
NCT01074047 (33) [back to overview]	HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea
NCT01074047 (33) [back to overview]	HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea
NCT01074047 (33) [back to overview]	HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain
NCT01074047 (33) [back to overview]	HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain
NCT01074047 (33) [back to overview]	HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain
NCT01074047 (33) [back to overview]	HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain
NCT01074047 (33) [back to overview]	HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain
NCT01074047 (33) [back to overview]	HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea
NCT01074047 (33) [back to overview]	HRU: Number of Participants Receiving Transfusions
NCT01074047 (33) [back to overview]	HRU: Rate of Transfusions Per Patient Year
NCT01074047 (33) [back to overview]	Kaplan-Meier Estimates for Overall Survival
NCT01074047 (33) [back to overview]	HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain
NCT01074047 (33) [back to overview]	Number of Participants Who Achieved a Cytogenetic Complete Response (CRc-10) as Determined by the IRC.
NCT01074047 (33) [back to overview]	HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain
NCT01074047 (33) [back to overview]	HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain
NCT01074047 (33) [back to overview]	HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain
NCT01074047 (33) [back to overview]	HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain
NCT01074047 (33) [back to overview]	Duration of Remission Assessed by the IRC Based on Kaplan-Meier Estimates
NCT01074047 (33) [back to overview]	Event-free Survival (EFS)
NCT01074047 (33) [back to overview]	Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain
NCT01074047 (33) [back to overview]	Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain
NCT01074047 (33) [back to overview]	One-year Overall Survival Rate
NCT01074047 (33) [back to overview]	Percentage of Participants Who Achieved a Morphologic CR + CRi as Determined by the Independent Review Committee (IRC) Based on International Working Group (IWG) Response Criteria for Acute Myeloid Leukemia (AML)
NCT01074047 (33) [back to overview]	Relapse-Free Survival (RFS) for Participants Who Achieved a Complete Remission (CR) or Complete Remission With Incomplete Blood Count Recovery (CRi)
NCT01074047 (33) [back to overview]	Number of Participants in the Extension Phase With Treatment Emergent Adverse Events (TEAEs)
NCT01074047 (33) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT01083706 (3) [back to overview]	Overall Survival
NCT01083706 (3) [back to overview]	Incidence of Grades II-IV Graft-versus-host Disease (GVHD)
NCT01083706 (3) [back to overview]	Rate of Response by IWG Criteria
NCT01093573 (5) [back to overview]	Toxicity Profile (Phase II)
NCT01093573 (5) [back to overview]	Duration of Response
NCT01093573 (5) [back to overview]	Maximum Tolerated Dose of Midostaurin in Combination With Azacitidine in Patients With Acute Myelogenous Leukemia (Phase I)
NCT01093573 (5) [back to overview]	Number of Participants With Hematologic Improvement (Phase I)
NCT01093573 (5) [back to overview]	Overall Survival (Phase II)
NCT01105377 (2) [back to overview]	Time to Progression
NCT01105377 (2) [back to overview]	Confirmed Tumor Response
NCT01120834 (1) [back to overview]	Overall Response Rate (ORR)
NCT01121757 (4) [back to overview]	Overall Response
NCT01121757 (4) [back to overview]	Response Predicted by Molecular Signatures Compared to True Response
NCT01121757 (4) [back to overview]	Number of Participants With Grade 3 and 4 Toxicities
NCT01121757 (4) [back to overview]	Overall Response
NCT01155583 (5) [back to overview]	Percent of Participants With Clinical Benefit and Response According to International Response Criteria
NCT01155583 (5) [back to overview]	Phase I: Highest Tolerated Low Dose (HTLD)
NCT01155583 (5) [back to overview]	Overall Survival
NCT01155583 (5) [back to overview]	Median Progression-free Survival (PFS)
NCT01155583 (5) [back to overview]	Percent of Participants With Clinical Benefit and Response According to International Response Criteria
NCT01165996 (7) [back to overview]	Proportion of Patients With Bone Marrow Evidence of Terminal Differentiation Response to Therapy.
NCT01165996 (7) [back to overview]	Number of Patients That Experience > Grade 2 Non-hematologic Toxicity by National Cancer Institute (NCI)/Cancer Therapy Evaluation Program (CTEP) v4 Criteria
NCT01165996 (7) [back to overview]	Proportion of Patients With Pharmacodynamic Evidence of Drug Effect.
NCT01165996 (7) [back to overview]	Proportion of Patients With Bone Marrow Evidence of Cytotoxicity.
NCT01165996 (7) [back to overview]	Number of Patients With Response as Defined by IWG (International Working Group) Criteria for Myelodysplasia
NCT01165996 (7) [back to overview]	Cytogenetic Response as Per IWG Criteria
NCT01165996 (7) [back to overview]	Proportion of Patients With Particular Genetic Abnormalities Detected by Whole Exome Sequencing Correlation With Clinical Response
NCT01168219 (3) [back to overview]	Overall Survival (OS)
NCT01168219 (3) [back to overview]	100-day Mortality
NCT01168219 (3) [back to overview]	Progression-free Survival
NCT01186939 (1) [back to overview]	Number of Participants in Different Categories of Treatment Emergent Adverse Events for the Extension Period
NCT01193517 (2) [back to overview]	Maximum Tolerated Dose (MTD) of Azacitidine, and Capecitabine and Oxaliplatin (CAPOX)
NCT01193517 (2) [back to overview]	Response Rate of Azacitidine, and Capecitabine and Oxaliplatin (CAPOX)
NCT01201811 (17) [back to overview]	Apparent Volume of Distribution (Vd/F) of Azacitidine
NCT01201811 (17) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Azacitidine
NCT01201811 (17) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Azacitidine
NCT01201811 (17) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Azacitidine
NCT01201811 (17) [back to overview]	Terminal Phase of Half-life (T1/2) of Azacitidine
NCT01201811 (17) [back to overview]	Time to Maximum Plasma Concentration (Tmax) of Azacitidine
NCT01201811 (17) [back to overview]	Number of Infections (Post-baseline Average) Requiring Intravenous Antibiotics, Anti-fungals, or Antivirals Per 28 Days
NCT01201811 (17) [back to overview]	Number of Participants With Adverse Events (AE)
NCT01201811 (17) [back to overview]	Number of Platelet Transfusions by Cycle
NCT01201811 (17) [back to overview]	Number of Red Blood Cell (RBC) Transfusions by Cycle
NCT01201811 (17) [back to overview]	Participants' Platelet Transfusion Status for Participants Who Were Transfusion Dependent at Baseline
NCT01201811 (17) [back to overview]	Participants' Platelet Transfusion Status for Participants Who Were Transfusion Independent at Baseline
NCT01201811 (17) [back to overview]	Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Dependent at Baseline
NCT01201811 (17) [back to overview]	Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Independent at Baseline
NCT01201811 (17) [back to overview]	Percentage of Participants Showing Hematologic Improvement Using International Working Group (IWG Criteria for Hematologic Improvement Cheson 2000) Criteria for Myelodysplastic Syndrome (MDS) and Assessed by Sponsor
NCT01201811 (17) [back to overview]	Percentage of Participants With a Hematologic Response Using International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS) and Assessed by Investigator
NCT01201811 (17) [back to overview]	Apparent Total Plasma Clearance (CL/F) of Azacitidine
NCT01202877 (2) [back to overview]	Overall Response (OR) Within 6 Months
NCT01202877 (2) [back to overview]	Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1
NCT01241786 (4) [back to overview]	the Rate of Response to the Combination of Azacitidine + Lenalidomide in Select Patients
NCT01241786 (4) [back to overview]	The Progression Free Survival of Patients Treated With the Combination of Lenalidomide and Azacitidine
NCT01241786 (4) [back to overview]	The Overall Survival of Patients Treated With the Combination of Lenalidomide and Azacitidine
NCT01241786 (4) [back to overview]	Assess for Treatment Related Toxicity Following Administration of Lenalidomide/ Azacitidine.
NCT01254890 (2) [back to overview]	Phase II: Number of Participants With Response
NCT01254890 (2) [back to overview]	Phase I: Maximum Tolerated Dose (MTD) of Sorafenib Given With Azacitidine
NCT01349959 (8) [back to overview]	Progression-free Survival (PFS)
NCT01349959 (8) [back to overview]	Confirmed Response Rate (Percentage of Participants With Complete or Partial Response Noted as the Objective Status on Two Consecutive Evaluations at Least 4 Weeks Apart) Assessed by RECIST
NCT01349959 (8) [back to overview]	Number of Participants With Change in Gene Methylation Evaluated Using Quantitative Multiple Methylation-specific Polymerase Chain Reaction (QM-MSP)
NCT01349959 (8) [back to overview]	Confirmed Response Rate to Azacitidine and Entinostat Plus the Addition of Hormone Therapy
NCT01349959 (8) [back to overview]	Clinical Benefit Rate
NCT01349959 (8) [back to overview]	Feasibility of the Addition of Hormone Therapy, Evaluated by Calculating the Number of Patients With Disease Progression That go on to Receive Hormonal Therapy
NCT01349959 (8) [back to overview]	Number of Participants With Change in Expression of Relevant Genes (e.g., ER Alpha and RAR Beta) Evaluated by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
NCT01349959 (8) [back to overview]	Overall Survival
NCT01350947 (1) [back to overview]	Percentage of Patients With Complete Hematologic Response (According to IWG 2006 Criteria) in CMML Patients Treated With 5-azacitidine.
NCT01358734 (6) [back to overview]	Kaplan Meier Estimates for One Year Survival
NCT01358734 (6) [back to overview]	Number of Participants With a Second Primary Malignancy
NCT01358734 (6) [back to overview]	Overall Survival
NCT01358734 (6) [back to overview]	Percentage of Participants Alive at One Year
NCT01358734 (6) [back to overview]	Percentage of Participants With 30-Day Treatment-Related Mortality
NCT01358734 (6) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAE)
NCT01442714 (3) [back to overview]	Median Duration of Response
NCT01442714 (3) [back to overview]	Overall Response Rate (ORR)
NCT01442714 (3) [back to overview]	Overall Survival
NCT01453140 (1) [back to overview]	Response Rate of Patients With Steroid-refractory Graft-versus-host Disease (GVHD) Using Cyclophospahmide and Sirolimus Combined With 3 Variations of Low-dose IL 2 and Low-dose Vidaza.
NCT01522976 (5) [back to overview]	Overall Survival
NCT01522976 (5) [back to overview]	Relapse-free Survival
NCT01522976 (5) [back to overview]	Pre-study Cytogenetic Abnormalities
NCT01522976 (5) [back to overview]	Toxicity Rate
NCT01522976 (5) [back to overview]	Response Rate (Phase II)
NCT01542684 (1) [back to overview]	Overall Response Rate (ORR)
NCT01566695 (49) [back to overview]	Mean Change From Baseline in the Physical Well-Being Component of the Functional Assessment of Cancer Therapy-Anemia (FACT-An) Endpoints at Cycle 6
NCT01566695 (49) [back to overview]	Mean Change From Baseline in the Functional Well-Being Component of the FACT-An Instrument at Cycle 6
NCT01566695 (49) [back to overview]	Mean Change From Baseline in the Functional Assessment of Cancer Therapy-Anemia-Total Score at Cycle 6
NCT01566695 (49) [back to overview]	Mean Change From Baseline in the Functional Assessment of Cancer Therapy-Anemia-General (FACT-G) Summary Scale Within the FACT-An Instrument at Cycle 6
NCT01566695 (49) [back to overview]	Mean Change From Baseline in the Functional Assessment of Cancer Therapy-Anemia Trial Outcome Index (FACT-An TOI) Summary Scale Within the FACT-An Instrument at Cycle 6
NCT01566695 (49) [back to overview]	Mean Change From Baseline in the Fatigue-Related Subscale Within the FACT-An Instrument at Cycle 6
NCT01566695 (49) [back to overview]	Mean Change From Baseline in the Emotional Well-Being Component of the Functional Assessment of Cancer Therapy-Anemia Instrument at Cycle 6
NCT01566695 (49) [back to overview]	Mean Change From Baseline in the Anemia Subscale Within FACT-An Instrument at Cycle 6
NCT01566695 (49) [back to overview]	Healthcare Resource Utilization (HRU): Total Number of Days Hospitalized Due to Any Reason During the Treatment Period
NCT01566695 (49) [back to overview]	Duration of RBC Transfusion Reduction for Participants Who Achieved RBC Transfusion Reduction of at Least 4 Units of RBCs for at Least 8 Weeks
NCT01566695 (49) [back to overview]	Duration of RBC Transfusion Independence Among Participants Who Achieved RBC Transfusion Independence for at Least 84 Days
NCT01566695 (49) [back to overview]	Duration of RBC Transfusion Independence Among Participants Who Achieved RBC Transfusion Independence for at Least 56 Days
NCT01566695 (49) [back to overview]	Percentage of Participants With Change From Baseline in Responses to the Fact-Anemia Item GP-5
NCT01566695 (49) [back to overview]	Time to RBC Transfusion Independence for at Least 56 Days Among Participants Who Achieved RBC Transfusion Independence for at Least 56 Days
NCT01566695 (49) [back to overview]	Time to RBC Transfusion Independence for at Least 84 Days Among Participants Who Achieved RBC Transfusion Independence for at Least 84 Days
NCT01566695 (49) [back to overview]	Healthcare Resource Utilization (HRU): Number of Participants Who Were Hospitalized During the Treatment Period
NCT01566695 (49) [back to overview]	Percentage of Participants With Change From Baseline in Responses to the Fact-Anemia Item GP-5
NCT01566695 (49) [back to overview]	Percentage of Participants With Improved, Worsened, or No Change in the European Quality of Life-Five Dimension-Three Level Usual Activities Dimension Responses at Cycle 6
NCT01566695 (49) [back to overview]	Percentage of Participants With Change From Baseline in Responses to the Fact-Anemia Item GP-5
NCT01566695 (49) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAE)
NCT01566695 (49) [back to overview]	Percentage of Participants With a Clinically Meaningful Improvment (CMI) From Baseline on the Physical Well-Being Domain Within the FACT-An Instrument at Cycle 6
NCT01566695 (49) [back to overview]	Percentage of Participants With a Clinically Meaningful Improvment (CMI) From Baseline on the Functional Well-Being Domain Within the FACT-An Instrument at Cycle 6
NCT01566695 (49) [back to overview]	Percentage of Participants With a Clinically Meaningful Improvment (CMI) From Baseline on the Emotional Well-Being Domain Within the FACT-An Instrument at Cycle 6
NCT01566695 (49) [back to overview]	Percentage of Participants With a Clinically Meaningful Improvment (CMI) From Baseline on the Anemia Subscale Domain Within the FACT-An Instrument at Cycle 6
NCT01566695 (49) [back to overview]	Percentage of Participants With a Clinically Meaningful Improvment (CMI) From Baseline in the Functional Assessment of Cancer Therapy-Anemia-General Subscale Domain Within the FACT-An Instrument at Cycle 6
NCT01566695 (49) [back to overview]	Mean Change From Baseline in the Social Well-Being Component of the Functional Assessment of Cancer Therapy-Anemia Instrument at Cycle 6
NCT01566695 (49) [back to overview]	Percentage of Participants With a Hematological Improvement Response in Platelets (HI-P) According to 2006 IWG Criteria
NCT01566695 (49) [back to overview]	Percentage of Participants With Significant Bleeding Events
NCT01566695 (49) [back to overview]	Percentage of Participants With a Clinically Meaningful Improvment (CMI) From Baseline in the Functional Assessment of Cancer Therapy-Anemia Trial Outcome Index Subscale Domain Within the FACT-An Instrument at Cycle 6
NCT01566695 (49) [back to overview]	Time to Platelet Transfusion Independence
NCT01566695 (49) [back to overview]	Time to Progression to Acute Myeloid Leukemia (AML) Among Participants Who Progressed to AML
NCT01566695 (49) [back to overview]	Percentage of Participants With a Clinically Meaningful Improvment (CMI) From Baseline in the Fatigue Related Symptoms Subscale Domain Within the FACT-An Instrument at Cycle 6
NCT01566695 (49) [back to overview]	Percentage of Participants With a Clinically Meaningful Improvement (CMI) From Baseline in the Functional Assessment of Cancer Therapy Anemia-Total Score Domain Within the FACT-An Instrument at Cycle 6
NCT01566695 (49) [back to overview]	Percentage of Participants Who Achieved Platelet Transfusion Independence With a Duration of ≥ 8 Weeks (56 Days)
NCT01566695 (49) [back to overview]	Percentage of Participants Who Progressed to Acute Myeloid Leukemia (AML)
NCT01566695 (49) [back to overview]	Percentage of Participants Who Achieved Red Blood Cell Transfusion Independence for ≥ 84 Days
NCT01566695 (49) [back to overview]	Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days
NCT01566695 (49) [back to overview]	Percentage of Participants With Improved, Worsened, or No Change in the European Quality of Life-Five Dimension-Three Level of Self-Care Dimension Responses at Cycle 6
NCT01566695 (49) [back to overview]	Percentage of Participants With a Clinically Meaningful Improvment (CMI) From Baseline on the Social Well-Being Domain Within the FACT-An Instrument at Cycle 6
NCT01566695 (49) [back to overview]	Percentage of Participants With a Hematologic Response According to the 2006 IWG Criteria for MDS
NCT01566695 (49) [back to overview]	Percentage of Participants With an Erythroid Hematological Improvement (HI-E) Response According to 2006 IWG Criteria
NCT01566695 (49) [back to overview]	Percentage of Participants With Change From Baseline in Responses to the Fact-Anemia Item GP-5
NCT01566695 (49) [back to overview]	Percentage of Participants With Change From Baseline in Responses to the Fact-Anemia Item GP-5
NCT01566695 (49) [back to overview]	Percentage of Participants With Change From Baseline in Responses to the Fact-Anemia Item GP-5
NCT01566695 (49) [back to overview]	Percentage of Participants With Improved, Worsened, or No Change in the European Quality of Life-Five Dimension-Three Level in the Pain/Discomfort Dimension Responses at Cycle 6
NCT01566695 (49) [back to overview]	Healthcare Resource Utilization (HRU): Total Number of Days Hospitalized Per Total Patient-Years
NCT01566695 (49) [back to overview]	Percentage of Participants With Improved, Worsened, or No Change in the European Quality of Life-Five Dimension-Three Level in the Anxiety/Depression Dimension Responses at Cycle 6
NCT01566695 (49) [back to overview]	Percentage of Participants With Improved, Worsened, or No Change in the European Quality of Life-Five Dimension-Three Level (EQ-5D-3L) Mobility Dimension Responses at Cycle 6
NCT01566695 (49) [back to overview]	Percentage of Participants With Change From Baseline in Responses to the Fact-Anemia Item GP-5
NCT01599325 (18) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Azacitidine
NCT01599325 (18) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Azacitidine
NCT01599325 (18) [back to overview]	Apparent Volume of Distribution (Vd/F) of Azacitidine
NCT01599325 (18) [back to overview]	Apparent Total Plasma Clearance (CL/F) of Azacitidine
NCT01599325 (18) [back to overview]	The Number of Units of Red Blood Cell (RBC) Transfusions by Cycle
NCT01599325 (18) [back to overview]	The Number of Platelet Transfusions by Cycle
NCT01599325 (18) [back to overview]	The Number of Units of Platelet Transfusions by Cycle
NCT01599325 (18) [back to overview]	The Number of RBC Transfusions by Cycle
NCT01599325 (18) [back to overview]	The Number of Infections (Post-baseline Average) Requiring Intravenous (IV) Antibiotics, Anti-fungals, or Antivirals by Cycle
NCT01599325 (18) [back to overview]	Percentage of Participants With a Hematologic Response Using IWG Criteria for MDS and Assessed by the Investigator
NCT01599325 (18) [back to overview]	Percentage of Participants With a Hematologic Response Based on the International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS) and Programmatically Assessed by the Sponsor Using Clinically Relevant Data.
NCT01599325 (18) [back to overview]	Percentage of Participants Achieving a Hematologic Improvement (HI) Based on 2000 IWG Response Criteria for MDS and Programmatically Assessed by the Sponsor Using Clinically Relevant Data.
NCT01599325 (18) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Parent Phase
NCT01599325 (18) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Extension Phase
NCT01599325 (18) [back to overview]	Kaplan Meier Estimates for Overall Survival (OS)
NCT01599325 (18) [back to overview]	Time to Maximum Plasma Concentration (Tmax) of Azacitidine
NCT01599325 (18) [back to overview]	Terminal Phase of Half-life (T1/2) of Azacitidine
NCT01599325 (18) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Azacitidine
NCT01607645 (13) [back to overview]	Duration of Thrombocytopenia Defined as Platelet Count Less Than 100,000
NCT01607645 (13) [back to overview]	Resistant Disease Defined as Patient Survives at Least 14 Days After Completion of the Last Dose of Induction or Re-induction But Has Persistent Leukemia in Peripheral Blood (PB) or BM
NCT01607645 (13) [back to overview]	TRM With Each Course of Decitabine-priming, Idarubicin, and Cytarabine
NCT01607645 (13) [back to overview]	Frequency and Severity of Grade 3, 4, and 5 Toxicities With Each Course of Decitabine-priming, Idarubicin, and Cytarabine According to NCI Common Terminology Criteria for Adverse Events Version (CTCAE) 4.0
NCT01607645 (13) [back to overview]	Number of Participants Who Achieved Morphologic CR
NCT01607645 (13) [back to overview]	Severe Prolonged Aplasia
NCT01607645 (13) [back to overview]	CRMRD- Defined as Morphologic CR Without Evidence of Minimal Residual Disease by Flow Cytometry, Cytogenetics, or Other Known Molecular Biomarkers
NCT01607645 (13) [back to overview]	Duration of Moderate Neutropenia Defined as an ANC Less Than 1000
NCT01607645 (13) [back to overview]	Cytogenetic Response Defined as no Detectable Cytogenetic Abnormality in a Subsequent BM Specimen After Induction or Re-induction
NCT01607645 (13) [back to overview]	Duration of Severe Neutropenia Defined as an ANC Less Than 500
NCT01607645 (13) [back to overview]	CRi Defined as Meeting All Criteria for a Morphologic CR But ANC Remains Less Than 1,000/μL and/or Platelet Count Less Than 100,000/μL
NCT01607645 (13) [back to overview]	CRMRD+ Defined as a Morphologic CR But With Minimal Residual Disease by Flow Cytometry, Cytogenetics, or Other Known Molecular Biomarkers
NCT01607645 (13) [back to overview]	CRiMRD+ Defined as Meeting All Criteria for a CRi But With Evidence of Minimal Residual Disease by Flow Cytometry, Cytogenetics, or Other Known Molecular Biomarkers
NCT01700673 (4) [back to overview]	Two-year Relapse Free Survival of Patients
NCT01700673 (4) [back to overview]	Overall Survival
NCT01700673 (4) [back to overview]	One-year RFS
NCT01700673 (4) [back to overview]	Hematologic Toxicity as Determined by Anemia
NCT01707004 (8) [back to overview]	Cumulative Incidence of Grade III-IV Acute GVHD
NCT01707004 (8) [back to overview]	Progression Free Survival
NCT01707004 (8) [back to overview]	Time to Neutrophil Recovery
NCT01707004 (8) [back to overview]	Percentage of Participants With Platelet Recovery by Day 30
NCT01707004 (8) [back to overview]	Number of Participants With Primary Graft Failure
NCT01707004 (8) [back to overview]	Number of Participants With Complete Remission After Transplantation
NCT01707004 (8) [back to overview]	Cumulative Incidence of Chronic GVHD According to BMTCTN
NCT01707004 (8) [back to overview]	Overall Survival (OS)
NCT01720225 (2) [back to overview]	Number of Participants Who Became Transfusion Independent
NCT01720225 (2) [back to overview]	Participants With a Response
NCT01743859 (7) [back to overview]	Progression-free Survival
NCT01743859 (7) [back to overview]	Determine Biomarkers That Predict Response/Toxicity
NCT01743859 (7) [back to overview]	Overall Response Rate
NCT01743859 (7) [back to overview]	Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts
NCT01743859 (7) [back to overview]	Response or Remission Duration
NCT01743859 (7) [back to overview]	Toxicity and SAEs Related to Treatment
NCT01743859 (7) [back to overview]	Overall Survival
NCT01747499 (7) [back to overview]	Overall Survival as Measured by Number of Participants Alive at 1 Year After Transplant
NCT01747499 (7) [back to overview]	Rate of Chronic GvHD
NCT01747499 (7) [back to overview]	Phase II: Number of Participants With Grades II-IV Acute GvHD
NCT01747499 (7) [back to overview]	Number of Participants Who Relapsed Within the First Year of Transplant
NCT01747499 (7) [back to overview]	Phase I: to Determine the Maximum Tolerated Dose (MTD) of Azacitidine in Patients Undergoing Matched (8 Out of 8) Unrelated Donor Transplant for Any Hematological Malignancy in Remission or With Stable Disease.
NCT01747499 (7) [back to overview]	Treatment-related Mortality
NCT01747499 (7) [back to overview]	Rate of Grades III-IV aGVHD at Day +180.
NCT01748240 (1) [back to overview]	Response Rate
NCT01757535 (13) [back to overview]	Time to Definitive Clinically Meaningful Deterioration for ≥ 2 Consecutive Visits as Measured Using the EQ-5D HRQoL Scale
NCT01757535 (13) [back to overview]	Kaplan-Meier Estimates of Time to Discontinuation From Treatment
NCT01757535 (13) [back to overview]	Kaplan-Meier Estimate of Time to Relapse
NCT01757535 (13) [back to overview]	Kaplan-Meier Estimate of Relapse Free Survival (RFS)
NCT01757535 (13) [back to overview]	Time to Definitive Clinically Meaningful Deterioration for ≥ 2 Consecutive Visits as Measured Using the Functional Assessment of Chronic Illness Therapy (FACIT-Fatigue Scale V 4.0)
NCT01757535 (13) [back to overview]	Mean Change in the Functional Assessment of Chronic Illness Therapy (FACIT-Fatigue Scale V 4.0) Score From Baseline
NCT01757535 (13) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT01757535 (13) [back to overview]	Healthcare Resource Utilization (HRU): Number of Days Hospitalized Per Person-Year
NCT01757535 (13) [back to overview]	Healthcare Resource Utilization (HRU): Rate of Hospital Events Per Person Year
NCT01757535 (13) [back to overview]	Kaplan-Meier (K-M) Estimate for Overall Survival (OS)
NCT01757535 (13) [back to overview]	Mean Change in the European Quality of Life-Five Dimensions-Three Levels (EQ-5D-3L) Score From Baseline
NCT01757535 (13) [back to overview]	Percentage of Participants Experiencing a Clinically Meaningful Change (Improvement, No Change and Deterioration) in the FACIT-Fatigue Scale From Baseline
NCT01757535 (13) [back to overview]	Percentage of Participants Experiencing a Clinically Meaningful Change (Improvement, No Change and Deterioration) in the EQ-5D-3L Scale From Baseline
NCT01814826 (29) [back to overview]	MTD Expansion Phase, Rac: Observed Accumulation Ratio for MLN4924
NCT01814826 (29) [back to overview]	Dose-escalation Phase, Lambdaz: Terminal Disposition Phase Rate Constant for MLN4924
NCT01814826 (29) [back to overview]	Dose-escalation Phase, Cmax: Maximum Observed Plasma Concentration for MLN4924
NCT01814826 (29) [back to overview]	Dose-escalation Phase, CLp: Systemic Clearance for MLN4924
NCT01814826 (29) [back to overview]	Dose-escalation Phase, AUCinf: Area Under the Plasma Concentration-time Curve Extrapolated to Infinity for MLN4924
NCT01814826 (29) [back to overview]	Dose-escalation Phase, AUC24hours: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours Post-Dose for MLN4924
NCT01814826 (29) [back to overview]	Dose-escalation Phase, AUC0-tau: Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (Tau) for MLN4924
NCT01814826 (29) [back to overview]	Best Overall Response Rate
NCT01814826 (29) [back to overview]	Dose-escalation Phase, Rac: Observed Accumulation Ratio for MLN4924
NCT01814826 (29) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
NCT01814826 (29) [back to overview]	Number of Participants With TEAEs Related to Clinically Significant Vital Sign Findings
NCT01814826 (29) [back to overview]	Number of Participants With TEAEs Related to Clinically Significant Laboratory Evaluation Findings
NCT01814826 (29) [back to overview]	MTD Expansion Phase, Vss: Volume of Distribution at Steady-state for MLN4924
NCT01814826 (29) [back to overview]	MTD Expansion Phase, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MLN4924
NCT01814826 (29) [back to overview]	MTD Expansion Phase, t1/2: Terminal Disposition Phase Half-life for MLN4924
NCT01814826 (29) [back to overview]	MTD Expansion Phase, Lambdaz: Terminal Disposition Phase Rate Constant for MLN4924
NCT01814826 (29) [back to overview]	Thirty-day Mortality Rate
NCT01814826 (29) [back to overview]	Overall Survival
NCT01814826 (29) [back to overview]	Dose-escalation Phase, Ctrough: Observed Plasma Concentration at the End of the Dosing Interval for MLN4924
NCT01814826 (29) [back to overview]	MTD Expansion Phase, Ctrough: Observed Plasma Concentration at the End of the Dosing Interval for MLN4924
NCT01814826 (29) [back to overview]	MTD Expansion Phase, CLp: Systemic Clearance for MLN4924
NCT01814826 (29) [back to overview]	MTD Expansion Phase, AUCinf: Area Under the Plasma Concentration-time Curve Extrapolated to Infinity for MLN4924
NCT01814826 (29) [back to overview]	MTD Expansion Phase, AUC24hours: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours Post-Dose for MLN4924
NCT01814826 (29) [back to overview]	MTD Expansion Phase, AUC0-tau: Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (Tau) for MLN4924
NCT01814826 (29) [back to overview]	Maximum Tolerated Dose (MTD) Expansion Phase, Cmax: Maximum Observed Plasma Concentration for MLN4924
NCT01814826 (29) [back to overview]	Duration of Response
NCT01814826 (29) [back to overview]	Dose-escalation Phase, Vss: Volume of Distribution at Steady-state for MLN4924
NCT01814826 (29) [back to overview]	Dose-escalation Phase, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MLN4924
NCT01814826 (29) [back to overview]	Dose-escalation Phase, t1/2: Terminal Disposition Phase Half-life for MLN4924
NCT01845805 (3) [back to overview]	Response Rate as Assessed by Number of Participants With Partial or Complete Response
NCT01845805 (3) [back to overview]	Progression-free Survival
NCT01845805 (3) [back to overview]	Overall Survival
NCT01846624 (5) [back to overview]	Overall Response Rate (ORR)
NCT01846624 (5) [back to overview]	Median Duration of Response (DoR)
NCT01846624 (5) [back to overview]	Overall Survival (OS)
NCT01846624 (5) [back to overview]	Progression-free Survival (PFS)
NCT01846624 (5) [back to overview]	Complete Remission (CR) Rate
NCT01861002 (1) [back to overview]	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)
NCT01896856 (4) [back to overview]	Number of Participants Experiencing a Dose Limiting Toxicity
NCT01896856 (4) [back to overview]	Objective Response Rate
NCT01896856 (4) [back to overview]	Overall Survival
NCT01896856 (4) [back to overview]	Progression Free Survival (PFS)
NCT01912274 (7) [back to overview]	Best Response Rate
NCT01912274 (7) [back to overview]	Overall Survival
NCT01912274 (7) [back to overview]	Overall Response Rate
NCT01912274 (7) [back to overview]	Duration of Response
NCT01912274 (7) [back to overview]	Complete Cytogenetic Response Plus Molecular Complete Remission
NCT01912274 (7) [back to overview]	Duration of Best Response
NCT01912274 (7) [back to overview]	Progression Free Survival
NCT01957644 (3) [back to overview]	Number of Participants With Dose Limiting Toxicities (DLT) in Cycle 1
NCT01957644 (3) [back to overview]	Percentage of Patients With Objective Response (OR)
NCT01957644 (3) [back to overview]	Determination of the Maximum Tolerated Dose (MTD) Based on the Occurrence of Dose-limiting Toxicity (DLT) in Cycle 1
NCT01983969 (2) [back to overview]	Frequency of DLT
NCT01983969 (2) [back to overview]	Participants With Event-free Survival (EFS)
NCT02029417 (1) [back to overview]	Frequency of Adverse Events, Graded According to NCI CTCAE v4.0
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, Cavg, and Ctrough of Azacitidine: Combination Cohort 3
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, Cavg, and Ctrough of Cytarabine: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, Cavg, and Ctrough of Daunorubicin: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, Cavg, and Ctrough of Daunorubicinol: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, Cavg, and Ctrough of PF-04449913: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, Cavg, and Ctrough of PF-04449913: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, Cavg, and Ctrough of PF-04449913: Combination Cohort 3
NCT02038777 (68) [back to overview]	Multiple Dose- T1/2 of Cytarabine: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of Ara-uridine: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of Azacitidine: Combination Cohort 3
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of Cytarabine: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of PF-04449913: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of PF-04449913: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of PF-04449913: Combination Cohort 3
NCT02038777 (68) [back to overview]	Number of Participants With Best Response: Combination Cohort 1
NCT02038777 (68) [back to overview]	Number of Participants With Best Response: Combination Cohort 2
NCT02038777 (68) [back to overview]	Number of Participants With Best Response: Combination Cohort 3
NCT02038777 (68) [back to overview]	Number of Participants With Best Response: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Number of Participants With TEAEs, Serious TEAEs, Treatment Related TEAEs, Grade 3 or 4 TEAEs Based on NCI CTCAE v4.0: Combination Cohort 1
NCT02038777 (68) [back to overview]	Number of Participants With TEAEs, Serious TEAEs, Treatment Related TEAEs, Grade 3 or 4 TEAEs Based on NCI CTCAE v4.0: Combination Cohort 3
NCT02038777 (68) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment Related TEAEs, Grade 3 or 4 TEAEs Based on NCI CTCAE v4.0: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Percentage of Participants With Complete Remission (CR) or CR With Incomplete Blood Count Recovery (CRi) and DMR: Combination Cohort 1
NCT02038777 (68) [back to overview]	Percentage of Participants With CR/CRi and DMR: Combination Cohort 3
NCT02038777 (68) [back to overview]	Single Dose- Area Under the Plasma Concentration Curve: From Time Zero to End of Dosing Interval (AUCtau), From Time Zero to Last Quantifiable Concentration (AUClast) and From Time Zero to Infinity (AUCinf) of PF-04449913 for Monotherapy Cohort
NCT02038777 (68) [back to overview]	Time to Complete Remission (CR) or CR With Incomplete Blood Count Recovery (CRi) and DMR Response: Combination Cohort 3
NCT02038777 (68) [back to overview]	Time to Response: Combination Cohort 1
NCT02038777 (68) [back to overview]	Number of Participants With Worst On-study Laboratory Abnormalities: Combination Cohort 1
NCT02038777 (68) [back to overview]	Number of Participants With Worst On-study Laboratory Abnormalities: Combination Cohort 2
NCT02038777 (68) [back to overview]	Number of Participants With Worst On-study Laboratory Abnormalities: Combination Cohort 3
NCT02038777 (68) [back to overview]	Number of Participants With Worst On-study Laboratory Abnormalities: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Single Dose- Clearance (CL/F) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Number of Participants With TEAEs, Serious TEAEs, Treatment Related TEAEs, Grade 3 or 4 TEAEs Based on NCI CTCAE v4.0: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- Accumulation Ratio (Rac) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Multiple Dose- AUCtau of Daunorubicinol: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- AUCtau of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Multiple Dose- Clearance (CL/F) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Multiple Dose- Steady State Accumulation Ratio (Rss) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Multiple Dose- T1/2 of Daunorubicin: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of Daunorubicin: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of Daunorubicinol: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Abnormalities: Combination Cohort 1
NCT02038777 (68) [back to overview]	Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Abnormalities: Combination Cohort 2
NCT02038777 (68) [back to overview]	Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Abnormalities: Combination Cohort 3
NCT02038777 (68) [back to overview]	Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Abnormalities: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Number of Participants With DLTs: Combination Cohort 1
NCT02038777 (68) [back to overview]	Number of Participants With DLTs: Combination Cohort 2
NCT02038777 (68) [back to overview]	Number of Participants With DLTs: Combination Cohort 3
NCT02038777 (68) [back to overview]	Number of Participants With Dose-limiting Toxicities (DLTs): Monotherapy Cohort
NCT02038777 (68) [back to overview]	Overall Survival: Combination Cohort 1
NCT02038777 (68) [back to overview]	Percentage of Participants Achieving Disease Modifying Response (DMR): Expansion Cohort
NCT02038777 (68) [back to overview]	Single Dose- Maximum Observed Plasma Concentration (Cmax) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Single Dose- Terminal Plasma Half-life (T1/2) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Single Dose- Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Single Dose- Volume of Distribution (Vz/F) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Duration of Complete Remission (CR) or CR With Incomplete Blood Count Recovery (CRi) and DMR Response: Combination Cohort 1
NCT02038777 (68) [back to overview]	Duration of Complete Remission (CR) or CR With Incomplete Blood Count Recovery (CRi) and DMR Response: Combination Cohort 3
NCT02038777 (68) [back to overview]	Multiple Dose Cmax, Minimum Observed Plasma Concentration (Cmin), Average Observed Plasma Concentration (Cavg), Trough Plasma Concentration (Ctrough) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Multiple Dose- AUCinf and AUCtau of Cytarabine: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- AUCinf and AUCtau of Daunorubicin: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- AUCtau and AUCinf of Azacitidine: Combination Cohort 3
NCT02038777 (68) [back to overview]	Multiple Dose- AUCtau of PF-04449913: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- AUCtau of PF-04449913: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- AUCtau of PF-04449913: Combination Cohort 3
NCT02038777 (68) [back to overview]	Multiple Dose- CL/F of PF-04449913: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- CL/F of PF-04449913: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- CL/F of PF-04449913: Combination Cohort 3
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, and Ctrough of Ara-uridine: Combination Cohort 1
NCT02085408 (4) [back to overview]	Overall Survival
NCT02085408 (4) [back to overview]	Overall Survival by Donor Status
NCT02085408 (4) [back to overview]	Proportion of Patients With Complete Remission
NCT02085408 (4) [back to overview]	Disease-free Survival for Maintenance
NCT02096055 (5) [back to overview]	Number of Participants With a Complete Response
NCT02096055 (5) [back to overview]	Leukemia-free Survival
NCT02096055 (5) [back to overview]	Remission Duration
NCT02096055 (5) [back to overview]	Survival
NCT02096055 (5) [back to overview]	Number of Participants With the Most Frequently Reports Grade 3 or 4 Adverse Event.
NCT02158936 (20) [back to overview]	Best Disease Response From Central Review (ITT)
NCT02158936 (20) [back to overview]	Summary of Progression Free Survival From Investigator Assessment (ITT)
NCT02158936 (20) [back to overview]	Bleeding Adverse Events (AEs) >= Grade 3
NCT02158936 (20) [back to overview]	Functional Assessment of Chronic Disease Therapy-fatigue Subscale (FACIT-Fatigue) (ITT)
NCT02158936 (20) [back to overview]	Hematologic Improvement (HI) in Platelets, Neutrophils, and Hemoglobin Based on the Modified IWG Criteria for MDS (ITT)
NCT02158936 (20) [back to overview]	Medical Resource Utilization (MRU): Event -Hospitalizations Inpatient and Outpatient
NCT02158936 (20) [back to overview]	Medical Resource Utilization (MRU): Use of Site Specific Medical Resources
NCT02158936 (20) [back to overview]	Number of of Subjects With Azacitidine Dose Delays, Dose Reductions, Interruptions
NCT02158936 (20) [back to overview]	Best Disease Response From Investigator Assessment (ITT)
NCT02158936 (20) [back to overview]	Summary of Post-Hoc Estimates of Steady-state Eltrombopag AUC0 Infinity Pharmacokinetic Parameters for a 50 mg Dose
NCT02158936 (20) [back to overview]	Overall Survival (OS)
NCT02158936 (20) [back to overview]	Number of Participants Who Were Platelet Transfusion Independent (ITT Set)
NCT02158936 (20) [back to overview]	Medical Resource Utilization (MRU): Event and Use of Site Specific Medical Resources - Non-study Laboratory Tests
NCT02158936 (20) [back to overview]	Number of Participants Who Were Platelet Transfusion Independent During Cycles 1-4 of Azacitidine Therapy
NCT02158936 (20) [back to overview]	Response Levels in All Domains of Euroquol-5 Dimensions of Health, 3 Response Levels (EQ-5D-3L™)
NCT02158936 (20) [back to overview]	Cmax -Pharmacokinetic Parameter of Azacitidine
NCT02158936 (20) [back to overview]	AUC0-infinity -Pharmacokinetic(s) Parameter of Azacitidine
NCT02158936 (20) [back to overview]	Summary of AML Progression From Investigator Assessment and Central Review (ITT)
NCT02158936 (20) [back to overview]	Summary of Post-Hoc Estimates of Steady-state Eltrombopag Cmax and Cmin Pharmacokinetic Parameters for a 50 mg Dose
NCT02158936 (20) [back to overview]	Summary of Progression Free Survival From Central Review (ITT)
NCT02196857 (2) [back to overview]	Toxicity Profile of Azacytidine and Sorafenib
NCT02196857 (2) [back to overview]	Participants With a Response CR + PR + CRi
NCT02201329 (5) [back to overview]	Area Under the Concentration-Time Curve of Volasertib 200 mg in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
NCT02201329 (5) [back to overview]	Overall Objective Response (OR): Complete Remission (CR), Partial Remission (PR), or Marrow CR (mCR)
NCT02201329 (5) [back to overview]	Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD)
NCT02201329 (5) [back to overview]	Maximum Tolerated Dose of Volasertib
NCT02201329 (5) [back to overview]	Maximum Measured Concentration of the Volasertib 200 mg in Plasma (Cmax)
NCT02250326 (12) [back to overview]	Dose Intensity Per Week of CC-486
NCT02250326 (12) [back to overview]	Percentage of Participants With Study Drug Dose Reductions
NCT02250326 (12) [back to overview]	Percentage of Participants With Study Drug Dose Reductions
NCT02250326 (12) [back to overview]	Percentage of Participants Who Achieved a Best Overall Response of Complete Response or Partial Response According to RECIST V 1.1 Criteria
NCT02250326 (12) [back to overview]	Percentage of Participants Who Discontinued Study Treatment
NCT02250326 (12) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Entire Treatment Period
NCT02250326 (12) [back to overview]	Percentage of Participants With Study Drug Dose Reductions
NCT02250326 (12) [back to overview]	Kaplan Meier Estimate of Progression-Free Survival (PFS) as Assessed by the Investigator
NCT02250326 (12) [back to overview]	Dose Intensity Per Week of Nab-Paclitaxel
NCT02250326 (12) [back to overview]	Dose Intensity Per Week of Durvalumab
NCT02250326 (12) [back to overview]	Kaplan Meier Estimate of Overall Survival (OS)
NCT02250326 (12) [back to overview]	Percentage of Participants Who Achieved a Complete Response (CR), Partial Response (PR) or Stable Disease (SD) According to RECIST V 1.1 Criteria
NCT02260440 (3) [back to overview]	Overall Survival (OS)
NCT02260440 (3) [back to overview]	Progression-free Survival (PFS)
NCT02260440 (3) [back to overview]	Objective Response Rate (ORR)
NCT02265510 (10) [back to overview]	Phase 2: Number of Participants With at Least One TEAE and SAE
NCT02265510 (10) [back to overview]	Phase 1a, 1b, and Phase 2: Tmax: Time to Maximum Plasma Concentration for INCB052793
NCT02265510 (10) [back to overview]	Phase 1a, 1b, and Phase 2: Tmax: Time to Maximum Plasma Concentration for Itacitinib
NCT02265510 (10) [back to overview]	Phase 2: Objective Response Rate (ORR) in Hematological Malignancies
NCT02265510 (10) [back to overview]	Phase 1a and 1b: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)
NCT02265510 (10) [back to overview]	Phase 1A and 1B: Percentage of Participants With Response as Determined by Investigator's Assessment
NCT02265510 (10) [back to overview]	Phase 1a, 1b, and Phase 2: AUC0-τ: Area Under the Plasma Concentration-time Curve Over Dosing Interval for INCB052793
NCT02265510 (10) [back to overview]	Phase 1a, 1b, and Phase 2: AUC0-τ: Area Under the Plasma Concentration-time Curve Over Dosing Interval for Itacitinib
NCT02265510 (10) [back to overview]	Phase 1a, 1b, and Phase 2: Cmax: Maximum Observed Plasma Concentration for INCB052793
NCT02265510 (10) [back to overview]	Phase 1a, 1b, and Phase 2: Cmax: Maximum Observed Plasma Concentration of Itacitinib
NCT02269943 (12) [back to overview]	Apparent Total Clearance (CL/F) Of CC-486
NCT02269943 (12) [back to overview]	Time to Reach Maximum Concentration (Tmax) Of CC-486
NCT02269943 (12) [back to overview]	Number of Participants With Treatment Emergent Adverse Events
NCT02269943 (12) [back to overview]	Terminal Half-Life (t1/2) of CC-486
NCT02269943 (12) [back to overview]	Kaplan Meier Estimate of Progression-Free Survival (PFS) Based on an Independent Radiology Assessment According to RECIST 1.1 Criteria
NCT02269943 (12) [back to overview]	Kaplan Meier Estimate of Overall Survival
NCT02269943 (12) [back to overview]	Apparent Volume of Distribution (Vz/F) Of CC-486
NCT02269943 (12) [back to overview]	Area Under the Plasma Concentration -Time Curve From 0 Extrapolated to Infinity (AUC-inf, AUC0-∞) Of CC-486
NCT02269943 (12) [back to overview]	Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration Of CC-486 (AUC-t)
NCT02269943 (12) [back to overview]	Maximum Observed Concentration (Cmax) Of CC-486
NCT02269943 (12) [back to overview]	Percentage of Participants Who Achieved a Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) Based on an Independent Radiology Assessment (IRA)
NCT02269943 (12) [back to overview]	Percentage of Participants With Stable Disease for ≥ 16 Weeks From the Date of the First Treatment, or CR or PR According to RECIST 1.1 Criteria and Based on an Independent Radiology Assessment
NCT02281084 (12) [back to overview]	Percentage of Participants Who Progressed to Acute Myelogenous Leukemia (AML)
NCT02281084 (12) [back to overview]	Percentage of Participants With Progressive Disease at Baseline Who Achieved Stable Disease
NCT02281084 (12) [back to overview]	Kaplan Meier Estimate of Time to Onset of First and Best Response
NCT02281084 (12) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT02281084 (12) [back to overview]	Kaplan Meier Estimate of Duration of Best Response
NCT02281084 (12) [back to overview]	Kaplan Meier Estimate of Duration of First Response
NCT02281084 (12) [back to overview]	Kaplan-Meier Estimate of Duration of Stable Disease
NCT02281084 (12) [back to overview]	Kaplan-Meier Estimate of Onset to Achieve Stable Disease
NCT02281084 (12) [back to overview]	Kaplan-Meier Estimate of Overall Survival
NCT02281084 (12) [back to overview]	Kaplan-Meier Estimate of Progression Free Survival (PFS)
NCT02281084 (12) [back to overview]	Kaplan-Meier Estimate of Time to Progression to AML
NCT02281084 (12) [back to overview]	Overall Response Rate Based on the Modified International Working Group (IWG) 2006 Response Criteria for Myelodysplastic Syndrome (MDS)
NCT02319369 (13) [back to overview]	Maximum Plasma Concentration (Cmax) Following Administration of Milademetan In Combination With 5-Azacitidine (AZA)
NCT02319369 (13) [back to overview]	Serum Macrophage Inhibitory Cytokine-1 (MIC-1) Fold Change From Baseline Following Administration of Milademetan In Combination With 5-Azacitidine (AZA)
NCT02319369 (13) [back to overview]	Number of Participants With Dose-Limiting Toxicities (DLTs) Following Administration of Milademetan Alone and In Combination With 5-Azacitidine (AZA)
NCT02319369 (13) [back to overview]	Time to Maximum Concentration (Tmax) Following Administration of Milademetan In Combination With 5-Azacitidine (AZA)
NCT02319369 (13) [back to overview]	Trough Plasma Concentration (Ctrough) Following Administration of Milademetan Alone
NCT02319369 (13) [back to overview]	Serum Macrophage Inhibitory Cytokine-1 (MIC-1) Fold Change From Baseline Following Administration of Milademetan In Combination With 5-Azacitidine (AZA)
NCT02319369 (13) [back to overview]	Area Under the Plasma Concentration Curve up to 24 Hours (AUC0-24) Following Administration of Milademetan Alone
NCT02319369 (13) [back to overview]	Area Under the Plasma Concentration Curve up to 24 Hours (AUC0-24) Following Administration of Milademetan In Combination With 5-Azacitidine (AZA)
NCT02319369 (13) [back to overview]	Maximum Plasma Concentration (Cmax) Following Administration of Milademetan Alone
NCT02319369 (13) [back to overview]	Time to Maximum Concentration (Tmax) Following Administration of Milademetan Alone
NCT02319369 (13) [back to overview]	Serum Macrophage Inhibitory Cytokine-1 (MIC-1) Fold Change From Baseline Following Administration of Milademetan Alone
NCT02319369 (13) [back to overview]	Number of Participants (≥10%) With Treatment-emergent Adverse Events (TEAEs) Following Administration of Milademetan Alone and In Combination With 5-Azacitidine (AZA)
NCT02319369 (13) [back to overview]	Serum Macrophage Inhibitory Cytokine-1 (MIC-1) Fold Change From Baseline Following Administration of Milademetan In Combination With 5-Azacitidine (AZA)
NCT02343939 (9) [back to overview]	Duration of Exposure of Entospletinib
NCT02343939 (9) [back to overview]	Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)
NCT02343939 (9) [back to overview]	Event Free Survival (EFS)
NCT02343939 (9) [back to overview]	Overall Survival (OS)
NCT02343939 (9) [back to overview]	Percentage of Participants Experiencing Treatment-Emergent Adverse Events
NCT02343939 (9) [back to overview]	Percentage of Participants With Composite Complete Remission at the End of Induction
NCT02343939 (9) [back to overview]	Percentage of Participants With Morphologic Complete Remission (CR) at the End of Induction
NCT02343939 (9) [back to overview]	Percentage of Participants With Overall Response at the End of Induction
NCT02343939 (9) [back to overview]	Percentage of Participants Who Experienced Laboratory Abnormalities
NCT02351037 (1) [back to overview]	Efficacy of Ibrutinib Monotherapy or in Combination With Either LD-AraC or Azacitidine Using the Overall Remission Rate (Defined as Proportion of Subjects Achieving a CR or CRi) According to the LeukemiaNet Guidelines
NCT02367456 (22) [back to overview]	Number of Participants With Disease-Specific Efficacy Measures in the AML Cohort
NCT02367456 (22) [back to overview]	Number of Participants Meeting Categorical Criteria of QTcF Values in LIC, AML and MDS Cohorts
NCT02367456 (22) [back to overview]	Number of Participants With SAEs in the AML and MDS Cohorts
NCT02367456 (22) [back to overview]	Maximum Plasma Concentration (Cmax) of Glasdegib Dosed in Combination With Azacitidine (C1D7) and When Dosed Alone (C1D15) in the Lead-in Cohort
NCT02367456 (22) [back to overview]	Number of Participants With Disease-Specific Efficacy Measures in the MDS Cohort
NCT02367456 (22) [back to overview]	Duration of CR in the AML and MDS Cohorts
NCT02367456 (22) [back to overview]	Percentage of Participants Achieving Complete Remission (CR) + Partial Remission (PR) in the LIC
NCT02367456 (22) [back to overview]	Kaplan-Meier Estimate of Median Overall Survival (OS) in the AML and MDS Cohorts
NCT02367456 (22) [back to overview]	Maximum Plasma Concentration (Cmax) of Azacitidine Dosed in Combination With Glasdegib (C1D7) and When Dosed Alone (C1D1) in the Lead-in Cohort
NCT02367456 (22) [back to overview]	Percentage of Participants Achieving Complete Remission (CR) in the AML and MDS Cohorts
NCT02367456 (22) [back to overview]	Area Under the Plasma Concentration Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Azacitidine Dosed in Combination With Glasdegib (C1D7) and When Dosed Alone (C1D1) in the Lead-in Cohort
NCT02367456 (22) [back to overview]	Time to CR in the AML and MDS Cohorts
NCT02367456 (22) [back to overview]	Area Under the Plasma Concentration Curve From Time Zero to End of Dosing Interval (AUCtau) of Glasdegib Dosed in Combination With Azacitidine (C1D7) and When Dosed Alone (C1D15) in the Lead-in Cohort
NCT02367456 (22) [back to overview]	Number of Participants With Efficacy Measures Other Than CR in the LIC
NCT02367456 (22) [back to overview]	Number of Participants With Laboratory Abnormalities in the AML and MDS Cohorts
NCT02367456 (22) [back to overview]	Number of Participants With Laboratory Abnormalities in the LIC
NCT02367456 (22) [back to overview]	Number of Participants With Serious Adverse Events (SAEs) in the LIC
NCT02367456 (22) [back to overview]	Number of Participants With TEAEs in the AML and MDS Cohorts
NCT02367456 (22) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Lead-in Cohort (LIC)
NCT02367456 (22) [back to overview]	Time to First Occurrence of Maximum Plasma Concentration (Tmax) of Glasdegib Dosed in Combination With Azacitidine (C1D7) and When Dosed Alone (C1D15) in the Lead-in Cohort
NCT02367456 (22) [back to overview]	Tmax of Azacitidine Dosed in Combination With Glasdegib (C1D7) and When Dosed Alone (C1D1) in the Lead-in Cohort
NCT02367456 (22) [back to overview]	Trough Plasma Concentration (Ctrough) of Glasdegib on C1D15 and C2D1 in the AML and MDS Cohorts
NCT02374099 (6) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT02374099 (6) [back to overview]	Percentage of Participants Who Achieved a Confirmed CR, PR or Stable Disease (SD) for ≥ 24 Weeks (Clinical Benefit Rate) by Investigator Assessment
NCT02374099 (6) [back to overview]	Percentage of Participants Who Achieved a Confirmed Complete Response (CR) or Partial Response (PR) to Treatment (Objective Response Rate) Based On the Investigator Assessment
NCT02374099 (6) [back to overview]	Kaplan Meier Estimate of Duration of Response (DoR)
NCT02374099 (6) [back to overview]	Kaplan Meier Estimate of Overall Survival
NCT02374099 (6) [back to overview]	Kaplan-Meier Estimate of Progression Free Survival (PFS)
NCT02399917 (5) [back to overview]	Participants With an Objective Response
NCT02399917 (5) [back to overview]	Disease Free Survival
NCT02399917 (5) [back to overview]	Duration of Response
NCT02399917 (5) [back to overview]	Maximum Tolerated Dose of Iirilumab in Combination With 5-azacitidine
NCT02399917 (5) [back to overview]	Overall Survival
NCT02421939 (12) [back to overview]	Duration of Overall Survival (OS)
NCT02421939 (12) [back to overview]	Duration of Leukemia-Free Survival (LFS)
NCT02421939 (12) [back to overview]	Percentage of Participants Who Underwent Hematopoietic Stem Cell Transplant
NCT02421939 (12) [back to overview]	Number of Participants With Adverse Events
NCT02421939 (12) [back to overview]	Duration of Event-Free Survival (EFS)
NCT02421939 (12) [back to overview]	Percentage of Participants With Complete Remission (CR) Rate
NCT02421939 (12) [back to overview]	Percentage of Participants With Complete Remission (CR) With Partial Hematological Recovery (CRh)
NCT02421939 (12) [back to overview]	Percentage of Participants With Composite Complete Remission (CRc Rate)
NCT02421939 (12) [back to overview]	Percentage of Participants With Complete Remission and Complete Remission With Partial Hematological Recovery (CR/CRh) in the Gilteritinib Arm
NCT02421939 (12) [back to overview]	Duration of Remission
NCT02421939 (12) [back to overview]	Change From Baseline in Brief Fatigue Inventory (BFI)
NCT02421939 (12) [back to overview]	Percentage of Participants Who Achieved Transfusion Conversion and Maintenance
NCT02458235 (8) [back to overview]	Frequency of System Specific Grade 3 or Higher Treatment-related Adverse Events
NCT02458235 (8) [back to overview]	Median Time to Relapse
NCT02458235 (8) [back to overview]	Proportion of Participants With Serious Infection
NCT02458235 (8) [back to overview]	Proportion of Participants With Severe Hematologic Toxicity Including Graft Failure
NCT02458235 (8) [back to overview]	Relapse Rate
NCT02458235 (8) [back to overview]	Proportion of Participants With Acute and Chronic Graft Versus Host Disease (GVHD)
NCT02458235 (8) [back to overview]	Median Relapse-free Survival
NCT02458235 (8) [back to overview]	Number of Participants Whom Had >2 Dose Reductions for Any Reason
NCT02497404 (9) [back to overview]	Disease Free Survival at 2 Years Post-transplant
NCT02497404 (9) [back to overview]	Disease Free Survival at 1 Year Post-transplant
NCT02497404 (9) [back to overview]	Overall Survival at 6 Months Post-transplant
NCT02497404 (9) [back to overview]	Acute Graft-versus-Host Disease (GVHD)
NCT02497404 (9) [back to overview]	Overall Survival at 2 Years Post-Transplant
NCT02497404 (9) [back to overview]	Overall Survival at 1 Year Post-Transplant
NCT02497404 (9) [back to overview]	High-Risk Extensive Chronic Graft-versus-Host-Disease
NCT02497404 (9) [back to overview]	Graft Failure
NCT02497404 (9) [back to overview]	Disease Free Survival at 6 Months Post-transplant
NCT02546986 (13) [back to overview]	Number of Participants With Treatment Emergent Adverse Events
NCT02546986 (13) [back to overview]	Percentage of Participants Who Achieved a Best Overall Response of Complete Response or Partial Response
NCT02546986 (13) [back to overview]	Terminal Phase of Half-life (T1/2) of CC-486
NCT02546986 (13) [back to overview]	Time to Maximum Plasma Concentration (Tmax) of CC-486
NCT02546986 (13) [back to overview]	Kaplan Meier Estimate of Progression-Free Survival (PFS) Based on European Medicines Agency Methodology
NCT02546986 (13) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of CC-486
NCT02546986 (13) [back to overview]	Kaplan Meier Estimate of Overall Survival
NCT02546986 (13) [back to overview]	Kaplan Meier Estimate of Progression-Free Survival (PFS) Based on Food and Drug Administration (FDA) Methodology
NCT02546986 (13) [back to overview]	Percentage of Participants Who Achieved a Complete Response (CR), Partial Response (PR) or Stable Disease (SD) for a Minimum Duration of 18 Weeks Compared to Baseline
NCT02546986 (13) [back to overview]	Apparent Total Plasma Clearance (CL/F) of CC-486
NCT02546986 (13) [back to overview]	Apparent Volume of Distribution (Vd/F) of CC-486
NCT02546986 (13) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of CC-486
NCT02546986 (13) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of CC-486
NCT02577406 (20) [back to overview]	Hematologic Improvement Rate
NCT02577406 (20) [back to overview]	Event-Free Survival
NCT02577406 (20) [back to overview]	The Percent of Participants Experiencing Clinically Significant Vital Sign Abnormalities
NCT02577406 (20) [back to overview]	The Percentage of Participants Experiencing Clinically Significant Electrocardiogram (ECG) Abnormalities
NCT02577406 (20) [back to overview]	Time to Response
NCT02577406 (20) [back to overview]	Duration of Response
NCT02577406 (20) [back to overview]	Time to Treatment Failure
NCT02577406 (20) [back to overview]	The Percent of Participants Experiencing Clinically Significant Laboratory Abnormalities - Serum Chemistry
NCT02577406 (20) [back to overview]	Treatment Mortality at 30 Days
NCT02577406 (20) [back to overview]	Treatment Mortality at 60 Days
NCT02577406 (20) [back to overview]	Change From Baseline in the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30)
NCT02577406 (20) [back to overview]	Change From Baseline in EQ-5D-5L Health Utility Index
NCT02577406 (20) [back to overview]	The Number of Participants Experiencing Adverse Events (AEs)
NCT02577406 (20) [back to overview]	The Percent of Participants Experiencing Clinically Significant Laboratory Abnormalities - Hematology
NCT02577406 (20) [back to overview]	The Number of Participants That Underwent Hematopoietic Stem Cell Transplantation (HSCT)
NCT02577406 (20) [back to overview]	Overall Survival (OS)
NCT02577406 (20) [back to overview]	Overall Response Rate
NCT02577406 (20) [back to overview]	Overall Remission Rate
NCT02577406 (20) [back to overview]	One-Year Survival Rate
NCT02577406 (20) [back to overview]	Complete Remission Rate
NCT02587598 (22) [back to overview]	Pharmacokinetics: Tmax of Combination Treatment Group A INCB053914 50 mg + Cytarabine
NCT02587598 (22) [back to overview]	Pharmacokinetics: Tmax of Combination Treatment Group C INCB053914 80 mg + Ruxolitinib
NCT02587598 (22) [back to overview]	Pharmacokinetics: Tmax of INCB053914 Monotherapy
NCT02587598 (22) [back to overview]	Pharmacokinetics: Cl/F of Combination Treatment Group A INCB053914 50 mg + Cytarabine
NCT02587598 (22) [back to overview]	Determination of the Safety and Tolerability of INCB053914 as Measured by the Number of Participants With Adverse Events
NCT02587598 (22) [back to overview]	Evaluation of Phosphorylated BCL--2 Associated Death Promoter Protein (pBAD)
NCT02587598 (22) [back to overview]	Pharmacokinetics: AUCtau of Combination Group B INCB053914 80 mg + Azatcitidine
NCT02587598 (22) [back to overview]	Pharmacokinetics: AUCtau of Combination Treatment Group A INCB053914 50 mg + Cytarabine
NCT02587598 (22) [back to overview]	Pharmacokinetics: AUCtau of Combination Treatment Group C INCB053914 80 mg + Ruxolitinib
NCT02587598 (22) [back to overview]	Pharmacokinetics: AUCtau of INCB053914 Monotherapy
NCT02587598 (22) [back to overview]	Pharmacokinetics: Cl/F of Combination Group B INCB053914 80 mg + Azatcitidine
NCT02587598 (22) [back to overview]	Pharmacokinetics: Cl/F of Combination Treatment Group C INCB053914 80 mg + Ruxolitinib
NCT02587598 (22) [back to overview]	Pharmacokinetics: CL/F of INCB053914 Monotherapy
NCT02587598 (22) [back to overview]	Pharmacokinetics: Cmax of Combination Group B INCB053914 80 mg + Azatcitidine
NCT02587598 (22) [back to overview]	Pharmacokinetics: Cmax of Combination Treatment Group A INCB053914 50 mg + Cytarabine
NCT02587598 (22) [back to overview]	Pharmacokinetics: Cmax of Combination Treatment Group C INCB053914 80 mg + Ruxolitinib
NCT02587598 (22) [back to overview]	Pharmacokinetics: Cmax of INCB053914 Monotherapy
NCT02587598 (22) [back to overview]	Pharmacokinetics: Cmin of Combination Group B INCB053914 80 mg + Azatcitidine
NCT02587598 (22) [back to overview]	Pharmacokinetics: Cmin of Combination Treatment Group A INCB053914 50 mg + Cytarabine
NCT02587598 (22) [back to overview]	Pharmacokinetics: Cmin of Combination Treatment Group C INCB053914 80 mg + Ruxolitinib
NCT02587598 (22) [back to overview]	Pharmacokinetics: Ctau of INCB053914 Monotherapy
NCT02587598 (22) [back to overview]	Pharmacokinetics: Tmax of Combination Group B INCB053914 80 mg + Azatcitidine
NCT02599649 (1) [back to overview]	Overall Response Rate (ORR)
NCT02610777 (27) [back to overview]	Percentage of Participants With CR and PR by Cycle 4
NCT02610777 (27) [back to overview]	Percentage of Participants With Overall Response by Cycle 4
NCT02610777 (27) [back to overview]	Six-month Survival Rate
NCT02610777 (27) [back to overview]	Time to AML Transformation in HR MDS or CMML Participants
NCT02610777 (27) [back to overview]	Time to First CR or PR
NCT02610777 (27) [back to overview]	Time to Progressive Disease (PD), Relapse, or Death
NCT02610777 (27) [back to overview]	Time to Subsequent Therapy
NCT02610777 (27) [back to overview]	Number of Participants in the Safety Analysis Population With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Values Reported as TEAEs
NCT02610777 (27) [back to overview]	Percentage of Participants With CR and Partial Remission (PR)
NCT02610777 (27) [back to overview]	Percentage of Participants With Complete Remission (CR)
NCT02610777 (27) [back to overview]	Percentage of Participants With at Least 1 Inpatient Hospital Admissions Related to HR MDS, CMML or Low-blast AML
NCT02610777 (27) [back to overview]	Overall Survival (OS)
NCT02610777 (27) [back to overview]	One-year Survival Rate
NCT02610777 (27) [back to overview]	Duration of Complete Remission (CR) in Low-blast AML
NCT02610777 (27) [back to overview]	Duration of Complete Remission (CR) and Partial Remission (PR)
NCT02610777 (27) [back to overview]	Duration of Complete Remission (CR)
NCT02610777 (27) [back to overview]	Number of Participants in the Safety Analysis Population With Clinically Significant Laboratory Abnormalities Reported as TEAEs
NCT02610777 (27) [back to overview]	Number of Participants in the Safety Analysis Population With Clinically Significant Change From Baseline Values in Vital Signs Reported as TEAEs
NCT02610777 (27) [back to overview]	Number of Participants Reporting One or More Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
NCT02610777 (27) [back to overview]	Number of Participants With Change From Baseline Values in Eastern Cooperative Oncology Group (ECOG) Performance Status
NCT02610777 (27) [back to overview]	Percentage of Participants With Red Blood Cells (RBCs) and Platelet-transfusion Independence
NCT02610777 (27) [back to overview]	Event-Free Survival (EFS)
NCT02610777 (27) [back to overview]	Duration of Overall Response
NCT02610777 (27) [back to overview]	Percentage of Participants With Overall Response
NCT02610777 (27) [back to overview]	Percentage of Participants With CR in Low-blast AML by Cycle 4
NCT02610777 (27) [back to overview]	Percentage of Participants With CR in Low-blast AML
NCT02610777 (27) [back to overview]	Percentage of Participants With CR by Cycle 4
NCT02677922 (23) [back to overview]	The Number of Participants Experiencing Adverse Events: Phase 2 (Randomized Stage)
NCT02677922 (23) [back to overview]	AUC (0-8)- Area Under the Plasma Concentration-Time Curve: Phase 2 (Randomized Stage)
NCT02677922 (23) [back to overview]	Change From Baseline in Health Utility Indices of the EQ-5D-5L: Phase 2 (Randomized Stage)
NCT02677922 (23) [back to overview]	Change From Baseline in Visual Analogue Scale (VAS) Scores of the EQ-5D-5L: Phase 2 (Randomized Stage)
NCT02677922 (23) [back to overview]	Cmax- Maximum Observed Plasma Concentration: Phase 2 (Randomized Stage)
NCT02677922 (23) [back to overview]	Complete Remission Rate: Phase 2 (Randomized Stage)
NCT02677922 (23) [back to overview]	Event-free Survival (EFS): Phase 2 (Randomized Stage)
NCT02677922 (23) [back to overview]	Hematologic Improvement (HI) Rate: Phase 2 (Randomized Stage)
NCT02677922 (23) [back to overview]	One Year Survival Rate: Phase 2 (Randomized Stage)
NCT02677922 (23) [back to overview]	AUC (0-24)- Area Under the Plasma Concentration-Time Curve: Phase 2 (Randomized Stage)
NCT02677922 (23) [back to overview]	The Number of Participants Experiencing Adverse Events: Phase 1B (Dose Finding and Expansion Stage)
NCT02677922 (23) [back to overview]	Cmax- Maximum Observed Plasma Concentration: Phase 1B (Expansion Stage)
NCT02677922 (23) [back to overview]	Change From Baseline in Health-related Quality-of-Life Domain Scores of the EORTC QLQ-C30: Phase 2 (Randomized Stage)
NCT02677922 (23) [back to overview]	AUC (0-8)- Area Under the Plasma Concentration-Time Curve: Phase 1B (Expansion Stage)
NCT02677922 (23) [back to overview]	Tmax- Time of Maximum Observed Plasma Concentration: Phase 2 (Randomized Stage)
NCT02677922 (23) [back to overview]	Time to Response: Phase 2 (Randomized Stage)
NCT02677922 (23) [back to overview]	The Number of Participants Experiencing Dose-limiting Toxicities (DLTs): Phase 1B (Dose Finding Stage)
NCT02677922 (23) [back to overview]	Duration of Response: Phase 2 (Randomized Stage)
NCT02677922 (23) [back to overview]	Sponsor Derived CR and CRh: Phase 1B (Dose Finding and Expansion Stage)
NCT02677922 (23) [back to overview]	Overall Survival: Phase 2 (Randomized Stage)
NCT02677922 (23) [back to overview]	Overall Response Rate: Phase 2 (Randomized Stage)
NCT02677922 (23) [back to overview]	Overall Response Rate: Phase 1B (Dose Finding and Expansion Stage)
NCT02677922 (23) [back to overview]	Tmax- Time of Maximum Observed Plasma Concentration: Phase 1B (Expansion Stage)
NCT02706899 (2) [back to overview]	Safety of the Combination of Vadastuximab Talirine and Azacitidine Measured by the Number of Participants With Adverse Events and Laboratory Abnormalities
NCT02706899 (2) [back to overview]	Phase 1 Outcome Measure: Recommended Dose of Vadastuximab Talirine for the Phase 2 Portion of the Study
NCT02711137 (17) [back to overview]	Part 2 - Cmax: Maximum Observed Plasma Concentration of INCB057643.
NCT02711137 (17) [back to overview]	Percent Inhibition of Total Cellular Myc Protein Concentrations Before and After Administration of INCB057643 When Administered as Monotherapy in an Ex-vivo Assay
NCT02711137 (17) [back to overview]	Part 2-Tmax: Time to Maximum Plasma Concentration of INCB057643
NCT02711137 (17) [back to overview]	Cmax: Maximum Observed Plasma Concentration of INCB057643.
NCT02711137 (17) [back to overview]	AUC0-t: Area Under the Single-dose Plasma Concentration-time Curve of INCB057643
NCT02711137 (17) [back to overview]	Objective Response Rate (ORR) With INCB057643 in Solid Tumors
NCT02711137 (17) [back to overview]	Objective Response Rate (ORR) With INCB057643 in Solid Tumors
NCT02711137 (17) [back to overview]	Objective Response Rate (ORR) With INCB057643 in Solid Tumors
NCT02711137 (17) [back to overview]	Objective Response Rate (ORR) With INCB057643 in Solid Tumors
NCT02711137 (17) [back to overview]	Objective Response Rate (ORR) With INCB057643 in Solid Tumors
NCT02711137 (17) [back to overview]	AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy
NCT02711137 (17) [back to overview]	AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy
NCT02711137 (17) [back to overview]	Objective Response Rate (ORR) With INCB057643 in Solid Tumors
NCT02711137 (17) [back to overview]	Objective Response Rate (ORR) With INCB057643 in Solid Tumors
NCT02711137 (17) [back to overview]	Objective Response Rate (ORR) With INCB057643 in Solid Tumors
NCT02711137 (17) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAE's).
NCT02711137 (17) [back to overview]	Tmax: Time to Maximum Plasma Concentration of INCB057643
NCT02712905 (21) [back to overview]	CL/F of INCB059872 in Plasma When Received as Monotherapy
NCT02712905 (21) [back to overview]	Cmax of INCB059872 in Plasma When Received as Combination Therapy
NCT02712905 (21) [back to overview]	Cmax of INCB059872 in Plasma When Received as Monotherapy
NCT02712905 (21) [back to overview]	Number of Participants Receiving INCB059872 Combination Therapy With Any TEAE
NCT02712905 (21) [back to overview]	Number of Participants Receiving INCB059872 Monotherapy With Any Treatment-emergent Adverse Event (TEAE)
NCT02712905 (21) [back to overview]	ORR for Altering the Natural History of the Disease in Participants With Acute Myeloid Leukemia (AML) Who Received INCB059872 Monotherapy
NCT02712905 (21) [back to overview]	ORR for Altering the Natural History of the Disease in Participants With AML Who Received Combination Therapy
NCT02712905 (21) [back to overview]	ORR for Altering the Natural History of the Disease in Participants With MDS Who Received Combination Therapy
NCT02712905 (21) [back to overview]	ORR for Altering the Natural History of the Disease in Participants With Myelodysplastic Syndrome (MDS) Who Received INCB059872 Monotherapy
NCT02712905 (21) [back to overview]	AUC(0-τ) of INCB059872 in Plasma When Received as Combination Therapy
NCT02712905 (21) [back to overview]	AUC(0-τ) of INCB059872 in Plasma When Received as Monotherapy
NCT02712905 (21) [back to overview]	Objective Response Rate (ORR) in Participants With the Indicated Type of Solid Tumors Who Received INCB059872 Monotherapy
NCT02712905 (21) [back to overview]	ORR in Participants With SCLC Who Received Combination Therapy
NCT02712905 (21) [back to overview]	Objective Response Rate (ORR) in Participants With the Indicated Type of Solid Tumors Who Received INCB059872 Monotherapy
NCT02712905 (21) [back to overview]	Objective Response Rate (ORR) in Participants With the Indicated Type of Solid Tumors Who Received INCB059872 Monotherapy
NCT02712905 (21) [back to overview]	CL/F of INCB059872 in Plasma When Received as Combination Therapy
NCT02712905 (21) [back to overview]	Tmax of INCB059872 in Plasma When Received as Monotherapy
NCT02712905 (21) [back to overview]	Tmax of INCB059872 in Plasma When Received as Combination Therapy
NCT02712905 (21) [back to overview]	Objective Response Rate (ORR) in Participants With the Indicated Type of Solid Tumors Who Received INCB059872 Monotherapy
NCT02712905 (21) [back to overview]	t1/2 of INCB059872 in Plasma When Received as Monotherapy
NCT02712905 (21) [back to overview]	t1/2 of INCB059872 in Plasma When Received as Combination Therapy
NCT02721875 (5) [back to overview]	Objective Response Defined as Best Overall Response of Complete Remission, Partial Remission or Haematological Improvement According to the International Working Group 2006 Criteria
NCT02721875 (5) [back to overview]	Maximum Tolerated Dose (MTD) of Volasertib
NCT02721875 (5) [back to overview]	Number of Patients With Dose Limiting Toxicities (DLT) in the First Cycle
NCT02721875 (5) [back to overview]	Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to the Last Measured Time Point tz of Volasertib (AUC0-tz) (for Monotherapy)
NCT02721875 (5) [back to overview]	Maximum Measured Plasma Concentration of Volasertib (Cmax) (for Monotherapy)
NCT02775903 (25) [back to overview]	MDS Cohort: Kaplan-Meier Estimate of Time to AML Transformation
NCT02775903 (25) [back to overview]	MDS Cohort: Kaplan-Meier Estimate of Duration of Response
NCT02775903 (25) [back to overview]	MDS Cohort: Kaplan-Meier Estimate of Progression-free Survival (PFS)
NCT02775903 (25) [back to overview]	Change From Baseline in Selected Chemistry Parameters I
NCT02775903 (25) [back to overview]	AML Cohort: Percentage of Participants With Hematologic Improvement
NCT02775903 (25) [back to overview]	Change From Baseline in Selected Hematology Parameters II
NCT02775903 (25) [back to overview]	Kaplan-Meier Estimate of Overall Survival
NCT02775903 (25) [back to overview]	MDS Cohort: Kaplan Meier Estimate of Relapse-free Survival
NCT02775903 (25) [back to overview]	MDS Cohort: Kaplan Meier Estimate of Time to First Response
NCT02775903 (25) [back to overview]	MDS Cohort: Overall Response Rate
NCT02775903 (25) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs)
NCT02775903 (25) [back to overview]	MDS Cohort: Percentage of Participants With Disease Transformation to AML
NCT02775903 (25) [back to overview]	AML Cohort: Kaplan-Meier Estimate of Duration of Response
NCT02775903 (25) [back to overview]	One-year Survival
NCT02775903 (25) [back to overview]	Change From Baseline in Selected Chemistry Parameters II
NCT02775903 (25) [back to overview]	Change From Baseline in Selected Chemistry Parameters III
NCT02775903 (25) [back to overview]	Change From Baseline in Selected Chemistry Parameters IV
NCT02775903 (25) [back to overview]	Change From Baseline in Selected Hematology Parameters I
NCT02775903 (25) [back to overview]	Durvalumab Serum Concentration
NCT02775903 (25) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs)
NCT02775903 (25) [back to overview]	MDS Cohort: Percentage of Participants Who Achieved a Cytogenetic Response
NCT02775903 (25) [back to overview]	AML Cohort: Kaplan Meier Estimate of Time to First Response
NCT02775903 (25) [back to overview]	AML Cohort: Kaplan Meier Estimate of Relapse-free Survival
NCT02775903 (25) [back to overview]	AML Cohort: Overall Response Rate
NCT02775903 (25) [back to overview]	AML Cohort: Percentage of Participants Who Achieved a Complete Cytogenetic Response
NCT02782468 (12) [back to overview]	CL: Total Clearance for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 5
NCT02782468 (12) [back to overview]	CL: Total Clearance for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 1
NCT02782468 (12) [back to overview]	AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 5
NCT02782468 (12) [back to overview]	Percentage of Participants With CR for Participants With MDS
NCT02782468 (12) [back to overview]	Percentage of Participants With CR for Participants With AML
NCT02782468 (12) [back to overview]	Overall Response Rate (ORR) for Participants With AML
NCT02782468 (12) [back to overview]	ORR for Participants With MDS
NCT02782468 (12) [back to overview]	Number of Participants With Clinically Significant Abnormal Laboratory Values
NCT02782468 (12) [back to overview]	Cmax: Maximum Observed Plasma Concentration for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 5
NCT02782468 (12) [back to overview]	Cmax: Maximum Observed Plasma Concentration for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 1
NCT02782468 (12) [back to overview]	Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
NCT02782468 (12) [back to overview]	Number of Participants With Dose Limiting Toxicities (DLTs) Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 During Cycle 1
NCT02785900 (10) [back to overview]	Mortality Rates at Day 30 and Day 60
NCT02785900 (10) [back to overview]	Minimal Residual Disease (MRD)-Negative Composite Complete Remission Rate
NCT02785900 (10) [back to overview]	Time to Complete Remission
NCT02785900 (10) [back to overview]	Overall Survival
NCT02785900 (10) [back to overview]	Leukemia-free Survival
NCT02785900 (10) [back to overview]	Event-free Survival
NCT02785900 (10) [back to overview]	Duration of Remission
NCT02785900 (10) [back to overview]	Composite Complete Remission (CRc) Rate
NCT02785900 (10) [back to overview]	Incidence of Grade 3 or Higher Laboratory Abnormalities
NCT02785900 (10) [back to overview]	Type, Incidence, Severity, Seriousness, and Relatedness of Adverse Events
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to First Course of Azacitidine
NCT02828358 (5) [back to overview]	Tolerability of Azacitidine in Combination With Interfant-06 Standard Chemotherapy in Evaluable Infant Patients With Newly Diagnosed ALL With KMT2A Gene Rearrangement (KMT2A-R). KMT2A Gene Rearrangement (KMT2A-R)
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of Second Course of Azacitidine
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of First Course of Azacitidine
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to Second Course of Azacitidine
NCT02900560 (2) [back to overview]	Number of Subjects With Treatment Emergent Adverse Events Related to Pembrolizumab as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.03.
NCT02900560 (2) [back to overview]	Number of Subjects With Treatment Emergent Adverse Events Related to CC-486 as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.03.
NCT02901899 (3) [back to overview]	Clinical Benefit Rate (CBR)
NCT02901899 (3) [back to overview]	Objective Response Rate (ORR) Using RECIST 1.1
NCT02901899 (3) [back to overview]	Incidence of Adverse Events
NCT02929498 (28) [back to overview]	Part 1: Change From Baseline in Respiratory Rate at Indicated Time-points
NCT02929498 (28) [back to overview]	Part 1: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Indicated Time-points
NCT02929498 (28) [back to overview]	Part 1: Change From Baseline in Total Bilirubin, Direct Bilirubin, Creatinine and Urate at Indicated Time Points
NCT02929498 (28) [back to overview]	Part 1: Number of Participants With Any Non-serious Adverse Event (Non-SAE), Serious AE (SAE), Dose Limiting Toxicities (DLT), Dose Reductions or Delays and Withdrawals Due to Toxicities
NCT02929498 (28) [back to overview]	Part 1: Change From Baseline in Body Temperature at Indicated Time-points
NCT02929498 (28) [back to overview]	Part 1: Plasma Concentration of GSK2879552
NCT02929498 (28) [back to overview]	Part 1: Change From Baseline in Blast/Leukocytes at Indicated Time-points
NCT02929498 (28) [back to overview]	Part 1: Change From Baseline in Partial Pressure Carbon Dioxide (pCO2) at Indicated Time Points
NCT02929498 (28) [back to overview]	Part 1: Overall Survival
NCT02929498 (28) [back to overview]	Part 1: Change From Baseline in Mean Corpuscular Volume (MCV) at Indicated Time-points
NCT02929498 (28) [back to overview]	Part 1: Percentage of Participants With Investigator-assessed Best Response Assessed by Objective Response Rate (ORR)
NCT02929498 (28) [back to overview]	Part 1: Progression-free Survival
NCT02929498 (28) [back to overview]	Part 1: Change From Baseline in Erythrocytes at Indicated Time-points
NCT02929498 (28) [back to overview]	Part 1: Change From Baseline in Heart Rate at Indicated Time-points
NCT02929498 (28) [back to overview]	Part 1: Change From Baseline in Hematocrit at Indicated Time-points
NCT02929498 (28) [back to overview]	Part 1: Change From Baseline in Mean Corpuscular Hemoglobin (MCH) at Indicated Time-points
NCT02929498 (28) [back to overview]	Part 1: Change From Baseline in Electrocardiogram (ECG) Mean Heart Rate at Indicated Time-points
NCT02929498 (28) [back to overview]	Part 1: Proportion of Participants With Disease Progression to Acute Myeloblastic Leukemia (AML)
NCT02929498 (28) [back to overview]	Part 1: Time to AML Progression
NCT02929498 (28) [back to overview]	Part 1: Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Lactate Dehydrogenase (LDH) and Gamma Glutamyl Transferase (GGT) at Indicated Time-points
NCT02929498 (28) [back to overview]	Part 1: Change From Baseline in Albumin and Protein at Indicated Time Points
NCT02929498 (28) [back to overview]	Part 1: Change From Baseline in Calcium, Chloride, Glucose, Potassium, Sodium, Phosphate and Urea Nitrogen at Indicated Time-points
NCT02929498 (28) [back to overview]	Part 1: Change From Baseline in ECG PR Interval, QRS Duration, QT Interval, QTc Corrected by Bazett's Formula (QTcB) and QTc Corrected by Fridericia's Formula (QTcF) at Indicated Time-points
NCT02929498 (28) [back to overview]	Part 1: Change From Baseline in Mean Corpuscular Hemoglobin Concentration (MCHC) and Hemoglobin (Hb) at Indicated Time-points
NCT02929498 (28) [back to overview]	Part 1: Number of Participants With Documented Platelet and Red Blood Cell (RBC) Transfusions Per Month
NCT02929498 (28) [back to overview]	Part 1: Change From Baseline in Percent Reticulocytes at Indicated Time-points
NCT02929498 (28) [back to overview]	Part 1: Change From Baseline in Platelets, Neutrophils, Monocytes, Lymphocytes, Leucocyte, Eosinophils and Basophils at Indicated Time-points
NCT02929498 (28) [back to overview]	Part 1: Percentage of Participants With Investigator-assessed Best Response Assessed by Clinical Benefit Rate (CBR)
NCT02951156 (18) [back to overview]	Programmed Death Receptor-1 Ligand-1 (PD-L1) Biomarker Expression in Tumor and Immune Cells as Assessed by Immunohistochemistry (IHC) at Baseline
NCT02951156 (18) [back to overview]	Number of Participants With Neutralizing Antibodies (nAb) Against Utomilumab by Never and Ever Positive Status
NCT02951156 (18) [back to overview]	Number of Participants With Minimal Residual Disease Burden (MRD) Positive, Negative and Not Evaluable (NE) Status
NCT02951156 (18) [back to overview]	Number of Participants With Dose Limiting Toxicities (DLT)
NCT02951156 (18) [back to overview]	Duration of Response (DOR) as Assessed by Investigator Per Lugano Response Classification Criteria
NCT02951156 (18) [back to overview]	Number of Participants With Laboratory Abnormalities As Per National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE), Version 4.03
NCT02951156 (18) [back to overview]	Number of Participants With Electrocardiogram (ECG) Abnormalities
NCT02951156 (18) [back to overview]	Number of Participants With Anti-Drug Antibodies (ADA) Against Utomilumab by Never and Ever Positive Status
NCT02951156 (18) [back to overview]	Number of Participants With Anti-Drug Antibodies (ADA) Against Rituximab by Never and Ever Positive Status
NCT02951156 (18) [back to overview]	Number of Participants With Anti-Drug Antibodies (ADA) Against Avelumab by Never and Ever Positive Status
NCT02951156 (18) [back to overview]	Concentration Verses Time Summary of Avelumab
NCT02951156 (18) [back to overview]	Concentration Verses Time Summary of Avelumab
NCT02951156 (18) [back to overview]	Disease Control Rate as Assessed by the Investigator Per Lugano Response Classification Criteria
NCT02951156 (18) [back to overview]	Time to Tumor Response (TTR) as Assessed by Investigator Per Lugano Response Classification Criteria
NCT02951156 (18) [back to overview]	Progression-Free Survival (PFS) as Assessed by the Investigator Per Lugano Response Classification Criteria
NCT02951156 (18) [back to overview]	Overall Survival
NCT02951156 (18) [back to overview]	Objective Response Rate (ORR) as Assessed by Investigator Per Lugano Response Classification Criteria
NCT02951156 (18) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Greater Than or Equal to (>=) Grade 3, As Per National Cancer Institute Common Terminology Criteria For Adverse Events (NCI-CTCAE), Version 4.03
NCT02953561 (4) [back to overview]	Overall Survival (OS)
NCT02953561 (4) [back to overview]	Progression Free Survival (PFS)
NCT02953561 (4) [back to overview]	Disease-free Survival
NCT02953561 (4) [back to overview]	Number of Participants With a Response
NCT02954653 (9) [back to overview]	Duration of Objective Response Rate (ORR) [Part 1]
NCT02954653 (9) [back to overview]	Number of Participants With Chemistry Laboratory Abnormalities by Type and Maximum National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Grade [Part 1]
NCT02954653 (9) [back to overview]	Number of Participants With Hematology Laboratory Abnormalities by Type and Maximum National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Grade [Part 1]
NCT02954653 (9) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) [Part 1]
NCT02954653 (9) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) by Maximum National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Grade [Part 1]
NCT02954653 (9) [back to overview]	Incidence of Anti-Drug Antibodies (ADA) Against PF-06747143 [Part 1]
NCT02954653 (9) [back to overview]	Progression Free Survival [Part 1]
NCT02954653 (9) [back to overview]	Objective Response Rate (ORR) - Percentage of Participants With Objective Response [Part 1]
NCT02954653 (9) [back to overview]	Number of Participants With Dose-Limiting Toxicities (DLTs) [Part 1]
NCT02959437 (5) [back to overview]	Parts 1 and 2: Progression-free Survival Based on RECIST v1.1.
NCT02959437 (5) [back to overview]	Part 1 and 2 : Number of Participants With Treatment Emergent Adverse Events
NCT02959437 (5) [back to overview]	Part 1 and 2: Objective Response Rate Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
NCT02959437 (5) [back to overview]	Parts 1 and 2: Duration of Response Based on RECIST v1.1
NCT02959437 (5) [back to overview]	Parts 1 and 2: Percentage of Responders Determined by Immunohistochemistry
NCT02993523 (2) [back to overview]	Overall Survival (OS)
NCT02993523 (2) [back to overview]	Percentage of Participants With Complete Remission (CR) and Complete Remission With Incomplete Marrow Recovery (CRi)
NCT03072043 (5) [back to overview]	Overall Survival (OS)
NCT03072043 (5) [back to overview]	Phase 2: Complete Response (CR) Rate
NCT03072043 (5) [back to overview]	Phase 2: Duration of Response
NCT03072043 (5) [back to overview]	Phase 2: Overall Response Rate
NCT03072043 (5) [back to overview]	Phase 1b: Maximum Tolerated Dose (MTD)
NCT03094637 (3) [back to overview]	Overall Response Rate (ORR) Defined as Complete Response + Partial Response + Hematological Improvement
NCT03094637 (3) [back to overview]	Event Free Survival
NCT03094637 (3) [back to overview]	Overall Survival
NCT03151304 (13) [back to overview]	Rate of Cytogenetic CR
NCT03151304 (13) [back to overview]	Rate of Leukemic Transformation
NCT03151304 (13) [back to overview]	Rate of Leukemic Transformation
NCT03151304 (13) [back to overview]	Rate of Leukemic Transformation
NCT03151304 (13) [back to overview]	Rate of Leukemic Transformation
NCT03151304 (13) [back to overview]	Clinical Benefit Rate
NCT03151304 (13) [back to overview]	Overall Survival (OS)
NCT03151304 (13) [back to overview]	Overall Response Rate (ORR)
NCT03151304 (13) [back to overview]	Overall Hematologic Improvement (HI) Response Rate
NCT03151304 (13) [back to overview]	Event-free Survival (EFS)
NCT03151304 (13) [back to overview]	Complete Response (CR) Rate
NCT03151304 (13) [back to overview]	Duration of Response (DoR)
NCT03151304 (13) [back to overview]	Progression-free Survival (PFS)
NCT03151408 (13) [back to overview]	Cytogenetic Complete Remission (CRc) Rate
NCT03151408 (13) [back to overview]	Duration of Composite Complete Remission
NCT03151408 (13) [back to overview]	Duration of Morphologic CR
NCT03151408 (13) [back to overview]	Morphologic Complete Remission (CR) Rate
NCT03151408 (13) [back to overview]	Change in Quality of Life From Baseline (EORTC QLQ-C30 - European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30)
NCT03151408 (13) [back to overview]	Complete Remission Without Minimal Residual Disease (CRmrd) Rate
NCT03151408 (13) [back to overview]	Transfusion Independence (TI)
NCT03151408 (13) [back to overview]	Composite Complete Remission (cCR) Rate
NCT03151408 (13) [back to overview]	Morphologic CR Within 6 Cycles Rate
NCT03151408 (13) [back to overview]	Overall Survival
NCT03151408 (13) [back to overview]	Progressive Free Survival Rate (PFS)
NCT03151408 (13) [back to overview]	Relapse Free Survival
NCT03151408 (13) [back to overview]	Time to CR
NCT03165721 (16) [back to overview]	Quality of Life (QOL) Relative to Any Degree of Response (Patient-Reported Outcomes Measurement Information System (PROMIS) Global Physical Health)
NCT03165721 (16) [back to overview]	Progression Free Survival Probability at 6 Months
NCT03165721 (16) [back to overview]	V(2)/F (Apparent Volume of Distribution)
NCT03165721 (16) [back to overview]	Quality of Life (QOL) Relative to Any Degree of Response (Patient-Reported Outcomes Measurement Information System (PROMIS) Global Mental Health)
NCT03165721 (16) [back to overview]	Progression Free Survival (PFS) Probability at 12 Months
NCT03165721 (16) [back to overview]	Percent Decrease in Long Interspersed Nuclear Element -1 (LINE-1) Demethylation
NCT03165721 (16) [back to overview]	Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
NCT03165721 (16) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Guadecitabine (SGI-110)
NCT03165721 (16) [back to overview]	Quality of Life (QOL) Relative to Any Degree of Response (Patient-Reported Outcomes Measurement Information System (PROMIS) Global Mental Health)
NCT03165721 (16) [back to overview]	Area Under the Concentration Time Curve (AUC 0-5hr)
NCT03165721 (16) [back to overview]	(CL/F) Apparent Total Body Clearance
NCT03165721 (16) [back to overview]	Number of Participants With an Overall Response (Complete Response or Partial Response) of SGI-11 Using the Response Evaluation Criteria in Solid Tumors (RECIST)
NCT03165721 (16) [back to overview]	Half Life (t1/2) of Guadecitabine (SGI-110)
NCT03165721 (16) [back to overview]	Change in Distress From Baseline
NCT03165721 (16) [back to overview]	Time to Maximum Observed Plasma Concentration (Tmax) of Guadecitabine (SGI-110)
NCT03165721 (16) [back to overview]	Change in Distress From Baseline
NCT03173248 (1) [back to overview]	Event-Free Survival (EFS)
NCT03238248 (5) [back to overview]	Rate of Marrow Complete Response (mCR)
NCT03238248 (5) [back to overview]	Rate of Hematologic Response Per IWG
NCT03238248 (5) [back to overview]	Overall Survial Time
NCT03238248 (5) [back to overview]	Objective Response Rate
NCT03238248 (5) [back to overview]	Time to Progression
NCT03264404 (1) [back to overview]	Progression-Free Survival (PFS)
NCT03268954 (29) [back to overview]	Overall Survival (OS)
NCT03268954 (29) [back to overview]	Number of Participants With Overall Response 2 (OR2)
NCT03268954 (29) [back to overview]	Number of Participants With Overall Response (OR)
NCT03268954 (29) [back to overview]	Number of Participants With Hematologic Improvement (HI)
NCT03268954 (29) [back to overview]	Number of Participants With CR, Partial Remission (PR) and Hematologic Improvement (HI)
NCT03268954 (29) [back to overview]	Number of Participants With CR and Marrow CR, PR and Hematologic Improvement (HI)
NCT03268954 (29) [back to overview]	Number of Participants With Overall Response by Cycle 6
NCT03268954 (29) [back to overview]	Number of Participants With Overall Response in Participants Who Have TP53 Mutations, 17p Deletions, and/or Are Determined to be in an Adverse Cytogenetic Risk Group
NCT03268954 (29) [back to overview]	Percentage of Participants With Red Blood Cells (RBCs) and Platelet-transfusion Independence
NCT03268954 (29) [back to overview]	Time to Acute Myelogenous Leukemia (AML) Transformation in Higher-Risk Myelodysplastic Syndromes (HR MDS), Higher-Risk Chronic Myelomonocytic Leukemias (HR CMML) and HR MDS/CMML Participants
NCT03268954 (29) [back to overview]	Time to First Complete Remission (CR) or Partial Remission (PR) or Complete Remission With Incomplete Blood Count Recovery (CRi)
NCT03268954 (29) [back to overview]	Time to Progressive Disease (PD), Relapse After CR (Low-blast AML), Relapse After CR or PR (HR MDS/CMML), or Death
NCT03268954 (29) [back to overview]	Duration of Red Blood Cells (RBCs) and Duration of Platelet-transfusion Independence and Duration of Red Blood Cells (RBCs) and Platelet-transfusion Independence
NCT03268954 (29) [back to overview]	Number of Participants With CR and Marrow CR and PR
NCT03268954 (29) [back to overview]	Number of Participants With CR and Marrow CR
NCT03268954 (29) [back to overview]	Number of Participants With Complete Remission (CR) and CR+ Complete Remission With Incomplete Blood Count Recovery (CRi)
NCT03268954 (29) [back to overview]	Number of Participants With at Least 1 Inpatient Hospital Admissions Related to HR MDS, CMML or Low-blast AML
NCT03268954 (29) [back to overview]	Kaplan-Meier Estimates of Six-Month Survival Rate
NCT03268954 (29) [back to overview]	Kaplan-Meier Estimates of One-Year Survival Rate
NCT03268954 (29) [back to overview]	Event-Free Survival (EFS)
NCT03268954 (29) [back to overview]	Duration of Overall Response 2 (OR2)
NCT03268954 (29) [back to overview]	Duration of Overall Response (OR)
NCT03268954 (29) [back to overview]	Duration of Complete Remission + Complete Remission With Incomplete Blood Count Recovery (CRi)
NCT03268954 (29) [back to overview]	Health-Related Quality of Life (HRQOL) Using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire- Core 30
NCT03268954 (29) [back to overview]	Overall Survival in Participants Who Have TP53 Mutations, 17p Deletions, and/or Are Determined to be in an Adverse Cytogenetic Risk Group
NCT03268954 (29) [back to overview]	Duration of Complete Remission (CR)
NCT03268954 (29) [back to overview]	Event-Free Survival in Participants Who Have TP53 Mutations, 17p Deletions, and/or Are Determined to be in an Adverse Cytogenetic Risk Group
NCT03268954 (29) [back to overview]	Sixty-Day Mortality Reported as Number of Participants Who Died Up to Day 60
NCT03268954 (29) [back to overview]	Thirty-Day Mortality Reported as Number of Participants Who Died Up to Day 30
NCT03390296 (2) [back to overview]	Overall Survival
NCT03390296 (2) [back to overview]	Number of Participants With a Response
NCT03416179 (30) [back to overview]	Intensive Study: Overall Survival (OS)
NCT03416179 (30) [back to overview]	Non-intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)
NCT03416179 (30) [back to overview]	Intensive Study: Number of Participants With Shift From Baseline in Coagulation Laboratory Abnormalities Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Non-intensive Study: Time to Response
NCT03416179 (30) [back to overview]	Non-intensive Study: Plasma Trough Concentration (Ctrough) of Glasdegib
NCT03416179 (30) [back to overview]	Non-intensive Study: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Non-intensive Study: Number of Participants With Shift From Baseline in Hematological Laboratory Abnormalities Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Non-intensive Study: Number of Participants With Shift From Baseline in Corrected QT (QTc) Interval
NCT03416179 (30) [back to overview]	Non-intensive Study: Number of Participants With Shift From Baseline in Coagulation Laboratory Abnormalities Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Non-intensive Study: Number of Participants With Shift From Baseline in Chemistry Laboratory Abnormalities Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Intensive Study: Plasma Trough Concentration (Ctrough) of Glasdegib
NCT03416179 (30) [back to overview]	Intensive Study: Percentage of Participants With Partial Remission (PR)
NCT03416179 (30) [back to overview]	Non-intensive Study: Percentage of Participants With Partial Remission (PR)
NCT03416179 (30) [back to overview]	Non-intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MDASI-AML/MDS Questionnaire at Week 12
NCT03416179 (30) [back to overview]	Intensive Study: Number of Participants With Shift From Baseline in Chemistry Laboratory Abnormalities Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Intensive Study: Number of Participants With Adverse Events (AEs),Serious Adverse Events (SAEs) and According to Severity AEs Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Intensive Study: Percentage of Participants With Complete Remission Including Negative Minimal Residual Disease (CRMRD-neg)
NCT03416179 (30) [back to overview]	Non-intensive Study: Percentage of Participants With Complete Remission (CR) Including Negative Minimal Residual Disease (CRMRD-neg)
NCT03416179 (30) [back to overview]	Non-intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)
NCT03416179 (30) [back to overview]	Non-intensive Study: Percentage of Participants With Complete Remission With Partial Hematologic Recovery (CRh)
NCT03416179 (30) [back to overview]	Non-intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg)
NCT03416179 (30) [back to overview]	Non-intensive Study: Overall Survival (OS)
NCT03416179 (30) [back to overview]	Intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Questionnaire
NCT03416179 (30) [back to overview]	Intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)
NCT03416179 (30) [back to overview]	Non-intensive Study: Number of Participants With Adverse Events (AEs),Serious Adverse Events (SAEs) and According to Severity AEs Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Intensive Study: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Intensive Study: Number of Participants With Shift From Baseline in Hematological Laboratory Abnormalities Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Intensive Study: Number of Participants With Shift From Baseline in Corrected QT (QTc) Interval
NCT03416179 (30) [back to overview]	Intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg)
NCT03416179 (30) [back to overview]	Intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)
NCT03465540 (14) [back to overview]	Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)
NCT03465540 (14) [back to overview]	Progression-free Survival (PFS)
NCT03465540 (14) [back to overview]	Area Under the Concentration Time Curve From Time 0 to 168 Hours (AUC0-168) for AMG 397
NCT03465540 (14) [back to overview]	Overall Response Rate (ORR) for Participants With Non-Hodgkin's Lymphoma (NHL)
NCT03465540 (14) [back to overview]	Overall Survival (OS)
NCT03465540 (14) [back to overview]	Time to Response (TTR)
NCT03465540 (14) [back to overview]	Duration of Response (DOR)
NCT03465540 (14) [back to overview]	Clearance (CL) of AMG 397
NCT03465540 (14) [back to overview]	Overall Response Rate (ORR) for Participants With Multiple Myeloma (MM)
NCT03465540 (14) [back to overview]	Half-life (t1/2) of AMG 397
NCT03465540 (14) [back to overview]	Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
NCT03465540 (14) [back to overview]	Maximum Observed Concentration (Cmax) of AMG 397
NCT03465540 (14) [back to overview]	Overall Response Rate (ORR) for Participants With Acute Myeloid Leukemia (AML)
NCT03465540 (14) [back to overview]	Time to Maximum Observed Concentration (Tmax) for AMG 397
NCT03542266 (3) [back to overview]	Kaplan-Meier Overall Survival
NCT03542266 (3) [back to overview]	Kaplan-Meier Progression-Free Survival
NCT03542266 (3) [back to overview]	Complete Response Rate
NCT03593915 (1) [back to overview]	Number of Participants With Adverse Events and Serious Adverse Events
NCT03614728 (22) [back to overview]	Part 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC[0-inf]) of GSK3326595 Following Administration of Single Dose
NCT03614728 (22) [back to overview]	Part 1: Area Under Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within Participant Across All Treatments (AUC[0-t]) of GSK3326595 Following Administration of Single Dose
NCT03614728 (22) [back to overview]	Part 1: Apparent Terminal Phase Half-life (t1/2) of GSK3326595 Following Administration of Single Dose
NCT03614728 (22) [back to overview]	Part 1: Accumulation Ratio Following Administration of GSK3326595
NCT03614728 (22) [back to overview]	Part 1: AUC(0-inf) of GSK3326595 Following Administration of Repeat Dose
NCT03614728 (22) [back to overview]	Part 1: Number of Participants With AEs by Severity
NCT03614728 (22) [back to overview]	Part 1: Progression Free Survival
NCT03614728 (22) [back to overview]	Part 1: Tmax of GSK3326595 Following Administration of Repeat Dose
NCT03614728 (22) [back to overview]	Part 1: Time of Maximum Concentration Observed (Tmax) of GSK3326595 Following Administration of Single Dose
NCT03614728 (22) [back to overview]	Part 1: Time Invariance Following Administration of GSK3326595
NCT03614728 (22) [back to overview]	Part 1: t1/2 of GSK3326595 Following Administration of Repeat Dose
NCT03614728 (22) [back to overview]	Part 1: Percentage of Participants With Clinical Benefit Rate (CBR)
NCT03614728 (22) [back to overview]	Part 1: Overall Survival
NCT03614728 (22) [back to overview]	Part 1: Overall Response Rate
NCT03614728 (22) [back to overview]	Part 1: Oral Clearance (CL/F) of GSK3326595 Following Administration of Single Dose
NCT03614728 (22) [back to overview]	Part 1: Number of Participants With DLTs
NCT03614728 (22) [back to overview]	Part 1: Maximum Observed Plasma Concentration (Cmax) of GSK3326595 Following Administration of Single Dose
NCT03614728 (22) [back to overview]	Part 1: Cmax of GSK3326595 Following Administration of Repeat Dose
NCT03614728 (22) [back to overview]	Part 1: CL/F of GSK3326595 Following Administration of Repeat Dose
NCT03614728 (22) [back to overview]	Part 1: AUC(0-t) of GSK3326595 Following Administration of Repeat Dose
NCT03614728 (22) [back to overview]	Part 1: Number of Participants With Common Non-STEAEs and STEAEs
NCT03614728 (22) [back to overview]	Part 1: AUC From 0 Hours to the Time of Next Dosing (AUC[0-tau]) of GSK3326595
NCT03684811 (14) [back to overview]	Progression-Free Survival (PFS)
NCT03684811 (14) [back to overview]	Duration of Response (DOR)
NCT03684811 (14) [back to overview]	Number of Participants With a Dose Limiting Toxicity (DLT)
NCT03684811 (14) [back to overview]	Olutasidenib Concentration Within Cerebro-spinal Fluid (CSF)
NCT03684811 (14) [back to overview]	Overall Response Rate (ORR)
NCT03684811 (14) [back to overview]	Overall Survival (OS)
NCT03684811 (14) [back to overview]	Rate of Drug Distribution Within the Blood Stream (Vd/F)
NCT03684811 (14) [back to overview]	Time for Half of the Drug to be Absent in Blood Stream Following Dose (T 1/2)
NCT03684811 (14) [back to overview]	Time to Progression (TTP)
NCT03684811 (14) [back to overview]	Time to Response (TTR)
NCT03684811 (14) [back to overview]	Area Under the Plasma Concentration Versus Time Curve (AUC)
NCT03684811 (14) [back to overview]	Peak Plasma Concentration (Cmax)
NCT03684811 (14) [back to overview]	Time of Peak Plasma Concentration (Tmax)
NCT03684811 (14) [back to overview]	Apparent Clearance (CL/F)
NCT03745716 (1) [back to overview]	Complete Response Rate (CR)
NCT03813147 (8) [back to overview]	Maximum Time to Concentration of MLN4924 (Pevonedistat) Added to the 3-drug Backbone of Azacitidine (Aza), Fludarabine, and Cytarabine Re-induction for Pediatric Patients With Recurrent/Refractory AML and MDS
NCT03813147 (8) [back to overview]	Number of Participants With Adverse Events Attributable to MLN4924 (Pevonedistat)
NCT03813147 (8) [back to overview]	Number of Participants With Antitumor Activity of MLN4924 (Pevonedistat)
NCT03813147 (8) [back to overview]	Elimination Half-life of MLN4924 (Pevonedistat) Added to the 3-drug Backbone of Azacitidine (Aza), Fludarabine, and Cytarabine Re-induction for Pediatric Patients With Recurrent/Refractory AML and MDS
NCT03813147 (8) [back to overview]	Maximum Concentration of MLN4924 (Pevonedistat) Added to the 3-drug Backbone of Azacitidine (Aza), Fludarabine, and Cytarabine Re-induction for Pediatric Patients With Recurrent/Refractory AML and MDS
NCT03813147 (8) [back to overview]	Total Plasma Clearance of MLN4924 (Pevonedistat) Added to the 3-drug Backbone of Azacitidine (Aza), Fludarabine, and Cytarabine Re-induction for Pediatric Patients With Recurrent/Refractory AML and MDS
NCT03813147 (8) [back to overview]	Number of Participants With Dose Limiting Toxicities of MLN4924 (Pevonedistat)
NCT03813147 (8) [back to overview]	Area Under the Plasma Concentration Versus Time Curve of MLN4924 (Pevonedistat) Added to the 3-drug Backbone of Azacitidine (Aza), Fludarabine, and Cytarabine Re-induction for Pediatric Patients With Recurrent/Refractory AML and MDS
NCT03941964 (4) [back to overview]	Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi)
NCT03941964 (4) [back to overview]	Percentage of Participants With Complete Remission With Incomplete Blood Count Recovery (CRi)
NCT03941964 (4) [back to overview]	Percentage of Participants With Post-baseline Transfusion Independence
NCT03941964 (4) [back to overview]	Percentage of Participants With Complete Remission (CR)
NCT04146038 (2) [back to overview]	Number of Participants Experiencing Adverse Events Incidence With of Salicylate + Venetoclax + Decitabine
NCT04146038 (2) [back to overview]	Number of Participants With Complete or Partial Response
NCT04266795 (1) [back to overview]	Event-Free Survival (EFS)
NCT04842604 (2) [back to overview]	Number of Participants With Treatment Emergent Adverse Event (AE) and Treatment Related AE
NCT04842604 (2) [back to overview]	Number of Participants With Treatment Emergent Serious Adverse Events (SAE) and Treatment Related SAEs

Kaplan-Meier Estimate for Median Time to Transformation to Acute Myeloid Leukemia (AML) or Death From Any Cause, Whichever Occurred First

The time to transformation to AML or death from any cause (whichever occurred first) was defined as the number of days from the date of randomization until the date of documented AML transformation or death from any cause. Patients who did not transform to AML or die were censored at the date of last follow-up. (NCT00071799)
Timeframe: Day 1 (randomization) to 42 months

Intervention	months (Median)
Azacitidine	13.02
Conventional Care	7.61

Intervention	participants (Number)
	Overall (Complete + Partial Remission)	Complete Remission	Partial Remission	Stable Disease
Azacitidine	51	30	21	75
Conventional Care	21	14	7	65

Intervention	participants (Number)
	Patients with >=1 treatment emergent AE (TEAE)	Patients with >=1 treatment related TEAE	Patients with >=1 serious TEAE	Patients with >=1 serious treatment related TEAE	Patients w TEAE leading to discontinued treatment	Patients w TEAE leading to dose reduction	Patients w TEAE leading to dose interruption
Azacitidine	175	169	114	43	22	20	82
Best Supportive Care Only	97	1	71	0	4	0	0
Low-dose Cytarabine	44	34	27	13	6	2	12
Standard Chemotherapy	19	19	14	13	2	0	0

Intervention	participants (Number)
	Any Improvement n=177, 178	Erythroid Response - Major n=157, 160	Erythroid Response - Minor n=157, 160	Platelet Response - Major n=141, 129	Platelet Response - Minor n=138, 127	Neutrophil Response - Major n=131, 111	Neutrophil Response - Minor n=131, 111
Azacitidine	87	62	2	46	6	25	5
Conventional Care	51	17	1	18	4	20	9

Intervention	participants (Number)
	Baseline Dependent; On-Treatment Independent	Baseline Dependent; On-Treatment Dependent
Azacitidine	16	22
Conventional Care	11	16

Intervention	participants (Number)
	Baseline Independent; On-Treatment Independent	Baseline Independent; On-Treatment Dependent
Azacitidine	126	15
Conventional Care	102	50

Intervention	months (Number)
	Age <65 years	Age >= 65 years	Age >= 75 years	Gender: Male	Gender: Female	FAB: Refractory anemia with excess blasts (RAEB)	FAB: RAEB in transformation	WHO: RAEB 1	WHO: RAEB 2	WHO: Other (AML, CMMoL-1 and 2, indeterminate)	IPSS: Intermediate 2	IPSS: High
Azacitidine	11.31	24.46	8.92	24.46	25.11	34.66	17.25	11.54	21.11	20.46	34.66	19.21
Conventional Care	7.87	13.87	6.20	15.02	14.85	15.21	15.25	6.72	15.02	15.25	16.89	14.52

Intervention	percentage of participants (Number)
	Grade 1, Nausea	Grade 1, Fatigue	Grade 1, Oral Mucositis	Grade 1, Pharyngolaryngeal pain	Grade 1, Decreased white blood cell	Grade 2, Fatigue	Grade 2, Decreased white blood cell	Grade 2, Neutrophil count decreased	Grade 2, Lymphocyte count decreased	Grade 3, Decreased white blood cell	Grade 3, Neutrophil count decreased	Grade 3, Febrile neutropenia	Grade 3, Infections	Grade 3, respiratory disorders	Grade 4, Decreased white blood cell	Grade 5
Treatment	42	33	25	25	25	25	25	16	16	42	25	8	8	8	58	0

Intervention	participants (Number)
	Baseline Dependent (n=6,12,12) - 24 mo Independent	Baseline Dependent (n=6,12,12) - 24 mo Dependent	Baseline Independent(n=16,9,15)- 24 mo Independent	Baseline Independent (n=16,9,15) - 24 mo Dependent
Initial Period Treatment Continued Into Maintenance	10	2	15	0
Maintenance Aza 5 Days q 4 Weeks	5	1	15	1
Maintenance Aza 5 Days q 6 Weeks	12	0	9	0

Intervention	participants (Number)
	Baseline Dependent(n=25,24,22) - 6 mo Independent	Baseline Dependent(n=25,24,22) - 6 mo Dependent	Baseline Independent(n=25,26,29)- 6 mo Independent	Baseline Independent(n=25,26,29) - 6 mo Dependent
Aza-5	16	9	19	6
Aza-5-2-2	14	10	16	10
Aza-5-2-5	13	9	19	10

Intervention	participants (Number)
	Baseline Dependent (n=1,1,2) - 24 mo Independent	Baseline Dependent (n=1,1,2) - 24 mo Dependent	Baseline Independent(n=21,20,25)-24 mo Independent	Baseline Independent(n=21,20,25) - 24 mo Dependent
Initial Period Treatment Continued Into Maintenance	2	0	25	0
Maintenance Aza 5 Days q 4 Weeks	1	0	21	0
Maintenance Aza 5 Days q 6 Weeks	1	0	20	0

Intervention	participants (Number)
	Baseline Dependent (n=4,2,1) - 6 mo Independent	Baseline Dependent (n=4,2,1) - 6 mo Dependent	Baseline Independent(n=46,48,50)- 6 mo Independent	Baseline Independent (n=46,48,50) - 6 mo Dependent
Aza-5	3	1	43	3
Aza-5-2-2	2	0	42	6
Aza-5-2-5	0	1	41	9

Intervention	participants (Number)
	Any Improvement n=50,49,47	Erythroid response - Major n=44,43,41	Erythroid response - Minor n=44,43,41	Platelet response - Major n=24,28,28	Platelet response - Minor n=24,28,28	Neutrophil response - Major n=24,22,16	Neutrophil response - Minor n=24,22,16
Aza-5	29	18	4	10	2	4	2
Aza-5-2-2	20	15	1	11	0	3	0
Aza-5-2-5	26	18	2	10	0	3	0

Intervention	participants (Number)
	Improved response from initial study period	Maintained response from initial study period
Initial Period Treatment Continued Into Maintenance	12	10
Maintenance Aza 5 Days q 4 Weeks	7	6
Maintenance Aza 5 Days q 6 Weeks	10	5

Intervention	participants (Number)
	Overall Response (CR+PR)	Complete remission (CR)	Partial remission (PR)	Stable disease
Aza-5	4	2	2	22
Aza-5-2-2	3	2	1	19
Aza-5-2-5	4	2	2	20

Intervention	infections per cycle (Median)
Maintenance Aza 5 Days q 4 Weeks	0.00
Maintenance Aza 5 Days q 6 Weeks	0.00
Initial Period Treatment Continued Into Maintenance	0.00

Intervention	x10^9/L (Median)
Maintenance Aza 5 Days q 4 Weeks	19.8
Maintenance Aza 5 Days q 6 Weeks	7.7
Initial Period Treatment Continued Into Maintenance	17.3

Intervention	x10^9/L (Median)
Maintenance Aza 5 Days q 4 Weeks	-0.1
Maintenance Aza 5 Days q 6 Weeks	-0.2
Initial Period Treatment Continued Into Maintenance	-0.4

Intervention	Proportion of patients (Number)
Arm A (Azacitidine; Non-treatment-induced Cohort)	0.32
Arm B (Azacitidine + Entinostat; Non-treatment-induced Cohort)	0.27
Arm A (Azacitidine; Treatment-induced Cohort)	0.46
Arm B (Azacitidine + Entinostat; Treatment-induced Cohort)	0.17

Intervention	Participants (Number)
Romiplostim (AMG 531) Placebo Plus Azacitidine	9
Romiplostim (AMG 531) 500 mcg Plus Azacitidine	6
Romiplostim (AMG 531) 750 mcg Plus Azacitidine	5
Romiplostim (AMG 531) Placebo Plus Decitabine	8
Romiplostim (AMG 531) 750 mcg Plus Decitabine	7

Intervention	cells of BM (10e^6/ML) (Mean)
	CD34 Baseline	CD34 After Three Cycles	CD34 After Six Cycles	CD71 at Baseline	CD71 After Three Cycles	CD71 After Six Cycles	CD36 at Baseline	CD36 after Three Cycles	CD36 after Six Cycles
Non-Responders	.49	.58	.52	7.23	10.13	9.69	5.12	6.08	3.57
Responders	.86	.93	1.15	18.32	27.31	35.45	11.69	14.33	21.35

azacitidine

Description

Cross-References

Synonyms (186)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (2)

Protein Targets (74)

Potency Measurements

Inhibition Measurements

Biological Processes (378)

Molecular Functions (96)

Ceullar Components (71)

Bioassays (238)

Research

Studies (7,281)

Study Types

Clinical Trials (635)

Trial Overview

Trial Outcomes

Kaplan-Meier Estimate for Median Time to Transformation to Acute Myeloid Leukemia (AML) or Death From Any Cause, Whichever Occurred First

Kaplan-Meier Estimates for Median Time to Transformation to Acute Myeloid Leukemia (AML)

Kaplan-Meier Estimates for Median Time to Transformation to Acute Myeloid Leukemia (AML) Based on the Last Bone Marrow Assessment

Number of Infections Per Treatment Year Requiring Intravenous Antibiotics, Antifungals or Antivirals

Number of Participants Who Died

Time to Disease Progression, Relapse After Complete or Partial Remission, or Death From Any Cause

Number of Participants Considered Hematologic Responders by Investigator Determinations Using International Working Group (IWG 2000) Criteria for Myelodysplastic Syndrome (MDS)

Number of Participants in Different Categories of Adverse Experiences During Core Study Period

Number of Participants Showing Hematologic Improvement Using International Working Group (IWG 2000) Criteria for Myelodysplastic Syndrome (MDS) Assessed by Independent Review Committee

Summary of Participants' Platelet Transfusion Status for Participants Who Were Transfusion Dependent at Baseline

Summary of Participants' Platelet Transfusion Status for Participants Who Were Transfusion Independent at Baseline

Summary of Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Dependent at Baseline

Summary of Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Independent at Baseline

Duration of Any Hematologic Improvement

Summary of Subgroup Analyses for Kaplan-Meier Estimates for Time to Death From Any Cause

Kaplan-Meier Estimates for Median Time to Death From Any Cause

Frequency of Adverse Events According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0

Restoration of Radioiodine Uptake in Metastatic Lesions as Demonstrated by Diagnostic Whole-body Scanning After Decitabine Administration

Red Blood Cell (RBC) Transfusion Status at Baseline and End of Maintenance Study Period (24 Months)

Red Blood Cell (RBC) Transfusion Status at Baseline and End of Initial Study Period (6 Months)

Platelet Transfusion Status at Baseline and End of Maintenance Study Period (24 Months)

Platelet Transfusion Status at Baseline and End of Initial Study Period (6 Months)

Number of Participants With Best Hematological Improvement Derived Using International Working Group 2000 (IWG 2000) Criteria for MDS During the Initial Study Period.

Number of Participants Who Improved or Maintained The Hematologic Response From the Initial Study Period (Based on IWG 2000 Criteria For MDS) During the Maintenance Period

Number of Participants In Best Hematological Response Categories as Determined by the Investigator Using International Working Group 2000 (IWG 2000) Criteria For Myelodysplastic Syndromes (MDS) During the Initial Study Period.

Number of Participants With Overall Best Hematologic Response and Hematologic Improvement Based on IWG 2000 Criteria For MDS During the Initial Study Period

Change From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Maintenance Study Period

Change From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Initial Study Period

Baseline Platelet Values

Baseline Absolute Neutrophil Count (ANC) Values

Change From Baseline in Platelets at the End of Initial Study Period (6 Months)

Change From Baseline in Platelets at the End of the Maintenance Study Period (Month 24)

Change From Baseline in Hemoglobin at the End of the Maintenance Study Period

Change From Baseline in Hemoglobin at End of Initial Study Period (6 Months)

Baseline Hemoglobin Values

Change From Baseline in Absolute Neutrophil Count (ANC) at the End of the Maintenance Study Period (Month 24)

Change From Baseline in Absolute Neutrophil Count (ANC) at the End of Initial Study Period (6 Months)

Proportion of Patients With Clinical Response

Platelet Transfusion

Occurrence of a Clinically Significant Thrombocytopenic Event

Hypomethylating Agent Dose Reduction and Delay Due to Thrombocytopenia

Achieving an Overall Response (Complete or Partial Response, CR or PR) at the End of the Treatment Period

Number of Participants With Response

PHASE II: Determine the Number of Patients With Responses for Efficacy(Measured as Response Rate)

Number of Patients That Experience Grade 3 or 4 Treatment Related Non-hematologic Adverse Events

Overall Survival Among Patients With Complete Response

PHASE I: Maximum Tolerated Dose of Azacitidine

PHASE I: Maximum Tolerated Dose of Lenalidomide

PHASE II: Determine the Number of Patients With Responses for Efficacy(Measured as Response Rate)

Time to Relapse After Achieving Complete Response

Time to Transformation to Acute Myeloid Leukemia or Death

Analysis of CD34, CD71, CD36 Cells in Aspirated Bone Marrow for Both Responders and Non-responders at Baseline and After Three and Six Cycles

Overall Response After Cycle 3

Overall Response Rate After Six Cycles

Safety Profile of the Modified Dose/Schedule of Azacitidine and Erythropoietin or a Modified Dose of Azacitidine Alone

Intervention	percentage L27 mRNA (Mean)
	BclXL Expression at baseline	BclXL Expression after three cycles	BclXL Expression after six cycles
Non-Responders	1.00	.77	1.21
Responders	1.0	1.50	3.89

Intervention	percentage of cells (Mean)
	% apoptosis at baseline	% apoptosis after three cycles	% apoptosis after six cycles
Non-Responders	31.19	63.43	38.10
Responders	17.04	24.70	42.58

Intervention	Participants (Number)
	Grade 1-2 Hematologic	Grade 3-4 Hematologic	Grade 1-2 Non-hematologic	Grade 3-4 Non-hematologic
Azacitidine	1	8	23	0

Intervention	participants (Number)
	Red blood cell	Platelet	Red blood cell and platelet
Azacitidine	2	1	0

Intervention	Participants (Count of Participants)
Phase I - 30mg/m2 Azacitidine	0
Phase I - 40mg/m2 Azacitidine	0

Intervention	delta delta CT values (Median)
	Expression levels of MiR-29b	Expression levels of DNMT3a
Non Responder	0.0024305	0.000341819
Responders	0.0056394	0.000196066

Intervention	mg (Number)
	Initial RPTD Prednisone (mg)	Reduced RPTD Prednisone (mg)
Phase 1 - Aza + Doc	5	5

Intervention	mg/m2 (Number)
	Initial RPTD Azacitidine (mg/m2)	Initial RPTD Docetaxel (mg/m2)	Reduced RPTD Azacitidine (mg/m2)	Reduced RPTD Docetaxel (mg/m2)
Phase 1 - Aza + Doc	150	75	75	75

Intervention	participants (Number)
	Complete Response (CR)	Partial Response (PR)
Phase 1: Level 1 - 75 Aza + 60 Doc	0	0
Phase 1: Level 3 - 100 Aza + 75 Doc	1	0
Phase 1: Level 4 - 150 Aza + 75 Doc	0	1
Phase 2 - Aza + Doc Initial RPTD	0	1

Intervention	participants (Number)
Level 1 - 75 Aza + 60 Doc	3
Level 2 - 75 Aza + 75 Doc	4
Level 3 - 100 Aza + 75 Doc	3
Level 4 - 150 Aza + 75 Doc	12